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ABSTRACT 
BACKGROUND: After Roux-en-Y gastric bypass bariatric surgery (RYGB) patients and animal models 
show a decreased preference for sweet/fatty foods. However, there are significant discrepancies in 
the findings of animal and human studies, and the mechanisms are not understood. 
AIMS: To investigate: 
1. The effect of a high-fat (HFD) vs. low-fat (LFD) pre-operative maintenance diet on the ingestive 
behaviour of rats after RYGB 
2. The effects of RYGB vs. gastric banding (BAND) surgery on food hedonics and brain reward 
systems in humans 
3. The effects of RYGB on taste in humans 
METHODS: 
Study 1: Rats were fed either LFD or HFD before RYGB or sham surgery. Ingestive behaviour was 
assessed after surgery using food preference tests. 
Study 2: Brain reward responses to food were investigated using functional magnetic resonance 
imaging (fMRI), eating behaviour and metabolic phenotyping in body mass index (BMI) matched un-
operated controls and patients after RYGB and BAND surgery. 
Study 3: The intensity and reward of sweet, fat and fat/sweet taste stimuli were assessed in patients 
undergoing RYGB using behavioural techniques. 
RESULTS: 
Study 1: Pre-operative maintenance diets with different fat contents, did not affect post-surgical 
weight loss or caloric intake. HFD-RYGB rats exhibited behaviour consistent with condition taste 
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aversion to a familiar stimulus, compared to condition taste aversion to a novel stimulus in the LFD-
RYGB rats. 
Study 2: Patients after RYGB had lower activation in brain reward systems to food and lower food 
hedonics than BAND patients and/or BMI-matched unoperated controls. Anorexigenic plasma gut 
hormones, plasma bile acids and dumping syndrome scores were higher in RYGB patients. 
Study 3: RYGB increased the intensity of fat/sweet taste solutions and reduced the reward value of 
fat/sweet stimuli. 
CONCLUSION: Pre-operative feeding may affect ingestive behaviour after RYGB. The mechanisms 
underlying the healthier food preferences after RYGB include the reduced reward value, and 
increased aversion to, high-calorie food and taste. Potential mediators are gut hormones, bile acids 
and altered gut nutrient sensing. 
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1.1 Basic concepts 
Obesity has already reached epidemic proportions in many parts of the world. The World Health 
Organisation (WHO) has adopted a classification system using body mass index (BMI) as the criterion 
[1] and based on this definition 24% of the world’s population was obese in 2008 (BMI ≥30 kg/m 2) 
[2]. At a population level BMI is associated with increased morbidity and mortality [3]. 
Understanding the heterogeneity of the condition and the underlying pathophysiological 
mechanisms will aid the development of effective treatments. In this section some of the potential 
causes are explored with a particular emphasis on the physiological mechanisms that are associated 
or contribute to weight gain and disordered eating behaviour. 
1.1.1 Eating behaviour  
The term eating behaviour describes the all the facets of the relationship between animals (including 
humans) with food. This relationship is characterised by the physiological, psychological and social 
forces that are integrated in the brain and determine not only how much we eat, but  also what, 
when, and how we eat. The study of eating behaviour is crucial not only from an academic point of 
view, but is also a translational research priority due to the exorbitant rise in obesity in most parts of 
the world.     
Up to relatively recently within human evolution, the concept of eating behaviour was limited to the 
recognition of hunger and fullness as the major driving forces. Hunger is the predominant 
physiological signal to seek for or initiate an eating episode or meal. During the consumption of a 
meal, hunger subsides and satiation increases up to the point at which a meal is terminated. Satiety 
is the term that describes the balance between these two opposing physiological states in the period 
between meals [4]. The homeostatic control of food intake takes place in the brain, responds to 
peripheral signals and is activated to counterbalance any drift in adiposity below a certain set point. 
This evolutionary protective mechanism has protected the human species from extinction through 
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famine and war [5]. For millennia, the quest for food was a struggle, and therefore the “hungry” 
brain eventually survived.  
Unlike other animals however, humans need gratification from other sources including emotional 
contact, professional and intellectual achievements. Our species has advanced in such a way as to 
minimise the time spent performing basic tasks, like hunting for food, in order to allow us more time 
to pursue these “higher” achievements.  As a result, only within the last century, food, and in 
particular high-calorie food, has become so readily available in many parts of the globe. Now that 
our hunger and fullness can be readily satisfied, the reward value of food has emerged as a major 
force affecting eating behaviour and in particular food preferences. For example, following a starter 
and main course in a restaurant the vast majority of us are much more likely to agree to have a 
chocolate dessert, rather than low fat yogurt. Interestingly we will consume this palatable and 
rewarding food even though we have reached satiation, suggesting that the hedonic control of food 
intake has overridden the homeostatic control [6].  
Food reward can be understood better if broken down to its appetitive and consummatory domains. 
The appetitive reward value of food reflects the effort the animal or human is willing to exert in 
order to obtain it (e.g. how much do I want this chocolate cake?). The consummatory reward value 
of food reflects the “pleasure” elicited when food is actually consumed (e.g. how much do I like this 
chocolate cake?). The terms “wanting” and “liking” are used in the literature [7] to describe these 
two domains but they are not as specific as “appetitive” and “consummatory” in terms of the 
mechanisms involved [8]. Indeed, appetitive behaviour is thought to be principally determined by 
dopamine neurotransmission [9, 10] and consummatory behaviour determined by opioid [11, 12] 
and endocannabinoid [13] neurotransmission in animals. As these two systems continuously interact 
both in animals and humans [14], their strict separation, especially in the context of human eating 
behaviour, is unnecessarily rigid and can lead to erroneous conclusions [15]. Indeed, Berridge 
himself suggested, “Subjective reports may contain false assessments of the underlying processes, or 
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even fail to register important reward processes. The core processes of liking and wanting that 
constitute reward are distinct from the subjective report or conscious awareness of those processes” 
[7]. 
Eating behaviour is not only affected by physiological signals, but also by psychological traits and 
social influences. Figure 1.1 illustrates some of the numerous factors that determine human eating 
behaviour. In the rest of this section the focus will be shifted on the brain regions involved in the 
homeostatic and hedonic control of food intake, how they are affected by peripheral signalling and 
the methodology currently used to study eating behaviour.  
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Figure 1.1: Factors affecting eating behaviour 
 
The physiological, personality, environmental and learning factors do not act in isolation but interact with each other in sh aping eating behaviour. 
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1.1.2 Homeostatic control of food intake  
The homeostatic control of food intake takes place predominantly within the hypothalamic and 
brainstem nuclei that communicate through neurotransmitters [16]. These nuclei respond to signals 
originating from the presence of nutrients in the gut and fat stores. Their activation either increases 
or decreases food intake both during a meal but also more chronically in an attempt to keep body 
weight stability. The interaction of these systems is complex and still the subject of intense scientific 
investigation, but the most well established pathways are outlined below. 
Lesion studies provided the first clue on the importance of the medial hypothalamus in the control 
of food intake. Lesions of the medial hypothalamus caused obesity and of the lateral hypothalamus 
weight loss, suggesting that the former is the satiety and the latter the feeding centre. Since these 
initial descriptions, hypothalamic anatomy and function have been further refined. The arcuate 
nucleus of the hypothalamus contains two groups of neurons with opposite effects [17]. The first 
group synthesize pro-opiomelanocortin derived peptides, amongst which α-melanocyte stimulating 
hormone acts via the melanocortin 4 receptors on the paraventricular nucleus, lateral hypothalamus 
and the ventromedial nucleus to lower food intake and increase energy expenditure [18]. The 
second group of neurons synthesize neuropeptide Y, agouti -related protein and gamma-
aminobutyric acid which increase food intake and lower energy expenditure by inhibiting pro-
opiomelanocortin neurons, but also by projecting to the paraventricular, ventromedial, dorsomedial 
nuclei and lateral hypothalamus via Y1, Y2 and Y5 receptors and antagonism of α-melanocyte 
stimulating hormone at melanocortin 4 receptors [19]. The arcuate nucleus is also in direct contact 
with blood through gaps in the blood-brain-barrier, while the hypothalamus is also exposed to 
cerebrospinal fluid in the third ventricle, allowing hypothalamic responsiveness to circulating 
nutrients and gut hormones [20]. 
The paraventricular nucleus neurons produce corticotrophin releasing hormone, thyrotropin 
releasing hormone and oxytocin which in turn lower food intake and increase energy expendi ture by 
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acting on the anterior pituitary or other hypothalamic or brainstem involved in autonomic output 
signalling [16].  
The ventromedial nucleus responds to signalling from glucose and leptin sensitive neurons but also 
from pro-opiomelanocortin by producing brain-derived neurotrophic factor, with the overall final 
effect of lowering food intake and increasing energy expenditure [21].  The dorsomedial nucleus is 
connected to the other hypothalamic neurons but is also affected by the suprachiasmatic nucleus 
and thus influence temperature control, arousal and food intake [22]. 
The lateral hypothalamus contains two different groups of cells that produce orexin (hypocretin) and 
melanin concentrating hormone that communicate with the arcuate, other hypothalamic areas, 
brainstem and the mesolimbic system to control food intake. The orexin neurons are active during 
fasting, inactive during sleep and inhibited by glucose [23]. They act through orexin 1 and 2 
receptors to regulate arousal, stress responses but also to alter brain reward systems, particularly 
dopaminergic function, through their effects on the ventral tegmental area. By contrast, the melanin 
concentrating hormone group are stimulated by glucose and active during sleep, project to the 
nucleus accumbens and increase food intake via melanin concentrating hormone 1 and 2 receptors 
[24].  
The brainstem is crucial in the perception of satiation which leads to meal termination. It receives 
afferent signals from gastric distension through vagal and spinal afferents. Most gut peptides act 
through vagal afferents at the nucleus of the solitary tract, but some can also enter the brain from 
the circulation and act at the arcuate nucleus [25]. Whilst decerebrate animals can regulate meal 
size, they are incapable of initiating meals or adjusting meal size depending on energy needs [26]. 
This suggests that projections from the hindbrain to the forebrain via the parabrachial nucleus are 
essential for the integrated control of food intake. The important role of the brainstem in taste 
perception is discussed below in Section 1.1.5.2, page 48. 
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1.1.3 Hedonic control of food intake  
Emotional and cognitive aspects of food or other stimuli are processed in the limbic and cortical 
areas of the brain. Most of the available evidence for this “reward system” has been provided by 
investigation of the effects of brain stimulation, electrophysiological recording, drug administration, 
neurotransmitter microdialysis and targeted gene knockout or expression in animals, or 
traumatic/vascular lesion and neuroimaging studies in humans. The descriptions below and the 
allocation of specific roles to brain regions is an oversimplification, considering the complexity of the 
human brain and behaviour. However, a basic understanding is essential for the interpretation of the 
rest of the thesis (Figure 1.2).   
The combined results of neuroimaging studies in humans, but also from lesion studies in animals 
have revealed the complex functions of the orbitofrontal cortex [27-29]. The orbitofrontal cortex 
receives inputs from the 5 basic senses (taste, olfaction, touch, hearing and vision), but also visceral 
sensory signals [27-29]. These signals converge in the posterior part of the orbitofrontal cortex 
before they undergo multimodal integration and the reward value of the stimulus is re presented in 
the most anterior parts [27-29]. The medial orbitofrontal cortex affects this processing by 
responding to learning, memory and monitoring, whilst the lateral orbitofrontal cortex is more 
involved with the evaluation of punishers. The integration of all these complex inputs leads to 
decision making, goal-directed behaviour, but also prediction of the anticipated reward value of 
specific actions. The balance between actions and reward is continuously monitored and behaviour 
constantly adjusted in order to obtain the greatest benefit [27-29]. Interestingly, more abstract non-
food rewards, including monetary, are also represented in the anterior orbitofrontal cortex [27-29].  
The orbitofrontal cortex does not act in isolation, but also communicates with other regions involved 
in the homeostatic and hedonic control of food intake including the hypothalamus, amygdala, insula, 
hippocampus and striatum [27-29]. Lesions of the orbitofrontal cortex in humans, either through 
vascular events or trauma, can lead to weight gain, a preference for sweet foods, difficulties with 
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decision making, lack of responding to environmental signals and inappropriate social behaviour [27-
29]. In healthy adults, the orbitofrontal cortex is activated preferentially to high-calorie vs. low 
calorie food cues in fMRI studies, and the increase in associated activation of medial and lateral 
orbitofrontal cortex when switching from fed to fasted state has been correlated with the increase in 
appeal bias towards high-calorie food [30]. The orbitofrontal cortex is involved in the process of 
sensory specific satiety as demonstrated early in electrophysiological studies in macaques [31] and 
more recently in a positron emission tomography (PET) study, in which as healthy volunteers ate 
increasing amount of chocolates to the point that it became unpleasant (i.e. they reached sensory 
specific satiety) the blood flow to the medial orbitofrontal cortex decreased and to the lateral 
orbitofrontal cortex increased [32]. The lateral orbitofrontal cortex also responds to the anticipation 
of receipt of a pleasant taste in healthy adults [33], and its activation in such fMRI tasks has been 
shown to correlate with future weight gain (which is modulated by dopamine receptor DRD2 gene 
polymorphisms) in adolescent girls [34].  
The amygdala has long been known to be key in the processing of emotions, mainly negative ones 
(e.g. fear) [35, 36]. However, it has also been shown to respond to positive emotions and thus play a 
role in stimulus-reward association and learning which eventually determines behaviour [35, 36].  
The central and basolateral amygdala also receive gustatory inputs, but are not involved in 
multimodal integration in the same way as the orbitofrontal cortex. Early PET studies showed that 
the administration of aversive tastants or olfactory cues was associated with increased cerebral flow 
in the amygdala in healthy women [37], but subsequent studies have shown that the amygdala, 
unlike the orbitofrontal cortex and insula, is similarly activated both in response to pleasant stimuli 
like glucose and aversive ones like sodium chloride [38-40]. 
Lesions to the insula lead to dysphasia indicating a role in the mechanics of speech production [41]. 
However, the insula also incorporates the primary taste cortex and is involved in the recognition of 
taste, memory for taste and condition taste aversion, i.e. the avoidance of a tastant if associated 
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with unpleasant post-ingestive effects [41, 42]. The anterior insula appears to integrate visceral and 
autonomic signals into motivation and emotion, and the posterior to integrate somatosensory, 
motor and vestibular signals [41]. Subsequent studies have also supported its role in risk taking, 
anticipation, decision making and addiction [41, 42]. FMRI activation of the insula correlated with 
cravings for food when healthy volunteers were asked to imagine the sensory properties of their 
favourite food [43]. Presenting food stimuli to healthy volunteers in the fasted state also increased 
18F-fluorodeoxyglucose (FDG) uptake in the anterior insula in PET and activation in fMRI studies (e.g. 
[44, 45]). In another PET study, eating chocolate and rating it as pleasant was associated with 
increased cerebral flow in the insula in healthy volunteers [32].  
The anterior cingulate cortex can be divided into the ventral and dorsal subdivisions [46, 47]. The 
ventral subdivision is involved in assigning emotional valence and determining motivation in 
response to a stimulus, and also has autonomic and endocrine functions (brain-gonadal and brain-
adrenal axis) [46, 47]. The dorsal subdivision is mostly involved with cognitive control including the 
processing of cognitively demanding information [46, 47]. The anterior cingulate and subcallosal 
cortices are involved both with the interpretation and regulation of emotional responses but also 
with motivation for a specific cue and the assessment of reward and risk [46]. The anterior cingulate 
cortex is activated in response to fatty tastants in human fMRI studies [48], and its activation in 
response to the anticipation of palatable food cues as assessed by fMRI in healthy volunteers 
(together with the medial orbitofrontal cortex and amygdala) also correlates with “food addiction 
scores”  [49]. In obese adults, higher fMRI activation in the anterior cingulate cortex (and also insula 
and nucleus accumbens) in response to high-calorie food cues at baseline was associated with less 
weight loss at 12 weeks of a lifestyle/psychosocial intervention and at 9 months follow up [50]. 
The dorsal striatum, including the caudate and putamen, as part of the reward system, is important 
in learning through the association of a specific action with their expected reward value, including 
both food and non-food rewards. This goal-directed behaviour is expressed through the release of 
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dopamine in the dorsal striatum in response to a specific cue, especially when hungry [51, 52]. The 
release of dopamine in the dorsal striatum in healthy volunteers also correlates with the subjective 
pleasantness of food in a seminal PET study [53]. In particular, fMRI activation of the caudate (and 
also hippocampus and insula) correlates with cravings for food when healthy volunteers are asked to 
imagine the sensory properties of their favourite food [43].  
The nucleus accumbens is part of the ventral striatum, and responds to both positive and negative 
stimuli from the environment and determines goal directed behaviour [54, 55]. In particular, novel 
stimuli activate the nucleus accumbens which in turn initiates seeking behaviour and motivation to 
the stimulus. Depending on the reward value of the stimulus, the same seeking behaviour will be 
continued or avoided in the future, both for this and other related stimuli [54, 55]. The nucleus 
accumbens responds directly to both the appetitive and consummatory reward of food/taste and 
forms parts of both the dopaminergic and opioid/endocannabinoid system [54]. In healthy women, 
fMRI activation of the nucleus accumbens in response to food pictures predicts subsequent food 
intake independent of subjective ratings of the desire to eat [56]. In healthy adults, differences in 
reward sensitivity correlate with fMRI activation in the nucleus accumbens (and also the 
orbitofrontal cortex, amygdala, midbrain and ventral pallidum) in response to pictures of appetizing 
foods [57]. Successful dieters exhibit higher nucleus accumbens activation in response to appetizing 
food pictures after a milkshake preload compared to non-dieters who exhibit higher nucleus 
accumbens activation after a water preload [58]. Nucleus accumbens activation to food cues in 
overweight adults is attenuated by satiation and further this predicts subsequent food intake [59]. 
The lateral prefrontal cortex has a role in higher cognitive function, and reward processing [29, 60]. 
It appears to be mostly involved in the expectancy and anticipation of a reward [29, 60]. In 
particular, the orbitofrontal cortex encodes reward value and signals this information to the 
prefrontal cortex which decides on the appropriate action in response to the rewarding stimulus [29, 
60]. The dorsolateral prefrontal cortex also serves to inhibit actions which aim to obtain an 
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immediate reward in response to its potential negative longer term effects [29, 60]. When dieters 
exercise restraint in response to food cues, this correlates with activation in the dorsolateral 
prefrontal cortex [61], and successful dieters exhibit higher blood flow in the same region and lower 
blood flow in the orbitofrontal cortex in response to a meal compared to non-dieters [62]. Even in 
the absence of dieting, the conscious application of restraint during presentation of favourite food 
pictures is associated with higher fMRI activation in cognitive control areas including the dorsolateral 
prefrontal cortex, inferior frontal gyrus, dorsal striatum and orbitofrontal cortex in normal weight 
and obese women [63]. fMRI activation in the ventromedial prefrontal cortex during wine taste in 
healthy adults also correlates with subjective ratings of the pleasantness of wine when marketed to 
appear expensive [64]. 
The hippocampus is not only involved in memory function; lesions of the hippocampus increase food 
intake but also appetitive behaviour in rodents [65]. Hippocampus fMRI activation correlated with 
cravings for food when healthy volunteers were asked to imagine the sensory properties of their 
favourite food [43]. A high concentration of insulin receptors are found in the hippocampus and 
increases in serum insulin concentration are associated with improvements in me mory function in 
patients with Alzheimer dementia [66]. 
Consistency amongst the published studies 
Even though each individual study on the activation of specific brain regions in response to food cues 
has provided useful insights on the involvement of brain reward systems in eating behaviour, it is 
also important to assess the reproducibility of these findings. A recent meta-analysis has examined 
studies in which food cues were presented as pictures, the most common method [67]. The highest 
rates of consistency for the contrast of food > non-food picture cues were obtained for clusters 
within the fusiform gyrus, the inferior frontal gyrus and the lateral orbitofrontal cortex (i.e. these 
areas were activated more by food compared to non-food pictures for the studies included in the 
metaanalysis [57, 68-82]). The highest rates of consistency for the contrast of hunger > satiated state 
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were obtained for clusters within the parahippocampal gyrus, amygdala, lateral orbitofrontal cortex 
and inferior frontal gyrus (i.e. these areas where more active in the hungry vs. the fed state for the 
following five studies [69, 73, 75, 82, 83]). The highest rates of consistency for the contrast of high-
calorie > low-calorie food were obtained for clusters within the hypothalamus and the nucleus 
accumbens/ventral striatum (i.e. these areas were more activated in response to high- vs. low- 
calorie foods for the following seven studies [30, 57, 70-72, 84, 85].  
Potential reasons for some of the differences between functional neuroimaging studies of eating 
behaviour are discussed in Section 1.2.4.2, page 85. The findings on the fusiform gyrus which is 
located in the visual association cortex suggest either that the food and non-food images are not 
well matched for colour and luminance, or that humans attend to them more as they are 
emotionally more salient [86]. 
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Figure 1.2: The brain reward system (3 dimensional top-down view, original artwork) 
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1.1.4 Signalling within the reward system 
The above mentioned areas do not act in isolation but are interconnected and signal to each other 
through specific neurotransmitters. Dopamine neurotransmission is important in mediating the 
appetitive reward value of food “wanting”, whereas opioids and endocannabinoids are thought to 
mediate the consummatory reward of food “liking” in animals [7].  
Dopamine  
The hedonic reward-based appetitive responses to obtain food are regulated by the mesolimbic 
system and dopamine is a major neurotransmitter in this network [14, 87, 88]. The major 
components of the dopamine system include the nigrostriatal, mesolimbic and tuberoinfundibular 
systems. The first is involved in motor control and originates in the substantia nigra and the ventral 
tegmental area which input to the dorsal striatum. The mesocorticolimbic system originates in the 
ventral tegmental area projecting to numerous areas including the nucleus accumbens, amygdala, 
central pallidum, dorsal striatum, hippocampus and frontal cortex. The tuberoinfundibular system 
originates in the hypothalamus and terminates in the pituitary where they control the  release of 
prolactin.  
The lateral hypothalamus regulates the motivation for food and motor outputs through connections 
with the nucleus accumbens whilst also responding to taste, smell, and sight of food from afferents 
from the thalamus and hindbrain and information on fuel stores from the arcuate nucleus and 
directly from the adipocyte hormone leptin [14, 87, 88]. Orexin neurons in the lateral hypothalamus 
form part of the striatum-hypothalamus-basal ganglia-striatum loop controlling the consumption of 
fatty foods [14, 87, 88].  
Opioids 
Opioid neuropeptides include enkephalins, dynorphins and endorphins which act predominantly on 
mu, but also kappa and delta receptors, to encode the consummatory reward of food [14, 87, 88]. 
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They are located in the brainstem, pons, nucleus accumbens, ventral pallidum, amygdala and 
prefrontal cortex [14, 87, 88]. They exert their effects in the nucleus accumbens and ventral 
tegmental area to increase food intake. In animals, stimulation of mu receptors in the  striatum and 
the shell of the nucleus accumbens increase the intake of sucrose and high fat food respectively [11]. 
The stimulation of the mu opioid receptors in the nucleus accumbens shell is also associated with 
positive orofacial reactions in the taste reactivity test [12]. In humans, systemic administration of 
non-selective opioid receptor antagonists reduces the preferences for sucrose, and pleasantness 
ratings for the taste of food [89]. Naltrexone in particular, reduces the latter independent of 
macronutrient composition [90]. Administration of the agonists buprenorphine and morphine 
increase and naloxone decrease food intake and the reward value of food in a progressive ratio task 
suggesting their role even in the control of the appetitive reward of food [91]. In a fMRI study, the 
administration of a mu opioid receptor antagonist reduced activation in the pallidum and putamen 
in response to high-calorie food pictures in obese adults with moderate binge eating disorder [92]. 
This was accompanied by a reduction in appetitive, but also an unexpected increase in 
consummatory, behavioural responses to high-calorie food.  
Endocannabinoids 
Endocannabinoids increase food intake through their effects on the hypothalamus, mesolimbic 
system but also the periphery [93]. The endogenous ligands anandamide and 2-arachydonlyglycerol 
act on cannabinoid-1 and 2 receptors in the cortex, hippocampus, amygdala, striatum and 
hippocampus. Cannabis and its active ingredient delta-9-tetrahydrocannabinol are known to 
increase food intake and preference for sucrose [93]. Cannabinoid-1 receptor stimulation increases 
the reinforcement of sweet, but not fat, food [94]. The administration of anandamide in the nucleus 
accumbens shell increases sweet taste reactivity [95]. The interaction between endocannabinoids 
and opioids has become apparent through the synergistic effects of the cannabinoid-1 and mu 
opioid receptors on the nucleus accumbens shell and striatum [96]. Rimonabant was a weight loss 
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medication that exerted its effects as an antagonist at the cannabinoid-1  receptor [97]. In a fMRI 
study of healthy normal weight volunteers, rimonabant (vs. placebo) reduced the activation of the 
orbitofrontal cortex and ventral striatum in response to the sight and flavour of rewarding foods and 
also reduced the activation of the caudate nucleus and ventral striatum to aversive food cues [98]. 
The medication was discontinued in 2008 in Europe due to the development or worsening of 
significantly high rates of depression and psychiatric illness during treatment [99].  
1.1.5 Peripheral signals 
1.1.5.1 Hormonal signals 
Glucagon-like peptide-1 
Glucagon-like peptide-1 (GLP-1) is a product of the cleavage of the proglucagon precursor, secreted 
by the L cells of the bowel together with PYY and oxyntomodulin with highest concentrations in the 
distal ileum and colon. Both GLP-17-37 and GLP-17-36 amide have similar physiological potency, but the 
latter is the major circulating form in humans [100]. GLP-1 acts on the GLP-1 receptor located in the 
hypothalamus, striatum, brainstem and substantia nigra, amongst other areas of the brain [101]. The 
30 amino acid peptide is released in response to a meal and decreases food intake through actions 
on the hypothalamus, but also through the vagus and brainstem [102]. It also slows down gastric 
emptying, inhibits glucagon release and acts on the pancreas to increase insulin secretion in a 
glucose-dependent manner (incretin effect) [103]. Administration of GLP-1 peripherally in rats 
increases c-fos expression (a marker of neuronal activation) in the arcuate nucleus [104], whereas 
intracerebroventricular administration increases c-fos expression in the area postrema, nucleus of 
the solitary tract and the periventricular nucleus [105]. GLP-1 infusions in humans reduce food 
intake in a dose dependent manner [106]. Administration of GLP-1 agonists in the form of Exenatide 
and Liraglutide decrease prospective calorie consumption and hunger ratings and long term 
treatment in obese patients with and without type 2 diabetes causes weight loss [103, 107].  
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Peripheral and central administration of a GLP-1 agonist (Exendin-4) in rats led to a reduction in the 
progressive ratio task response (appetitive reward) for sucrose and a reduction in the conditioned 
place preference for an environment previously associated with chocolate pellets [108]. These 
effects were centrally mediated, as administration of a specific GLP-1 receptor antagonist in the 
nucleus accumbens and the ventral tegmental area reversed these effects. GLP-1 also decreased the 
intake and appetitive responses to alcohol in rats, and the alcohol-induced release of dopamine from 
the nucleus accumbens [109]. In a recent fMRI study, intravenous infusion of GLP-1 in healthy, non-
obese adults led not only reduced ad libitum food intake but also to reduce activation across the 
brain reward system (amygdala, insula, caudate, nucleus accumbens, orbitofrontal cortex, and 
putamen) though this was only significant in the insula alone, in response to passive viewing of food 
pictures [110]. GLP-1 receptors are expressed on taste afferent nerve fibres and GLP-1 knockout 
mice are less responsive to low sucrose concentrations in a brief access test [111, 112]  
Oxyntomodulin 
Oxyntomodulin is a 37 amino acid peptide co-secreted by intestinal L cells together with GLP-1 and 
PYY in proportion to caloric intake [113]. Oxyntomodulin is anorexigenic, delays gastric emptying and 
has a weak incretin effect [114]. Administration of oxyntomodulin in obese humans reduces food 
intake (independently, but also additively to PYY) and weight [115, 116], and increases energy 
expenditure partly though its effects on the GLP-1 receptor, for which it has low affinity [117]. The 
effects of oxyntomodulin on food reward and the brain reward system have not been investigated as 
yet.  
Peptide tyrosine tyrosine 
Peptide tyrosine tyrosine (PYY) is a 36 amino acid peptide released from the L cells of the distal 
bowel in two forms, PYY 1-36 and PYY 3-36 (biologically active major form) and acts through the five Y 
receptors (Y1-Y5). Levels of PYY rise after a meal in proportion to the consumed calories, peak at 1-2 
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hours and stay elevated for a number of hours [118]. PYY 3-36 acts on the Y2 receptor found in many 
parts of the brain [102, 119]. It acts directly in the arcuate nucleus of the hypothalamus to decrease 
food intake [120], but also probably via vagal afferents terminating at the nucleus of the solitary 
track to signal satiety directly [104], but also indirectly via the parabrachial nucleus to the 
hypothalamus and the forebrain [121]. Administration of PYY peripherally increases c-fos expression 
in the arcuate nucleus and administration of PYY in the arcuate nucleus decreases food intake in rats 
[120]. Peripheral administration of PYY in rodents can also cause a conditioned taste aversion 
through activation of brainstem neurons [122]. In mice, taste cells produce PYY and chronic 
increases in salivary PYY can reduce food intake [123]. PYY has been reported to increase energy 
expenditure and delay gastric emptying [124]. Intravenous infusions of PYY reduce hunger ratings 
and food intake in both normal weight obese and humans [120, 125]. Co-administration of GLP-1 
and PYY in humans has additive effects in reducing food intake in normal weight humans [126]. 
In an early human resting state fMRI study (i.e. without specific cues), food intake was predicted by 
the degree of activation of the hypothalamus in the fasted state [127]. When PYY was infused 
intravenously, there were increases in the activation of the orbitofrontal cortex, anterior cingulate 
cortex, ventral striatum and for the orbitofrontal cortex this predicted subsequent food intake. The 
conclusion of this study was that PYY “moved” the control of food intake, from the homeostatic to 
the reward system. In a task-related human fMRI study, administration of PYY not only reduced ad 
libitum food intake but also reduced activation of the brain reward systems in response to food 
pictures in healthy adults [110]. Furthermore the combined administration of GLP-1 and PYY was 
additive in its reduction of food intake and activation across the brain reward system (amygdala, 
insula, caudate, nucleus accumbens, orbitofrontal cortex, and putamen) and in the insula in 
particular, in response to passive viewing of food pictures [110]. 
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Cholecystokinin (CCK) 
 CCK is a peptide produced by the I cells of the duodenum and jejunum particularly in response to fat 
and protein ingestion [128]. It has a short plasma half life of a few minutes, transiently decreasing 
food intake. It stimulates the release of digestive enzymes by the pancreas and gallbladder, 
increases intestinal motility and delays gastric emptying. CCK exerts its anorexigenic effects through 
the CCK1 receptor on the vagus nerve [129]. CCK receptors can also been found in the hypothalamus 
and brainstem [130]. Whilst infusions of CCK reduce food intake, intermittent prandial infusions 
reduce meal size but increase meal frequency in rats [131]. Clinical trials using CCK continuous 
infusions did not reduce food intake in humans [132].  
Leptin 
Leptin is a 167 amino acid hormone synthesized by adipose tissue which crosses the blood brain 
barrier through a saturable transporter mechanism. Leptin acts in the arcuate nucleus to increase 
expression of pro-opiomelanocortin  and decrease the expression of neuropeptide Y/agouti related 
peptide, and in the ventomedial hypothalamic nucleus to increase brain derived neurotrophic factor 
signalling [133, 134]. The end result is to decrease food intake and increase energy expenditure 
[135]. During weight and fat mass loss, leptin levels are reduced and this leads to increases in hunger 
and decreases in energy expenditure as part of a homeostatic negative feedback loop. Leptin is 
therefore one of the hormones that resist weight loss below the established set point [20].  
The nucleus of the solitary tract also contains leptin receptors and leptin may modulate the nucleus 
of the solitary tract sensitivity to feeding signals from the gut by acting synergistically to stomach 
distension, GLP-1 and CCK [87, 135]. It is unclear if leptin acts directly to the nucleus of the solitary 
tract or through projections from the arcuate nucleus. Leptin interacts with GLP-1 receptors in 
nucleus of the solitary tract; administration of the GLP-1 receptor antagonist exendin (9-39) blocks 
the reduction of food intake in animals that have been treated with leptin [136].   
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Leptin may act on dopaminergic neurons expressing the leptin receptor on the gateway to the 
mesolimbic system, the ventral tegmental area, to reduce food intake and the preference for 
palatable food through projections to limbic nuclei [137]. Leptin inhibits orexin neurons but not 
melanin concentrating hormone in the lateral hypothalamus [135]. Central administration of leptin 
inhibits dopamine release in the nucleus accumbens and suppresses the preference for high fat and 
sucrose [135]. Food restriction in mice increases the rewarding value of sucrose, while it is 
decreased by administration of leptin [138]. 
In obesity, leptin levels are elevated in proportion to fat mass, suggesting the presence of leptin 
resistance [139]. Support that this resistance contributes to the pathogenesis of obesity comes from 
studies in which rodents fed a high-fat diet develop a loss to leptin sensitivity in the arcuate nucleus, 
even after short periods of feeding [140]. Inflammation may be the cause of such disturbed 
signalling, even before the onset of obesity itself [141].   
Leptin administration to congenital leptin deficient obese adolescents and adults (due to leptin gene 
mutations) resulted in significant reduction of energy intake, weight loss and reduction in the 
activation of brain reward systems to food cues, including activation of the nucleus accumbens and 
dorsal striatum to food pictures [142], and activation of the insula and the temporal/parietal cortex 
to high-calorie foods [143]. In a fMRI study of obese, but not leptin deficient subjects, 10% weight 
loss through dietary means was associated with higher activation of brain reward systems, including 
the brainstem and parahippocampal gyrus, in response to food pictures compared to baseline [144]; 
leptin administration following weight loss reversed the heightened activation in these regions. In 
patients with lipodystrophy, in which plasma leptin levels are low, the suppression of activation in 
the amygdala, insula, nucleus accumbens and dorsal striatum in response to food pictures after a 
meal was lower compared to healthy controls, and this was reversed with leptin treatment [145].  
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Ghrelin 
Ghrelin is an acetylated 28 amino acid peptide produced by the X/A like cells in the fundus of the 
stomach which acts on the growth hormone secretagogue receptor to stimulate growth hormone 
secretion [146]. Inactive ghrelin (des acyl ghrelin) is activated to acyl ghrelin in the stomach through 
the action of the ghrelin O-acyltransferase enzyme [147]. Plasma ghrelin levels are highest when 
fasting and fall after eating, with carbohydrates having more of a suppressive effect compared to 
protein and lipids [148]. Ghrelin levels rise through the day and fall overnight [148]. It is probably 
released as a result of a sympathetically mediated cephalic response. Ghrelin stimulates 
neuropeptide Y/agouti related peptide neurons within the arcuate nucleus [149], but also through 
the vagus nerve and brainstem, to increase food intake and/or decrease energy expenditure [150]. 
In rodents, both central and peripheral administration of ghrelin increase food intake and body 
weight [151]. Conversely, administration of growth hormone secretagogue receptor antagonists in 
mice reduced food intake and body weight [152].  
Growth hormone secretagogue receptors are also located in the mesolimbic regions and highly 
expressed on ventral tegmental area dopamine neurons [153]. Central administration of ghrelin 
increases dopamine release from ventral tegmental area neurons that project to the nucleus 
accumbens and stimulates the intake of palatable food over normal chow [154, 155]. Peripheral 
treatments with a growth hormone secretagogue receptor antagonist decreased the preference and 
motivation selectively for both sweet and high-fat foods [154, 156-158]. Ghrelin interacts both with 
opioids and neuropeptide Y neurons; increases in appetitive responding for sucrose following central 
administration of ghrelin was blocked by mu opioid receptor and neuropeptide Y1 receptor 
antagonists [159]. For ghrelin to exert its central effects on food reward orexin and endocannabinoid 
signalling need to be intact [160, 161]. Ghrelin is also involved in the modulation of other 
behaviours; for example chronic stress in mice led to an increase in ghrelin levels, hyperphagia and 
conditioned place preference for high-fat diets, which is not seen in growth hormone secretagogue 
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receptor knockout mice [162]. Additionally ghrelin increases the reward value of non-food reward in 
rodents, for example to drugs of abuse and alcohol [163].  
In humans, ghrelin levels are high in patients with anorexia nervosa, heart failure cachexia and after 
diet-induced weight loss [164-167], whereas in obesity ghrelin levels are low and the fall in ghrelin 
after a meal is attenuated [168]. Following subcutaneous or intravenous ghrelin, humans increased 
their food intake in an ad libitum test meal, rated their hunger higher and found food more palatable 
compared to when administered saline [169, 170]. Administration of ghrelin also improves the 
detection, but not the hedonic value, of odours in rodents and humans [171]. 
In a human resting fMRI study (i.e. without a task), administration of ghrelin attenuated the dietary 
lipid-induced increased activation in the hypothalamus, brainstem, insula, parahippocampal gyrus 
and the thalamus [172]. In a fMRI study, supraphysiological bolus administration of ghrelin to 
healthy participants increased the activation of the brain reward system in response to food pictures 
[81]. Activation was increased in the amygdala, orbitofrontal cortex, anterior insula, and dorsal 
striatum, and in the first 2 regions activation correlated with hunger ratings. Outside the scanner, 
participants recognised the pictures shown during scanning much better after ghrelin infusion 
compared to when the pictures were shown under the control condition. This finding is in line with 
the effects of ghrelin in the hippocampus (in mice) to improve spatial learning and memory [173]. In 
an fMRI study of healthy non-obese volunteers performed by our group, the subcutaneous 
administration of ghrelin in healthy adults mimicked fasting to significantly increase the appeal of 
high-calorie foods, and associated orbitofrontal cortex activation [174]. Both fasting and ghrelin also 
increased hippocampal activation to food pictures. 
The administration of ghrelin in patients with cachexia due to heart failure, uraemia and cancer has 
yielded promising results to increase food intake and body weight [175-177].  A number of growth 
hormone secretagogue receptor and ghrelin O-acyltransferase enzyme antagonists are currently 
undergoing evaluation for the treatment of obesity [178]. 
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Insulin 
Insulin is produced by the β cells of the pancreas following a meal and its primary role is to maintain 
glucose homeostasis. However, it also enters the brain through a receptor-mediated transport 
process [179]. Insulin is also an anorexigenic hormone and may potentiate the effects of leptin at the 
arcuate nucleus and ventral tegmental area [180, 181]. Intracerebroventricular administration of 
insulin blocks the increase in neuropeptide Y induced by fasting in the arcuate and periventricular 
nuclei [182]. Insulin also affects the mesolimbic system through its receptors in the striatum and 
midbrain [183], as it has been shown to decrease dopamine tonic release in the striatum to 
attenuate the feeding responses caused by opioids in the ventral tegmental area [183]. 
Intracerebroventricular and arcuate injections of insulin not only reduce food intake, but also 
appetitive responses to sucrose in animals [184, 185].  Insulin resistance in obesity negates the 
anorexigenic effects of this peripheral hormone in rodents [183].   
Intranasal administration of insulin in healthy volunteers has been shown to improve the speed of 
detection of food (vs. non-food) pictures and to reduce associated activation of the hippocampus, 
temporal superior cortex, and frontal middle cortex in an fMRI study [186]. The intranasal 
administration allowed the absorption of insulin into the cerebrospinal fluid and reduced any 
systemic effects on glucose homeostasis [186]. Intranasal insulin administration also reduced resting 
state activity in the orbitofrontal cortex and hypothalamus of normal weight women [187], but also 
reduced peripheral insulin sensitivity simultaneously, perhaps through an indirect central effect 
[188].  
In an early fMRI study, administration of oral glucose resulted in a decrease resting state activity of 
the ventromedial hypothalamus and periventricular nucleus in normal weight volunteers, but this 
was attenuated in the obese [189]. In a 18FDG-PET study, the administration of low dose exogenous 
insulin resulted in increases in glucose uptake in the anterior cingulate cortex, prefrontal cortex, 
insula and ventral striatum and reduced glucose uptake in the amygdala and hippocampus [190]. In 
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participants with peripheral/hepatic insulin resistance, glucose uptake in the ventral striatum and 
prefrontal cortex was attenuated compared to insulin sensitive participants, suggesting increased 
central insulin resistance in the former group. In another PET study of lean and obese participants, 
which assessed the central availability of the dopamine DRD2 receptor using 18F-fallypride (a 
radioligand that competes with endogenous dopamine), insulin sensitivity was inversely associated 
with DRD2 availability in the ventral striatum [191]. The latter finding may suggest that the higher 
the insulin resistance, the higher the dopamine signalling in the ventral striatum leading to a “reward 
deficiency”-like syndrome. These studies may also explain in part why patients with type 2 diabetes 
mellitus and peripheral/central insulin resistance gain weight when exogenous insulin is added to 
their regimen; these patients may have diminished satiation and reward responses to food in the 
brain, while the higher levels of insulin still exert their anabolic effects in the periphery.  
Contrary to the reward and satiation deficiency syndrome hypothesis,  in a fMRI study of lean and 
obese subjects, resting activity in the orbitofrontal cortex and putamen did not correlate with BMI 
but correlated positively with fasting insulin levels [192]. fMRI activation of the striatum, insula and 
hypothalamus in response to favourite food cues was higher in an obese than lean group [193]. 
More importantly, the activity in these areas correlated with the Homeostasis Model of Assessment 
- Insulin Resistance in the obese but not the lean groups. Similarly, the activation of the insula and 
hippocampus in response to food pictures in an fMRI study of adolescents correlated with fasting 
insulin and waist circumference, but not BMI [194].  
Interestingly, the results of a study in which cerebral insulin sensitivity was measured indirectly 
(through insulin stimulated cortical activity using magnetoencephalography) suggested that the 
patients with a higher insulin sensitivity lost more weight and fat mass during a lifestyle intervention 
compared to those with lower insulin sensitivity at baseline [195]. 
Overall, and similar to the controversies in obesity, there are discrepancies in the above literature 
with some neuroimaging studies showing reduced glucose uptake (a surrogate marker for activation) 
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and others increases in fMRI regional activation in insulin resistant vs. insulin sensitive subjects. 
These may be due to the different paradigms and analyses used and limited inferences that can be 
made from neural correlates amongst other factors discussed in Section 1.2.4.2, page 85. 
Nevertheless, the further characterisation of obese patients based on their peripheral and even 
central insulin resistance, and not just BMI, is an important step forward in the understanding of this 
heterogeneous condition. Central insulin resistance may not only be important physiologically, but 
also a target for pharmacological modulation.  
1.1.5.2 Neuronal signals  
Taste system 
Taste buds are onion shaped groups of cells located on the tongue and palate [196]. Each bud 
contains 4 types of cell types. Type I cells envelop neural fibres and therefore work as glia [196]. 
Type II and III cells are taste receptor cells with a chemosensing function [196]. Type III cells synapse 
with intragemnal nerve fibres [196]. Type IV cells are responsible for proliferation and maintenance 
of a constant number of the appropriate cells [196]. The taste receptor cells have microvilli which 
come in contact with food in the oral cavity. Transmembrane proteins are the receptors for sweet 
(T1R2, T1R3), bitter (T2R), and umami (T1R1, T1R3), and initiate an intracellular cascade which 
results in neural signalling [197]. Taste cells are innervated by branches of the facial, 
glossopharyngeal and vagal nerves. Branches of the facial VII nerve innervate the anterior tongue 
and palate, those of the IX nerve innervate posterior tongue and pharynx, whereas the branches of 
the vagus nerve innervate epiglottis, larynx and oesophagus [196]. Dietary fats are sensed by Cluster 
of Differentiation (CD) 36, a fatty acid receptor and transporter, but also through their texture [198, 
199]. Signalling through the cranial nerves converge in the nucleus of the solitary track which then 
projects to the parabrachial nucleus (Figure 1.3). From there, third order neurons project either to 
the thalamus or the forebrain [198, 199].   
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The dorsal thalamocortical pathway originates from the medial parabrachial nucleus, synapses in the 
thalamus and terminates in the insula [198, 199]. The insula (primarily anterior) is the primary taste 
cortex and responds to the identity and intensity of the five prototypical tastes, but also viscosity, 
texture, temperature and capsaicin. The insula projects to the orbitofrontal cortex which is the 
secondary taste cortex, as it encodes the reward value of taste [198, 199]. It also encodes the 
reward value of flavour and taste due to multiple inputs from olfactory, somatosensory and visual 
neurons [198, 199]. The orbitofrontal cortex projects firstly to the striatum, cingulate cortex and 
medial prefrontal cortex providing necessary information that determine actual behaviour, and 
secondly to the lateral hypothalamus which determines autonomic responses [198, 199]. Satiety 
signals also affect the reward of taste and food through projections from the hypothalamus to the 
orbitofrontal cortex [198, 199]. The interaction of the orbitofrontal cortex with the lateral 
hypothalamus is key to the process of sensory specific satiety, i.e. the selective reduction in the 
appeal of a specific food when eaten to satiety, even before overall satiety for the whole meal has 
been reached [198, 199]. 
The ventral forebrain pathway originates from the lateral parabrachial nucleus and projects to the 
hypothalamus and the central and basolateral amygdala, amongst other limbic forebrain structures 
[198, 199]. The amygdala acts as an interface of the taste and dopaminergic systems. From the 
amygdala, projections to the other structures of the mesolimbic system, including the nucleus 
accumbens, anterior cingulate cortex determine ingestive behaviour [198, 199].  
From a functional point of view the 3 major domains of taste include [8, 200, 201]: 
a) sensory domain (detection i.e. is this taste sweet and if so how sweet is it?),  
b) hedonic domain (reward i.e. how much do I want and like this sweet taste?), and 
c) physiological domain (what happens when a tastant enters the oral cavity e.g. sweet taste in 
mouth results in salivation).  
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The hedonic domain can be further subdivided into the appetitive (effort elicited to get the reward, 
“wanting”) and consummatory (reward obtained when the tastant is in the oral cavity, “liking”) 
components. 
Figure 1.3: Taste pathways in primates  
 
 
 
(Adapted from Rolls ET [202]). The arrows represent neural connections/inputs. 
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1.1.5.3 Post-ingestive signals 
 
The investigation of the signals generated by nutrients even before absorption in the bl ood stream is 
an area which is expanding rapidly due to its high translational value.  Evidence so far has shown 
that gut wall enteroendocrine cells can sense the presence of intraluminal nutrients through “taste” 
receptors (e.g. T1R2, T1R3) [203, 204]. These receptors then generate an intracellular signalling 
cascade which has a number of effects, including the release of gut hormones and the absorption of 
nutrients [203, 204]. Therefore gut hormones can signal through the vagus to the brain very fast, 
even before these compounds can be detected in the portal vein or the rest of the circulatory 
system [203, 204]. This process provides the hypothalamus and brainstem with second to second 
information about a meal and allows them to adjust eating behaviour in a tightly controlled manner. 
The vagus not only relates information about nutrients or gut hormones but also about luminal 
pressure and distension [203, 204]. 
1.1.6 Integration of homeostatic and hedonic systems 
The homeostatic and hedonic networks that govern food intake and body weight are not 
anatomically or functionally distinct but continuously interact (Figure 1.4). This is facilitated by the 
functional connections between the hypothalamic, mesolimbic and cortical circuits but also by the 
peripheral metabolic peptides which exert their effects on targets within these circuits at multiple 
points in the brain [205]. For example, neurons originating from pro-opiomelanocortin within the 
arcuate nucleus project via thalamic nuclei to the anterior cingulate cortex and insula, and melanin 
concentrating hormone and orexin neurons in the lateral hypothalamus project to the nucleus 
accumbens and the cerebral cortex [205]. 
The interaction of the two systems can be further understood when examined in the context of 
hunger or caloric restriction. Indeed as mentioned in Section 1.1.3 page 30, hunger increases the 
appeal of food, in particular high-calorie food, and increases activation of brain reward areas 
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including the parahippocampal gyrus, insula, nucleus accumbens, amygdala, orbitofrontal cortex and 
inferior frontal gyrus in response to food and/or high-calorie food pictures compared to the sated 
state [30, 69, 73, 75, 82, 83]. 
In a fMRI study of obese, but not leptin deficient subjects, weight loss through dietary means was 
associated with higher activation of the brain reward systems, including the brainstem and 
parahippocampal gyrus, in response to food pictures, compared to baseline [144]. In a PET study, 
cerebral blood flow in the middle insula increased after tasting a liquid meal and decreased in the 
posterior hippocampus in obese participants, whilst no differences were observed in participants 
who had successfully lost weight (post-obese subjects) [206]. This prospective neuroimaging study 
therefore assessed whether the neural abnormalities associated with obesity are reversible with 
intentional weight loss and found that they were not. Such abnormalities may therefore make 
weight loss maintenance through dieting even harder for patients. Acute and chronic caloric 
restriction in adolescents was associated with increased fMRI activation in the anterior cingulate 
cortex, ventral medial prefrontal cortex, caudate and hippocampus in response to food images but 
also receipt and anticipation of receipt of a palatable milkshake [207]. By contrast, overfeeding for 2 
days attenuated fMRI activation of the insula in the hypothalamus and insula to appealing food 
pictures in lean participants, but not in “post-obese” subjects that had previously lost weight [78]. In 
terms of cognitive restraint, successful dieters exhibit higher blood flow in the dorsolateral 
prefrontal cortex after a meal compared to non-dieters [62, 208].  
A very low calorie diet in humans increased the rating of food hedonics using visual analogue scales 
but had no effect of appetitive reward to snacks as assessed by food reinforcement tasks [209]. 
Other human studies have however shown that the appetitive responses to high-calorie food in a 
progressive ratio task are increased after food restriction and that similar responses remain stable 
throughout a dieting period [210-213]. 
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Energy restriction for 15 and 18 weeks in obese patients led to increases in hunger and “desire to eat 
ratings” and decreases in fullness after a standard meal. Peripheral signals to the hypothalamus and 
reward centres are also at play. In a recent study, overweight and obese patients who underwent a 
10-week weight loss programme had significantly lower levels of leptin, PYY, CCK, insulin, and amylin 
and significant increases in ghrelin levels from baseline [167]. These differences persisted at one 
year, and were accompanied by significant increases in appetite and preoccupation with food that 
may contribute to the long-term failure of dietary restriction for weight loss [167]. Similar alterations 
in peripheral signals (including reductions in GLP-1) secondary to weight loss have been shown in 
other human studies [165, 214, 215].  
Food restriction and weight loss in rats leads to higher level of engagement with rewarding lateral 
hypothalamus stimulation, and the administration of leptin and insulin centrally reduces the 
rewarding efficacy of this stimulation in both lean and obese rats [216, 217]. Food restriction also 
leads to the augmentation of amphetamine or dopaminergic drug reward in rodents [218, 219]. In 
rats chronic food restriction is associated with increased stress and production of corticosteroids 
[220]. Weight loss in rats following exercise was associated with increases in the acceptability of 
palatable compared to unpalatable food [221].  
Overall, these studies suggest that weight loss leads to a heightened activation of both the 
homeostatic and reward controls of food intake in such a way as to make long-term weight loss 
maintenance difficult. The combination of higher cognitive restraint and pharmacological 
“assistance” in these maintenance efforts may increase the chances of successful outcomes.  
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Figure 1.4: Integration of the homeostatic and hedonic systems in the control of food intake 
 
 
1.1.7 Methodologies used to study eating behaviour 
Behavioural research is exceptionally difficult in humans and to a lesser degree in animals, due to 
the large variability even within the same organism from day to day, even when attempts have been 
made to keep all other factors and confounders constant. On top of this, eating behaviour research 
in humans is also affected by social desirability and the stigma associated with obesity. Nevertheless, 
eating behaviour research has been based for decades on verbal or written reports.  
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1.1.7.1 Behavioural methods in humans 
Total food intake and macronutrient composition can be estimated through the use of interviews or 
food diaries [4, 222, 223]. Whilst interviews can provide some quantitative information, this may be 
misleading as many participants forget what they have consumed, snacks in particular [4, 222, 223]. 
Therefore, interviews are more useful for qualitative data collection. Food diaries can provide much 
more detailed quantitative information as they are completed prospectively by participants. They 
are reflective of real life as they are not limited by the artificial standardisation of the laboratory. 
Their drawback is that by recording every meal, many participants start realising that what they are 
consuming may be too much or too unhealthy and this may affect their reporting [4, 222, 223]. The 
underreporting of caloric intake in the context of obesity (by about 20%) can be partially corrected 
through assessment of energy expenditure for each participant [224]. A more objective way of 
quantifying food intake is through laboratory experiments, in which the participants visit a 
designated unit and are offered an ad libitum meal under standardised conditions. Even though the 
latter is scientifically important, the laboratory environment can be very “sterile” and not 
representative of real life, during which humans eat together with others, in environments they have 
chosen and with the food they have chosen [4, 222, 223]. Nevertheless, the laboratory setting offers 
the opportunity of more detailed measurements including eating rate and bite size through the use 
of eating monitors. The assessment of food choices, as well as total food intake, is performed in a 
more reliable manner in “buffet” type experiments where many food options are available. 
Participants are videotaped eating and their food is weighed before and after consumpti on. This 
type of experiment has been shown to have good reproducibility in the laboratory or ecological (e.g. 
restaurant) settings [225].  
The assessment of the internal states of hunger, satiety and food reward is even trickier to study as 
it relies on individual interpretation of physiological signals [226, 227]. This increases variability 
dramatically, as minimum and maximum ratings have different meanings between humans. Visual 
55
analogue scales have been traditionally used to quantify these “appetite sensations”.  These have 
been based predominantly on pain research in which they are considered to be the gold standard. 
They are normally 100-200 mm horizontal lines accompanied by a question (e.g. How hungry are you 
now?) and the two anchors “not at all” and “extremely” on either side of the line. The coefficients of 
variation of these ratings can be significant, but this can be reduced through the use of means of a 
series of measurements and more specific questions [226, 227]. Validity is almost impossible to 
determine in the absence of a “gold standard”. However, when subsequent food intake in a test 
meal is considered as the standard, the mean of hunger ratings in the hours preceding it can have a 
25% predictive value [227]. The use of electronic systems in which participants record their ratings 
inside or outside the laboratory may be more practical and allow the collection of more data, but 
still suffer with the same interpretative limitations [226]. 
Categorical or Likert scales, instead of a continuous line, are equally divided in a number of distinct 
categories. The participant has to choose which statement in each category best described their 
sensation. Whilst this may limit variability, participants may not recognise the subtly differences 
between the categories or not agree with any of them [4, 222, 223]. Additionally, the difference 
between category 4 and 8 for example, does not imply a doubling of hunger or satiety. The use of 
labelled magnitudes scales may be more useful in this respect as these use categorical statements 
on an actual visual analogue scale line in a quasilogarithmic format [228]. These scales have been 
used extensively in taste intensity research and further discussed in Section 1.2.4.3, page 86.  
The use of biomarkers like ghrelin, GLP-1 or other gut hormones may be a promising and objective 
way of studying the internal state compared to verbal report. Their use in eating behaviour research 
has not been tested for validity or reliability as yet.  
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1.1.7.2 Behavioural methods in animals 
Food intake can be readily measured in rodents and in the absence of experimentation remains very 
consistent from day to day and even from animal to animal [229]. Food preferences can also be 
assessed in a simple manner through the use of two or more bottle/food preference tests. In these a 
number of diets can be placed in the hopper and the measurement of consumption reflects the 
preference of the animal compared to a control diet, which is normal chow in most experiments. The 
investigator needs to swap the position of the diets in the hopper to avoid a position preference and 
ensure that enough diet is available to avoid ceiling effects. This methodology only provides 
information of overall preference but does not give an indication of the underlying mechanisms. 
Appetitive and consummatory responses can be studied further and when small amounts of stimuli 
are used, they lend themselves to investigation of the contribution of taste to the overall preference. 
The progressive ratio task was developed in 1961 and assesses appetitive responses [230]. The 
animal is required to press a lever in order to obtain a reinforcer (or “reward”). The lever pressing 
requirements can be adjusted so that they progressively increase, requiring the animal to exert 
increasing amounts of work in order to obtain the reinforcer. The point at which the animal stops 
pressing is called the “breakpoint” and presumably is the point at which the effort required to obtain 
the reinforcer is too great relative to reinforcing efficacy of the stimulus. The breakpoint is there fore 
is a marker of the rewarding value of the stimulus. Concentration-response curves can also be 
performed. 
The taste reactivity test measures consummatory responses [229]. Liquid stimuli can be delivered in 
the oral cavity of the animal through a cannula and the facial reactions are videotaped and analysed 
by the investigator. These facial reactions can be classified into either ingestive/”positive” (i.e. 
tongue protrusions, paw licking in response to sweet) or aversive/”negative” (i.e. gapes, chin rubs in 
response to bitter). Concentration-response curves can also be performed. 
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The brief access test measures both appetitive and consummatory taste responses and takes place 
in an apparatus called a “Davis rig” [229]. The animal is presented with taste stimuli for a short 
period of time (e.g. 10 seconds). The appetitive part of the test measures whether the animal will 
approach the device’s spout to obtain the stimulus. The consummatory part of the test measures 
the number of tongue protrusions in the 10 second period. A number of concentrations can be used 
in the same trial allowing and the number of trials can be increased to improve the estimate of 
responsiveness.  
1.1.7.3 Neuroimaging methods 
Neuroimaging has been the most recent and exciting development in the study of behaviour in the 
last 2 decades as it allows the direct or indirect measurement of activation the brain in the living 
human. Whilst its resolution and interference from physiological parameters such as cardiac and 
respiratory cycles and head motion can make the assessment of hypothalamic or brainstem 
activation troublesome, the activation of reward and cognitive systems is much more readily 
performed and this has greatly advanced the field of eating behaviour. In neuroimaging protocols, 
the participant can be exposed either to no task (resting brain activity) or to food cues including 
pictures, odours or tastants and the objective response to these stimuli can be quantified with good 
temporal and anatomical resolution. The basic principles of the two main neuroimaging techniques 
used in humans are outlined below to allow comprehension of the rest of the thesis. They are based 
on information provided by a combination of fMRI textbooks [231], and the Functional MRI of Brain 
Software Library (FSL) course material [2].  
Principles of MRI 
MRI uses the physical characteristic of the hydrogen nucleus (proton) to detect a signal. Hydrogen 
nuclei have two basic characteristics: they behave like magnets and spin around themselves (Figure 
1.5). In the scanner a magnetic field called B0 is applied in the same plane as the patient and 
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directed towards their head (the z plane). This makes the protons align with the field, whereas 
before they were randomly orientated (Figure 1.5). At this stage, each proton oscillates in the field at 
its own “resonance frequency”. Extra magnetic fields can now be applied perpendicular to the B0 
field (at the x, y plane) and their effect is to disturb the alignment of the protons with B0 and give 
them energy (i.e. “excite” them). The maximum amount of energy can be achieved by introducing 
this extra field at the frequency of the protons and in pulses (i.e. switching it on and off, very much 
like pushing a child in a swing at a specific frequency, the radiofrequency pulse). When the 
radiofrequency pulse is off, the protons, and their net magnetic moment, will then “relax” into 
alignment with B0 and whilst doing so they emit the absorbed energy. It is this emitted energy that 
is sensed by the receiver coils and converted into an image. The time taken for the protons to realign 
with B0 is called T1 and the time taken for the protons’ energy to decay in the x, y plane is called T2. 
The major determinant of T1 and T2 is the proton density of the tissue being imaged. By altering the 
timing of the successive radiofrequency pulses, and therefore the T1 and T2 times, the image can be 
“weighted” to either T1 or T2 and this will enhance the properties of the tissue under investigation.  
 
 
 
 
 
 
 
 
 
59
Figure 1.5: Magnetic moment of hydrogen nuclei 
 
Behaviour of the hydrogen nuclei at rest (when no external field is applied) and when magnetic field (B0) is 
applied. Figure taken from FSL course with the kind permission of Prof. Stephen Smith  
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Principles of functional MRI  
fMRI uses similar principles to structural MRI, but also uses changes in blood flow as a contrast agent 
(Figure 1.6). Oxyhaemoglobin is diamagnetic, has magnetic properties similar to surrounding tissue, 
whereas deoxyhaemoglobin is paramagnetic. When a region of the brain is activated (e.g. in 
response to any stimulus) it becomes metabolically active and consumes more oxygen than when it 
is at “rest”. To compensate, the local vasculature increases the blood flow and therefore oxygen to 
this region. This increases the oxygenated/deoxygenated haemoglobin ratio near the activated 
tissue, with the net result of a decrease in the perturbation of the local magnetic field and an 
increase in the blood oxygen level dependent (BOLD) signal from this region. The signal is sensed by 
the receiver coils and converted into a T2* weighted image, which will have a higher intensity 
compared to another brain region which is not active and has lower intensity. A digital image is a 
matrix composed of “pixels” which correspond to a particular anatomical position. In three 
dimensions, pixels become “voxels” which are boxes (normally square in shape) containing neurons. 
The most common fMRI protocols detect not absolute, but relative, changes in the BOLD signal; 
from the “resting” baseline to the signal generated from a specific stimulus. The resting activation is 
inherently unstable within and between subjects in fMRI experiments. To compensate for this 
activation is always assesses as a contrast of two stimuli, i.e. the difference in the activation elicited 
in response to stimulus we are examining and the activation elicited in response to a control 
stimulus. The haemodynamic response function in response to a stimulus can be seen in Figure 1.6. 
The change in the BOLD signal is only in the order of 1-4% and therefore any fMRI protocol should 
attempt to maximise the signal detection and minimise “noise”, i.e. improve the signal to noise ratio. 
Processing of the reconstructed images even before statistical analysis plays an important role and is 
normally achieved in a specific order.  
 
 
61
Figure 1.6: Blood oxygen level dependent effect and the haemodynamic response function 
 
At the top of the figure the response of the brain circulation is shown as a response of increasing oxygen 
demands when a specific brain region is activate (e.g. from a specific cue). This process gives rise to the 
haemodynamic response function which is shown in the bottom right of the figure.  HbO 2: oxygenated 
haemoglobin, Hbr: deoxygenated haemoglobin, CBF: cerebral blood flow, CBV: cerebral blood volume, CMRO2 
cerebral metabolic rate for oxygen, MRI: magnetic resonance imaging, BOLD: blood oxygen level dependent. 
Figure taken from FSL course with the kind permission of Prof. Stephen Smith 
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Brain extraction: This is performed automatically by the analysis software (e.g. FSL), which segments 
tissue into brain and non-brain and “extracts” only the brain tissue from the image (Figure 1.7). 
Figure 1.7: Brain extraction function in FSL 
 
The FSL software recognises the differences in intensity between brain and non-brain tissue and automatically 
extracts only brain tissue for the purposes of the subsequent analysis. Figure taken from FSL course with the 
kind permission of Prof. Stephen Smith 
 
Motion correction: Head motion happens between every MRI volume and so each echo planar 
image needs to be realigned to a common reference to allow consistent analysis. The FSL software 
corrects for motion between volumes by aligning each image to one image in the series e.g. the first 
or middle volume. There is no agreement on motion cut-offs for fMRI scanning so each investigator 
uses their own. However, the FSL software alerts the user when the average relative motion 
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(between volumes as opposed to overall absolute motion over the whole scan) exceeds >0.5 
mm/repetition time. Any motion causes artefacts and a large degree of relative motion causes more 
problems with processing and interpretation of activation compared to absolute motion. The degree 
of motion for each volume can be entered as a covariate in the general linear model as discussed 
below. 
Slice timing correction: Each brain slice is acquired separately at slightly different time points. There 
are a number of ways to correct for this, for example by shifting the data through the process of 
“interpolation” before analysis or by adding the temporal derivative of the haemodynamic response 
function x stimulus onset interaction as a co-variate of no interest in the general linear model 
analysis.   
Field map unwarping: Signal loss due to magnetic disturbances can take place in regions where air 
and brain are close (e.g. air-tissue interface between the frontal lobe of the brain and the frontal 
sinus). To minimise signal loss in the regions the image can be acquired in a specific tilt [232]. 
However, echo planar images can still be distorted in these regions even if signal has been acquired. 
This can be partially corrected by including a fieldmap scan (Figure 1.8). This acquisition allows 
detection and estimation of the B0 field map distortion, unwarps the echo planar image and also 
“deweights” areas with substantial signal loss during registration. The fieldmap therefore allows for 
better registration with the structural image, and recovery of some signal loss in areas such as the 
medial orbitofrontal cortex and lateral temporal cortex. 
Spatial filtering/smoothing: This is performed so as to increase the signal to noise ratio, improve 
registration and to allow the data to fulfil the criteria for the Gaussian random field theory for 
thresholding. Each voxel’s intensity is replaced by the average intensity of neighbouring voxels 
through a 2 dimensional process of convolution. The space over which this takes place is defined by 
the full width half maximum, which is the full width of the Gaussian curve at the point of the half 
maximum activation. This is typically 6-8 mm for voxel dimensions of 2-3 mm2. 
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Temporal filtering/smoothing: The BOLD signal across time in a voxel can be affected by low 
frequency drifts that may be the result of physiological function (e.g. respiration) or high frequency 
noise. This can hide activation and can be minimised through the use of high-pass or low-pass filters. 
High-pass filters remove low frequency noise and linear trends e.g. due to heating up of scanner 
coils; whereas low pass filters remove high frequency noise.  
Global intensity normalisation: The mean intensity of the whole dataset between subjects changes 
between sessions due to confounders that we do not want to affect our results (e.g. caffeine levels 
after coffee). Through normalisation and scaling, the overall signal mean is kept constant across 
sessions. 
Registration: This refers to the “alignment” of voxels from different MRI modalities and differe nt 
participants with different brain sizes and shapes, so that they can be analysed consistently. For 
example the functional images from the same participant during a scan need to be aligned with each 
other (due to head and brain motion), with the anatomical images from the same subject, and also 
with all the other images from other participants of a group study, onto a standard space. This 
standard image or “space” with widely accepted stereotactic coordinates is the Montreal 
Neurological Institute space which was created on the basis of 152 scanned brains and has now 
superseded the Talairach coordinates system. 
To achieve registration, images need to be transformed. This can be achieved in a number of ways 
that are described by degrees of freedom, i.e. how many movements are needed to achieve 
registration. Rigid body transformations are used for within-subject registration during a scan and 
include 6 degrees of freedom; 3 rotations and 3 translations (e.g. motion correction and alignment 
of low resolution echo planar images and high resolution T1 anatomical images). Affine 
transformations have 12 degrees of freedom; 3 rotations, 3 translations and 3 scalings and allow for 
lower quality registration. Non-linear transformations have more than 12 degrees of freedom and 
are used for the acquisition of high quality images. Cost-function measures the “goodness” of the 
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alignment and should be kept to the minimum. In FSL, the extracted echo planar T2* images are 
registered onto the first or middle echo planar image, and then registered onto the subject’s 
anatomical T1 image through a linear transformation with 6 degrees of freedom. This is then 
registered to the standard Montreal Neurological Institute space using non-linear transformation 
using more than 12 degrees of freedom.  
Figure 1.8: Use of the fieldmap 
 
The top image is the echo planar image showing signal drop in the frontal lobes of the brain. The bottom 
image shows the unwarped echo planar image after the fieldmap correction. Figure taken from FSL course 
with the kind permission of Prof. Stephen Smith 
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fMRI processing and statistical analysis  
General linear model 
Following pre-processing, the analysis of fMRI data can be performed. The processing from 
individual data and up to group comparisons takes a specific format in FSL. For each subject the raw 
activation of specific voxel in the brain in response to a specific stimulus is averaged across a single 
scanning session. These “descriptive statistics” about activation for each individual subject are then 
passed on to the group level and then allow comparisons between groups. For robust comparisons, 
the analysis for each group should be “mixed-effects” which means that the mean activation 
incorporates the mean activation of each subject and the variance incorporates variance across all 
subjects of the group, not within each subject of the group (fixed effects). The general linear model 
allows comparison between two or more groups, very much like a t-test, analysis of variance or 
analysis of covariance analysis outside fMRI analysis. 
Before analysis, a general linear model is set up in FSL to describe what the BOLD signal (surrogate of 
activation) in response to the stimuli of our experiment should look like based on our hypothesis (for 
example that BOLD signal takes place when a food image is shown/”on” compared to when it is 
shown/”off”), (Figure 1.9). The analysis software then assesses how well the observed BOLD signal 
“fits” to the model and provides a measure of goodness of fit (parameter estimate or β; if  β is not 
zero then this suggests that the voxel is activated by the stimulus).  
It is very unusual for the BOLD signal in the voxels to fit our model 100% and therefore there is 
always some variance or residuals around this best fit. By adding covariates,  or explanatory 
variables, within the general linear model, we are trying to make our data fit better to the model, 
therefore reducing noise and residuals. These covariates are usually confounds that may affect 
activation (and therefore our result), other than the stimulus under question. By adding these 
covariates and “correcting” the activation of our groups for the presence of this factor, we manage 
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to reduce the variation around the two groups, making the general linear model more likely to give 
us a statistically significant result. For example if we are comparing the activation of two groups in a 
fMRI task we may end up with groups that have different mean age. If age has an effect on 
activation, independent of the task, the presence of a difference in age between the groups can 
affect our results. By adding the age as a covariate in the general linear model we can correct for 
this. Other covariates that can be included in the general linear model are the motion parameters 
(i.e. degree of motion for each volume during scanning). Temporal derivatives can also be added; 
this is the differential (i.e. rate of change) of the predicted BOLD response. As there may be a small 
difference between the timing of the cue presentation and the haemodynamic response function 
related to slice timing and delayed responses in different brain regions, the addition of the temporal 
derivative in the model allows for better “fit” of the data on a voxel by voxel basis.  
Figure 1.9: Modelling of the haemodynamic response function 
 
In the general linear model, we predict the neural activity based on our hypothesis by assuming that the neural 
activity increases when our cue is “on” and goes back to baseline when the cue is “off”. The analysis software 
then integrates the haemodynamic response function (the predicted change in BOLD signal to a single stimulus 
as a result in changes in blood blow and oxygenation) with the onsets of the stimuli to see how well the 
observed BOLD signal “fits” to the model to provides a parameter estima te. Figure taken from FSL course with 
the kind permission of Prof. Stephen Smith 
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The absolute magnitude of the BOLD signal in response to a cue is of limited interpretative value as 
the baseline (i.e. the signal when the cue is “off”) fluctuates. Therefore meaningful comparisons can 
only be made from the difference in BOLD activation, or contrast, between 2 different cues (e.g. the 
difference in BOLD signal in response to food vs. object images). The software examines each voxel 
separately and tries to find which voxels fit to the direction of the contrast best and assigns each 
voxel with a t-statistic which is a measure of “fit”.  The t-statistic is then converted to a Z statistic. By 
thresholding our experiment with a specific Z-statistic cut-off, we provide some statistical meaning 
to our data and therefore make inferences only from the voxels that best fit our model. For example, 
if we use a Z>1.7 cut-off (equating to an approximate p value of <0.05) we can be certain that the 
voxels that are coloured in our screen are statistically significantly activated (as they “survived” the 
thresholding), whilst accepting that <5% of them will be falsely positive active/coloured. 
Whole brain analysis 
As the brain contains >100,000 voxels and these are individually compared with our model we can 
end up with a large number of false positive activations (or family wise error rate) due to the 
problem of multiple comparisons. Even though there are a number of fMRI papers published with 
data that have not been corrected for multiple comparisons, it is strongly recommended that 
statistics incorporate a correction for multiple comparisons. This can be done with the Bonferroni 
correction which means dividing our statistical threshold by the number of comparisons (or voxels) 
and ending up with a new corrected statistical threshold. This method is very stringent and unlikely 
to yield any positive results in fMRI experimentation. The Gaussian random field theory is a complex 
mathematical method which however is less strict than the Bonferonni correction and incorporates 
the activation of a cluster, or collection of voxels, based on their anatomical proximity. Another 
method is to use a statistical threshold not for each voxel separately, but for a cluster of voxels, 
anatomically contiguous group of voxels. Even though each of these voxels may not have survived 
the statistical thresholding in a voxel based analysis, as a group they survive. This methodology also 
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makes more “physiological sense” as a specific region of the brain, rathe r a specific voxel, tend to 
respond together to a specific stimulus. Finally, a widely acceptable and popular method is the 
correction for the false discovery proportion, i.e. the fraction of observed activated voxels (or 
clusters) that are false positives (false discovery rate). This method ensures that “on average” across, 
but not within, comparisons the false positive proportion will not exceed a specific number (e.g. 5 or 
10%). The choice of statistical method may depend on whether there is widespread activation in a 
task or a more selective number of clusters. 
Region of interest analysis 
As mentioned in the above section, whole brain analysis does not provide information about the 
magnitude of activation, but only the anatomical areas in which activation is statistically different 
when comparing two groups for example. Region of interest analysis provides measurable activation 
data and also decreases the problems of multiple comparisons by limiting analysis to pre-defined 
areas. These areas should be defined a priori based on a hypothesis and data from previous studies, 
and not based on the results of the current study. The regions of interest can be defined based 
purely on anatomical data acquired from atlases or a combination of functional and anatomical data 
(i.e. the combination of activation from a previous experiment/different group and anatomical 
coordinates from an atlas). The activation in these regions of interest is then “extracted” separately 
for each subject and each group by the fMRI software and the data is used to perform statistical 
comparisons outside the fMRI software, in conventional statistical packages. It is important that the 
ROIs are defined carefully as choosing large areas may “dilute” the effect of any activation. Other 
methods incorporate the activation only around the voxel with the maximum activation.  
Positron Emission Tomography (PET) imaging 
This type of imaging utilises radioactive tracers that can provide information about cerebral blood 
flow, glucose uptake, neurotransmission and neuroreceptors [233]. Cerebral blood flow or glucose 
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uptake are both surrogate markers of neuronal activation. The tracers commonly used include H2
15O 
for the assessment of cerebral blood flow and 18F-fluorodeoxyglucose for glucose uptake. These 
tracers decay by emitting positrons which collide with surrounding tissue electrons [233]. This 
collision is sensed as signal by detectors placed around the brain. Similar to fMRI the signal can be 
processed and registered on a high-resolution MRI anatomical image in order to improve anatomical 
localisation of its source. The main problems with PET scanning are its costs, exposure to radiation 
and lower spatial and temporal resolution compared to fMRI [233].  
 
1.1.8 Summary of the introduction section 1.1 
 The study of eating behaviour is challenging, in humans in particular, but highly important for 
the understanding of the causes and the development of treatments for obesity. 
 The integration of the homeostatic and hedonic control of food intake takes place in the brain 
and is influenced by numerous physiological, psychological and social signals. 
 Physiological signals arise from the periphery and include hormonal and neural messaging from 
the gut in response to nutrients.  
 Eating behaviour can be optimally studied through the use of multiple complimentary 
behavioural and neuroimaging techniques in humans and animals. 
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1.2 Potential causes of obesity  
Human obesity appears to be the result of the combination of genetic, physiological, environmental, 
sociological and psychological factors (Figure 1.10). This makes this condition very heterogeneous 
and more difficult to study. It is even more challenging trying to identify whether the physiological 
changes observed in obesity are causes or indeed effects of the condition itself.  
Figure 1.10: Factors contributing to weight gain and/or obesity 
 
The physiological, environmental and personality-specific factors do not act in isolation but interact with each 
other. 
 
1.2.1 Genetics 
Heritable factors, including the effects of both genetics and epigenetics, account for ~70% of the 
variation of BMI in humans [234]. There are very high correlations in BMI between related 
individuals; 15% for first cousins, 25% for parent-children and siblings and 80-90% for monozygotic 
twins [235].  Mutations in single genes or deletions involving genes encoding proteins involved in the 
homeostatic and hedonic control of food intake have been identified. These include the genes 
encoding for leptin, leptin receptor, prohormone convertase 1 involved in the processing of insulin 
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and pro-opiomelanocortin precursors, melanocortin receptor 4 and pro-opiomelanocortin, brain 
derived neurotrophic factor (WAGR syndrome: Wilms tumour, Aniridia, Genitourinary abnormalities 
and mental Retardation), TrkB (brain derived neurotrophic factor receptor), and several genes in the 
Prader-Willi syndrome region including the small nucleolar ribonucleic acid cluster SNORD116, 
leading to increased hunger, lower fullness and/or energy expenditure, and profound obesity and 
hyperphagic phenotypes. Melanocortin receptor 4  mutations are the most common disorder and 
present in 1-6% of obese individuals [236]. Melanocortin receptor 4 variants are associated with 
higher hunger, lower fullness, and increased fat intake and snacking [237].  
Genome wide association studies have led to significant breakthroughs in the identification of genes 
contributing to polygenic obesity or “common obesity” identifying associations with single 
nucleotide polymorphisms that are more common than monogenic defects, but contribute less to 
BMI, and may not necessarily be pathogenic in themselves [238]. The fat mass and obesity-
associated gene (FTO) has the largest effect size on polygenic obesity (~7% of BMI or 0.5 kg) as it is 
associated with higher hunger, lower fullness after a meal, higher fat intake in children and adults 
[238-240]. The mechanisms through which the FTO variants lead to these behaviours is still unclear, 
but an effect in the hypothalamus and the leptin signalling pathway is likely as FTO is expressed 
there. Recently discovered genes (SH2B1, KCTD15, MTCH2, NEGR1 and brain derived neurotrophic 
factor) are associated with differences in dietary intake and with nutrient-specific food preferences 
independently of BMI [241]. The interaction of genetics with the environment has also received 
significant attention in the last decade. In obesity for example exercise can blunt the effects of FTO 
or 12 other obesity associated single-nucleotide polymorphisms on BMI by 40% [242]. On the other 
hand, there are other factors that can increase the effects of these genes. These include a low 
education, female gender, age and Pima Indian, eastern Asian or Korean ethnicity [243].  
In neuroimaging studies of eating behaviour the effects of variants in the dopamine D2 receptor 
(DRD2) have been studied in some detail. Subjects with the A1 allele of the TaqIA restriction 
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fragment length polymorphism near to DRD2 have up to 40% fewer DRD2 receptors in their striatum 
[244]. This not only increases their predisposition to weight gain but also the risk for addiction to 
alcohol and drugs of abuse [245-247].   
1.2.2 Environment 
The recent obesity epidemic cannot be explained by changes in genetics, as the time span is too 
short. Instead, in the last 20-30 years it is the environment that has changed, mainly in industrialised 
countries. In the modern food environment, processed food is more palatable and energy dense and 
these result in weight gain. There is greater variety of food which can overcome the innate sensory 
specific satiety mechanism leading to overeating during a meal [202]. Humans tend to eat at fixed 
meal times even if they are not hungry or “graze” between meals [248]. Food is more prominent and 
advertised, thus increasing its salience. The cost of high-calorie processed food has decreased whilst 
the cost of healthier food choices have bizarrely either stayed the same or even increased. Portion 
sizes have also increased and this leads to overconsumption [249]. With faster lifestyles, meals are 
also faster, with the net results of lower production of satiety gut hormones and an overall higher 
caloric intake during a meal [250]. The contribution of the above has resulted in a 200-250 
kCal/person/day increase in energy intake in the last 25 years [251]. On the other side of the energy 
balance equation, there is decreased requirement for energy expenditure [252]. This is the result of 
better means of transportation, machines available to do household chores and manual labour, and 
information technology allowing us to perform a number of daily activities from home and even at 
higher room temperatures during the winter. It should be noted that once obesity develops, energy 
expenditure increases due to the presence of higher amounts of lean mass which is necessary for 
the support of the higher fat mass [253].   
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1.2.3 Psychological factors 
Personality-specific psychological traits are increasingly recognised as important contributors to 
disordered eating behaviour and overeating. Dietary restraint refers to “the concepts around the 
purposeful restriction of food intake to control one’s image or prohibit weight gain” [4, 254]. Rigid 
restraint refers to the use of very robust and strict rules regarding dieting, whereas flexible restraint 
refers to a more varied way of responding to environmental or emotional situations. Rigid dietary 
restrainers are at higher risk of overeating and more likely to respond to factors that allow them to 
violate their strict dietary rules [4]. On the other hand, flexible restrainers are much more likely to 
avoid weight gain, more successful at losing it but also more likely to be depressed, pre occupied 
with their body image, and have a lower self esteem and emotional stability. Questionnaires such as 
the Dutch Eating Behavior Questionnaire can be used to measure dietary restraint, emotional and 
external eating [255, 256]. It has been shown to be more internally consistent and reliable across 
subjects of different weight and gender compared to other questionnaires [257]. The Eating Disorder 
Examination Questionnaire can measure dietary restraint, preoccupation with weight and shape, 
and binge eating [258]. In a metanalysis of published studies it has been found to be reliable in 
distinguishing cases with and without disordered eating [259]. 
 
Stress is another stimulus for the overconsumption of energy dense food, both in animals and 
humans [254, 260, 261]. Emotional eating refers to the coping mechanism whereby the individual 
deals with low mood, anxiety or stress by consuming more fatty and sweet foods [4]. These foods 
have been shown to increase opioid and serotonin neurotransmission in the brain and therefore act 
as mood enhancers [9].  Negative affect as assessed by the Positive and Negative Affect Schedule has 
been shown to be associated with obesity [262]. The Beck Depression Inventory can be used to 
identify symptoms of depression and has been used extensively in the context of obesity [263-265].  
Disinhibited eating refers to any stimulus which distracts and leads to eating more than usual and 
thus weight gain [4]. These stimuli can be either external or internal. Impulsivity is another trait that 
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may contribute to disinhibited eating and refers to the initiation of eating for immediate 
gratification, but without considering the long term consequences [4]. Higher impulsivity and 
delayed discounting (the inability to resist a small immediate reward instead of a larger reward that 
will be available in the future) are also associated with overeating [266, 267]. The Barratt Impulsivity 
Scale has been used as a tool to reliably measure impulsivity in the context of obesity and binge 
eating disorder [268, 269]. Finally, the inability to resist external sensory cues to eat (e.g. palatability, 
smell), described as “external” eating, is another personality trait associated with higher body 
weight [4]. All the above psychological entities do not work in isolation. Instead, they interact in the 
same individual and have additive or synergistic effects.    
1.2.4 Physiological factors 
1.2.4.1 Hunger and satiation 
Surprisingly, there is very little evidence in the literature to suggest that hunger levels are different 
between obese and lean humans. Most evidence comes from surrogate markers of appetite, like gut 
hormones. For example, whilst plasma ghrelin levels are negatively correlated with BMI, the fall in 
ghrelin levels after a meal are lower in the obese [165, 270, 271]. There is again disagreement as to 
whether fasting levels of PYY are lower in obesity, whereas the rise in PYY, GLP -1 and ratings of 
satiation are blunted after a meal in obese individuals in some studies [272, 273]. This suggests that 
hunger levels may be lower in obesity, but it is fullness/satiety that is impaired.  
As discussed in Section 1.1.7.2 page 57, the assessment of total caloric intake in obesity is 
challenging in view of the social desirability bias in the responses of obese subjects [224, 274]. The 
consequent underreporting in food diaries can be partially corrected through measurements of 
energy expenditure [224]. When this is done, obese subjects do indeed consume more calories, than 
normal weight subjects [275]. In some, but not all, laboratory experiments, the obese eat more 
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calories, in absolute terms, compared to normal weight controls during a laboratory test meal and 
eating rates have been shown to be faster in the obese [276-280].  
1.2.4.2 Food reward 
Food preferences  
A number of epidemiological and small case-control studies over the last 60 years have attempted to 
address the question of whether obese people consume diets higher in fat and/or sugar. The 
methodologies used included dietary records, interviews, dietary recall, actual weighed consumption 
and food frequency questionnaires. Their results are summarised and referenced in Table 1.1.  
There are a number of inconsistencies in the published literature. Nevertheless, some patterns start 
to surface. The first is that the relative consumption of carbohydrates (compared to protein and fat) 
may be lower in the context of obesity, independently of whether it is expressed as percentage of 
energy intake, glycaemic index or glycaemic load. By contrast, the reverse appears to be the case for 
the relative consumption of fat which may be higher in obesity. In fact, the higher consumption of 
fat correlated in many studies with the subsequent development of obesity. These results should be 
considered with some caution, as comparative studies are not always consistent and are prone to 
responder and publication bias and the limited cause-effect inferences that can be made from 
epidemiological studies.  
Behavioural testing 
The higher consumption of fatty food described in the above section provides only limited indirect 
evidence to the notion that this type of food has higher reward value in the context of obesity. More 
robust evidence has been provided by paradigms incorporating behavioural tasks. Leonard Epstein 
has led the way in the study of human ingestive behaviour using behavioural experiments rather 
than subjective ratings. He used the progressive ratio task, in which participants have to work 
progressively harder to obtain different reinforcers, i.e. high-calorie vs. low-calorie foods. The 
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breakpoint is the maximum amount of work performed to obtain a reinforcer and provides a 
measure of the relative reinforcer efficacy. The task had been used for decades before in animal 
experiments following the first publication by Hodos in 1961 [230].   
When used to compare obese vs. lean women, Epstein showed that the obese worked harder to get 
palatable food instead of other activities [281]. Using computer software in which children have to 
work to obtain either appetising food or other activities (e.g. playing a video game, reading a 
magazine), overweight children worked harder to get the reward of cheeseburgers and French fries 
and habituated slower compared to non-overweight children [282-284]. Obese participants with the 
DRD2 TaqI A1 allele polymorphism worked harder in these tasks compared to the obese without the 
Taql A1 allele [285]. These behavioural tests and their results have been replicated since 1996 by the 
same group and have yielded consistent findings of higher reward of food and in particular high-
calorie food in childhood and adult obesity [286].  
Another very useful assessment of the sensitivity to reward can be conducted through the use of 
delay discounting tasks measuring “unwillingness to wait for larger rewards at some future date in 
preference to smaller immediate rewards” [287-289]. A number of these tasks have been used to 
assess predominantly non-foods reward such as money and have shown reasonable consistency in 
that the obese, and in particular women and binge eaters, delay discount more steeply compared to 
normal weight subjects, although results may be explained by difference s in socioeconomic status 
[287-289]. Similar paradigms have linked the inability to inhibit control in a delay discounting task 
with actual intake of palatable food [290, 291]. Obese children also choose smaller immediate 
rewards, cannot delay gratification and this predicts weight gain [292-294]. 
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Table 1.1: Food preferences in human obesity 
Year of 
publication 
Author Country Participant 
characteristics 
Age Gender Comparison / Method Results 
1952 Beaudoin [295] USA 59 OB, 58 NW <60 F CS-interviews OB>NW energy intake 
OB=NW macronutrient composition 
1966 Maxfield [296]  USA 25 OB, 25 NW 40s F CS-food diaries OB=NW energy intake 
OB=NW macronutrient composition 
1973 
 
Ries [297] Germany 916 OW/OB 253 
NW 
18-59 M/F CS - interviews OB>NW energy intake (marginal) 
OB=NW macronutrient composition 
1979 
 
Keen [298] UK 1488, all BMIs Middle 
aged 
M/F EP - food records BMI correlated (-) with total energy, fat, 
carbohydrate and protein intake  
1982  Kulesza [299] Poland 100 OB / 50 NW 30 - 40 F CS - dietary histories / 
24 hour recall 
OB=NW energy intake 
OB=NW macronutrient composition 
1983 Baecke [300] Denmark 266, all BMIs 19-31 M/F CS- food records % BF correlated (-) with fruit/vegetable intake 
in M and fat/sugar intake in F 
1983  Kromhout [301] Holland 211 OB / 189 NW Middle 
aged 
M CS - dietary histories OB<NW energy intake 
OB<NW macronutrient composition from 
carbohydrate, fat, protein  
1984 Fehily [302] UK 493, all BMIs 45 - 59 M CS - weighed inventory BMI correlated (+) with protein intake and (-) 
with sugar intake 
1988 Dreon [303] USA 155 OB 30-59 M CS - food diaries % BF correlated (+) with % intake of fat and (-) 
with carbohydrates  
1988  Romieu [304] USA 141, all BMIs 34-69 F CS - food diaries BMI correlated (+) with energy intake. 
OB>NW macronutrient composition from fat 
1990 Miller[305] USA 216, all BMIs 18 - 71 F CS - questionnaires % BF correlated (+) with % intake of fat and (-) 
with % intake of sugar 
1992  
 
Drewnowski [306] USA 459 OB 30 - 50s M/F CS - Food preference 
list 
High preference for fat, high fat-high protein 
for M, sweet-fat for F 
1992 Tucker [307] USA 205, all BMIs ≥18 F CS-Diet questionnaires Adiposity correlated (+) with fat intake 
independently of calorie intake 
1992  
 
Slattery [308] USA 5115, all BMIs 18 - 30 M/F EP - diet history 
questionnaire 
BMI correlated (-) with %  energy from 
carbohydrate and fat in M and F respectively 
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1993 Price [309] USA 2,500, all BMIs 15-65 M/F EP- food frequency 
questionnaire 
Parallel increases in BMI and fat intake in 
Pima Indians 
1994 
 
Bolton –Smith  [310] UK 11,626, all BMIs 25-64 M/F EP-food frequency 
questionnaire 
OB correlated (+) with consumption of fat and 
fat/sugar and (-) with sugar 
1995 Popkin [311] China 3,901, all BMIs 20-45 M/F EP-weighed 
consumption 
BMI correlated (+) with fat intake  
1996/2007 Gibson [312] UK 2297, all BMIs 16-64 M/F EP - Weighed 
consumption 
BMI correlated (-) with %  energy contribution 
from sugars  
1998  
 
Macdiarmid [313] UK 2197, BMIs 16-64 M/F EP - food records BMI correlated (+) with fat intake in M/F, 
fat/sweet in F, and (-) with sweet in M 
1998 
 
Cox [314] UK 35 OB, 41 NW 18-64 M/F CS - food diaries  OB>NW in consumption of ED salty foods   
1998  
 
Lissner [275] Sweden 179 OB, 139 NW  37-60 F CS - food diaries OB>NW energy intake and % fat 
NW>OB vegetable intake 
2002 Bowman [315] USA 4, 711, all BMIs ≥ 19 M/F EP - 24 hour recall Higher BMI - lower carbohydrate intake 
2003 Yang [316] USA 6,125, all BMIs ≥ 20 M/F EP - 24 hour recall Higher BMI - lower  carbohydrate intake 
2004 Schaumberg [317] USA 71,919, all BMIs >45 M/F EP - food frequency 
questionnaires 
Higher BMI - lower glucose load 
2004 Wu [318] USA 1999, all BMIs 25-69 F EP - food frequency 
questionnaires 
Higher BMI - lower fructose intake and 
glucose load  
2004 Schulze [319] USA 88,710, all BMIs 24-44 F EP - food frequency 
questionnaires 
Higher BMI - lower glucose index and load  
2004 Cho [320] USA 90,655, all BMIs 26-46 F EP - food frequency 
questionnaires 
Higher BMI - lower carbohydrate intake and 
glycaemic load 
2004 Higginbotham [321] USA 38,446, all BMIs >45 F EP - food frequency 
questionnaires 
Higher BMI - lower glycaemic load  
2006 Flood [322] USA 44,572, all BMIs 55-74 M/F EP - food frequency 
questionnaires 
Higher BMI - lower carbohydrate intake, 
glycaemic load and index 
2008 Lajous [323] France 62,739, all BMIs Post 
menopausal 
F EP - food frequency 
questionnaires 
Higher BMI - lower carbohydrate intake 
In this table cross-sectional (CS) and epidemiological (EP) studies are included and referenced. Abbreviations: BMI: body mass index, BF: body fat, ED: 
energy dense/density, F: female, M: male, NW: normal weight, OB: obese, OW: overweight, (+): positive, (-): negative. 
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Food reward in obesity: Neuroimaging  
In the last 10 years there has been a marked rise in the number of functional neuroimaging studies 
in the context of obesity and eating behaviour in humans. Despite some inconsistencies, this has 
improved our understanding of the mechanisms of central reward processing in obesity. Studies 
using PET neuroimaging (e.g. 15H2O and FDG) have provided information on the effects of the 
internal state, hunger and satiety, but also the effect of tastants on the activation of both the 
homeostatic and reward systems and how this activation is different between obese and lean 
participants. In fMRI participants can be exposed to multiple cues during scanning and these stimuli 
have predominantly been visual, e.g. pictures of any food, high-calorie or low-calorie foods, 
appetising or bland foods, or control images (household objects or scenery); gustatory (e.g. 
milkshake); olfactory (e.g. odour of fried chips); or auditory (e.g. words of food). As “baseline ” brain 
activation fluctuates in fMRI acquisition protocols, the results from these studies are not expressed 
as absolute activation, but as contrasts i.e. difference in activation e.g. between high-calorie vs. low-
calorie foods. The ingestion of solid food is not possible during imaging as participant have to lie in 
the supine position in the scanner but also because of the significant distortions to the image quality 
due to the motion involved with the process of swallowing itself. 
In terms of differences in the activation of the homeostatic system, PET studies have showed that 
the activation of the hypothalamus in response to glucose or a meal was reduced in lean subjects, 
whereas the pattern was much more “sluggish” in the obese, suggesting that the same  meal led to 
satiation in the lean but not the obese [324]. In an early fMRI study, administration of oral glucose 
resulted in a decrease in activation of the ventromedial hypothalamus and periventricular nucleus in 
normal weight volunteers, but this was attenuated in the obese [189]. Similar results in the 
hypothalamus were seen after a meal in a fMRI study which used food pictures as cues [144].  
The majority of fMRI studies which have used visual cues during scanning have shown that obese 
subjects have a higher activation of the reward system (including the ventral or dorsal striatum, 
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orbitofrontal cortex, insula, amygdala, hippocampus) in response  to pictures of foods and/or high-
calorie foods compared to lean subjects [49, 71, 193, 325-332]. Others have shown higher activation 
in some and lower activation in other areas of the reward system, without consistency as to the 
specific areas [144, 333-336]. Differences in activation of areas involved in cognitive control and 
restraint (e.g. dorsolateral prefrontal cortex) are less consistent between studies with some showing 
increases in the obese [80, 329] and other decreases [325, 327, 334, 335, 337]. What is unclear and 
almost impossible to ascertain is what the response to these visual cues actually reflects. Even 
though the distinction between appetitive and consummatory responses in humans is very blurred 
and perhaps unnecessarily rigid, many researchers interpret the results of these findings as 
appetitive in nature (especially when the viewing of pictures is “active” i.e. accompanied by ratings 
the pictures simultaneously) and conclude that the appetitive reward value of food, and in particular 
high-calorie food, is higher in obesity. It is even more unclear what passive viewing of pictures 
actually represents in terms of brain processing.  
Consummatory responses can be perhaps studied more robustly through the use of gustatory or 
olfactory cues, i.e. the actual consumption of the reward. Using these stimuli, some fMRI studies 
have shown that the reward system is more active upon receipt of the stimulus in obesity [338, 339] 
whereas others have made a distinction between the anticipation and receipt of a palatable 
chocolate milkshake. The somatosensory cortex, insula and frontal operculum activation in 
anticipation of a milkshake stimulus was higher in obese vs. normal weight adolescent girls whereas 
the activation of the caudate in response to actual milkshake receipt was lower in the obese [340]. In 
a fMRI study of female college students with BMIs ranging from normal to obese, the negative 
correlation between BMI and caudate activation to a chocolate milkshake was particularly strong in 
subjects with the DRD2 TaqI A1 allele [341]. Even in the absence of obesity, healthy adults with the 
TaqI A1 allele had lower activation in the ventral tegmental area, substantia nigra, thalamus and 
orbitofrontal cortex in response to palatable milkshake compared to non-carriers [342]. Adult 
females who prospectively gained weight over 6 months exhibited a reduction in the activation of 
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the caudate to chocolate milkshake receipt compared to women who maintained their weight [343], 
whilst caudate activation correlated negatively with weight gain at 1 year in the female college 
students with TaqI A1 allele and positively in non-carriers [341]. The hyporesponsivity of the caudate 
to palatable food has however not been shown in all genetic studies from the same group [328, 
332].  
Evidence from some PET studies indirectly supports the latter finding, with reduced dopamine 
receptor availability (using DRD2/3 ligands) in the striatum of obese subjects (and also prefrontal 
cortex, anterior cingulate cortex, orbitofrontal cortex in some studies) and with dopamine receptor 
levels negatively correlating with BMI [344-347]. Similarly, DRD2 levels in the striatum and dopamine 
levels in the nucleus accumbens are reduced in rodents who have been fed an energy-dense diet 
[348, 349].  However, other PET studies investigating cerebral flow, instead of dopamine receptor 
availability, have not demonstrated decreases in striatum responsiveness to liquid tastants or 
feeding in obese humans [206, 208, 350, 351]. 
In an attempt to explain these discrepant findings, a number of models have been developed. The 
one which is currently predominant in the literature suggests that both appetitive and 
consummatory responses are higher in the obese (or those predisposed to obesity) and lead to the 
overconsumption of high-calorie foods. Eventually, this repeated exposure to palatable foods leads 
to the down-regulation of dopamine receptors and reduced consummatory responses. This state of 
high appetitive and low consummatory responses resembles the addiction model to recreational 
drugs. Consequently, obese subjects overconsume food/high-calorie food in an attempt to 
compensate for the reduced initial “kick” they get from their consumption. At this stage, this 
dynamic model works as a vicious cycle causing weight gain, which is incredibly difficult to break. 
More support for this theory comes from animal studies. Electrical stimulation of the lateral 
hypothalamus can be very rewarding and animals work hard in order to engage in this stimulation. 
Overfeeding and access to palatable foods that eventually lead to obesity in rodents is associated 
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with decreased effort to engage in lateral hypothalamus stimulation [352], and the effects of the 
latter are diminished [348]. Interestingly similar responses can be seen in animals that have 
previously been exposed to recreational drugs including heroin and cocaine [353, 354]. 
There is however significant amount of evidence against this addiction model. For example, 
tolerance to repeated use of recreational drugs or alcohol and withdrawal symptoms following 
abstinence are not typically seen for food [355]. However, features of food addiction can be seen in 
the subgroup of obese patients who suffer with binge eating disorder. These patients can consume 
excessive amounts of food in a single meal in response to a stressful event or low mood, and  the 
episode is characterised by loss of control and a feeling of disgust and guilt after termination of the 
binge [356]. Neuroimaging studies have shown higher responses in the frontal lobes, dorsal striatum 
and insula in response to feeding or food cues in obese subjects with binge eating disorder or high 
food-addiction scores compared to obese or lean subjects without the disorder [49, 74, 357, 358]. 
The greater activation in the cognitive control area is intriguing and may suggest that these patients 
are trying hard to engage their restraint mechanisms in the face of binge-promoting external stress. 
An overlap in addictive behaviour in response to food and recreational drugs in subjects predisposed 
with the TaqI DRD2 A1 allele has been shown is some [244-247] but not all studies [359, 360].  
In terms of personality traits and their influence on the brain reward system responses, emotional 
eating scores from the Dutch Eating Behavior Questionnaire have been correlated with lower DRD2 
availability in the striatum, but this was in normal weight volunteers [361]. In a fMRI study of young 
women in the normal or overweight range, the anticipation and/or receipt of a milkshake was 
associated with higher activation in the parahippocampal gyrus, anterior cingulate cortex, ventral 
pallidum and thalamus in the subgroup of emotional eaters compared to the non-emotional eaters 
[362]. As far as dietary restraint is concerned, differences in activation of areas involved in cognitive 
control (e.g. dorsolateral prefrontal cortex) are less consistent between studies with some showing 
increases in the obese [80, 329], and other decreases [325, 327, 334, 335, 337]. 15H2O PET studies in 
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successful dieters have been more consistent in showing greater blood flow responses in the 
dorsolateral prefrontal cortex [62, 208]. 
Why the inconsistencies? 
The major problem with the results of these numerous neuroimaging studies in obesity is that there 
are significant discrepancies between them, not just as to which areas of the brain are activated and 
which not, but even as to the direction of the activation. There are a number of reasons behind this 
variability. The most important one is probably in the nature of obesity itself, which is not a 
homogeneous condition. The same degree of obesity between two subjects does not necessarily 
imply similar aetiology, therefore imaging participants based purely on a crude measure like BMI 
may have led to inconsistent and misleading results [363].  
Another reason is variability in the study design and neuroimaging paradigms used. Differences in 
the length of fasting [76, 364], caloric value of meal pre-loads (and whether adjusted for gender, 
resting energy expenditure, valence of cues used), inter-individual differences in food preference, 
gender distribution [76, 364], genetic predisposition [34, 82, 332], education level, ethnic and 
socioeconomic background, personality and psychological traits [57, 269, 365, 366], co-morbid 
conditions including type 2 diabetes and insulin resistance [190-192] and binge eating disorder [74, 
269, 357], use of centrally acting medications, stage of the menstrual cycle [367, 368] are some of 
the confounders that may have a significant effect on results between the published studies. Specific 
caution should be exercised in the interpretation on hypothalamic and brainstem activation as these 
regions are very small, with variable anatomy that may not allow satisfactory anatomical 
registration, whilst the presence of significant physiological “noise” from the surrounding large 
arteries and respiratory movement and edge effects from motion make their assessment 
problematic using fMRI. More importantly, the allocation of specific behavioural “roles” to specific 
brain areas is over-simplistic, especially in humans, and the inference that their activation leads to 
specific patterns of behaviour should be either limited or interpreted with great caution.  
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The analysis of neuroimaging data is also highly variable. Numerous statistical methods can be used 
and indeed many of the above studies have not performed one of the most basic steps in statistics 
which is to correct their findings for multiple comparisons [369, 370]. The definition of regions of 
interest is another significant source of variability, as some investigators use only anatomical criteria, 
whereas others use functional criteria or a combination of the two.   
It is therefore crucial that neuroimaging studies are always accompanied with as many other 
techniques as possible (including direct behavioural testing, but also questionnaires, visual analogue 
scales, food diaries) and the overall pattern of these complimentary methodologies evaluated before 
conclusions are made regarding eating behaviour. Additionally, neuroimaging studies should be as 
standardised as possible, control for confounders but also phenotype their subjects in-depth, so as 
to allow direct comparisons of their results within and between different laboratories [371]. 
Furthermore control fMRI tasks should ideally be included to control for non-specific differences in 
fMRI BOLD activation related to alterations in neurovascular coupling. 
1.2.4.3 Taste  
Sensory domain 
It is not clear how any differences in taste perception (for any taste modality) may affect eating 
behaviour in the “real-world” of suprathreshold taste concentrations with some studies suggesting 
no association [372, 373], and others suggesting an inverse association with the rewarding value of 
food and high-fat food consumption [374-377]. 
The literature is consistent in that there are probably no differences in taste detection thresholds for 
sweet taste in obesity [378-380]. However, beyond detection thresholds, the intensity of 
suprathreshold sweet taste concentrations appears to be different in obesity in that the intensity of 
sweet decreases with increasing BMI [381]. 
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Jessica Stewart’s group in Australia have recently presented a series of very elegant experiments of 
fatty acid detection thresholds [375, 376]. Using rather cumbersome, but reliable, techniques they 
identified detection thresholds for oleic, linoleic and lauric fatty acids. Based on their performance, 
participants were identified as non-tasters, tasters or supertasters for fatty acids. Supertasters 
consumed less fat in their diets, based on self-reported food diaries and had lower BMIs compared 
to tasters and non-tasters. Work from the same group has shown that obese men have higher 
detection thresholds for fatty acids compared to lean men [382]. 
Reward domain 
Sweet  
In 1973 Underwood tested 18 obese and 11 lean adults by randomly administering sucrose  solutions 
of different concentrations before and 1 hour after a 50 g glucose load [383]. There was no change 
in the pleasantness ratings in the obese group whereas the lean group found the sucrose solutions 
aversive after the glucose load. Unexpectedly the majority of participants rated the sucrose solution 
unpleasant even before the glucose load. The results of this small trial supported Cabanac’s theory 
of decreased sensitivity to internal signals in obesity [384].  
Rodin performed a series of experiments on taste responsiveness [385]. In the first study, 53 female 
participants were divided into 4 groups: normal weight, low overweight, overweight and obese. They 
were randomly presented with 6 ascending concentrations of glucose (0.125-3M) in 4 trials using the 
sip and spit technique. In two of the trials, the participants rated the pleasantness using a 9 point 
scale. The test was performed mid-afternoon 3 hours after a 500 kCal lunch. Participants were 
tested at baseline and in the last week of an 8 week weight reduction programme of daily exercise 
and caloric restriction. The normal weight group found high sucrose concentrations (>1 M) less 
pleasant compared to the overweight groups. This is in contrast to other studies which showed no 
differences in valence ratings between overweight and normal weight subjects [221, 380] and may 
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be a reflection of the different tastants used, ranging from sucrose flavoured water to chocolate 
milkshakes [380, 386]. Following weight loss pleasantness ratings did not change in any of the 
groups.  
In the second study, 11 obese females were tested before and 6 months after jejunoileal bypass 
surgery for obesity. Subjects were again asked to rate the pleasantness of ascending concentrations 
of glucose, salt, citric acid and quinine representing the 4 modalities of taste. Intensity ratings for 
glucose did not change after surgery. Pleasantness ratings were variable pre -operatively with no 
consistent pattern, whereas after surgery pleasantness ratings were consistently  high for most 
concentrations of sweet, apart from the 3M concentration which was lower. The post-operative 
curve resembled the response of normal weight individuals from similar experiments. The responses 
for the other taste modalities did not change. The authors did not explain why the results of the pre-
JIB group were not consistent yet tried to interpret the post-operative results in which the same 
methodology was used and concluded that the reduced preference of high glucose solutions may be 
only partially explained by the “dumping” phenomenon and conditioned taste aversion but also 
probably by other “peripheral mechanisms”. Opposite to the views of Nisbett and Schachter, who 
consider taste as an external cue, Rodin supports Cabanac’s views and suggests  that interpretation 
of taste is influenced by internal changes including hunger, reduced fat mass or surgical 
interventions for example. 
In the last experiment, 30 overweight and 30 obese patients from experiment 1 were compared to 6 
normal weight controls before and after the same weight loss programme. They were asked to rate 
the pleasantness of a chocolate milkshake’s sweet taste, thickness and creaminess before or 45 
minutes after a 500 kCal preload of sandwich, fruit and milk. Before weight loss there were no 
differences in ratings before or after the preload amongst the groups. After weight loss the 
pleasantness ratings before a preload were identical to the ratings before weight loss, but the rating 
after the preload were higher in all groups to those made before weight loss. These results support 
88
the notion that in the deprived state internal signals to short term changes (preload) are ignored and 
the subject rates sweet food as highly pleasant. The degree of obesity did not alter these responses, 
suggesting that any decrease of adiposity away from the set point has similar results on increasing 
the pleasantness of sweet taste. The most helpful point this experiment makes is that in the 
deprived state, feeding increases the affective attributes of sweet taste. Interestingly, these 
attributes do not differ between lean and obese participants. The study does actually support 
Nisbett’s concept of sweet taste becoming more rewarding after adipose tissue loss, the only 
difference being that this applies to any weight category, lean or obese[387].  
Frijters [378] studied 13 overweight females and compared them to 12 normal weight subjects in 
terms of sweet taste detection, intensity, pleasantness and preference. Using the constant stimuli 
and sip and spit methods, 18 sweet stimuli made of sugar diluted in distilled water and ranging from 
0.0006 to 0.02 M, were presented randomly in one session. The pleasantness of the 18 solutions was 
determined on a different session in which subjects rated them on a 170 mm scale with the anchor 
“ideal” in the middle, “not liked as not sweet enough” on the left and “not liked as too sweet” on the 
right. The curves obtained from these ratings and the maximal sweetness preference did not change 
between the groups even thought there was a trend for overweight subjects to rate every solution 
as more pleasant compared to the normal weight subjects and the maximally pleasant sweet 
concentration was higher in the obese group compared to the normal weight group (0.1912 vs. 
0.1542 M).  Possible confounders include the recruitment of overweight but not obese patients and 
the use of sugar solutions in water at room temperatures which does not relate to everyday food 
items. 
A similar “Just About Right” (JAR) scale was successfully used by Conner and Booth in 1988 [388] and 
shown to correlate strongly with sweet food consumption in 344 young volunteers  with only very 
few of them in the overweight or obese weight range. Lime drinks were presented in one setting in 
room temperature and mixed with sugar to make six 20 ml sweet concentrations. Each subject was 
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presented with only 3 samples. After tasting the subjects pointed to a scale made of boxes which 
were numbered from 1 to 9: Box 1 was assigned the label “so little sweetness I’d never choose to 
drink it”, Box 5 “Sweetness just right for me” and Box 9 “so much sweetness that I’d never chose to 
drink it” and the responses were shown to be linear with a positive slope against the log sugar 
concentration. The mean ideal point was 0.12 M (similar to the concentration of cola). The ideal 
point correlated positively with the amount of sugar they added to hot drinks and preference for 
sweet foods as obtained from food choices questionnaires. Additionally men were found to have a 
higher preference for sweets compared to women but BMI did not correlate with these preferences. 
The large sample size and the use of a lime drink which is closer to a real life beverage was an 
advantage of the study, although the investigators were not blinded to the testing solutions as they 
chose the stimuli used to obtain the best fit to the linear plot for each subject.  
Linda Bartoshuk reviewed the above literature and improved the ways in which scaling experiments 
are performed [381]. Firstly, she has shown that taste detection thresholds do not predict food 
preferences and for the comparison of obese with normal weight subjects suprathreshold 
concentrations should be used [373, 379]. Secondly, both visual analogue scales and nine point 
category magnitude scales for intensity and hedonic characteristics of food or taste assume wrongly 
that the labels used denote the same experience amongst different subjects. A good example is that 
of pain; the “most intense pain ever experienced” label in such a scale is very different to women 
who have experienced the pain of childbirth compared to women who never have. Guiding analgesia 
treatment based on such a scale would result in lower medication doses being given to the former 
women.  
The solution proposed was the use of the general labelled magnitude scale (gLMS) in which the 
labels include phrases like “strongest sensation ever experienced”. This way the modality tested is 
not mentioned in the scale and the subject is allowed to rate it based on comparison with their own 
strongest sensation ever experienced (i.e. pain, brightness, loudness), which can now act as a 
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standard for intensity. The gLMS can therefore be used to compare intensity of taste in a valid 
manner between non-tasters, medium tasters and super tasters. The spacing of the labels on the 
scale is such that for example a rating of 70 mm in a 200 mm scale denotes intensity double from a 
rating of 35 mm. This methodology has been used for the development of hedonic scales using the 
anchors “strongest imaginable disliking/liking” on either side of a 200 mm scale with “neutral in the 
middle”.  The application of these concepts showed that intensity of sweet decreases with increasing 
BMI. Using the hedonic form of the gLMS, Bartoshuk also showed that the “liking” for sweet taste 
increased as a function of BMI. Her results are in line with those of Moskowitz [389] who by plotting 
liking against perceived sweetness showed that for the same perceived sweetness, hedonic liking 
goes up as BMI increases.  
Fat 
Further investigations on fat reward have been conflicting in their results, similar to the sugar story. 
Pangborn studied 186 women who were underweight, normal weight or overweight using different 
concentrations of fat in milk [390]. Hedonic ratings did not differ between the three groups. 
Discrimination between different fat concentrations proved to be very poor. In terms of food diaries, 
the frequency of consumption of food high in fat was higher in the overweight when compared to 
the underweight group only. The most reproducible results came from a behavioural task in which 
participants were asked to mix different milk types to a mix of their liking. Subjects who consumed 
higher amounts of fat in their food diaries also mixed to higher concentrations of fat in milk during 
the task compared to those consuming less fat from their food diaries [390].  
Mela studied 30 women with food diaries and pleasantness ratings after consumption of fat 
products [391]. He found wide variations between individuals in their most preferred fat level and 
no correlation of these preferences with the stimuli used. However, a positive correlation between 
overall fat preference and percent body fat was found, albeit of small magnitude. This finding is of 
questionable importance considering the presence of high variability in this experiment.  
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Fat and sweet 
In an attempt to explain the discrepant results of previous investigators (obese finding sweet taste 
more pleasant [384-386, 392] but no changes in sweet taste in reward  in obesity [379, 380, 383, 
392-396]), Drewnonski [397] suggested that the differences were due to the nature of the different 
stimuli used. It was argued that the combination of sweet with fat taste as experienced in everyday 
life should be the subject of further investigation, and 12 female obese, 8 reduced obese (following a 
minimum of 13.6 kg weight loss through a low calorie diet) and 15 normal weight subjects were 
studied. Buttock fat biopsies were taken and adipose cell size and lipoprotein lipase activity were 
measured. Participants were presented with 20 chilled fat and sugar samples containing a mixture of 
5 ascending concentrations of fat and 4 ascending concentrations of sugar and made up to 10 mls. 
Subjects rated the pleasantness of sweet, fat and creamy in 9 point category scales. The stimuli were 
presented after a balanced meal and a 6-12 hour fast. In order to quantify the hedonic responses the 
authors used the response surface method, a model which assumes that reward responses are a 
function of sweet and fat and created a 3 dimensional surface from interpolating data from the 20 
stimuli used. In the normal weight group, ratings increased up to a maximum sweetness of 10% 
sucrose followed by a drop and the same pattern was seen for fat up to 20% lipid followed by a 
drop. The predicted maximum pleasantness rating for this group was 20.7% fat and 7.7% sweet.   
Obese patients “liked” highly sweet and fatty solutions but “disliked” equally sweet solutions in a 
low fat mixture. For the same concentration of fat, the sweeter the solution the lower the 
pleasantness, results similar to those obtained by Underwood [383]. Maximum pleasantness ratings 
were obtained for the combination of 34.4% fat and 4.4% sweet. Finally subjects after weight loss 
reported a paradoxical reduction in pleasantness along all fat concentrations at low sweetness but a 
heightened pleasure from higher concentrations of sweetness at low fattiness. The maximum 
pleasantness rating was estimated at 35.1% fat, i.e. similar to the obese group and at 10.1% sweet, 
significantly higher than the obese group. This suggests that weight loss leads to increased valence 
92
of sweet when this is combined with fat. There were no correlations between optimal sweet/fat 
ratios and lipoprotein lipase activity per adipose cell. This study combined ingredients, making them 
more applicable to everyday food experiences and acknowledged the effect fat texture can have on 
tasting, but did lack information on age, weight loss, average ratings in the fed and fasted state and 
a description of the meal provided.  
Pima Indians who have a high risk for developing obesity, had significantly lower hedonic responses 
when rating solutions of milk containing different concentrations of fat and sugar than the white 
control population which was at lower risk for obesity [398]. 
Physiological domain 
Salivation is a classical manifestation of taste induced physiological response. In particular, the rate 
of decrease in salivation is a measure of sensory specific satiety which refers to the decrease in the 
hedonic response of a food/tastant just eaten while still desiring more food. Epstein showed that 
obese women have a slower decline in salivation to repeated lemon yoghurt cues compared to lean 
women [399]. These results have been replicated by others [282, 400, 401]. Snoek failed to replicate 
these results but used visual analogue ratings instead of actual salivation rates [402].  
1.2.5 Summary of introduction section 1.2 
 Obesity results from the interaction of numerous factors including genetics, environment, 
psychological traits and physiology. 
 The available evidence suggests that the obese are not hungrier, but probably less sated after a 
meal compared to normal weight individuals. 
 Although there are significant discrepancies in the behavioural literature, it appears that the 
obese exhibit a higher preference and consumption of a combination of high-fat, low-sugar 
foods compared to normal weight subjects. 
93
 Although there are significant discrepancies in the behavioural and neuroimaging li terature, it 
appears that high-calorie food is more rewarding in the obese, and this may lead to its 
overconsumption. 
 The distinction between appetitive and consummatory brain responses to food and/or taste is 
blurred in humans, and more so in obesity, and therefore no definitive conclusions, on the 
relative contribution of each component to obesity, can be drawn from the available data. 
 Sensory domain of taste (behavioural testing): Taste acuity (for fat) and taste intensity (for fat 
and sweet) are lower in the obese.  
 Reward domain of taste (behavioural testing): There are no data on appetitive reward responses 
in obesity; the combination of sweet and fat taste has a higher consummatory reward value in 
obesity. 
 Physiological domain of taste (behavioural testing):  In response to sweet/fat tastants, the obese 
salivate more and habituate slower. 
 The study of eating behaviour is particularly challenging in obesity. The combination of 
complimentary techniques, appreciation of the heterogeneity of the condition and the control 
for confounding variables is crucial if robust conclusions can be made from the study of obesity 
in humans. 
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1.3 Treatments of obesity 
 
1.3.1 Lifestyle Modification 
 
Appetite reduction is a compelling goal for long-term weight loss and resolution of the metabolic 
effects of obesity and overweight. The abundance of highly palatable food that influences eating 
patterns can make caloric restriction an unachievable goal for many individuals. In obese patients 
who have achieved weight loss through lifestyle changes, clinical data suggest the presence of 
compensatory mechanisms that lead to weight regain in 80-90% of individuals [167, 403]. One study 
reported that overweight and obese patients who underwent a 10-week weight loss programme had 
significantly lower levels of leptin, PYY, CCK, insulin, and amylin and significant increases in ghrelin 
levels from baseline. These differences persisted at one year and were accompanied by significant 
increases in appetite and preoccupation with food [167]. Acute fasting and chronic dieting have 
been shown to induce changes both in the hypothalamic and reward areas of the brain, with the net 
effect of further increasing hunger, and pre-occupation and craving for calorically dense food [30, 
69, 209, 404].  
Once weight loss has been achieved, appetite control is critical to prevent subsequent regain of 
weight. In general, diets to reduce and maintain weight should be higher in protein (30% of calories) 
and include a high proportion of low-glycaemic index carbohydrates (40%) [405, 406]. The effect of 
nutrient content on weight maintenance was examined in overweight or obese adults who had 
achieved at least an 8% reduction in body weight with a very low calorie diet (VLCD) [406]. 
Individuals who completed a high-protein, low-glycaemic index diet regimen for 26 weeks following 
initial weight loss exhibited a higher maintenance rate of weight loss compared to those who 
completed a low-protein, high-glycaemic index diet. Furthermore, individuals assigned to the high-
protein, low-glycaemic index diet continued to lose weight over the course of the study, whereas 
participants assigned to the low protein, high-glycaemic index diet demonstrated significant weight 
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regain. Diets high in protein and low in carbohydrates appear to be superior in the reduction of 
hunger and increasing satiety and their ketogenic effects may play a role [407]. 
 
1.3.2 Pharmacotherapy 
 
The ability to achieve weight loss and maintenance with pharmacological agents has been an 
attractive yet elusive goal. For instance, while drugs such as rimonabant (a centrally acting 
cannabinoid 1 receptor antagonist) and sibutramine (a centrally acting serotonin-noradrenaline 
reuptake inhibitor) were previously used as a pharmacological strategy for obesity management, 
these agents were withdrawn following reports of increased risks of psychological and 
cardiovascular adverse events, respectively [97, 408]. 
 
Orlistat is the only drug that has stood the test of time. It decreases fat absorption by 30% through 
inhibition of pancreatic and gastric lipase. In practice, it works by making patients consciously reduce 
their fat intake to avoid unpleasant and socially embarrassing oily diarrhoea. A number of 
randomised controlled trials (RCTs) and meta-analyses have shown small decreases in weight of 2.9 
kg [409], with beneficial effects on cardiometabolic risk factors and reductions in the incidence of 
type 2 diabetes mellitus [410]. Gastrointestinal side effects remain common, whilst the rare 
occurrence of severe liver injury has also been reported [409].  
 
After 13 years with no new drug approvals, in 2012 the USA FDA sanctioned 2 agents that reduce 
appetite and lead to modest weight loss. Lorcaserin is a serotonin (5-hydroxytryptamine) 2C 
receptor (5HT2C) agonist that leads to reductions of food intake and perhaps food reward. The 5HT2C 
receptor is located in the hypothalamus, but is also located in some brain reward areas, including 
the prefrontal cortex, nucleus accumbens and amygdala. Phase 3 trials have demonstrated that 
patients on the 10 mg, twice-daily dose lose an extra 3.0-3.6% of weight compared to placebo [411-
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413]. This was accompanied by a 0.5% absolute decrease in HbA1c, improvements in lipids and 
blood pressure and no increase in the rate of cardiac valvular disease compared to placebo. The 
most frequent side effects of headache, dizziness, dry mouth and nausea were mild and tolerated by 
most patients.  
 
The combination of phentermine and the antiepileptic topiramate has also been recently approved 
by the USA Food and Drug Administration. Phentermine is a sympathomimetic drug, and its use with 
fenfluramine was discontinued in 1997 due to the association of fenfluramine with cardiac valvular 
disease and pulmonary arterial hypertension. Topiramate works through augmentation of γ-
aminobutyric acid neurotransmission and attenuates appetite through mechanisms that remain to 
be elucidated. The high-dose combination of the two medications led to an impressive 8.7% weight 
loss, a 0.4% absolute reduction in (glycated haemoglobin) HbA1c and a decrease in the incidence of 
type 2 diabetes mellitus at 2 years compared to placebo [414-416]. Side effects include increase in 
heart rate (but no adverse clinical events), anxiety, suicidal ideation, teratogenicity, upper 
respiratory tract infections, constipation and paresthesiae. Its longer-term effects on cardiovascular 
and psychiatric morbidity remain to be determined. 
 
1.3.3 Bariatric Surgery  
The first bariatric surgery procedures were developed back in the 1950s.  At the time, surgeons 
attempted to promote weight loss through the development of procedures that either restrict food 
intake or lead to the malabsorption of calories, predominantly from fat and carbohydrates. 
However, many of these procedures, including the jejunoileal bypass and the vertical or horizontal 
banded gastroplasty lead to either significant post-operative complications or the adoption of 
compensatory eating behaviour practices causing weight regain, and eventually became obsolete. 
Some of the surgical and nutritional complications were so severe, that many clinicians who treated 
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patients developed a very negative view of these surgical techniques and this perhaps led to the 
slower adoption of the more successful procedures in the last 2 decades. The Roux-en-Y gastric 
bypass (RYGB), adjustable gastric banding (BAND) and biliopancreatic diversion (with or without a 
duodenal switch) are the 3 techniques that have stood the test of time and certainly the first 2 are 
still performed widely around the world.  
The RYGB has evolved and undergone modifications after the original procedure described by 
Mason and Ito [417]. The stomach is divided into the upper stomach pouch, which is 15 to 30 ml in 
volume and the lower, gastric remnant. The stomach pouch is then anastomosed to the mid-jejunum 
through a gastrojejunal anastomosis in a Roux-en-Y fashion [418]. The continuity of the bowel is 
restored via a jejuno-jejunal anastomosis, between the excluded biliary limb and the alimentary 
limb, performed 75 - 150 cm distally to the gastrojejunostomy. The gastric remnant is not excised, 
but it is no longer exposed to food; however gastric, pancreatic and biliary secretions still flow 
undiluted in the biliopancreatic limb and mix with food in the jejuno-jejunal anastomosis. The BAND 
technique involves the insertion of an adjustable plastic and silicone ring around the proximal aspect 
of the stomach, immediately below the gastro-oesophageal junction creating a small proximal 
pouch. The volume of fluid in the band is adjusted through injections in a subcutaneous port. The 
biliopancreatic diversion includes a partial gastrectomy, leaving a 400 ml gastric pouch. The small 
bowel is divided 250 cm proximally to the ileocaecal valve and the alimentary limb is connected to 
the gastric pouch to create a gastroenterostomy. An anastomosis is performed between the 
excluded biliopancreatic limb and the alimentary limb at 50 cm proximally to the ileocaecal valve. 
The duodenal switch which has been traditionally used to treat the “very obese”, can be performed 
as a 2 stage procedure; a vertical sleeve gastrectomy (VSG)  is performed through the excision of 
the lateral 70-80% of the stomach and following satisfactory weight loss the biliopancreatic diversion 
component is surgically added to the design. In the last decade, the VSG as a single stage procedure 
has become increasingly popular due to its relative simplicity and good clinical outcomes [419]. The 
vast majority of these procedures are currently performed laparoscopically, thus reducing the risk of 
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post-operative complications [420]. The anatomical manipulations in each procedure are illustrated 
in Figure 1.11. 
 
Figure 1.11: Anatomical changes in the most commonly performed bariatric surgery procedures 
 
a) gastric bypass (RYGB), b) adjustable gastric banding (BAND), c) vertical sleeve gastrectomy (VSG) 
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The RYGB, BAND and VSG are the most commonly preformed procedures and cause a 20-35% total 
body weight loss and long term maintenance (data for the VSG in particular are limited to 3 years) 
[421, 422]. Their clinical efficacy is particularly important in the improvement of obesity associated 
comorbidities including metabolic, cardiovascular, respiratory, reproductive, musculoskeletal, renal 
disease and neoplastic amongst others [423, 424]. Even though the impact of surgery on these 
conditions can be impressive, very few RCTs have directly compared it with non-surgical therapies. 
The few RCTs in the field have consistently shown that bariatric surgery is superior to non-surgical 
therapies for the glycaemic control of type 2 diabetes mellitus, but not sleep apnoea [425-428]. The 
Swedish Obese Subject study, the longest and highest quality case-control study, has also 
demonstrated that bariatric surgery is associated with a significantly reduced overall and 
cardiovascular mortality and morbidity compared to non-surgical treatments for obesity [423, 424]. 
There are significant variations in the indications for bariatric surgery around the world. These stem 
from the limited data on the best predictive markers, limited funding and in some cases 
discrimination against the obese. Even though BMI does not capture individual differences in 
comorbidities and is a poor predictor of long term outcomes, it still remains the main and most 
widely accepted criterion, with most organisations allowing bariatric surgery in patients with BMI>40 
or >35 with significant obesity associated illness [3, 429, 430].   
Even though the first bariatric procedures received negative attention and press because of the high 
rates of clinically severe complications, the risks of modern procedures have been substantially 
reduced and are considered acceptable in view of the health benefits. The overall early mortality 
rates after bariatric surgery should be as low as 0.3% in experienced high-throughput centres of 
excellence, and therefore similar to a laparoscopic cholecystectomy [420]. The rates of post-
operative complications can vary depending on the procedure performed and the patient’s 
comorbidities. The most common early ones are bleeding, staple line leaks, infection and venous 
thromboembolism and the late ones include internal hernias, gallstone and ulcer formation, band 
100
slippage or erosion and nutritional deficiencies [431]. These deficiencies can be low in severity for 
BAND and moderate for RYGB and VSG and they include vitamin B12, folate and iron, calcium, 
vitamin D and trace element deficiencies [432]. 
 
1.3.3.1 Mechanisms of weight loss after bariatric surgery 
 
Changes in hunger and satiety 
 
Patients after bariatric surgery report that they are generally less hungry and reach satiety f aster 
during a meal [433-435]. Even though these procedures were originally designed to cause 
mechanical, and consequently caloric restriction, patients rarely report symptoms consistent with 
this; whilst caloric restriction leads to a compensatory increase in the consumption of energy dense 
food, this is not seen in patients or animals after RYGB or VSG [436, 437]. Additional evidence 
against the contribution of restriction comes from the responses after RYGB and VSG to caloric 
restriction. When humans and animals lose excessive weight after a bariatric surgical complication or 
an experimental manipulation respectively, they eventually compensate for this by increasing their 
food intake to pre-surgical levels [438]. This allows them to gain weight and follow their predicted 
weight trajectory after surgery. Intriguingly, patients for whom the bariatric operations have “failed” 
and they have regained most of the initial weight loss, can also consume the same amount of 
calories as pre-operatively, even though the size of their gastric remnant has not increased 
significantly [439, 440]. 
In terms of meal patterns, patients and rats after RYGB and rats eat smaller more frequent meals 
[441, 442]; patients exhibit a reduced eating rate compared to pre-operatively and as a result the 
total meal duration remains unaltered. “Uncontrolled” and “emotional” eating, as measured by the 
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three factor eating questionnaire is lower at 1 and 2 years after RYBG compared to pre-operatively 
[441]. 
Hypothalamic signalling  
The direct expression of pro-opiomelanocortin, agouti related peptide and neuropeptide Y has not 
been assessed in animal models of RYGB as yet. The expression of agouti related peptide remained 
unchanged in rats undergoing VSG compared to sham surgery, whereas it increased in rats pair-fed 
to the VSG group [438]; this suggests that the calorically restricted rats were hungry and the VSG 
were not. However, in the same experiment, there was no change in the expression of pro-
opiomelanocortin or neuropeptide Y after VSG. In humans, RYGB has been shown to be effective in 
inducing weight loss even in patients with heterozygous mutations for the melanocortin 4 receptor 
[443-445]. Therefore, there is currently very little evidence that RYGB or VSG alters the expression of 
key signalling elements in the hypothalamic nuclei. 
Gut hormones and leptin 
RYGB and VSG may alter signalling from the gut to the hypothalamus and brainstem. The 
postprandial release of the anorexigenic hormone PYY is significantly higher after both RYGB and 
VSG, but not BAND or caloric restriction (e.g. [167, 433, 446, 447]). PYY is released from the L cells of 
the distal small bowel after a meal, in proportion to the consumed calories and acts at the arcuate 
nucleus of the hypothalamus to decrease food intake [120], but also via vagal afferents terminating 
at the nucleus of the solitary track to signal satiety. PYY has been reported to increase energy 
expenditure and delay gastric emptying [124]. Patients with higher PYY response after RYGB had 
more weight loss [448, 449]; by blocking the release of PYY in humans with octreotide food intake 
was increased in humans and rats after RYGB, but not BAND [433]. Mechanistic studies in rodents 
have also demonstrated the physiological importance of PYY; the weight loss of PYY knockout mice 
after a variant of the RYGB was lower compared to the wild type mice [450].  
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GLP-1 responses are very similar to those of PYY after both RYGB and VSG (e.g. [451]). GLP-1 is 
secreted by the L cells of the small bowel together with PYY, with higher concentrations in the distal 
ileum and colon. It acts on the GLP-1 receptor which has been located in the hypothalamus, 
striatum, brainstem and substantia nigra, amongst other areas of the brain[101]. The peptide is 
produced in response to a meal and decreases food intake through its e ffects on the hypothalamus, 
but and brainstem [102]. GLP-1 slows gastric emptying, inhibits glucagon release and acts on the 
pancreas to produce insulin (incretin effect)[103].  Whether GLP-1 is necessary for VSG-induced 
weight loss has been questioned, as the procedure was equally effective in both GLP-1 receptor wild 
type and knockout mice [452]. 
The rapid delivery of nutrients to the distal ileum after RYGB may be responsible for the exaggerated 
rise of both PYY and GLP-1 (e.g. [453]). In the absence of a shorter small bowel in VSG, the rise in 
these gut hormones has been attributed to rapid gastric emptying [454].  However, this is probably 
just part of the story as nutrient sensing in the proximal small bowel can signal to the distal small 
bowel to release gut hormones [455]. Gut hormones are elevated within days after surgery and 
appears to remain elevated for at least a decade after RYGB (e.g. [456]).  
Ghrelin is a peptide produced by the X/A like cells in the fundus of the stomach during fastin g and 
acts on growth-hormone secretagogue receptors [146]. Inactive ghrelin (des acyl ghrelin) is activated 
to acyl ghrelin in the stomach through the action of the ghrelin O-acyltransferase enzyme [147]. 
Ghrelin levels are decreased after eating, with carbohydrates having more of a suppressive effect 
compared to protein and lipids [148]. Ghrelin stimulates neuropeptide Y/agouti related peptide 
neurons within the arcuate nucleus [149], but also through the vagus and brainstem to increase food 
intake[150]. The levels of ghrelin are reduced after VSG (e.g. [457]) and increase after BAND [434]. 
There is disagreement as to what happens to ghrelin levels after RYGB (e.g.[165, 458]) and this may 
be related to whether the active or inactive form has been measured but also due to the inherent 
difficulties in the laboratory handling and quantification of ghrelin [459]. In the case of VSG, it may 
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even be the case that ghrelin is not a key physiological player as the procedure was equally effective 
in ghrelin deficient models and ghrelin intact mice [460].  
Both surgical and non-surgical caloric restriction cause fat mass loss and decreases in plasma leptin 
levels (e.g. [167, 461]). This leads to hyperphagia in the latter but not the former, suggesting that the 
additional physiological alterations after surgery are enough to counterbalance the lower leptin 
levels. In animal models of VSG, the expression of leptin receptors was equally reduced after surgery 
or pair-feeding and therefore surgery does not appear to have a superior effect on central leptin 
sensitivity [438]. 
Vagal signalling 
The vagus is a key signalling relay system between the gut and the brain and an important regulator 
of food intake and body weight. The presence of nutrients in the small intestine leads to the release 
of gut hormones which exert part of their physiological effects through the vagus [203]. Indeed, the 
preservation of vagal fibres during surgery leads to greater and more sustained body weight loss in 
animal models of the RYGB [462]. In a human study, pressure generated in the proximal alimentary 
limb of the RYGB by a 20 ml balloon predicted meal size [463]. Thus the rapid entry of food from the 
oesophagus, through the small gastric pouch may trigger vagal signalling in the alimentary limb 
which may contribute to a reduction in food intake. Against the hypothesis that the vagus is 
important after RYGB, a selective vagotomy to the hepatic branch of the vagus in rat models of the 
surgery did not have an effect on food intake, weight loss and metabolic control [464]. However, the 
other vagal branches that innervate the small bowel were not disrupted in this experiment and it 
cannot be excluded that they may be partly responsible for the changes in food intake.  
In terms of the BAND, its mechanism of action still remains to be determined. In a randomised blind 
cross-over trial, patients’ bands were either filled with fluid or fluid was partially or completely 
removed [434]. When the bands were optimally adjusted, patients rated their pre-breakfast hunger 
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significantly lower and their satiation after breakfast significantly higher compared to when the fluid 
in the bands was partially or completely removed. In the same study, levels of glucose and insulin 
were unchanged, but total ghrelin levels were higher in patients with bands compared to 
unoperated obese controls. This study is one of the few to provide clues into the mechanism of 
action of the BAND and suggest that it is not a restrictive procedure, but one that reduces hunger 
and increases fullness potentially through neural mechanisms.  
Food transit studies have also shown that whilst the band increases the transit time between the 
oesophagus and the lower stomach [465], there is no delay in gastric emptying [466, 467].  The 
intraluminal pressure generated inside the stomach appears to be optimal at 25-30 mmHg [468]; 
interestingly this pressure can only be reached after a certain “threshold” of fluid volume in the 
band and this threshold is different between different patients with different band types. Further 
addition of fluid leads to a rapid linear increase in intraluminal pressure, eventually causing the side 
effects of unwanted mechanical restriction and vomiting. In rodents with BAND, inflation of the band 
led to higher levels of fos protein expression in the brainstem (a marker of neuronal activation) 
[469]. Therefore, the available evidence suggests that the higher intraluminal pressure generated by 
the BAND may be key in the signalling of decreased hunger to the hypothalamus and the brainstem. 
Levels of anorexigenic PYY and GLP-1 are either not altered or only marginally increased after BAND 
[446].  
Mechanical factors 
There is significant controversy on whether the size of the gastric pouch and stoma in the case of 
RYGB and the residual gastric volume in VSG affect food intake and body weight. Currently no 
consensus has been reached as some studies have shown that the larger the gastric pouch/stoma 
diameter the less weight patients/animal models lose (e.g. [470, 471]) and others that there is no 
correlation between the two variables (e.g. [439, 472, 473]). Similarly incongruent results have been 
found for the residual gastric volume after VSG (e.g. [474-477]). Whilst these differences may be 
105
partly due to the variable ways used to measure gastric volume, patient characteristics and other 
significant confounders, the lack of a clear association between gastric volume and weight loss and 
evidence from a RCT suggest that the physiological role of this component may be  minimal, if any at 
all.  
In the absence of a pylorus, one would expect gastric pouch emptying to be faster after RYGB. Whilst 
a number of studies have shown that this is the case [453, 478] and may be responsible for the rapid 
delivery of nutrients to the distal ileum and the exaggerated release of gut hormones, others have 
not [479, 480], or shown that the faster gastric emptying is only for liquid food [481]. Counter-
intuitively, gastric emptying and intestinal transit appear to be faster after VSG [454, 482-484], apart 
from one study in which the antrum was preserved [485]. The mechanisms behind this are unclear 
but may include the generation of very high intraluminal gastric remnant pressures, the excision of 
the gastric pacemaker at surgery, but also hormonal and neural signalling. Nevertheless, the rapid 
gastric emptying and intestinal motility may explain why the release of anorexigenic gut hormones 
after VSG is very similar in magnitude compared to RYGB.  
Caloric Malabsorption 
Even though some human and animal studies after RYGB have demonstrated some degree of fat 
[486-490], but not carbohydrate [478], malabsorption, this rarely lead to clinically significant 
steatorrhoea and malnutrition, which is different from the biliopancreatic diversion[491]. Patients 
after RYGB usually complain of constipation and the reduction in combustible energy absorption is 
low or moderate. The dietary fat intake of patients and length of the common channel may also be 
partly responsible for the degree of malabsorption. A non-significant increase in faecal caloric 
density has been demonstrated in animal models of VSG [489] and no studies have quantified it 
after BAND. 
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Bile acids 
Alterations in the levels or types of bile acids in the gut or the circulation after bariatric surgery have 
been implicated in the glycaemic improvements and even the reduction in food intake observed 
after RYGB.  Total plasma bile acids and their subfractions have been shown to be higher after RYGB 
[492-495], but not BAND, and their levels to negatively correlate with glycaemic excursions [492]. 
Plasma bile acids are also elevated in animal models of VSG [496]. Bile acids can directly or indirectly 
affect food intake, energy expenditure and glycaemic control through their actions on membrane 
TGR5 receptors or nuclear FXR receptors and the release of fibroblast growth factors (e.g. fibroblast 
growth factors 19 and 21) which can exert their action in a wide range of tissues including the 
hypothalamus [497-499]. Bile acids cross the blood-brain-barrier [500] and the TGR5 receptor has 
been identified in the brain in animals [501].   
Gut microbiota 
The role of gut microbiota in the context of obesity and weight loss has attracted significant interest. 
Obesity is associated in some, but not all studies, with an unfavourable colonisation of the bowel 
with bacteria that are more efficient in extracting energy from nutrients and storing it as fat [502]. A 
profound disturbance of this colonisation has been observed after RYGB in particular and includes 
the reduction in Prevotellaceae, Archea, Firmicutes, Bacteroidetes and an increase in the 
Bacteroidetes/Prevotella ratio and Gammaproteobacteria [503-505]. These alterations may be due 
to weight loss itself, changes in macronutrient proportions in the diet, anatomical manipulations, pH 
and bile flow amongst others. The confounding effects of variations in these factors together with 
the antibiotic use and metabolic control may be the cause of the variability of the results in the 
handful of published studies.  
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Energy expenditure 
A number of human and animal investigators have assessed energy expenditure after bariatric 
surgery and in particular RYGB. The vast majority, but not all [490], have shown that resting energy 
expenditure is either reduced [506-510] or remains stable [511]. Resting energy expenditure after 
VSG has only been assessed in rodent models which have demonstrated either stability [438] or a 
trend for a decrease [489]. Out of 3 studies in AGB, 2 have shown a decrease [495, 512] in resting 
metabolic rate and one an increase (when corrected for body weight) [513]. Any discrepancies 
between and within species arise due to the variability in the methodologies used, including 
differences in the normalisation for total, fat or lean body mass, the method used to quantify body 
composition, the inherent limitations of indirect calorimetry and the assessment of subjects with 
different food intake at different time points after surgery.  
However, human [514] and animal studies [515] have demonstrated that diet-induced energy 
expenditure is increased after RYGB compared to controls. This finding has significant mechanistic 
implications considering that both serum anorexigenic gut hormones and bile acids are higher after 
RYGB and may also modulate energy expenditure through their actions on the hypothalamus and 
brown adipose tissue respectively [516]. The only 2 mechanistic studies so far have not however 
supported this exciting hypothesis; no increase in brown adipose tissue activation was observed 
after RYGB in rats [517] and a higher TGR5 expression in skeletal muscle after RYGB did not translate 
to an increase in energy expenditure in humans [495]. 
1.3.3.2 Food preferences after surgery 
Halmi was the first to show that RYGB not only reduced total food intake, but also reduced the 
consumption of high-calorie carbohydrate food and suggested altered “digestion” of these as the 
cause (by digestion the authors perhaps mean altered post-ingestive effects or dumping)  [518]. In 
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the same study of 80 patients studied up to 24 months after surgery, the consumption of vegetables 
remained unchanged.   
Sugerman made the first efforts of “personalising” surgery depending on the patient’s eating habits. 
He used dietary interviews and randomised 40 patients to either RYGB or vertical banded 
gastroplasty. He showed that patients who preferred sweets lost more weight after RYGB compared 
to vertical banded gastroplasty. Patients reported being afraid to try sweets in fear of the dumping 
syndrome which was experienced by 80% of them or that they had “lost their taste” for sweets 
[519]. However, sweet eating before surgery did not predict weight loss in subsequent studies of the 
vertical banded gastroplasty and BAND, with sweet eaters doing equally well to non-sweet eaters 
after these procedures [520, 521].  
Coughlin found a continuous decrease in total caloric intake in 25 patients after RYGB up to 12 
months after surgery due predominantly to a reduction of calories eaten as fat [522].  
Kenler performed a non randomised but controlled 2 year study on the food preferences in patients 
before and after RYGB (n=48) and horizontal banded gastroplasty (n=34) [523]. One day dietary 
recall method was used at interviews with dieticians. The gastroplasty patients lost significantly less 
weight and consumed more total calories compared to the RYGB patients at 2 years. Interestingly 
only 16 patients in the former group vs. 44 in the latter completed the 2 year follow up. The 
consumption of sweet and dairy product items, as a proportion of total energy, decreased by 14-
21% in the RYGB group and was unchanged in the gastroplasty group. The percentage of energy 
contribution from protein increased and from fat and carbohydrates stayed the same in the RYGB 
group and remained unchanged in the gastroplasty group. Again no mechanistic reason was 
provided for these differences. However, the authors mention that RYGB patients reported that 
these food groups either cause gastrointestinal side effects, or they have “lost taste” for them. The 
longitudinal comparisons and the inclusion of a surgical control group in this study are very useful, 
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especially considering the significant limitations of 1 day diet recall (recall, expectations bias, poor 
estimation of portions eaten).  
Brolin performed a retrospective study of 136 patients that were followed up for 3 years and had 
their food preferences documented through 24 h recall [524]. They found that even though “sweet 
and snack” eaters were assigned to the RYGB group, they lost more weight and ate 9-17% less solid 
sweets, 3-7% liquid sweets and 5-8% of milk products (as a percentage of total caloric intake) 
compared to vertical banded gastroplasty patients who preferred high-calorie foods after surgery. 
The percentage contribution of fat, protein and carbohydrates, decreased, stabilised and increased 
in the RYGB group at the 3 year period compared to pre-operatively. This suggests that even through 
RYGB patients consumed more carbohydrates compared to pre-operatively, these were probably of 
low-glycaemic index. 
Opposite to the results so far, Trostler found that 19 post RYGB patients studied for 12 months using 
1 day intakes from 7 day diet records that the decrease in fat and protein intake decreased over 
time, whilst the consumption of sweets remained the same pre- and post-operatively [525]. Fruit 
and vegetable consumption also remained low at 5-10% of total energy intake.   
In 2004, Warde-Kamar’s group sent questionnaires to 360 patients though only 69 replied. All of 
them were at least 18 months and up to 4 years post RYGB [526]. They reported a reduction in total 
caloric intake but also intolerance to sweets (71%) due to the unpleasantness effects of the dumping 
syndrome.  
Thomas et al. studied the selection of fatty food in a post RYGB cohort of 38 patients who completed 
a 236-food item questionnaire 3-29 months post operatively [527]. There was a significantly higher 
selection of low compared to high fat foods, even though contra intuitively the f ormer caused 
“intolerance” at a higher rate than the latter. This report did not explain the reasons for this shift in 
preferences. Additionally, the patients were not studied pre-operatively and no control groups were 
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included. Two years later, the same group published the results of a larger cohort of 48 patients 
using exactly the same methodology. In contradiction to the first study, the RYGB group 
preferentially selected fruit/vegetable and fatty food compared to sweets, which were the least 
selected food items from the questionnaire [528] 
Ernst et al used food frequency questionnaires in a cross sectional study comparing 48 RYGB, 73 
BAND and 45 un-operated obese patients [529].  The two surgical groups were at least 1 year post-
operative. RYGB patients consumed food high in protein (poultry, eggs) and vegetable more 
frequently and fatty sweets less frequently compared to the un-operated obese group. Compared to 
the BAND group, RYGB patients consumed more fruit and eggs, but less chocolate. In a later study 
the same group assessed the hedonic drive to eat in 123 obese, 110 normal weight and 136 patients 
at least 1 year after RYGB, through the use of the “power of food” scale [319]. This questionnaire 
does not quantify food intake or preferences, but the motivation to eat palatable food. This cross-
sectional study showed that the motivation for palatable food was lower in RYGB patients compared 
to un-operated obese participants. Indeed, the RYGB scores in the scale were not different from 
those of normal weight participants. Using exactly the same methodology, but comparing 116 BAND 
with 138 obese and 133 normal weight control participants, the same group found that the power of 
food scale scores were lower in the BAND compared to the un-operated obese group [530].  
Olbers et al. performed a randomised controlled clinical trial in which patients were randomised to 
either RYGB (N=37) or vertical banded gastroplasty (N=46). Food preferences were assessed 1 and 6 
years post-operatively in a cross-sectional manner and showed that RYGB had a lower contribution 
of their energy intake from sweet and fatty food and a higher contribution from fruit and vegetable 
compared to the vertical banded gastroplasty group [506, 531]. The same group prospectively 
studied 43 patients before and after RYGB and assessed dietary energy density through dietary 
questionnaires [532]. Indeed, energy density decreased at 1 and 2 years compared to pre-
operatively, but this change did not correlate with percentage weight loss. In terms of other aspects 
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of eating behaviour, patients after RYGB increased the frequency of meals during the day, together 
with the rate of eating during a meal, whilst meal duration remained stable at 1 and 2 years 
compared to pre-operatively [441]. In the same cohort, emotional and uncontrolled eating, as 
assessed by the three factor eating questionnaire, were significantly lower post-operatively whilst 
restraint decreased only transiently. Similar results were obtained in an RCT comparing RYGB with 
the duodenal switch procedure [533]. 
Bavaresco et al. retrospectively analysed 24 hour recall diet data collected prospectively in 48 
patients [534]. They found that total caloric intake and absolute intake of protein, carbohydrates and 
fats were all reduced at 1 year after surgery. However, the percentage contribution from these 
macronutrients were only transiently decreased and certainly returned to pre-operative levels at the 
1 year follow up visit. 
Kruseman et al. performed the longest prospective follow up study in a group of 80 women who 
underwent RYGB. At 8 years the percentage contribution of protein decreased, carbohydrates 
remained stable and fats decreased compared to pre-operatively. Post-operatively, RYGB patients 
exhibited healthier eating behaviour in terms of lower bulimic tendencies, drive for thinness and 
body dissatisfaction [535].   
In conclusion, the overall suggestion from the above studies is that patients after RYGB have lower 
consumption and/or preference for sweet and fatty foods compared to pre-operatively, or 
compared to un-operated obese or patients after the gastroplasty or BAND procedures. There are 
however significant discrepancies in the literature and this partly reflect the weakness of the 
methodologies used, which in their majority rely on verbal report. It is well documented that obese 
patients underreport their food intake [224] and the methods used in many of these studies did not 
account for this. Other sources of variability include differences in surgical technique, time  since 
surgery, dietary advice, gender distribution and the stage in the menstrual cycle for women as this is 
known to affect food preferences [536]. Additionally, many of the studies do not report the 
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percentage contribution of a particular food or macronutrient to the total caloric intake, something 
which is crucial in the context of the longitudinal reduction of total caloric intake that takes place 
after bariatric surgery. The above studies however, have provided some clues as to the mechanisms 
behind the healthier food preferences after RYGB, through the use of verbal quotes in the published 
papers. The words “taste”, “intolerance/nausea/sickness”, “loss of interest/desire” are mentioned 
numerous times suggesting changes in taste function, aversive post-ingestive effects and/or a loss of 
the appetitive drive for sweet and fatty food. 
 
Animal studies 
Zheng et al. performed a prolonged and detailed paradigm in male Sprague-Dawley  rats that 
underwent RYGB or sham surgery and exposed to a choice of normal chow, liquid chocolate Ensure® 
(22% fat) and solid high-fat diet (60% fat) both pre- and post-operatively [442]. The RYGB model 
indeed lost ~20% of weight, predominantly in fat mass. Rats also decreased their meal size after 
RYGB, but partly compensated for this by increasing their meal frequency. In the early stage after 
RYGB (1-7 weeks) rats ate significantly less high fat solid diet compared to the sham rats but this 
difference became even more pronounced in the chronic stages after surgery (8-20 weeks). This 
suggests that early on after surgery a number of factors may be causing the reduction in fat 
preference, including its reward value, taste and adaptation of the gut to the new post-operative 
anatomy. However, the further reduction in fat intake later on after surgery strongly points to a 
learned mechanism, through which RYGB rats learn to avoid high-fat diets probably because of their 
unpleasant post-ingestive effects. The second important point from this study was that when 
exposed to only normal chow, RYGB rats ate more of it compared to sham rats, confirming not only 
that they preferred it but also that RYGB does not cause “restriction”. In the same experiment, a 
“lean” group of rats, which was fed normal chow pre-operatively, lost substantial amounts of weight 
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and showed a similar avoidance pattern to high-fat diet after RYGB as the obese, high-fat fed group 
of rats.  
An unexplained finding is that the intake of Ensure®, which contains a reasonable amount of fat and 
sugars, decreased transiently after RYGB and then increased to levels higher than sham controls, in 
contrast to the reduction in solid high-fat diet consumption. Additionally the authors did not 
perform experiments to determine the presence of fat malabsorption, as this could have contributed 
to the observed food preferences. 
Food preference tests after RYGB have also been performed by our group. Rat models of RYGB 
exhibited a lower preference for moderate and high concentrations of sucrose and Intralipid® (liquid 
mixture of fatty acids) and similar preference for low concentrations of both solutions to the sham 
rats [537, 538]. However, pre-operative dietary exposure had a significant effect on this behaviour; 
rats that were exposed to sucrose pre-operatively had a similar intake of sucrose to the sham 
operated rats for the low and moderate, but not the high, concentrations of sucrose, suggesting that 
the effect of surgery was attenuated in these rats. Therefore, the novelty of a food stimulus and its 
avoidance (also known to neophobia) is another factor that can affect food choices af ter RYGB. 
Further support for this learning process comes from the finding that it is difficult for rats to develop 
condition taste aversion to a familiar food stimulus, but much easier to a novel one, especially if the 
latter is associated with unpleasant post-ingestive effects [539, 540]. The contribution of pre-
operative exposure to a high-fat diet on food preferences and ingestive behaviour after RYGB has 
not been investigated before. 
Additionally, large discrepancies have been observed when trying to explain the mechanisms 
underlying this change in food preferences (Table 1.2). In paradigms assessing the appetitive reward 
value of a sweet reinforcer, Berthoud’s lab found that RYGB rats run faster than sham animals on a 
“runway” test in order to obtain the reward [541]. Firstly, this finding is not consistent with the 
reduced consumption of sweets after RYGB in animals or humans [506, 537]. Secondly, the runway 
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test is not a good test to perform in this context, as the slimmer rats after RYGB will inevitably run 
faster than the obese sham controls, independently of their motivation. A far supe rior test is the 
progressive ratio task, but this has not been used yet. The progressive ratio task was developed in 
1961, assesses appetitive responses and is therefore not influence by the effects of body weight as 
the runway test is [230]. The animal is required to press a lever in order to obtain a reinforcer (or 
“reward”). The lever pressing requirements can be adjusted so that they progressively increase, 
requiring the animal to exert increasing amounts of work in order to obtain the reinforcer. The point 
to which the animal stops pressing is called the “breakpoint” and presumably is the point at which 
the effort required to obtain the reinforcer is too great relative to reinforcing efficacy of the 
stimulus. The breakpoint is therefore a marker of the rewarding value of the stimulus. 
Concentration-response curves can also be performed. 
The taste reactivity test measures consummatory responses [229]. Liquid stimuli can be delivered in 
the oral cavity of the animal through a cannula and the facial reactions are videotaped and analysed 
by the investigator. These facial reactions can be classified into either ingestive/”positive” (i.e. 
tongue protrusions, paw licking in response to sweet) or aversive/”negative” (i.e. gapes, chin rubs in 
response to bitter). Concentration-response curves can also be performed. In paradigms assessing 
taste reactivity, Berthoud’s lab found that the positive orofacial reactions to low sucrose 
concentrations are higher and to high-sucrose concentrations lower after RYGB [541]. Even though 
this finding is consistent with the change in overall food preferences, the technique used deviates 
from the original technique described by Grill and Norgren [542], in that the tastant was not 
delivered through an intraoral infusion to the animal’s tongue, but instead the animal had to 
approach a drop on the floor of the cage. This behaviour has therefore a significant appetitive 
component, and is not purely consummatory as it was originally designed to be. Additionally, the 
observer counting the orofacial reactions could not have been blinded to the type of surgery the 
animals had, as the difference between an obese and lean animal is easy to spot. 
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The brief access test measures both appetitive and consummatory taste responses and takes place 
in an apparatus called a “Davis rig” [229]. The animal is presented with taste stimuli for a short 
period of time (e.g. 10 seconds). The appetitive part of the test measures whether the animal will 
approach the device’s spout to obtain the stimulus. The consummatory part of the test measures 
the number of tongue protrusions in the 10 second period. A number of concentrations can be used 
in the same trial allowing and the number of trials can be increased to improve the estimate of 
responsiveness. The brief access test has been used by 4 independent investigators after RYGB and 
has yielded contradictory results. In the hands of Berthoud, Tichansky and Hajnal, the 
consummatory component (number of licks) was higher for low concentrations of sucrose and/or 
corn oil and lower for high concentrations after RYGB [541, 543, 544]. In the hands of le Roux and 
Spector, the consummatory responses were higher for sucrose and unchanged for a solution of fatty 
acids (Intralipid®) after RYGB [538, 545].  
These discrepant results may be due to the differences in the animal strains used, the use of pair-fed 
or ad libitum shams as controls, timing after surgery and the variable anatomic manipulations in 
each RYGB model (Table 1.2). Therefore no definitive conclusions can be drawn on the results of the 
brief access test after RYGB in rats. Differences in the anatomical manipulations in rat and mice 
models appear to play a more significant role that in humans. For example, even small variations in 
the length of the common limb has resulted different phenotypes in rats even within our own 
laboratory. When the common limb is “too long” (i.e. >25 cm) the rats do not lose weight, whereas if 
it is less than 22 cm, the rats start to malabsorb and lose excessive amounts of weight. Variations 
between laboratories will only exaggerate this variability in phenotypes.  
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Table 1.2: Ingestive behaviour in animal models of gastric bypass  
Group Surgical technique 
Strain 
Pouch size (%) 
Alimentary (cm) 
Biliopancreatic (cm) 
Common (cm) 
Maintenance 
diet 
Weight 
loss (%) 
Control 
group(s)  
Intake 
Complex food 
Timing (wk) 
Result 
Preference 
Stimulus 
Timing (wk) 
Result 
Brief access 
Stimulus 
Timing (wk) 
Licks 
Trials 
Appetitive 
Stimulus 
Timing (wk) 
Result 
Consummatory  
Stimulus 
Timing (wk) 
Result 
CTA 
Stimulus 
Timing (wk) 
CTA seen 
le Roux 
[537, 538, 
545] 
Wistar/SD 
<5 
50 
10 
25 
LF chow 10-15 Sham 
operated ad 
libitum fed 
HF and LF chow 
2 
↓HF/↑LF 
Sucrose 
2 
↓ in high 
concentrations 
Sucrose 
2-3 
↑ 
↑ 
N/A N/A Sucrose 
N/A 
Intralipid 
2 and 28 
↓ in high 
concentrations 
Intralipid 
21 
→ 
→/↑ 
N/A N/A Corn oil 
14 
Yes 
Berthoud 
[442, 541] 
SD 
20 
15 
40 
25 
HF and LF 
chow/Ensure ® 
~20 Sham 
operated ad 
libitum fed 
Ensure
®
/HF and LF 
chow 
1-20 
↓Ensure®/↓HF/↑LF 
N/A Sucrose 
17-23 
↑ licks to low and ↓ licks  to 
high concentrations 
N/A 
Frui t loop serial 
17-23 
↑ speed 
 
 
 
Sucrose 
17-23 
↑ (+) reactions 
to low and ↓(+) 
reactions  to 
high 
concentrations 
Sucrose 
N/A 
N/A Corn oil 
↑ licks to low and ↓ licks  to 
high concentrations 
N/A 
Corn oil 
N/A 
Corn oil 
N/A 
Corn oil 
N/A 
Tichansky
[543] 
SD 
10 
10 
15 
N/A 
LF chow <14 Sham 
operated ad 
libitum fed 
N/A N/A Sucrose 
4 
↓ in high concentrations 
→/↓ 
Sucrose 
N/A 
Sucrose 
N/A 
Sucrose 
N/A 
Hajnal 
[544] 
OLEFT/LETO 
20 
10 
16 
33 
LF chow ~26 Sham 
operated ad 
libitum and 
pair fed rats 
N/A Sucrose 
6 
↓ in high and low 
concentrations 
Sucrose/Fructose 
3 
↑ licks to low and ↓li cks  to 
high concentrations 
N/A 
Sucrose 
N/A 
Sucrose 
N/A 
Sucrose 
N/A 
Abbreviations: SD: Sprague-Dawley, HF: high-fat, LF: low-fat, Surgical technique: percentage of original stomach and limb lengths shown, CTA: conditioned taste aversion, 
↑/↓/→: higher/lower/ not different compared to sham operated rats, (+)/(-): positive/negative, N/A: not available, OLETF: Otsuka Long-Evans Tokushima Fatty rats, LETO:  
Long-Evans Tokushima Fatty rats, wk: weeks. 
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 Neuroimaging studies 
One fMRI and two PET studies have provided preliminary data on the effects of bariatric surgery on 
brain activation and dopaminergic function. Geliebter’s group in New York scanned 10 obese women 
before and 1 month after RYGB using fMRI [546]. Participants were scanned 1 hour after a small fixed 
meal of 250 kCal and were exposed to both visual and auditory cues within the scanner; these 
included pictures and references to high-calorie and low-calorie foods. Participants were also asked 
to rate verbally their “desire to eat” the pictures they had just seen. The study showed that 
activation in response to the high-calorie vs. low-calorie (both visual and auditory) cue contrast was 
significantly reduced after surgery in the dorsolateral prefrontal cortex, precuneus, dorsal cingulate, 
lentiform nucleus, and ventral striatum and that patient’ ratings decreased more for high -calorie 
than low-calorie foods. Even though this study was the first of its kind, it suffers from a number of 
limitations, the most important of which was the lack of properly conducted correction for multiple 
comparisons in brain activation. Additionally, patients were studied very early after surgery (1 
month) and before they had resumed to normal eatin; other than the “desire to eat” rating, little 
information was provided on behavioural measures, there was no control of time of the menstrual 
cycles during which the women were scanned [367], and there was no control group for order effects 
or effects of weight loss or the early post-operative diet. 
More conclusions can be drawn from the second study from the same group in which 14 patients 
were scanned and a post-operative reduction in the activation of the lentiform nucleus, putamen and 
dorsolateral prefrontal cortex was seen in response to high-calorie vs. low-calorie food cues (visual 
and auditory) [547]. These changes were also accompanied and predicted the reduction in the 
subjective “desire to eat” of high-calorie but not low-calorie foods.   
Dunn et al. studied 5 obese female patients before and 6-11 weeks after RYGB or VSG using  18F-
fallypride PET a ligand that binds to dopamine receptor D2 and D3 sub-types, similar to raclopride 
[548]. They found reduced DRD2/3 availability only in the substantia nigra region of interest and 
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 postulated that this was the result of higher dopamine levels in this region after surgery. This study is 
limited by the small sample size, lack of controls for weight loss itself, lack of measurement of 
dopamine release (e.g. by using an amphetamine challenge), “mixing” RYGB and VSG patients in the 
same cohort and lack of behavioural measures. Additionally, it is unclear whether the substantia 
nigra can be readily distinguished with the resolution of PET scanners. 
A study published in the same year showed exactly the opposite result [549]. Steele et al. scanned 5 
female patients before and 4-6 weeks after RYGB using the DRD2/3 ligand 11C-raclopride. They found 
that the DRD2/3 availability across 5 regions of interest (anterior putamen, posterior putamen, 
anterior caudate nucleus, posterior caudate nucleus and ventral striatum) increased after surgery, 
therefore “reversing” the low dopamine receptor availability present in obesity. This study has 
similar limitations to that by Dunn et al. The discrepancy between the two PET studies may  be 
explained by differences between the cohorts e.g. in the Steele study participants were older and 
more depressed, and the mixture of bariatric procedures.  
The only fMRI study on BAND, assessed 10 obese patients before and 3 months after BAND [550]. 
Using food pictures as cues, they found that in the fasted state activation in the middle frontal and 
superior frontal gyri was higher after BAND, whereas in the post-prandial state activation in the right 
frontal gyrus, insula, inferior frontal gyri and parahippocampal gyrus were lower after surgery. The 
authors suggest that this allowed patients to exercise more cognitive “restraint” over food intake, as 
supported by their questionnaire results. The interpretation of these results should be very cautious 
in view of the uncorrected statistics, lack of a control group and lack of any information on the how 
much fluid was inserted in each patient’s band at the time of scanning. As in the RYGB studies, the 
absence of a control group cannot exclude an order effect and a reduction the activation in brain 
reward systems due to increased familiarity with the cues [174, 551]. Nevertheless, the results are 
consistent with the only human behavioural study showing reduction in the reward value of food 
after BAND [530].  
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 Therefore the evidence for a change in activation of brain reward systems following RYGB i s based on 
studies with some methodological limitations. 
 
Effects of surgery on taste function 
Scruggs et al. were the first group to investigate the effects of RYGB on taste acuity [552], testing 6 
obese and 10 lean women at baseline and 1,2 and 3 months post-RYGB in the obese using the Henkin 
forced choice three stimulus drop technique. This involves placing one drop of tastant and two of 
deionised water on the tongue at the same spot at different times. The detection threshold was 
defined as the concentration at which the participant detected a difference between the stimuli, and 
the recognition threshold the concentration at which they identified the nature of the taste stimulus. 
Hydrochloric acid, urea, sucrose and sodium chloride were used to represent sour, bitter, sweet and 
salt tastes. No difference in taste acuity was shown at baseline between lean and obese. After RYGB 
there was a reduction in the taste recognition and detection thresholds for hydrochloric acid and 
urea and a trend towards a decrease in the sucrose and sodium chloride detection and recognition 
thresholds. The weaknesses in this study include the small obese group sample size, one drop of 
tastant only stimulated a very small area of total receptor field, and there was no control over the 
effects of repeated testing which can on its own improve sensory detection performance. 
Burge studied the taste acuity for sweet and bitter in patients before and after both RYGB and VLCD 
[553]. They used the Cornsweet’s method in which 10 concentrations of sucrose and 9 of urea are 
presented to participants in an up and down forced choice way. Fourteen RYGB patients completed 
the test for sweet, 12 for bitter before, 6 and 12 weeks post-operatively, whilst only 4 VLCD 
participants completed both tests at similar intervals. Sweet taste recognition thresholds decreased 
significantly in the RYGB but not in the VLCD group. There was no change in the bitter thresholds in 
either group. Zinc deficiency which has been shown to altered taste acuity was not detected in this 
patient cohort. This was the first paper to show that RYGB may affect the sensory domain of sweet 
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 taste. The weaknesses of the study include the expectation bias in the staircase taste detection 
method and the small sample size in the VLCD group. 
Our unit has recently performed a similar experiment, but used the method of repeated stimuli 
[537]. In this method, 7 ascending concentrations of sweet solutions were presented, 8 times each, 
to the participant in a random order (56 trials). The sweet solutions were randomly inter-dispersed 
with water trials (56 trials), therefore the participant has no expectations of the nature of the next 
stimulus. The participant sipped and spat the solution before providing an answer as to whether 
what they had tasted was sweet or non-sweet, correct answers interpreted as a “hit” and incorrect 
as “misses”. These responses are then fitted to a sigmoidal function which gave a measure of the 
concentration of sweet that the subject identified correctly 50% of the time; this can be used as an 
index of detectability. Using this method, 9 obese patients were studied before and after RYGB and 
compared to 9 normal weight volunteers. Sweet taste detection was not different between the 
groups at baseline, but decreased significantly in the obese group only after RYGB, suggesting that 
these patients’ acuity for sweet taste was improved. Even though food preferences were not 
assessed, the improved taste acuity may have led to the consumption of less sweet food post-
operatively.  
Therefore the available evidence suggests that taste acuity for sweet improves, at least early, after 
RYGB and this may lead to a higher intensity of sweet and consequently consumption of foods lower 
in sugar. So far, no studies have investigated the effects of bariatric surgery on the reward and 
physiology domain of taste. 
 
Post-ingestive factors 
The dumping syndrome has been reported to contribute to the development of food preferences 
after bariatric surgery. This is an “umbrella” syndrome that includes a number of symptoms including 
nausea, flushing and abdominal pain/discomfort after the ingestion of food high in refined 
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 carbohydrates or fat. The underlying pathophysiology of the condition is poorly understood, but the 
rapid delivery of an osmotically high bolus of food in the small bowel triggers the flow of fluid from 
the intravascular compartment, resulting in hypotension and tachycardia [554]. However, many 
patients get similar symptoms in the absence of hypotension, suggesting the contribution of neural 
signals and even hypoglycaemia to their presentation. The diagnosis of the dumping syndrome is 
based on questionnaires or provocation with an oral glucose tolerance test [554]. The dumping 
syndrome is more common after RYGB (occurring in up 75% of patients) compared to the 
gastroplasty procedures (with no patients having been diagnosed with dumping) [555] and these 
aversive symptoms may be contributing to the reduced preference of high fat/sweet foods after 
RYGB. Surprisingly, there are no studies regarding the prevalence of dumping after BAND.  
 
1.3.4 Summary of introduction section 1.3 and relevance to the thesis 
 Bariatric surgery is the most effective treatment for weight loss and some of the obesity related 
comorbidities.  
 Contrary to what was previously thought, RYGB and VSG do not cause restriction or significant 
malabsorption, but increase satiety partly through the exaggerated release of anorexigenic gut 
hormones after the consumption of smaller meals. BAND may reduce food intake through 
increased vagal signalling to the hypothalamus.  
 Even though there are discrepancies in the human and animal literature, RYGB appears to shift 
food preferences away from foods high in fat and sugar, to healthier and less energy-dense 
options. 
 In rodent studies, pre-operative exposure to sucrose was associated with an attenuated effect of 
RYGB surgery on sucrose preference (compared to rats that were not exposed to sucrose pre-
operatively).  
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  The effects of pre-operative exposure to a high-fat diet pre-operatively on weight loss, caloric 
intake and the development of food preferences after RYGB in rodents have never been 
investigated before.  
 The mechanisms for the food preference change are unclear but may include reduced activation 
of brain reward systems to high-calorie food, changes in taste function, and aversive post-
ingestive effects of the dumping syndrome or a combination of the above. 
 The evidence for a change in activation of brain reward systems following bariatric surgery in 
humans is based on studies with some methodological limitations. 
 So far, no studies have investigated the effects of bariatric surgery on the reward and 
physiological domain of taste in humans. 
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CHAPTER 2 
EFFECTS OF GASTRIC BYPASS SURGERY AND PRE-
OPERATIVE DIET ON INGESTIVE BEHAVIOUR IN RATS 
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 2.1 ABSTRACT 
 
Introduction: The consumption of high-fat and sugar diets is decreased after gastric bypass surgery 
(RYGB) in humans and rodents. However, pre-operative exposure to sucrose can attenuate this 
change in food preferences. The effects of pre-operative exposure to a high-fat diet on food 
preferences after RYGB have not been examined before. In this study, an established RYGB rat model 
was used to determine whether the fat content of pre-operative maintenance diets affects weight 
loss, calorie intake, and macronutrient selection after surgery. 
Methods: Male Wistar rats were fed either a low-fat diet (LFD) or a high-fat diet (HFD) before 
randomisation to RYGB or sham surgery. In Food Preference Test 1, animals were offered a choice of 
a vegetable drink (V8®) and a high-calorie liquid (Ensure®), and in Food Preference Test 2, a choice of 
solid normal chow and high-fat diet.  
Results: There were no significant differences in body weight loss and caloric intake between the 
RYGB groups who had a LFD or HFD pre-operatively. In Food Preference Test 1, both groups 
responded similarly, by reducing their preference for Ensure ® and increasing preference for V8®. In 
Food Preference Test 2, the HFD-RYGB rats reduced their preference for solid high-fat diet gradually, 
compared to the immediate reduction observed in the LFD-RYGB rats. 
Conclusion: RYGB surgery in rats was associated with a shift away from fatty/sweet solids and liquids 
and an increase in the consumption of healthier low-fat and vegetable foods. The consumption of 
pre-operative maintenance diets with different fat contents, did not affect post-surgical weight loss. 
Although the trends in feeding behaviour were in the same direction for both RYGB groups, HFD-
RYGB rats took longer to change their preference away from a high-fat diet to normal chow post-
operatively. From a mechanistic point of view, the behaviour of the HFD-RYGB animals was 
consistent with a condition taste aversion to a known stimulus, compared to a condition taste 
aversion to a novel stimulus in the LFD-RYGB animals. From a translational point of view, these 
results suggest that RYGB may be equally effective in facilitating weight loss in patients who consume 
either high or low-fat diets pre-operatively.  
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 2.2 INTRODUCTION 
 
Gastric bypass surgery (RYGB) for morbid obesity results in approximately 25% body weight loss over 
20 years while also improving obesity-related comorbidities and mortality [423, 424]. Reduction in 
food intake is one of the major contributing factors to induce and maintain long term body weight 
loss [556]. There is increasing interest focusing on changes in ingestive behaviour and food selection 
especially with respect to dietary macronutrient composition that may occur after RYGB ( Section 
1.3.3.2, page 108).  
The majority of the human literature on the changes in food preferences after RYGB suggests that 
patients consume fewer calories from energy dense high-fat and sugar foods and may even increase 
their consumption of fruit and vegetables [506, 522-525, 534, 535, 557].  It is unclear whether the 
observations in humans are due to nutritional counselling or due to surgery-induced changes in 
physiology. There are also some inconsistencies in the magnitude and durability of the reported 
RYGB-related changes in food selection [558]. One source of the disparities in the literature may be 
the methodology used to assess eating behaviour and food intake, i.e. food diaries, retrospective 
dietary recall and interviews which are vulnerable to bias, and inter- and intra-subject variability. 
Another possibility is that pre-operative dietary habits (e.g. high-fat vs. low-fat) may influence the 
nature of dietary shifts that take place after the operation and ultimately affect the success of the 
procedure itself.  
The use of rodent models of RYGB to investigate changes in food preference circumvents many of 
the caveats of human experimentation whilst allowing more in-depth interrogation of the 
responsible physiological mechanisms (Section 1.3.3.2, page 113). A number of studies have 
investigated the effects of RYGB on food preferences in rats. In the first one, the RYGB models lost 
~20% of weight, predominantly in fat mass [442]. RYGB rats also decreased their meal size, but partly 
compensated for this by increasing their meal frequency. In the early stage after surgery, RYGB rats 
ate significantly less high-fat solid diet compared to the sham rats but this difference became even 
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 more pronounced in the chronic stages after surgery. In the same experiment, a “lean” group of rats, 
which was fed normal chow pre-operatively, lost substantial amounts of weight and showed a similar 
avoidance pattern to high-fat diet after RYGB as the “obese”, high-fat fed group of rats. Whilst this 
was a comparison of the effects of pre-operative weight on outcomes after RYGB, no studies have 
examined the effects of pre-operative exposure to a high vs. a low-fat diet (in animals of similar pre-
operative weight at the time of surgery) on ingestive behaviour and weight loss outcomes after 
RYGB. 
Indeed, in a subsequent study performed by our group, rat models of RYGB exhibited a lower 
preference for moderate and high concentrations of sucrose and Intralipid® (liquid mixture of fatty 
acids) and similar preference for low concentrations of both solutions to the sham rats [537, 538]. 
Pre-operative dietary exposure had a significant effect on this behaviour; rats that were exposed to 
sucrose pre-operatively had a similar intake of sucrose to the sham operated rats (at least for low 
and moderate sucrose concentrations), suggesting that the effect of surgery was attenuated in these 
rats. Therefore, the novelty of a food stimulus and its avoidance (also known to neophobia) is 
another factor that can affect food choices after RYGB. Further support for this learning process 
comes from the finding that it is difficult for rats to develop condition taste aversion to a familiar 
food stimulus, but much easier to a novel one, especially if the latter is associated with unpleasant 
post-ingestive effects [539, 540]. 
Although there is still no consensus as to the definition of diet-induced obesity in rats [559] most 
researchers feed rats with a high-fat diet to render them obese before RYGB. This may have 
significant confounding effects on various tests to assess feeding behaviour and food selection after 
RYGB, and, secondly does not allow the translation of these results to the clinical subgroup of RYGB 
patients who have a low-fat diet pre-operatively.     
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 2.3 HYPOTHESIS 
1. The fat content of the pre-operative maintenance diet affects weight loss, caloric intake, and 
food preferences after RYGB surgery in rats. 
 
2.4 AIM 
In this context, an established RYGB rat model was used to determine whether: 
1. Feeding the RYGB rats with a high vs. low-fat diet pre-operatively resulted in different weight loss 
and caloric intake profiles, and macronutrient choices in food preference paradigms post-
operatively. 
 
2.5 METHODS  
Rats 
Wistar rats (Harlan, UK) were housed under a 12/12 h light–dark cycle at room temperature (21 ± 2 
°C). Water and standard laboratory chow (RM1 diet, Special Diet Services Ltd, UK) were available ad 
libitum, unless otherwise stated. All experiments were performed in accordance to UK Home Office 
regulations under the project licence (PL 70/6669).  
The experimental design is illustrated in Figure 2.1, and Table 2.1 provides the detailed 
macronutrient composition of the diets used. Twenty-eight male Wistar rats (12-14 weeks of age) 
were divided into two groups based on their body weight.  The low-fat diet fed group (LFD) included 
all rats with a body weight above the median of 310.1 g (mean ± SEM: weight 317.7 ± 16.4 g); they 
received ad libitum standard chow (LFD). The high-fat diet fed group (HFD) included all rats with a 
weight below the median of 310.1 g (mean ± SEM weight: 279.6 ± 16.9 g); they had free access to 
solid high-fat diet (C1090-60, Altromin GmbH & Co. KG, Germany, HFD). This was done to allow the 
age-matched rats in the LFD and HFD groups to achieve similar body weight at the same time prior to 
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 surgery. Both groups stayed on their respective diets for 63 days. Between day -63 and day -48 
animals were housed 2-3 per cage and body weight was recorded weekly.  From day -14 onwards, all 
rats were kept singly housed and food intake and body weight were measured daily.  
When the body weight of every rat exceeded 500 g, animals in both groups were randomized to 
either gastric bypass (LFD-RYGB n=10 vs. HFD-RYGB n=7) or sham procedures (LFD-SHAM, n=6 vs. 
HFD-SHAM n=5). Post-operatively, all animals were given a diet of normal chow powder mixed with 
water (wet diet) for one day. Thereafter, all rats were offered standard normal chow ad libitum until 
post-operative day +15.  
 
 
 
Figure 2.1: Experimental design  
 
Rats were either high-fat (HFD) or normal chow (LFD) diet for 63 days prior to surgery. All  rats were offer ed 
normal chow between days 0 to +16. In Food Preference Test 1 (FPT 1), rats were offered Ensure
®
, V8
®
, water 
and 5 g of normal chow per day between post-operative days +15 to +21. In Food Preference Test 2 (FPT 2), 
rats were offered solid high-fat diet, normal chow and water between post-operative days +26 to +29. 
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 Table 2.1: Macronutrient composition of the diets used  
 % energy contribution from Energy density  
Carbohydrates  Protein  Fat  
 
 
Solid High-Fat Diet 19.8 17.7 62.5 5.0 kcal/g 
Normal chow 75.1 17.5 7.4 3.5 kcal/g 
Ensure® liquid 54.5  15.0  30.5 1.5 kcal/ml 
V8® liquid 67.2 21.3 12.5 0.2 kcal/ml 
 
Surgery 
All surgical procedures were performed by one surgeon (Dr. Florian Seyfried) as previously described 
[473] (Figure 2.2). Food was removed from the rats 6 h before surgery. Anaesthesia was induced in a 
chamber with 5% isoflurane and 2% oxygen. Animals were then placed on a heating pad and were 
given 1.25 mg/Kg amoxicillin intraperitoneally and 3 mg/kg carprofen subcutaneously as prophylactic 
antibiotic and analgesia, respectively. Anaesthesia was maintained with 2-3% isoflurane and 2% 
oxygen.  
The abdominal wall was opened through a midline incision. For the gastric bypass, the jejunum was 
transected 16 cm below the pylorus to create the biliopancreatic limb. In the next step, the gastro-
oesophageal junction was exposed and the oesophagus was mobilized. The left gastric vessels and 
vagal fibres were gently shifted laterally in order to avoid intra-operative bleeding and ischaemia of 
the remnant stomach. The stomach was then divided 3 mm below the gastro-oesophageal junction 
in order to create a small pouch. After closure of the gastric remnant, the mid-jejunum was 
anastomosed in an end-to-side fashion to the small pouch. The caecum was then identified and a 7 
mm side-to-side jejuno-jejunostomy was made between the biliopancreatic limb and the alimentary 
limb creating a common channel of 25 cm in length.  
For the sham operations, the small bowel and the gastro-oesophageal junction were mobilized and a 
gastrostomy (1 cm in length) was performed on the anterior wall of the stomach with subsequent 
closure. The abdominal wall was closed using continuous sutures and the skin was closed intra-
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 cutaneously. Buprenorphine (0.1 g/kg) was administered i.p. for post-operative analgesia during 
surgery and on post-operative days 1 and 2 once a day.   
Figure 2.2: Surgical manipulations 
 
Anatomical manipulations of the gastrointestinal tract for a) sham-operated rats and b) RYGB. BP representing 
the bil iopancreatic limb, AL the alimentary l imb and CC the common channel. The grey areas represent parts of 
the gastrointestinal tract which are bypassed from nutrient flow after RYGB. The arrows represent the flow of 
nutrients after each intervention. 
 
Food Preference Tests    
The macronutrient composition and energy density of the diets used is detailed in Table 2.1. Food 
Preference Test 1 took place between post-operative days +15 and +21. Animals were offered three 
different types of ad libitum liquids in three single bottles: 450 ml of water, 75 ml of a commercially 
available vegetable drink (V8®, Campell foods, Belgium) and 150 ml of a commercially available 
balanced high calorie liquid diet equivalent to a mixed meal (Ensure ®, Abbot, UK). Each day the 
contents of the bottles were freshly prepared and weighed at room temperature before they were 
given to the rats at the onset of the dark phase. The position of the bottles was swapped every 24 
hours to avoid the development of a preference for a specific bottle position. To control for spillage 
three additional bottles containing the same liquids were placed in an empty cage that was handled 
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 similarly to the cages containing rats. The spillage was measured and subtracted from the consumed 
volumes of the rats prior to analysis. Preference/relative intake for V8® was expressed as a 
proportion of total fluid intake (V8®/ (V8® + Ensure® + water intake)). All rats were also offered 5 
grams of normal chow and the duration of the test was limited to 6 days, as pilot studies showed that 
the RYGB group reduced their caloric intake to such a degree that they started to lose weight during 
the test. Between days +22 and +25 the rats received ad libitum standard chow before Food 
Preference Test 2 was started.  
In Food Preference Test 2, between post-operative days +26 to +29, all rats were offered free access 
to both standard chow (RM1 diet, Special Diet Services Ltd, UK) and solid high-fat diet (C1090-60, 
Altromin GmbH & Co. KG, Germany, HFD). From post-operative day +29 onwards, all rats were 
offered standard chow ad libitum. 
Statistical Analysis 
Two basic types of analysis of the data were conducted, using Graph Pad® Prism® version 5.  First, to 
discern the effect of surgical condition (SHAM vs. RYGB) on measures within the HFD and LFD groups, 
a 2-way ANOVA (surgical condition vs. time in days) was performed for each dietary group. Second, 
to discern the effect of pre-operative dietary condition (HFD vs. LFD) on measures within the RYGB 
and SHAM groups, a 2-way ANOVA (diet x time in days) was performed for each surgical group.  
Finally, to discern the effect of each Food Preference Test on measures within each of the four 
groups (before vs. during the Food Preference Test), a 2-way ANOVA (Food Preference Test x time in 
days) was performed for each of the 4 groups.  
2.6 RESULTS 
There was a mortality of 23% (4/17) after RYGB, while none of the sham-operated animals died. In 
the LFD group, 8 LFD-RYGB and 6 LFD-SHAM rats completed both food preference tests, whilst in the 
HFD group 5 HFD-RYGB and 5 HFD-SHAM rats completed both food preference tests.  
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 Body Weight 
The plots of the body weight of each of the groups of rats are illustrated in Figure 2.3. There was no 
difference in body weight between the HFD and LFD groups prior to surgery (p=0.47). From the first 
few days after surgery, the body weight of the RYGB rats was significantly lower than the body 
weight of SHAM rats in both the HFD and LFD groups (p<0.0001). Pre-operative dietary exposure did 
not have a significant main effect on body weight in either the RYGB (p=0.38) or SHAM groups 
(p=0.60), (Table 2.2).  
 
 
 
Figure 2.3: Body weight plots throughout the study  
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Body weight plots of the HFD (A, HFD-SHAM n=5 fi lled circles, HFD-RYGB n=5 empty circles) and LFD groups (B, 
LFD-SHAM n=6 fi lled squares, LFD-RYGB n=8 empty squares) throughout the study. Data are presented as 
means ± SEM. HFD: high-fat diet fed, LFD: low-fat diet fed, RYGB: gastric bypass. 
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 Caloric intake 
Figure 2.4 shows the daily calorie intake of all 4 groups from day 0 onwards. The daily caloric intake 
of all 4 groups had stabilised by post-operative day +10, and was 20-30% lower in the RYGB 
compared to the SHAM groups (HFD: p=0.019, LFD: p<0.0001). Within both the RYGB and SHAM 
groups, pre-operative dietary exposure did not have a significant main effect on the daily caloric 
intake (p=0.64 and p=0.06 respectively). The interaction of pre-operative dietary exposure and time 
had a significant effect only in the SHAM group (p=0.01), Table 2.2).   
 
Figure 2.4: Caloric intake between days +10 and the end of the experiment 
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Total calorie intake from post-operative day +10 until  the end of the study for the HFD (A: HFD-SHAM n=5 fi lled 
circles, B: HFD-RYGB n=5 empty circles) and LFD groups (C: LFD-SHAM n=6 fil led squares, D: LFD-RYGB n=8 
empty squares). Data are presented as means ± SEM. HFD: high-fat diet fed, LFD: low-fat diet fed, RYGB: gastric 
bypass, FPT 1: food preference test 1, FPT 2 : food preference test 2.  
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 Table 2.2: Between group comparisons for the entire study 
 
 
HFD-SHAM 
(n=5) 
HFD-RYGB 
(n=5) 
LFD-SHAM 
(n=6) 
LFD-RYGB 
(n=8) 
HFD group  
Effect of surgery 
Effect of time 
Interaction  
LFD group 
Effect of surgery 
Effect of time 
Interaction  
RYGB group 
Effect of diet 
Effect of time 
Interaction  
SHAM group 
Effect of diet 
Effect of time 
Interaction  
Body weight (g) 543.3 ± 7.0 420.1 ± 10.3 537.3 ± 7.4 432.9 ± 8.4 F (1,8)=64.9, P<0.0001 
F (13,104)=7.8, P<0.0001 
F (13,104)=56.7, P<0.0001 
F (1,12)=92.4, P<0.0001 
F (13,156)=9.6, P<0.0001 
F (13,156)=66.4, P<0.0001 
F (1,11)=0.8, P=0.38 
F (13,143)=59.5, P<0.0001 
F (13,143)=1.4, P=0.15 
F (1,9)=0.3, P=0.60 
F (13,117)=141.1, P<0.0001 
F (13,117)=0.3, P=1.00 
Overall caloric 
intake (kCal/day) 
102.1 ± 5.0 70.2 ± 3.9 110.3 ± 5.5 74.5 ± 3.3 F (1,8)=20.7, P=0.019 
F (39,312)=25.9, P<0.0001 
F (39,312)=14.8, P<0.0001 
F (1,12)=139.2, P<0.0001 
F (39,468)=26.6, P<0.0001 
F (39,468)=19.7, P<0.0001 
F (1,11)=0.2, P=0.64 
F (39,429)=23.5, P<0.0001 
F (39,429)=1.4, P=0.08 
F (1,9)=4.9, P=0.06 
F (39,351)=57.9, P<0.0001 
F (39,351)=1.7, P=0.01 
 
Data described using mean ± SEM. To discern the effect of surgical condition (SHAM vs. RYGB) on measures within the HFD and LFD groups, a 2-way ANOVA 
(surgical condition vs. time in days) was performed for each dietary group.  To discern the effect of presurgical dietary condition (HFD vs. LFD) on measures 
within the RYGB and SHAM groups, a 2-way ANOVA (diet x time in days) was performed for each surgical group.  
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 Food Preference Test 1 
 
Figure 2.5 illustrates the food intake and Figure 2.6 the relative intake of V8® of all 4 groups which 
took place during Food Preference Test 1 on post-operative days +16 to +21. Table 2.3 summarises 
the results of Food preference Test 1.  
Within both the HFD and LFD groups, surgery had a significant effect in that RYGB rats showed a 
significantly lower absolute intake of Ensure® compared to SHAM animals (HFD: p<0.0001, LFD: 
p<0.0001). Within both the RYGB and SHAM groups, pre-operative dietary exposure did not have a 
significant main effect on the intake of Ensure® (p=0.49 and 0.17 respectively). The interaction of pre-
operative dietary exposure and time had a significant effect on the absolute intake of Ensure® only in 
the SHAM group (p=0.013).  
Neither surgery nor pre-operative dietary exposure had a significant effect on the absolute intake of 
V8® (Table 2.3). Within both the HFD and LFD groups, surgery had a significant effect, in that the 
relative V8® intake of the RYGB rats was significantly higher than that of the SHAM rats (HFD: p=0.02, 
LFD: p=0.013). Pre-operative dietary exposure did not have a significant effect on the relative intake 
of V8® in either the RYGB or SHAM groups (p=0.77 and 0.51 respectively).  
Within both the HFD and LFD groups, surgery had a significant effect in that RYGB rats consumed 
significantly fewer calories per day compared to SHAM animals (HFD: p<0.0001, LFD: p<0.0001). 
Within both the RYGB and SHAM groups, pre-operative dietary exposure did not have a significant 
main effect on daily caloric intake (p=0.52 and 0.14 respectively). The interaction of pre-operative 
dietary exposure and time had a significant effect on daily caloric intake in both the RYGB and SHAM 
groups (p=0.046 and 0.004 respectively). 
Within group comparisons of daily caloric intake during (post-operative days +16 to +21) versus 
before Food Preference Test 1 (post-operative days +10 to +15) revealed that it increased 
significantly in both the HFD-SHAM (p<0.0001) and LFD-SHAM groups (p<0.0001), showed a trend for 
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 a decrease in the HFD-RYGB group (p=0.054), and decreased significantly in the LFD-RYGB group 
(p=0.022), (Table 2.4, Figure 2.4). 
 
The RYGB rats from both groups consumed all 5 g normal chow available every day, whereas the 
SHAM rats of both groups did not consume all of it. 
 
Figure 2.5: Food intake during Food Preference Test 1  
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Food intake of Ensure in purple, V8
®
 in red, and normal chow in brown of the HFD (A: HFD-SHAM n=5 fi lled 
circles, B: HFD-RYGB n=5 empty circles) and LFD groups (C: LFD-SHAM n=6 fil led squares, D: LFD-RYGB n=8 
empty squares) during Food Preference Test 1 which took place between post-operative days +16 to +21. Data 
are presented as means ± SEM. HFD: high-fat diet fed, LFD: low-fat diet fed, RYGB: gastric bypass, FPT: food 
preferenc e test 1. 
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 Figure 2.6: Relative intake of a vegetable drink during Food Preference Test 1 
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Relative V8
®
 consumption (relative intake = V8
® 
/ V8
® 
+ Ensure
® 
+ water) of the HFD (A: HFD-SHAM n=5 fi lled 
circles, HFD-RYGB n=5 empty circles) and LFD groups (B: LFD-SHAM n=6 fi lled squares, LFD-RYGB n=8 empty 
squares) during Food Preference Test 1 which took place between post-operative days +16 to +21. Data are 
presented as means ± SEM. HFD: high-fat diet fed, LFD: low-fat diet fed, RYGB: gastric bypass. 
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 Table 2.3: Between group comparisons for Food Preference Test 1 
 
HFD-SHAM 
(n=5) 
HFD-RYGB 
(n=5) 
LFD-SHAM 
(n=6) 
LFD-RYGB 
(n=8) 
HFD group  
Effect of surgery 
Effect of time  
Interaction  
LFD group 
Effect of surgery 
Effect of time  
Interaction  
RYGB group 
Effect of diet 
Effect of time  
Interaction  
SHAM group 
Effect of diet 
Effect of time  
Interaction  
Ensure
®
 intake  
(g/day) 
99.6 ± 3.7 33.3 ± 2.5 107.6 ± 2.8 29.2 ± 1.5 F (1,8)=83.9, P<0.0001 
F (5,40)=3.3, P=0.014  
F (5,40)=1.4, P=0.23  
F (1,12)=323.8, P<0.0001 
F (5,60)=1.1, P=0.39  
F (5,60)=2.2, P=0.06  
F (1,11)=0.5, P=0.49  
F (5,55)=0.5, P=0.73  
F (5,55)=2.1, P=0.07  
F (1,9)=2.2, P=0.17 
F (5,45)=1.8, P=0.13  
F (5,45)=3.3, P=0.013  
V8
®
  intake  
(g/day) 
12.2 ± 2.7 12.3 ± 2.6 13.8 ± 1.2 15.9 ± 2.1 F (1,8)=0.0, P=0.98 
F (5,40)=1.9, P=0.12  
F (5,40)=0.3, P=0.91  
F (1,12)=0.1, P=0.75  
F (5,60)=1.4, P=0.24  
F (5,60)=0.4, P=0.37  
F (1,11)=0.2, P=0.63  
F (5,55)=2.3, P=0.05  
F (5,55)=0.4, P=0.85  
F (1,9)=0.4, P=0.56 
F (5,45)=1.7, P=0.16  
F (5,45)=0.8, P=0.58  
V8
®
 relative intake  
(%/day) 
10.0 ± 1.7 28.5 ± 2.9 11.3 ± 0.9 31.1 ± 3.2 F (1,8)=9.1, P=0.02 
F (5,40)=1.1, P=0.38  
F (5,40)=1.0, P=0.46  
F (1,12)=8.4, P=0.013  
F (5,60)=1.5, P=0.21  
F (5,60)=1.3, P=0.28  
F (1,11)=0.1, P=0.77  
F (5,55)=1.2, P=0.31  
F (5,55)=1.5, P=0.19  
F (1,9)=0.5, P=0.51 
F (5,45)=1.5, P=0.21  
F (5,45)=0.5, P=0.78  
Caloric intake  
(kCal/day) 
164.0 ± 5.2 70.3 ± 4.2 177.6 ± 4.2 64.6 ± 1.9 F (1,8)=72.6, P<0.001  
F (5,40)=2.8, P=0.028  
F (5,40)=1.7, P=0.16  
F (1,12)=290.8, P<0.0001 
F (5,60)=1.4, P=0.23  
F (5,60)=2.7, P=0.03  
F (1,11)=0.4, P=0.52  
F (5,55)=1.0, P=0.41  
F (5,55)=2.4, P=0.046  
F (1,9)=2.7, P=0.14 
F (5,45)=1.4, P=0.24  
F (5,45)=4.1, P=0.004  
 
Data described using mean ± SEM. To discern the effect of surgical condition (SHAM vs. RYGB) on measures within the HFD and LFD groups, a 2-way ANOVA 
(surgical condition vs. time in days) was performed for each dietary group.  To discern the effect of presurgical dietary condition (HFD vs. LFD) on measures 
within the RYGB and SHAM groups, a 2-way ANOVA (diet x time in days) was performed for each surgical group. Relative V8® intake is expressed as a proportion 
of total fluid intake (V8®/ (V8® + Ensure® + water intake)). HFD: high-fat diet fed, RYGB: gastric bypass, LFD: low-fat diet fed. 
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 Table 2.4: Within group comparisons for Food Preference Test 1  
GROUP 
Caloric intake before food 
preference test (kCal/day)  
Caloric intake during food 
preference test (kCal/day)  
Effect of food preference test Effect of time (days) 
Interaction  
(food preference test x time)  
HFD-SHAM 
(n=5) 
97.6 ± 2.5 164.0 ± 5.2 F (1,24)=269.1, P<0.0001 F(5,24)=1.1, P=0.41  F(1,24)=2.1, P=0.11  
HFD-RYGB 
(n=5) 
77.3 ± 2.6 70.3 ± 4.2 F (1,24)=4.1, P=0.054  F(5,24)=0.77, P=0.58  F(5,24)=1.4, P=0.26  
LFD-SHAM 
(n=6) 
107.0 ± 2.2 177.6 ± 4.2 F (1,30)=684.5, P<0.0001 F(5,30)=1.2, P=0.32  F(5,30)=2.9, P=0.03  
LFD-RYGB 
(n=8) 
75.0 ± 1.6 64.6 ± 1.9 F (1,42)=5.6, P=0.022  F(5,42)=0.5, P=0.79  F(5,42)=0.3, P=0.91  
 
Data described using mean ± SEM. To discern the effect of the Food Preference Test on measures within each of the four groups (before vs. during the Food 
Preference Test), a 2-way ANOVA (Food Preference Test x time in days) was performed for each of the 4 groups. HFD: high-fat diet fed, RYGB: gastric bypass, 
LFD: low-fat diet fed). The post hoc comparisons for time are not shown for simplicity and relevance.
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 Food Preference Test 2 
 
Figure 2.7 demonstrates the food intake of all 4 groups during Food Preference Test 2 which took 
place on post-operative days +26 to +29. Table 2.5 summarises the results of Food preference Test 2.  
Within both the HFD and LFD groups, surgery had a significant effect in that RYGB rats showed a 
significantly lower absolute intake of solid high-fat diet compared to SHAM animals (HFD: p<0.0015, 
LFD: p<0.0001). Within the RYGB group, pre-operative dietary exposure had a significant effect, in 
that the rats exposed to LFD pre-operatively consumed significantly less solid high-fat diet compared 
to the rats exposed to HFD pre-operatively (p<0.0001). By contrast, pre-operative dietary exposure 
did not have an effect on solid high-fat intake in the SHAM group (p=0.3).  
The RYGB rats in the LFD group, but not in the HFD group, consumed significantly more normal chow 
(in grams) to the SHAM rats (HFD: p=0.27, LFD: p<0.0001). Pre-operative dietary exposure had a 
significant effect on normal chow consumption in the RYGB group (p<0.0001), but not in the SHAM 
group (p=0.35) in that the RYGB rats exposed to LFD pre-operatively consumed significantly more 
normal chow compared to the rats exposed to HFD pre-operatively. 
The RYGB rats in the LFD group, but not in the HFD group, consumed significantly more calories per 
day from normal chow to the SHAM rats (HFD: p=0.09, LFD: p<0.0001). Pre -operative dietary 
exposure had a significant effect on the percentage of calorie consumed from normal chow in the 
RYGB group (p=0.0008), but not in the SHAM group (p=0.77) in that the RYGB rats exposed to LFD 
pre-operatively consumed significantly more calories per day from normal chow compared to the 
rats exposed to HFD pre-operatively. 
Within both the HFD and LFD groups, surgery had a significant effect in that RYGB rats consumed 
significantly fewer calories per day compared to SHAM animals (HFD: p=0.016, LFD: p=0.0005). 
Within both the RYGB and SHAM groups, pre-operative dietary exposure had a significant main effect 
on daily caloric intake in that it was higher in animals exposed to LFD compared to HFD pre-
operatively (RYGB: p=0.045, SHAM: p=0.023.  
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 Within group comparisons of daily caloric consumption during (post-operative days +26 to +29) 
versus before Food Preference Test 2 (post-operative days +22 to +25) revealed that it increased 
significantly in both the HFD-SHAM (P<0.0001) and LFD-SHAM groups (p<0.0001), decreased 
significantly in the HFD-RYGB group (p=0.0004) and did not change in the LFD-RYGB group (p=0.63), 
(Table 2.6, Figure 2.4).  
 
Figure 2.7: Food intake during Food Preference Test 2 
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Food intake of solid high-fat diet in green and normal chow in brown for of the HFD (A: HFD-SHAM n=5 filled 
circles, B: HFD-RYGB n=5 empty circles) and LFD groups (C: LFD-SHAM n=6 fil led squares, D: LFD-RYGB n=8 
empty squares) during Food Preference Test 2 which took place between post-operative days +26 to +29. Data 
are presented as means ± SEM. HFD: high-fat diet fed, LFD: low-fat diet fed, RYGB: gastric bypass, FPT 2: food 
preferenc e test 2.  
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 Table 2.5: Between group comparisons for Food Preference Test 2 
 
HFD-SHAM 
(n=5) 
HFD-RYGB 
(n=5) 
LFD-SHAM 
(n=6) 
LFD-RYGB 
(n=8) 
HFD group  
Effect of surgery 
Effect of time  
Interaction  
LFD group 
Effect of surgery 
Effect of time  
Interaction  
RYGB group 
Effect of diet 
Effect of time  
Interaction  
RYGB group 
Effect of diet 
Effect of time  
Interaction  
Solid High-fat diet  
(g/day) 
15.3 ± 1.4 6.7 ± 1.8 17.6 ± 0.5 1.6 ± 0.8 F (1,8)=22.2, P<0.0015 
F (3,24)=37.0, P<0.0001 
F (3,24)=2.4, P=0.10  
F (1,12)=136.6, P<0.0001 
F (3,36)=5.4, P=0.003  
F (3,36)=0.8, P=0.50  
F (1,11)=48.6, P<0.0001 
F (3,33)=34.2, P<0.0001 
F (3,33)=5.5, P=0.004  
F (1,9)=1.1, P=0.33 
F (3,27)=7.5, P=0.0009 
F (3,27)=2.2, P=0.11  
Normal chow  
(g/day) 
8.5 ± 2.1 12.4 ± 3.1 11.1 ± 1.2 24.6 ± 2.0 F (1,8)=1.4, P=0.27 
F (3,24)=27.3, P<0.0001 
F (3,24)=1.3, P<0.31  
F (1,12)=30.8, P=0.0001 
F (3,36)=7.6, P=0.0005 
F (3,36)=3.5, P=0.024  
F (1,11)=17.2, P=0.002 
F (3,33)=18.7, P<0.0001 
F (3,33)=1.8, P=0.16  
F (1,9)=1.0, P=0.35 
F (3,27)=17.0, P<0.0001 
F (3,27)=2.7, P=0.07  
% of calories from 
normal chow 
28.2 ± 6.9 50.2 ± 12.9 30.3 ± 2.4 90.1 ± 5.0 F (1,8)=3.5, P=0.09 
F (3,24)=27.1, P<0.0001 
F (3,24)=2.8, P=0.06  
F (1,12)=30.8, P<0.0001 
F (3,36)=7.6, P<0.0001 
F (3,36)=3.5, P=0.02  
F (1,11)=21.0, P=0.0008 
F (3,33)=30.6, P<0.0001 
F (3,33)=6.2, P=0.002  
F (1,9)=1.0, P=0.09 
F (3,27)=20.9, P<0.0001 
F (3,27)=7.2, P=0.001  
Caloric intake  
(kCal/day) 
106.6 ± 1.7 77.6 ± 2.2 127.5 ± 2.0 95.0 ± 3.5 F (1,8)=9.2, P=0.016 
F (3,24)=0.6, P=0.63  
F (3,24)=0.4, P=0.73  
F (1,12)=26.8, P=0.0002 
F (3,36)=0.6, P=0.60  
F (3,36)=1.1, P=0.38  
F (1,11)=5.1, P=0.045  
F (3,33)=1.1, P=0.35  
F (3,33)=0.4, P=0.77  
F (1,9)=7.5, P=0.023 
F (3,27)=1.0, P=0.42  
F (3,27)=0.1, P=0.98  
 
Data described using mean ± SEM. To discern the effect of surgical condition (SHAM vs. RYGB) on measures within the HFD and LFD groups, a 2-way ANOVA 
(surgical condition vs. time in days) was performed for each dietary group.  To discern the effect of presurgical dietary condition (HFD vs. LFD) on measures 
within the RYGB and SHAM groups, a 2-way ANOVA (diet x time in days) was performed for each surgical group. HFD: high-fat diet fed, RYGB: gastric bypass, 
LFD: low-fat diet fed. 
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 Table 2.6: Within group comparisons for Food Preference Test 2 
GROUP 
Caloric intake before food  
preference test (kCal/day)  
Caloric intake during food 
preference test (kCal/day)  
Effect of food preference test Effect of time (days) 
Interaction  
(food preference test x time)  
HFD-SHAM 
(n=5) 
86.9 ± 1.5 106.6 ± 1.7 F (1,16)=33.0, P<0.0001 F(3,16)=0.17, P=0.92  F(3,16)=0.64, P=0.60  
HFD-RYGB 
(n=5) 
96.6 ± 3.6 77.6 ± 2.2 F (1,16)=20.1, P=0.0004 F(3,16)=0.2, 0.89 F(3,16)=1.2, 0.34 
LFD-SHAM 
(n=6) 
90.3 ± 2.4 127.5 ± 2.0 F (1,20)=32.7, P<0.0001 F(3,20)=0.1, P=0.98  F(3,20)=0.4, P=0.73  
LFD-RYGB 
(n=8) 
93.0 ± 2.9 95.0 ± 3.5 F (1,28)=0.2, P=0.63  F(3,28)=0.9, P=0.44  F(3,28)=1.9, P=0.15  
 
Data described using mean ± SEM. To discern the effect of the Food Preference Test on measures within each of the four groups (before vs. during the Food 
Preference Test), a 2-way ANOVA (Food Preference Test x time in days) was performed for each of the 4 groups. HFD: high-fat diet fed, RYGB: gastric bypass, 
LFD: low-fat diet fed). The post hoc comparisons for time are not shown for simplicity and relevance. 
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 2.7 DISCUSSION 
 
RYGB surgery reduced preference for high-fat solids and high-fat/sweet liquids and increased 
preference for low-fat vegetable liquids. Additionally, pre-operative exposure to diets that differ in 
their fat content did not result in differences in weight loss, but did result in subtle changes in food 
preferences after RYGB surgery (see Table 2.7 for summary). The results of this study point to 
condition taste aversion to high-fat/sweet food as an important contributor to the development of 
food preferences after RYGB. 
 
Table 2.7: Summary of the main results  
 Effects of RYGB surgery (vs. SHAM) 
Food Preference Test 1 - liquid Ensure® vs. vegetable drink (V8®)  diet  
Ensure® intake (g) ↓ (both HFD and LFD) 
V8®  intake (g) → (both HFD and LFD) 
V8® relative intake (%) ↑ (both HFD and LFD) 
Caloric intake (kCal/day) ↓ (both HFD and LFD) 
Food Preference Test 2 - solid high fat vs. normal chow diet 
Solid High-fat diet (g) ↓ (both HFD and LFD) 
Normal chow intake (g) ↑ (only LFD) 
% of calories from normal chow ↑ (only LFD) 
Caloric intake (kCal/day) ↓ (both HFD and LFD) 
 
RYGB: gastric bypass, HFD: high-fat diet fed before RYGB, LFD: low-fat diet fed before RYGB. 
 
In Food Preference Test 1, the absolute Ensure® intake of the RYGB rats was reduced compared to 
the SHAM rats in both the HFD and LFD groups. These results suggest that RYGB led to the reduced 
consumption of a liquid diet high in fat and sugar content, and pre-operative exposure to different 
diets did not have an effect on this change in ingestive behaviour. 
The V8® findings in particular were novel and in line with some of the studies from the human 
literature in which patients after RYGB increase their preference for fruits and vegetables [506]. V8® 
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 intake was unaffected by diet or RYGB, but because of the overall reduction in total grams of fluid 
consumed, a two- to three-fold increase in the relative intake of V8® was observed in the RYGB, but 
not the SHAM, rats in both and LFD and HFD groups. From a mechanistic point of view, the relative 
increase in V8® may represent an attempt of the RYGB rats to obtain more calories. The duration of 
Food Preference Test 1 was limited to only 6 days because pilot studies indicated that RYGB rats 
continued to increase their V8® intake, but this was not sufficient to compensate for the caloric 
deficit, even after 5 g/day of normal chow were offered. In fact, the RYGB rats from both groups also 
consumed all 5 g normal chow available every day, whereas the SHAM rats of both groups did not 
consume all of it.  
It was surprising to observe that when the RYGB rats were exposed to the calorie -dense Ensure®, 
they avoided it to such a degree as to reduce their total caloric intake resulting in additional weight 
loss. Mechanistically, this suggests that even though reductions in the appetitive or consummatory 
responses to a fatty/sweet food may have taken place after RYGB, the most likely explanation is that 
their behaviour was due to aversive post-ingestive effects. It is also important to note that both RYGB 
groups increased their food intake immediately after Food Preference Test 1 to compensate for this 
weight loss during the test. This illustrates the absence of a surgically induced restrictive component, 
as the rats were able to increase both the mass of food (normal chow) consumed and their caloric 
intake when physiologically required to do so. 
The only difference in the ingestive behavior between the two pre-operative diet groups of RYGB rats 
was observed in Food Preference Test 2. Even though the intake of solid high-fat diet was 
significantly lower in RYGB rats compared to SHAM in both the HFD and LFD groups, the LFD-RYGB 
rats showed an immediate avoidance of the high-fat solid food, consistent with the rapid formation 
of a conditioned taste aversion to a novel stimulus. The HFD-RYGB rats reduced their intake of the 
solid high-fat food gradually over 4 days perhaps because the acquisition of a conditioned taste 
aversion was retarded due to the familiarity of the stimulus as a function of their exposure to it 
during the pre-operative period, as described in different paradigms previously [540]. In line with 
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 this, the amount of total calories consumed was reduced only in the HFD-RYGB group. The amount of 
total calories consumed remained unchanged in the LFD-RYGB rats, as they avoided the high-fat diet 
immediately and continued to consume the same low-fat diet as before Food Preference Test 2.  
The findings of altered food preferences are in line with those seen in humans and animals [319, 441, 
442, 506, 518, 519, 522-529, 531, 532, 537, 538, 541, 543, 544], but may also have translational 
relevance. The inference that can be made is that RYGB surgery may be equally effective in reducing 
weight and caloric intake independently of pre-operative dietary habits. Pre-operative dietary habits 
and post-RYGB weight loss outcomes have not been examined in any of the human studies to my 
knowledge. The only comparisons that have been made have been between bariatric surgical 
procedures and suggested that patients who are sweet eaters lose more weight after RYGB 
compared to other procedures like the now obsolete vertical banded gastroplasty [519]. Indeed, in 
that randomised study, sweet eaters lost similar amounts of weight to the non-sweet eaters within 
the RYGB group, a finding in line with the current study. The findings on food preferences may also 
suggest that the avoidance to high-fat after RYGB may be even more pronounced in those patients 
who predominantly consume diets low in fat pre-operatively.  
The RYGB rats with different pre-operative fat diets exhibited similar patterns in their food 
preferences, with only a subtle difference in their responses to the solid high-fat diet after surgery; 
the HFD-RYGB rats reduced their intake slowly compared to immediately in the LFD-RYGB rats. This 
factor should be considered in future experimentation as, for example, the responses of rats fed a 
low-fat pre-operative diet to a condition taste aversion paradigm may be more pronounced to that of 
rats fed a high-fat diet pre-operatively. Even though in this study I had to “artificially” and rigidly 
provide either the low-fat or the high-fat to the rats pre-operatively in order to make more robust 
conclusions about their influences on post-operative outcomes, future studies animal studies should 
provide the animals with a choice of diets, in order to mimic the human situation more closely. 
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 Potential neural and hormonal mediators 
Animal investigators have attempted to provide more detailed mechanisms of the hormonal or 
neural signals that underlie the healthy shift in food preferences. Hajnal’s group used 
electrophysiological assessments and quantified the recordings of pontine parabrachial nucleus 
neurons in response to sucrose solutions delivered orally to the anterior part of the tongue. They 
found that the neuronal responses to low sucrose concentrations were higher and to high sucrose 
concentrations lower after RYGB [544]. The parabrachial nucleus is an important part of the taste 
system, relaying information on the sensory, and even hedonic, properties of taste. It is responsive to 
leptin and insulin, mediators which are altered after RYGB [560]. However, the concentration-
response curves shown by Hajnal should be interpreted with some caution as the stimulation of the 
anterior part of the tongue responds poorly to sweet. In terms of the contribution of the vagus to the 
change in food preferences, Berthoud’s lab performed a selective vagotomy to the hepatic branch of 
the vagus in rats after RYGB and did not find an effect on food preferences, or indeed weight loss, 
energy intake and satiety [464]. Selective vagotomy of other branches that innervate the small bowel 
was not performed in this experiment and we cannot exclude that they may be partly  responsible for 
the changes in food preferences. 
It is tempting to implicate gut hormones as mediators of the change in taste and food responses. 
GLP-1 receptors are expressed on taste afferent nerve fibres and GLP-1 knockout mice are less 
responsive to low sucrose concentrations in a brief access test [111, 112]. Enteroendocrine cells in 
the small bowel also sense the presence of sucrose in ingested nutrients and release anorexigenic 
GLP-1 and PYY [203]. Administration of GLP-1 and PYY in rodents can also cause a conditioned taste 
aversion through activation of brainstem neurons [122, 561]. Even though anorexigenic gut 
hormones including GLP-1 and PYY have been found to be higher after RYGB in rats [562], they have 
not be shown to be directly and causally responsible for the change in food preferences. In fact, the 
use of GLP-1 agonists or antagonists did not change responses to the brief access test to sucrose 
after RYGB [545]. The expression of T1R2 and T1R3 taste receptors, which respond to sweeteners 
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 and gut hormones, has also been shown to be altered after RYGB, but again this has not been shown 
to be causally related to the changes in food or taste preferences after RYGB [537]. 
The unexpected finding that the VSG procedure is associated with similar changes in food 
preferences has provided more clues for the underlying mechanisms (Table 2.8). The  VSG is 
anatomically much simpler than RYGB, in that 70-80% of the stomach is excised, without any 
manipulation of the small bowel. Therefore Seeley et al. were understandably surprised to find that 
after the surgery, animal models do not behave as if they have had a restrictive procedure like the 
gastric band (BAND) or vertical banded gastroplasty [437, 563]. Whilst the authors do not report 
whether the VSG animals lost the same amount of weight as the RYGB animals, both groups reduced 
their intake of fat and increased their intake of carbohydrates similarly, compared to sham operated 
rats. VSG rats also preferred less energy dense Ensure ®, compared to the full strength and lower 
concentrations of corn oil compared to higher concentrations. 
In an ingestive behaviour analysis after VSG, there were no differences in progressive ratio task 
responses to peanut oil or sucrose, but peanut oil caused condition taste aversion [437, 563]. Gavage 
of sucrose and Intralipid® also induced higher c-fos activation in the area postrema and the nucleus of 
the solitary tract, regions which respond to aversive and distension signals from the gut. 
Anorexigenic gut hormones PYY and GLP-1 are also increased after VSG [562]. However as discussed 
above, these have not been shown to be causally related to the change i n food preferences. On the 
other hand, a reduction in both active acyl and inactive desacyl ghrelin is a relatively consistent 
finding after VSG, but VSG surgery in ghrelin knockout mice did not affect food preferences, weight 
loss or glycaemic control, adding further doubts as to the physiological significance of changes in 
ghrelin after VSG or even RYGB [460]. However, it is possible that the knockout mice may have 
developed compensatory mechanisms to counteract the lack of ghrelin and this allowed them to 
exhibit the same phenotype as wild type animals. 
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 To confuse matters further, Stylopoulos’s group compared animal models of RYGB and VSG and did 
not replicate the above findings [489]. They found that RYGB rats lost more weight than VSG rats, 
whilst the VSG group did not alter their preference for high-fat or low-fat diets. In this study, RYGB 
rats were shown to malabsorb fat but also to have increases in energy expenditure, even during 
weight loss. Therefore similarly to the inconsistencies in RYGB experimentation, the discrepant 
findings on VSG are also likely to be the result of differences in the anatomical manipulations, 
experimental methodologies and timing of food choices assessment after surgery. 
Looking at the above data and my study, what becomes clear even with the numerous discrepancies, 
is that condition taste aversion is a key player in the shift in food preferences in both RYGB and VSG 
(if there are any changes after VSG). The rapid delivery of sucrose or fat in the small intestine, and in 
particular the jejunum, seems to provoke a strong neural aversive response leading to avoidance of 
these foods. This rapid delivery is facilitated by rapid gastric emptying in VSG [454] and the bypass of 
the duodenum in RYGB. This aversion may be enough to cause the change in ingestive behaviour 
independently but it may also affect taste responses through learning. In humans, aversion may be 
either “subconscious” or take the form of the unpleasant symptoms of the dumping syndrome which 
is more common after RYGB and VSG, compared to the gastroplasty procedures [449, 555, 564], 
(section 1.3.3.2, page 121).  
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 Table 2.8: Ingestive behaviour in animal models of sleeve gastrectomy   
Group Surgical technique 
Strain 
Sleeve size/bougie 
 
Maintenance  
diet 
Weight loss  
(%) 
Control 
group(s)  
Intake 
Complex food 
Timing 
Result 
Preference 
Stimulus 
Timing (wk) 
Result 
Brief access 
Stimulus 
Timing (wk) 
Licks 
Trials 
Appetitive 
Stimulus 
Timing (wk) 
Result 
Consummatory  
Stimulus 
Timing (wk) 
Result 
CTA 
Stimulus 
Timing (wk) 
CTA seen 
Seeley  
[437, 563] 
LETO 
20% 
HF chow ~15 Unoperated 
and sham 
operated ad 
libitum fed 
rats 
Ensure
®
/HF and LF chow 
2, 8 and 14-27 weeks 
↓ Ensure®/HF chow and 
↑ LF chow 
 
Sucrose 
?14 
→ 
N/A Sucrose 
2 
→ 
N/A N/A 
Corn oil 
?14 
↓ high 
concentrations 
N/A Peanut oil 
2 
→ 
N/A Peanut oil 
12 
Yes 
Stylopoulos 
[489] 
LETO 
7Fr 
HF chow N/A Sham and 
RYGB 
operated ad 
libi tum fed 
rats 
N/A HF and LF chow 
8 
→ 
N/A N/A N/A N/A 
 
Abbreviations: HF: high-fat, LF: low-fat, Surgical technique: percentage of original stomach and limb lengths shown, CTA: conditioned taste aversion, ↑/↓/→: 
higher/lower/ not different compared to sham operated rats, ?: unclear, N/A: not available, LETO: Long-Evans Tokushima Fatty rats, wk: weeks, Fr: French 
(diameter of bougie). 
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 Limitations  
Limitations of the current study include the small number of rats in each group and the non-
randomised nature of the group allocation to normal chow or high-fat diet prior to surgery. The 
latter was unavoidable due to the design which allowed control for the confounders of age and 
weight differences between groups. The observation that the LFD-RYGB rats (with weights above the 
median when they were randomized to LFD or HFD) had an immediate reduction in consumption of 
solid high-fat chow in Food Preference Test 2 was reassuring, suggesting that the impact of the 
surgery and the pre-intervention chow was dominant compared to the possibility that the behaviour 
of the rats could have been influenced by them being “obesity prone”. The possibility that the 
texture differences between the diets or nutrient malabsorption may have influenced the food 
preference observed in this set of experiments cannot be excluded. However, no malabsorption has 
been detected previously in this established rat model of RYGB [515]. Even though this study has 
provided clues for potential mechanisms based on the novelty of food stimuli, detailed ingestive 
behaviour testing, e.g. specific condition taste aversion paradigms, were not performed.  Another 
limitation is that I should have waited a bit longer to perform food preference test 2, because at the 
time, rats were probably still recovering from food preference test 1. 
Conclusion 
In conclusion, RYGB surgery in rats is associated with a shift away from fatty/sweet solids and liquids 
and an increase in the consumption of healthier low-fat and vegetable foods.  The consumption of 
pre-operative maintenance diets with different fat contents, did not affect postsurgical weight loss. 
Although the trends in feeding behaviour were in the same direction for both RYGB groups, rats 
exposed to high-fat diets pre-operatively exhibited a behaviour consistent with a condition taste 
aversion to familiar stimulus, as opposed to condition taste aversion to a novel stimulus in the rats 
fed only a low-fat diet pre-operatively. The preference of vegetable-based liquids (as a percentage of 
total volume of fluid consumed) increased in RYGB rats, independently of pre -operative dietary 
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 exposure. These results are consistent with the majority of studies investigating humans and animals 
after RYGB, where reduced fat and increased vegetable intake result from physiologically driven 
behaviour and not only due to dietary concordance. The underlying mechanisms and their mediators 
remain a matter of debate due to the inconsistent findings in the literature. Standardisation of the 
surgery in animal models, availability of both high and low-fat diets pre-operatively, uniform 
methodological testing and co-operation between the different labs may help resolve this debate 
and allow further progress in the field. These should be performed alongside translational and 
mechanistic experiments in humans that compare the effects of RYGB to other surgical techniques 
that do not alter food preferences, using a comprehensive set of eating behaviour methodologies. 
2.8 SUMMARY OF CHAPTER 2 
 RYGB rats showed a reduced preference for high calorie sweet/fatty foods and an increased 
preference for low-calorie food after surgery compared to sham operated controls. 
 Pre-operative maintenance diets did not have an effect on weight loss or caloric intake. 
However, rats fed a LFD pre-operatively reduced their preference for high-fat food immediately 
whereas rats fed a HFD did so more gradually.  
 From a mechanistic point of view, the responses of the RYGB rats to fatty/sweet foods were 
consistent with condition taste aversion; this was of such a magnitude that it led to excess 
weight loss. The weight lost was regained through an increase in food intake after food 
preference testing, further adding support to the notion that RYGB does not cause restriction in 
food intake.  
 Potential mediators of the change in eating behaviour include altered nutrient sensing in the 
jejunum, and the actions of gut hormones both to cause aversion and/or reduce the rewarding 
value of energy-dense food.  
 Future animal studies should provide them with the choice of low and high-fat diets in order to 
mimic the human situation more closely and allow the translation of their findings.  
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 Harmonisation of the surgical techniques and methodological testing in rodents will also help 
resolve some of the conflicting results of the animal literature. 
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CHAPTER 3 
COMPARISON OF BRAIN-HEDONIC AND GUT 
RESPONSES TO FOOD AFTER GASTRIC BYPASS AND 
BANDING SURGERY IN HUMANS 
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 3.1 ABSTRACT 
Introduction:  Roux-en-Y gastric bypass (RYGB) has greater efficacy for weight loss in obesity than 
gastric banding (BAND) surgery. This may result from different effects on food hedonics via 
physiological changes secondary to distinct gut anatomy manipulations.  
 Methods: Functional MRI, eating behaviour and hormonal phenotyping were used to compare body 
mass index (BMI) matched un-operated controls, and patients after RYGB and BAND surgery for 
obesity.  
Results: Obese patients after RYGB had healthier brain-hedonic responses to food than patients 
after BAND surgery. RYGB patients had lower activation than BAND patients in brain reward systems 
to foods, including the orbitofrontal cortex, amygdala, caudate nucleus, nucleus accumbens and 
hippocampus. This was associated with lower palatability and appeal of high-calorie foods and 
healthier eating behaviour, including less fat intake, in RYGB compared with BAND patients and/or 
BMI-matched unoperated controls. These differences were not explicable by differences in hunger 
or psychological traits between the surgical groups, but anorexigenic plasma gut hormones (GLP-1 
and PYY), plasma bile acids and symptoms of dumping syndrome were higher in RYGB patients.    
Conclusion: The identification of these differences in food hedonic responses as a result of al tered 
gut anatomy/physiology provides a novel explanation for the more favourable long-term weight loss 
seen after RYGB than BAND surgery, highlighting the importance of the gut-brain axis in the control 
of reward-based eating behaviour.   
 
 
 
 
 
 
 
 
156
 3.2 INTRODUCTION 
 
In the previous chapter, animals that underwent RYGB surgery reduced their preference for sweet 
and/or high-fat liquids and solids, and increased their preference for low-fat choices. The 
mechanisms underlying this change in ingestive behaviour may include the reduction in the 
appetitive and/or consummatory value of energy dense food, and post-ingestive signals of aversion 
in response to food high in fat and sugar.  
 
Patients after RYGB, but also gastric banding (BAND) and vertical sleeve gastrectomy (VSG), are less 
hungry and more sated after a meal compared to pre-operatively, suggesting that the surgery has 
altered the homeostatic control of food intake [433, 434, 447]. The potential mediators for this 
reduction in food intake include altered signals from the periphery, e.g. gut hormones, bile acids, 
vagal/taste neural network and gut-nutrient sensing [203, 433, 436, 495]. However, weight loss may 
also be due to changes in the hedonic control of food intake. The human literature has shown that 
patients after gastric bypass surgery (RYGB) have healthier food preferences compared to pre-
operatively or compared to the now obsolete procedures vertical and horizontal banded 
gastroplasty [319, 441, 506, 518, 519, 522-529, 531, 532]. However, there are still significant 
inconsistencies in the published papers, in terms of the magnitude and durability of this observation 
[558]. These inconsistencies are partly due to the uni-modal methodologies used to study eating 
behaviour (e.g. interviews or food diaries in isolation).  
 
The study of eating behaviour in humans, and the obese in particular, is challenging due to the 
effects of the social desirability bias [224], the variability of human nature itself and the behavioural 
experimental methodologies  [4, 222, 226]. It is therefore important that participants in eating 
behaviour studies are phenotyped using complimentary techniques. Functional neuroimaging has 
accelerated the study of eating behaviour in humans as it allows the understanding of the underlying 
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 brain mechanisms. Activation in the brain reward system (including orbitofrontal cortex, insula, 
amygdala, nucleus accumbens, caudate/putamen, ventral tegmental area), as assessed indirectly 
from fMRI and PET methods, has been shown to correlate with subjective ratings of the hedonic 
attributes of food [32, 37, 53], has shed light in the pathophysiology of obesity [565], including the 
contribution of an “addictive” eating behaviour [49, 357] and to predict weight loss or gain [34, 50, 
343].   
 
Additionally, the significant confounder of pre- and immediately post-operative dietary advice has 
not been excluded as the force driving the healthier eating habits after surgery. It may well be the 
case that patients that have abdominal surgery to lose weight are more motivated to follow dietary 
counselling after a procedure that carries risk, and that dietary modifications may have nothing to 
do with the physiological effects of surgery. A direct and comprehensive comparison of the effects of 
the two most commonly performed procedures around the world, RYGB and BAND, on eating 
behaviour has not been performed previously. Such a comparison is “ideal” from a scientific point of 
view, as patients in both groups lose weight and receive very similar dietary advice. Therefore any 
differences in eating behaviour between the groups would essentially exclude, or at the very least 
minimise, dietary advice and weight loss itself as confounders. Additionally, differential responses in 
neural and metabolic parameters between the two groups may provide clues as to the mechanisms 
underlying differences in eating behaviour.  
 
3.3 HYPOTHESES 
 
1. Patients after RYGB have a lower preference for high-calorie and higher preference for low-
calorie foods compared to BAND.  
2. Patients after RYGB have healthier eating behaviour compared to patients after BAND of eating 
behaviour.  
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 3. The mechanism underlying the healthier eating behaviour after RYGB include lower activation of 
brain reward systems in response to high-calorie food cues after RYGB compared to BAND. 
4. Mediators of this mechanism include the early and exaggerated release of anorexigenic gut 
hormones and bile acids after RYGB compared to BAND. 
 
3.4 AIMS 
 
The aim of this cross-sectional study was therefore to study three groups of BMI-matched subjects: 
(i) obese patients after RYGB,  
(ii) obese patients that underwent the same nutritional counselling, but chose to have BAND instead, 
and  
(iii) BMI-matched subjects who did not receive any form of lifestyle, medical or surgical weight loss 
intervention, to: 
1. Characterize food preferences and psychological aspects of eating behavi our using 
questionnaires, appetite visual analogue scales, food appeal scores and dietary records. 
2. Identify the neural correlates underlying any differences in eating behaviour and the hedonic 
value of food between the groups using functional neuroimaging at the same internal state. 
3. Explore possible mediators of the different neural responses between the groups through the 
use of hormonal and metabolic markers. 
 
3.5 METHODS 
 
Participants 
 
Eighty three participants [30 RYGB, 28 BAND, 25 BMI-matched (BMI-M) unoperated controls] were 
recruited between June 2009 and June 2011 from the Imperial Weight Centre, Charing Cross 
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 Hospital in London or via public advertisement. Surgical patients were recruited more than 2 months 
after surgery and after they had lost at least 8% body weight. All surgical procedures were 
performed by one of two surgeons (Mr. Torsten Olbers and Mr. Ahmed Ahmed), with RYGB as 
previously described [418]. Sixty one participants (21 RYGB, 20 BAND, 20 BMI-M) were eligible for a 
scanning visit. All participants provided written informed consent.  The study was approved by the 
Local Research Ethics Committee, performed in accordance with the principles of the Declaration of 
Helsinki (Appendix 1).  
 
Inclusion and exclusion criteria 
 
Inclusion criteria: for surgical groups (i) loss of more than 8% of their total body weight since surgery, 
and (ii) surgery more than 2 months before the study.  
Exclusion criteria for all participants were: (i) smoking, (ii) pregnancy or breast feeding, (iii) 
significant neurological, psychiatric or cardiovascular disease including addiction, stroke and 
epilepsy, other than previous depression, (iv) commencement of anti-depressants less than 6 
months ago, (v) type 2 diabetes mellitus treated with agents other than metformin alone, (vi) type 1 
diabetes mellitus. 
 
Exclusion criteria for the scanning visit were: (i) inability to use right-handed button keypad, (ii) 
claustrophobia, (iii) shoulder width >58 cm (inability to fit in scanner bore), (iv) metal implants which 
would preclude safe MRI scanning, (v) vegetarianism or veganism, (vi) reported gluten or lactose 
intolerance, and (vii) non-Western diet assessed by dietary record.  
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 Screening visit 
 
Eligible subjects attended an initial assessment visit during which they completed a medical history, 
physical examination and questionnaires to assess mood, psychological traits and eating behaviour. 
Medical notes were examined to ascertain pre-operative clinical information including body weight, 
presence of type 2 diabetes, and binge eating disorder from review by the clinic psychiatrist (Dr 
Samantha Scholtz) or psychologist, and calculation of obesity comorbidity score using the modifie d 
King’s criteria [566]. These criteria incorporate a wide range of comorbidities including respiratory, 
metabolic, cardiac and psychiatric disease.  The following questionnaires were completed at the 
screening visit (Appendices 2-8): 
 
1. Dutch Eating Behaviour Questionnaire (DEBQ): to measure dietary restraint, emotional (e.g. 
stress-induced eating) and external (e.g. food palatability) influences on eating behavior [255]. 
2. Eating Disorder Examination Questionnaire (EDE-Q): to measure dietary restraint, 
preoccupation with weight and shape, and binge eating [258]. 
3. Positive and Negative Affect Schedule (PANAS): to measure symptoms of positive  and negative 
affect over the previous week which have previously been correlated with fMRI responses to 
food pictures [567, 568]. 
4. Beck Depression Inventory (BDI-II): to identify symptoms of depression [263]. 
5. Barratt Impulsivity Scale: to measure impulsivity which has been linked to overeating [268, 569].  
6. Eysenck Personality Questionnaire (EPQ-R): to measure extraversion, psychoticism, neuroticism 
and tendency to lying [570]. 
7. Behavioural Activation / Behavioural Inhibition Scales (BAS/BIS): to measure punishment and 
reward sensitivity. BIS/BAS (reward responsiveness) scores have previously been correlated 
with fMRI responses to food pictures [57, 571].  
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 Study visit protocol 
On the day before scanning, subjects were instructed to avoid exercise and alcohol intake, to eat 
their usual supper at 8.00 pm, and attend the Sir John McMichael Centre Clinical Investigation Unit, 
Hammersmith Hospital, London on the next morning having eaten nothing since supper. Patients 
were asked to refrain from strenuous exercise and alcohol the day before and day of the study.  
Subjects had measurements of height, weight, % body fat by bio-electrical impedance analysis 
(Bodystat 1500, Isle of Man, UK), and completed the Positive and Negative Affect Schedule (PANAS) 
to measure mood over the preceding week. Pregnancy was excluded at each visit.  
 
Patients were scanned for 1 hour starting between 11 am and noon (Figure 3.1). Female participants 
were scanned in the first half phase of their menstrual cycle to avoid variations in reward responses 
including food over the menstrual cycle [368].  
 
Figure 3.1: Study protocol 
 
 
Abbreviations: AMV: audio-motor-visual task, BAND: gastric banding, BP: blood pressure, fMRI: functional 
magnetic resonance imaging, RYGB: gastric bypass, VAS: visual analogue scales. 
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 fMRI acquisition 
 
Whole brain fMRI data were acquired on a 3 Tesla Philips Achieva MRI scanner (Robert Steiner MRI 
Unit, Hammersmith Hospital, London, UK) with T2* weighted gradient-echo echoplanar imaging with 
an automated higher-order shim procedure: 44 ascending contiguous 3.25 mm thick slices, 2 x 2 mm 
voxels; SENSE factor 2 repetition time (TR) 3000 ms; echo time (TE) 30 ms; 90o flip angle; field of 
view (FOV) 190 x 219, matrix 112 x 112, slice acquisition angle -30o from anterior and posterior 
commissure line to reduce frontal lobe signal drop out [232]. 
 
High-resolution T1-weighted turbo field echo structural scans were also collected: (TE 4.6 ms; TR 9.7 
ms; flip angle 8°; FOV 240 mm; voxel dimensions, 0.94 x 0.94 x 1.2 mm). B0 field maps were used to 
correct for geometric distortions caused by inhomogeneities in the magnetic field as follows: TR 29 
ms; TE 3.6 ms, 30o flip angle; FOV 190 x 219, 44 ascending contiguous 3.25 mm thick slices, 2 x 2 mm 
voxels, ∂TE 0 and 2.5.  
 
fMRI paradigm 
 
During the fMRI food picture paradigm, 4 types of colour photographs were presented in a block 
design split across two 9 minute, 192 volume runs: (1) 60 high-calorie foods (e.g. pizza, cakes and 
chocolate), (2) 60 low-calorie foods (e.g. salads, vegetables, fish), (3) 60 non-food related household 
objects (e.g. furniture, clothing) and (4) 180 Gaussian blurred images of the other pictures (as a low-
level baseline), similar to those used previously [572]. Food images were selected to represent 
familiar foods that are typical to the modern European-North American diet. Pictures were obtained 
from freely available websites and the International Affective Picture System (IAPS, NIMH Centre for 
the Study of Emotion and Attention, University of Florida, Gainesville, FL, USA). Food and object 
pictures were of similar luminosity and resolution.  
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 Each run contained different pictures in 5 blocks each of high-calorie and low-calorie foods and 
objects interleaved with 31 blocks of blurred pictures (6 pictures per 18 seconds) using one of four 
pseudorandom block orders with a randomized picture order within each block. Every image was 
displayed for 2500 ms, followed by a 500 ms inter-stimulus interval of a fixation cross.  
 
A 6 min, 114-volume auditory-motor-visual control task was performed. Over nine 33 second blocks, 
subjects performed two of each of the following tasks simultaneously: (i) listening to a story, (ii) 
tapping their right index finger once every second, or (iii) watching a 4 Hz colour (yellow/blue) 
flashing checkerboard, with each task performed in 6 blocks, and instructions about whether to start 
or stop the motor task displayed for 3 seconds prior to each block. 
 
Images were viewed via a mirror mounted above an 8 channel radiofrequency head coil which 
displayed images from a projector using the IFIS image presentation system (In Vivo, Wurzburg, 
Germany) and ePrime 2 software (Psychology Software Tools Inc., Pittsburgh, PA, USA). Whilst each 
image was on display to subjects in the scanner, they were asked to immediately and simultaneously 
rate how ‘appealing’ each picture was to them using a 5 button hand-held keypad (1=not at all, 
2=not really, 3=neutral, 4=a little, 5=a lot) [572]. The appeal rating was thus made and recorded 
simultaneously with the stimulus presentation used for fMRI activation. 
 
Food pictures 
 
Each high-calorie food block consisted of equal numbers of foods containing chocolate, non-
chocolate sweet and savoury non-sweet foods (2 of each). The total caloric load, caloric density and 
macronutrient composition of the food pictures used in the fMRI task were assessed using Dietplan 
6 (Foresfield Software Ltd, West Sussex, UK) - high-calorie foods: 834 ± 100 kCal, 321 ± 13 kCal/100 
g, 42 ± 2 % fat, 48 ± 1 % carbohydrate, 10 ± 1 % protein; low-calorie foods: 157 ± 18 kCal, 64 ± 5 
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 kCal/100 g, 35 ± 3 % fat, 35 ± 3 % carbohydrate, 29 ± 3 % protein; high-calorie vs. low-calorie foods: 
P<0.001 for energy content, density, % protein and % carbohydrate; and P=0.03 for % fat (unpaired 
t-test). 
 
fMRI processing 
 
The first 6 scans were discarded to allow for the BOLD signal to stabilize. Processing was performed 
as described in the introduction of the thesis using the tools provided by FSL software (Oxford 
Centre for Functional MRI of the Brain): 
1. Brain extraction: using the Brain Extraction Tool (BET) [573]. 
 
2. Motion correction: using Motion Correction of the MRI Linear Image Registration Tool 
(MCFLIRT) [574]. Subjects were excluded from fMRI analysis if their average relative motion 
over the food evaluation or control Audio-Motor-Visual fMRI task was greater than 0.5 mm/TR. 
 
3. Field inhomogeneity correction: fieldmap-based EPI unwarping using PRELUDE and the 
Functional MRI Utility for Geometrically Unwarping EPIs (FUGUE) [575, 576]. 
 
4. Spatial filtering/smoothing: using a Gaussian kernel of full width at half maximum (FWHM) 6.0 
mm. 
 
5. Temporal filtering/smoothing: high-pass temporal filtering (Gaussian-weighted least-squares 
straight line fitting, with sigma=100.0 s). 
 
6. Global intensity normalisation: grand-mean intensity normalization of the entire 4D dataset by 
a single multiplicative factor. 
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 7. Generation of general linear model: Time-series statistical analysis was carried out using FILM 
with local autocorrelation correction including picture block onsets and duration, temporal 
derivative (to correct for slice timing) and motion parameters as covariates. Similar time-series 
statistical analysis was performed for the single run Audio-Motor-Visual paradigm including the 
onsets of each task (auditory, motor and visual) to contrast activation during performance of 
each task with that when the other tasks were being performed. 
 
8. Registration: Registration to high resolution T1 structural and/or standard space images was 
carried out using the Oxford Centre for Functional MRI Linear Image Registration Tool (FLIRT). 
Registration from high resolution structural to standard space was then further refined using 
the Oxford Centre for Functional MRI Linear Image Non-linear Registration Tool (FNIRT) [577, 
578]. 
 
9. Fixed effect analysis of runs:  For the food pictures, higher level analysis was carried out using a 
fixed effect model to combine the two runs, by forcing the random effects variance to zero in 
the Oxford Centre for Functional MRI Local Analysis of Mixed Effects (FLAME) and in order to 
determine activation for the following contrasts: food > objects (high-calorie or low-calorie 
food), high-calorie food only > objects and low-calorie food only > objects [579, 580]. This was 
not necessary for the single run Audio-Motor-Visual fMRI task. 
 
Whole brain analysis 
 
FMRI data processing used the Oxford Centre for Functional MRI Expert Analysis Tool v5.98 
(www.fmrib.ox.ac.uk/fsl). General Linear Modelling analysis was used to measure blood oxygen-
dependent (BOLD) signal activation to: (i) any food (high-calorie or low-calorie), only (ii) high-calorie 
or (iii) low-calorie foods (compared to objects) in the food evaluation task, and for (iv) auditory, 
166
 motor or visual tasks in the control paradigm. Whole brain mixed effects analysis compared BOLD 
signal between the 2 surgical groups using unpaired t-test with cluster threshold Z>2.1, corrected 
P<0.05 including age, gender and BMI as covariates.  
 
Region of interest analysis 
Functional regions of interest (fROIs) for the following areas: bilateral orbitofrontal cortex, 
amygdala, nucleus accumbens, anterior insula and caudate nucleus (Figure 3.2, Table 3.1) were 
determined from a separate cohort of 24 overweight/obese subjects who underwent an identical 
protocol fasting overnight, using the food > objects contrast, false discovery rate (FDR) corrected 
P<0.05 (Table 3.2). Similar functional localizers were made from this separate cohort for the control 
auditory, motor and visual tasks for bilateral superior posterior temporal gyrus (auditory), left pre-
central gyrus (motor), and bilateral lingual gyrus (visual) (Figure 3.6A).  
The fROIs were obtained by masking these group activation maps with a priori anatomical ROI. 
These were defined by the relevant bilateral ROIs from the cortical and subcortical structural 
Harvard FSL atlases thresholded at 10% probability. The orbitofrontal cortex fROI included regions in 
the orbitofrontal cortex and frontal pole (MNI co-ordinates y>22 and z<-6), since analysis of 
functional activation in this region demonstrated distinct bilateral clusters overlapping the 
anatomical Harvard atlas regions. The insula mask was subdivided into the anterior (y>4) and 
posterior (y≤4) insula [581].   
 
The median magnitude of bilateral BOLD activation within each a priori fROI was then extracted for 
each individual subject separately for any food, high-calorie food and low-calorie food (>object) 
contrasts using Featquery in FSL, to measure the differences in activation between groups for the 
different picture categories, or different control auditory-motor-visual tasks. Average BOLD 
activation for each of these contrasts within each fROI was then compared between groups outside 
FSL, adjusting for age, gender and BMI. 
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 Figure 3.2: A priori functional regions of interest for reward system activation during food 
evaluation task 
 
 
 
Group activation in separate cohort of obese/overweight patients for any food (high -calorie or low-calorie) vs. 
object picture contrast. Activation was thresholded at FDR P<0.05, overlaid onto the average T1 scan for all 
subjects (n=23). A priori functional regions of interest (ROIs) are indicated: nucleus accumbens (NAcc, yellow), 
orbitofrontal cortex (OFC, l ight blue), caudate (Caud, dark blue), amygdala (Amy, green), anterior insula (Ins, 
magenta). Co-ordinates are given in standard MNI space. 
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 Table 3.1: Spatial coordinates of functional regions of interest in brain activation analysis 
Functional region of interest  Hemisphere 
Number 
of voxels 
Z statistic x y z 
Food vs. Object contrast       
Anterior orbi tofrontal cortex Right 170 3.81 18 36 -18 
 Left 63 3.60 -20 38 -14 
Amygdala Right 110 3.85 18 0 -26 
 Left 16 3.99 -18 0 -26 
Nucleus  Accumbens Right 62 3.45 8 14 -4 
 Left 91 4.11 -6 10 -2 
Anterior Insula Right 188 5.08 40 8 -14 
 Left 116 4.43 -38 8 -12 
Caudate Right 129 3.88 8 6 2 
 Left 74 4.18 -6 -6 0 
Auditory task       
Posterior division of superior temporal 
gyrus 
Right 1109 5.56 64 -14 4 
 Left 1108 5.39 -62 -22 2 
Motor task       
Precentral gyrus Left 873 5.78 -36 -24 56 
       
Visual task       
Lingual gyrus Bilateral 1412 5.59 6 -90 -10 
 
Stereotactic coordinates  (x, y, z) for peak voxel  of group activation, adjusting for age, gender and BMI,  thresholded at FDR 
P<0.05 (n=24), given in s tandard MNI space.  
 
Table 3.2: Characteristics of separate cohort of overweight/obese subjects used to create 
functional regions of interest in brain activation analysis 
n 24 
Age (years) 
29.0 [26.0 - 38.5] 
(20.0 - 48.0) 
Gender (Male :  Female) 6:18 
Ethnicity: European Caucasians, n (%) 14 (58%) 
Current BMI (kg/m2) 
30.7 [26.3 - 32.8]  
(25.4 - 42.7) 
Current body fat (%)  
36.3 ± 2.0 
(17.1 - 54.5) 
Current DM, n (%) 0 (0%) 
Current obesity co-morbidity score 
0.0 [0.0 - 0.0] 
(0.0 - 8.0) 
Duration fasting (hours) 
15.9 [15.4 - 16.8] 
(13.7 - 19.7) 
 
Data  are expressed as  mean ± SEM or median [25th - 75th centile] when normally or not normally distributed respectively, 
followed by the range in brackets . Actual  number of patients (n) and percen tages  (%) are also shown. BMI: body mass 
index, DM: type 2 diabetes  mellitus. 
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 Appetite and food palatability ratings 
 
Visual analogue scale (VAS) ratings (0-10 cm) were recorded at serial time points to measure hunger, 
pleasantness to eat, volume of food wanting to eat, fullness, sickness and sleepiness [227, 582], 
Appendix 10. Area under the curve (AUC) for VAS ratings were calculated from +40 to +150 minutes 
to cover the period over the MRI scan in all three groups; and postprandial changes in VAS ratings 
were calculated as delta AUC from baseline at +150 to +240 minutes in the two surgical groups. 
 
Test meal 
 
Scanning was followed by an ad libitum ice-cream test meal for the two surgical groups only. Ad 
libitum Hagen Daz™ vanilla or pralines and cream flavoured ice cream, was given to subjects in the 
operated groups in 43 g portions every 5 minutes and subjects were asked to eat until comfortably 
full [583]. Upon completion, they were asked to rate using VAS the sweetness, tastiness and 
pleasantness to eat of the ice cream test meal. As the BMI-M control subjects had different test 
meals (e.g. macaroni cheese or chicken tikka masala), their consumption is not included in the 
comparisons performed.  
 
Hormonal and metabolic testing 
 
Serial blood samples before and after scanning were collected for measurement of plasma glucose, 
insulin, gut hormones (PYY, GLP-1, acyl ghrelin) and bile acids (Figure 3.1). Blood samples for gut 
hormone analysis were collected into chilled lithium heparin polypropylene tubes, containing 4-(2-
Aminoethyl) benzenesulfonyl fluoride hydrochloride (AEBSF) (A8456 Sigma-Aldrich) and aprotinin 
(Nordic Phama UK) protease inhibitor to give final concentration of 1 mg/mL and 200 kIU/mL of 
whole blood respectively. Blood samples were centrifuged at 4oC, 4000 rounds per minute for 10 
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 min. Aliquots of separated plasma were immediately mixed with hydrochloric acid (final 
concentration of 0.05 M) for subsequent assay of acyl ghrelin, and separate unacidified aliquots for 
assay of GLP-1 and PYY. All plasma samples were stored at -80°C until assay. Other metabolic and 
hormonal assays were done on plain serum or fluoride oxalate plasma samples sent immediately to 
the hospital clinical laboratory. 
 
Plasma glucose and serum insulin were measured in the Department of Clinical Biochemistry, 
Imperial College Healthcare NHS Trust using either an Abbott Architect ci8200 analyzer (Abbott 
Diagnostics, Maidenhead, UK) or an Axsym analyzer (Abbott Diagnostics, Maidenhead, UK). Intra-
assay coefficients of variation of all measurements were 1.0–5.0%. Plasma GLP-1 (GLP-11-36 amide, 
GLP-17-36 amide and GLP-19-36 amide) and PYY (total PYY1-36 and PYY3-36) were assayed using 
established in-house radio-immunoassays [584, 585]. Plasma acyl ghrelin was measured by a two-
site sandwich ELISA in a single run [586]. Intra-assay coefficients of variation for gut hormones were 
<10%.  
 
Extraction of bile acids from plasma was performed as described previously [587]. Bile acid fractions 
were analysed using high-performance liquid chromatography (Jasco, Essex, UK) tandem mass 
spectrometry (Applied Biosystems, Cheshire, UK). The method was linear be tween 0.1 and 10 
µmol/L for all BAs and their conjugates with CV of 1.5-6.8% at the lower limit of quantification (0.1 
µmol/L). The inter-assay CV was 3.6-8.0%. 
 
Area under the curve (AUC) for metabolites and hormones were calculated from +40 to +150 
minutes, and for bile acids from +70 to +150 minutes, to cover the period before and over the MRI 
scan in all three groups; and in the two surgical groups post-prandial changes in metabolites, 
hormones and bile acids were calculated as delta AUC from baseline at +150 to +210 minutes per 
kCal ice cream eaten at lunch. 
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 Dumping syndrome assessment 
 
Symptoms and signs of dumping syndrome in the surgical groups were assessed from post-prandial 
changes in nausea, sleepiness, blood pressure and heart rate and retrospective completion of 
validated questionnaires (Sigstad’s and Arts’) for the 3 months following surgery (Appendix 9) [554].  
 
The presence of symptoms of possible ‘dumping syndrome’ was also assessed during the study visit 
using change in nausea and sleepiness from before lunch to 1.5 hours after lunch (ΔAUC +150 to 
+240 minutes), and change in physiological markers indicative of dumping syndrome, pulse and 
blood pressure, from before lunch to 1 hour after lunch (difference +150 to +210 min) [588].  
 
Dietary records 
 
Caloric intake and diet macronutrient composition was assessed using 3-day self-reported dietary 
records (Appendix 11) at home in the two surgical groups and analyzed using Dietplan 6 (Foresfield 
Software Ltd., West Sussex, UK). 
 
Statistical analysis 
 
Results are presented as mean ± SEM or median [interquartile range] depending on normality 
distribution. Comparisons of averages between groups used unpaired t-tests or one way ANOVA 
with post-hoc Fisher’s Least Significant Difference (LSD) test or, if not normally disturbed, Mann 
Whitney U test or Friedman ANOVA on Ranks with post-hoc Dunn’s test. Comparison of prevalence 
between groups used chi-squared test. Comparisons between groups for BOLD signal activation, 
questionnaires for eating behaviour and psychological traits were adjusted for age, gender and BMI. 
Significance was taken as P<0.05. Analyses used SPSS version 19.0 and GraphPad Prism version 5.01.  
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 3.6 RESULTS  
 
The results for participant characteristics and psychological assessment are shown for both the 
whole cohort of 83 screened subjects and for the cohort of 61 subjects that actually underwent the 
scanning visit (scanned cohort). The rest of the results are shown for the scanned participants only. 
 
Participant characteristics 
 
The three groups were similar in age, gender ratio, current BMI, ethnic background distribution, 
percentage body fat, and current prevalence of type 2 diabetes mellitus, for both the whole cohort 
and the scanned cohort (Tables 3.3 and 3.4). The RYGB group had more obesity-associated 
comorbidities pre-operatively, predominantly due to a higher prevalence of type 2 diabetes than the 
BAND group. The two surgical groups also had similar pre-operative BMI, but the RYGB patients lost 
significantly more weight than the BAND patients (in both the whole cohort and the scanned 
cohort). The surgical patients were scanned at a median of 8-9 months after their surgery. 
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 Table 3.3: Subject characteristics of the whole cohort 
 BMI-M BAND RYGB P value  
N 25 28 30  
Age (years) 
41.0 [30.5 - 47.5] 
(20.0 - 56.0) 
42.5 [32.5 - 48.0] 
(22.0 - 59.0) 
44.5 [40.0 - 49.0] 
(23.0 - 59.0) 
0.35 
Gender (Male : Female) 4:21 2:26 4:26 0.59 
Ethnicity: European Caucasians, n (%) 15 (60%) 22 (79%) 22 (73%) 0.31 
Pre-operative BMI (kg/m
2
) n/a 
46.0 [42.2 - 51.5] 
(36.5 - 60.6) 
47.6 [42.8 - 53.8] 
(34.7 - 74.6) 
0.53 
Current Weight (kg) 
99.9 [81.9 -120.9] 
(65.5 - 168.0) 
96.8 [88.3 - 106.9] 
(68.3 - 126.3) 
93.8 [84.3 - 106.2] 
(63.6 - 144.0) 
0.73 
Current BMI (kg/m2) 
39.5 [29.3 - 44.1] 
(24.7 - 59.5) 
35.6 [32.4 - 38.2] 
(24.8 - 50.0) 
34.4 [30.2 - 38.4] 
(23.4 - 54.2) 
0.47 
Current Body fat (%)  
44.2 ± 1.9 
(26.0 - 63.2) 
43.3 ± 1.4 
(21.7 - 54.1) 
41.4 ± 2.0 
(16.8 - 68.2) 
0.54 
Weight loss (% of pre-operative weight) n/a 
22.0 [15.2 - 29.4] 
(8.9 - 52.4) 
28.0 [23.4 - 33.0] 
(16.3 - 40.4) 
0.01 
RYGB > BAND 
Time since surgery (months) n/a 
15.5 [6.25 - 28.5] 
(2 - 45) 
9.75 [8 – 13] 
(4 - 18) 
0.03 
BAND > RYGB 
Pre-operative DM, n (%) n/a 3 (11%) 13 (43%) 
0.01 
RYGB > BAND 
Current DM, n (%) 3 (12%) 1 (4%) 3 (10%) 0.51 
Pre-operative obesity co-morbidity score n/a 
6.0 [4.5 - 8.0] 
(1.0 - 13.0) 
9.0 [7.0 – 11.0] 
(2.0 - 19.0) 
0.001 
RYGB > BAND 
Current obesity co-morbidity score  
2.0 (0.0 - 7.3) 
(0.0  - 18.0) 
1.5 [1.0 - 2.5] 
(0.0 - 9.0) 
1.0 [0.0 - 2.0] 
(0.0 - 10.0) 
0.60 
Pre-operative BED, n (%) n/a 7 (25%) 9 (30%) 0.90 
Current BED, n (%) 4 (16%) 2 (7%) 1 (3%) 0.23 
 
Data are presented as mean ± standard error of the mean (SEM) or median [interquartile range] for data that is not normally distributed, and range in brackets. 
Comparisons between groups used Student’s unpaired t-tests or one-way ANOVA with post hoc Fisher’s LSD test or, if not normally distributed, Mann Whitney U test or 
Friedman ANOVA on Ranks with post hoc Dunn’s test. Categorical data were compared using the chi square test. Below the statistically significant P values (<0.05) f or the 
overall  ANOVA, the statistically significant pairwise comparisons and the direction of the result are shown using > or <. BMI BMI -M: body mass index matched, BAND: 
gastric banding, RYGB: gastric bypass, n/a not applicable, BMI: body mass index, DM:  type 2 diabetes mellitus, BED: binge ea ting disorder. 
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 Table 3.4: Characteristics of obese patients after gastric bypass and gastric banding and unoperated controls at time of fMRI scanning 
 
 BMI-M BAND RYGB P values  
N 20 20 21  
Age (years) 
39.1 ± 2.3 
(20.0 - 55.0) 
40.9 ± 2.5 
(22.0 - 59.0) 
43.5 ± 2.0 
(23.0 - 59.0) 
0.38 
Gender (Male : Female) 3:17 1:19 4:26 0.57 
Ethnicity: European Caucasians  
n (%) 
10 (50%) 15 (75%) 16 (76%) 0.14 
Pre-operative BMI (kg/m
2
) n/a 
44.8 [41.9 - 49.2] 
(36.5 - 57.0) 
48.4 [40.7 - 58.0] 
(34.7 - 74.6) 
0.23 
Current BMI (kg/m2) 
35.4 ± 1.9 
(24.7 - 55.6) 
35.1 ± 1.4 
(25.3 - 49.2) 
35.3 ± 1.7 
(22.6 - 52.4) 
0.99 
Current Height (m) 
1.64 ± 0.02 
(1.49 - 1.78) 
1.66 ± 0.02 
(1.53 - 1.79) 
1.66 ± 0.02 
(1.52 - 1.85) 
0.64 
Current Weight (kg) 
97.0 ± 3.1 
(73.9 - 119.8) 
97.0 ± 3.1 
(73.9 - 119.8) 
98.1 ± 4.9 
(63.7 - 137.9) 
0.97 
Current body fat (%) 
42.1 ± 2.2 
(26.0 - 58.2) 
41.9 ± 1.8 
(23.3 - 54.7) 
41.3 ± 1.9 
(28.4 - 56.0) 
0.96 
Weight loss  
(% of pre-operative weight) 
n/a 
23.1 [14.5 - 29.3] 
(9.7 - 52.4) 
29.9 [23.4 - 36.5] 
(16.3 - 40.4) 
0.018 
RYGB > BAND 
Time since surgery (months) n/a 
9.1 [5.2 - 19.2] 
(3.6 - 64.6) 
8.1 [5.9 - 11.5] 
(2.6 - 26.2) 
0.25 
Pre-operative DM, n (%) n/a 2 (10%) 10 (48%) 
0.02 
RYGB > BAND 
Current DM, n (%) 2 (10%) 0 (0%) 3 (14%) 0.23 
Pre-operative obesity co-morbidity score n/a 
6.0 [4.5 - 6.0] 
(1.0 - 10.0) 
10.0 [6.6 - 11.5] 
(3.0 - 19.0) 
<0.001 
RYGB > BAND 
Current obesity co-morbidity score 
0.0 [0.0 - 5.0] 
(0.0 - 18.0) 
0.0 [0.5 - 2.0] 
(0.0 - 9.0) 
1.0 [0.8 - 3.0] 
(0.0 - 10.0) 
0.85 
Pre-operative BED, n (%) n/a 4 (25%) 4 (19%) 1.00 
Current BED, n (%) 2 (10%) 2 (10%) 1 (5%) 0.78 
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 Data are presented as mean ± standard error of the mean (SEM) or median [interquartile range] for data that is not normally distributed, and range in brackets. 
Comparisons between groups used Student’s unpaired t-tests or one-way ANOVA with post hoc Fisher’s LSD test or, if not normally distributed, Mann Whitney U test or 
Friedman ANOVA on Ranks with post hoc Dunn’s test. Categorical data were compared using the chi square test. Below the statistically significant P values (<0.05) for the 
overall  ANOVA, the statistically significant pairwise comparisons and the direction of the result are shown using > or <. BMI  BMI-M: body mass index matched, BAND: 
gastric banding, RYGB: gastric bypass, n/a not applicable, BMI: body mass index, DM:  type 2 diabetes mellitus, BED: binge eating disorder. 
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 Psychological assessment 
The three groups were not significantly different in the prevalence of a current diagnosis of binge 
eating disorder or preoperative binge eating disorder diagnosis for the two surgical groups (Tables 
3.3 and 3.4). There were no significant differences between the groups for any of the psychological 
measures, including the prevalence and severity of depression, use of anti-depressant medication, 
positive and negative affect, reward sensitivity, impulsivity and extraversion, psychoticism or 
neuroticism (both in the whole cohort and the scanned cohort), (Tables 3.5 and 3.6).  
 
Table 3.5: Psychological assessment of the whole cohort 
 
BMI-M 
n=25 
BAND 
n=28 
RYGB 
n=30 
P value 
 
Beck Depression Inventory II (score/63) 
8.0 [2.0 - 14.0] 
(1.0 - 44.0) 
6.0 [3.0 -14.5] 
 (1.0 - 38.0) 
4.5 [2.0 - 11.0] 
 (0.0 - 32.0) 
0.99  
              Mild (≤15) 20 (80%) 21 (75%) 23 (77%) 0.91 
              Moderate/Severe (>15) 5 (20%) 7 (25%) 7 (23%)  
On antidepressants treatment n (%) 3 (12%) 5 (18%) 8 (27%) 0.38 
PANAS      
               Negative affect (score/50) 
18.0  [12.5 - 24.3] 
(10.0 - 43.0) 
15.0 [13.0 - 20.5] 
(9.0 - 33.0) 
15.0 [12.0 - 18.0] 
(10.0 - 35.0) 
0.67  
               Posi tive affect (score/50) 
32.3 ± 1.7 
(18.0 - 49.0) 
30.6 ± 2.0 
(15.0 - 49.0) 
32.8 ± 1.7 
(12.0 - 47.0) 
0.63 
Behavioural activation and inhibition scale     
        BAS drive (score/16) 
11.0 [9.0 - 13.0] 
(7.0 -15.0) 
10.0 [8.5 - 11.5] 
(5.0 - 15.0) 
10.0 [7.0 - 12.0] 
(4.0 - 16.0) 
0.35  
        BAS reward responsiveness (score/20) 
18.0 [15.8 - 19.0] 
(9.0 -20.0) 
17.0 [15.0 - 19.5] 
(8.0 - 20.0) 
17.0 [14.0 - 19.0] 
(11.0 - 20.0) 
1.00  
       BAS fun-seeking (score/16) 
12.1 ± 0.4 
(8.0 - 16.0) 
11.6 ± 0.4 
(7.0 - 16.0) 
11.0 ± 0.5 
(5.0 - 16.0) 
0.32 
       BIS (score/28) 
21 [17.8 -24.0] 
(11.0 - 28.0) 
21.5 [19.0 - 22.5] 
(11.0 - 28.0) 
20.0 [18.0 - 21.0] 
(12.0 -28.0) 
0.87  
Impulsivity      
             Barratt impulsivi ty scale (score/120) 
60.5 ± 2.4 
(30.0 -77.0) 
66.6 ± 2.6 
(45.0 - 99.0) 
63.2 ± 2.4 
(25.0 - 93.0) 
0.20 
EPQ-R     
              Extraversion (score/23) 
14.9 ± 0.9 
(2.0 - 22.0) 
14.2 ± 1.0 
(5.0 - 23.0) 
13.7 ± 1.0 
(4.0 - 23.0) 
0.49 
              Psychoticism (score/32) 
6.4 ± 0.6 
(0.0 - 13.0) 
6.6 ± 0.5 
(2.0 - 13.0) 
5.4 ± 0.6 
(1..0 - 13.0) 
0.35 
              Neuroticism (score/24) 
12.9 ± 0.9 
(6.0 - 23.0) 
11.9 ± 1.3 
(1.0 - 24.0) 
12.6 ± 1.0 
(2.0 - 24.0) 
0.73 
              Lying (score/21) 
8.7 ± 1.0 
(1.0 - 17.0) 
9.6 ± 0.7 
(3.0 - 17.0) 
9.8 ± 0.8 
(0.0 - 18.0) 
0.83 
Data are presented as mean ± standard error of the mean (SEM) or median [interquartile range] for data that is not 
normally distributed, and range in bra ckets . Data  appear in the raw format, but were analyzed adjusting for age, gender 
and BMI as covariates . Comparisons between groups used one-way ANOVA with post hoc Fisher’s  LSD test or, if not 
normally dis tributed, Friedman ANOVA on Ranks  with post hoc Dunn’s  test. Categorical data  were compared using the chi 
square test. Below the s tatistically significant P values  (<0.05) for the overall  ANOVA, the s tatistically significant pairwi se 
comparisons  and the direction of the result are shown using > or <. BMI -M: body mass index matched, BAND: gastric 
banding, RYGB: gastric bypass, PANAS: Positive and Negative Affect Schedule, BAS/BIS: Behavioural  Activation and 
Inhibition Scale, EPQ-R: Eysenck’s  Personality Questionnaire.  
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 Table 3.6: Psychological assessment of the scanned cohort 
 
 
Data are presented as mean ± standard error of the mean (SEM) or median [interquartile range] for data that 
is not normally distributed, and range in brackets. Data appear in the raw format, were analyzed adjusting for 
age, gender and BMI as covariates. Comparisons between groups used one-way ANOVA with post hoc Fisher’s 
LSD test or, if not normally distributed, Friedman ANOVA on Ranks with post hoc Dunn’s test. Categorical data 
was compared using the chi square test. Below statistically significant P values (<0.05) for the overall  ANOVA, 
the statistically significant pairwise comparisons and the direction of the result are shown using > or <. BMI -
M: body mass index matched, BAND: gastric banding, RYGB: gastric bypass, PANAS: Positive and Negative 
Affec t Schedule, BAS/BIS: Behavioural Activation and Inhibition Scale, EPQ-R: Eysenck’s Personality 
Questionnaire. 
 
 
BMI-M 
n=20 
BAND 
n=20 
RYGB 
n=21 
P value 
Beck Depression Inventory II (score/63) 
8.0 [2.0 - 12.5] 
(0.0 - 33.0) 
6.0 [3.0 - 13.0] 
(1.0 - 35.0) 
7.0 [2.8 - 17.3] 
(0.0 - 32.0) 
0.87  
              Mild (≤15) 17 (85%) 14 (70%) 15 (71%) 0.56 
              Moderate/Severe (>15) 3 (15%) 6 (30%) 6 (29%)  
On antidepressants treatment n (%) 0 (0%) 4 (20%) 5 (25%) 0.07 
PANAS      
               Negative affect (score/50) 
18.0 [13.5 - 22.5] 
(10.0 - 43.0) 
15.0 [13.0 - 21.0] 
(11.0 - 33.0) 
15.0 [12.0 - 18.0] 
(10.0 - 35.0) 
0.71  
               Posi tive affect (score/50) 
33.5 ± 1.8 
(18.0 - 49.0) 
29.7 ± 2.0 
(15.0 - 49.0) 
31.6 ± 2.2 
(12.0 - 47.0) 
0.38 
Behavioural activation and inhibition scale     
        BAS drive (score/16) 
11.7 ± 0.5 
(8.0 - 16.0) 
10.3 ± 0.5 
(7.0 - 15.0) 
9.4 ± 0.8 
(4.0 - 16.0) 
0.11 
        BAS reward responsiveness (score/20) 
18.0 [16.0 - 19.0] 
(9.0 - 20.0) 
17.5 [16.0 - 20.0] 
(13.0 - 20.0) 
17.0 [14.0 - 18.3] 
(11.0 - 20.0) 
0.34  
       BAS fun-seeking (score/16) 
12.4 ± 0.5 
(8.0 - 16.0) 
12.1 ± 0.4 
(9.0 - 16.0) 
10.5 ± 0.6 
(5.0 - 16.0) 
0.058 
       BIS (score/28) 
20.4 ± 0.8 
(14.0 - 27.0) 
21.5 ± 0.7 
(16.0 - 28.0) 
21.1 ± 0.8 
(16.0 - 28.0) 
0.87 
Impulsivity      
             Barratt impulsivi ty scale (score/120) 
64.0 [59.3 – 68.0] 
(30.0 - 75.0) 
63.5 [58.0 – 72.0] 
(45.0 - 92.0) 
62.5 [61.0 – 70] 
(25.0 - 93.0) 
0.77  
EPQ-R     
              Extraversion (score/23) 
16.3 ± 0.8 
(9.0 - 22.0) 
15.1 ± 0.9 
(8.0 - 21.0) 
12.7 ± 1.3 
(4.0 - 23.0) 
0.07 
              Psychoticism (score/32) 
6.5 ± 0.6 
(0.0 - 11.0) 
5.9 ± 0.6 
(2.0 - 10.0) 
5.3 ± 0.6 
(1.0 - 12.0) 
0.59 
              Neuroticism (score/24) 
11.8 ± 0.9 
(6.0 - 19.0) 
12.5 ± 1.3 
(1.0 - 23.0) 
12.6 ± 1.2 
(2.0 - 24.0) 
0.63 
              Lying (score/21) 
9.0 ± 1.0 
(2.0 - 14.0) 
9.4 ± 0.7 
(4.0 - 17.0) 
9.5 ± 0.9 
(0.0 - 17.0) 
1.00 
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 Eating behaviour assessment 
In the whole cohort, the RYGB group had consistently healthier eating behaviour and less eating 
disorder psychopathology with significantly lower scores for dietary restraint (EDE-Q), external 
eating (DEBQ), weight and shape concerns (EDE-Q) compared to the BAND and/or BMI-M groups 
(Figure 3.3, Table 3.7). Furthermore the BAND group had higher dietary restraint (EDE-Q) scores 
compared to the BMI-M group. However no significant differences were detected between the 
groups in emotional eating (DEBQ). In the scanned cohort, the RYGB had significantly lower EDE-Q 
restraint scores than both the BMI-M and BAND groups and significantly lower EDE-Q disordered 
eating compared to the BAND group (Table 3.8). 
 
Figure 3.3: Eating behaviour questionnaires 
 
(A) Dietary restraint, (B) external eating and (C) weight concerns of body mass index-matched unoperated 
controls (BMI-M, white), and obese patients after gastric banding (BAND, dotted) and gastric bypass (RYGB, 
striped) surgery. Data are presented as mean ± SEM. 
#
P<0.05, 
###
P<0.005 vs. BMI-M; *P<0.05 vs. BAND; n=20-
21 per group. EDE-Q: Eating Disorders Examination Questionnaire, DEBQ: Dutch Eating Behaviour 
Questionnaire 
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 Table 3.7:  Eating behaviour of the whole cohort 
 
BMI-M 
n=25 
BAND 
n=28 
RYGB 
n=30 
P value 
Dietary restraint     
               EDE-Q - Restraint (score/6) 
0.8 [0.3 - 2.0] 
 (0.0 - 3.2) 
2.0 [0.8 - 3.1] 
 (0.0 - 4.8) 
0.5 [0.0 - 1.8] 
(0.0 - 4.4) 
0.013 
RYGB < BAND 0.011 
BAND > BMI-M 0.011  
               DEBQ - Restraint (score/5) 
2.6 ± 0.1 
(1.4 – 3.5) 
3.0 ± 0.4 
(1.4 – 4.5) 
2.6 ± 0.2 
(0.0 – 4.4) 
0.14 
Disinhibited  eating      
               DEBQ - External eating (score/5) 
3.1 ± 0.2 
(1.5 – 5.0) 
2.9 ± 0.1 
(1.7 – 3.7) 
2.5 ± 0.1 
(0.6 – 4.2) 
0.004 
BMI-M > RYGB 0.001 
               DEBQ - Emotional eating (score/5) 
3.9 ± 0.3 
(1.3 – 6.5) 
3.9 ± 0.3 
(1.5 – 6.2) 
3.3 ± 0.3 
(0.0 – 6.5) 
0.31 
Disordered eating questionnaire      
               EDE-Q - Weight concerns (score/6) 
3.0 ± 0.6 
 (0.4 - 5.6) 
2.7 ± 0.3 
(0.0 - 5.2) 
1.9 ± 0.3 
(0.0 - 5.9) 
0.024 
RYGB < BMI-M 0.012 
RYGB < BAND 0.032 
               EDE-Q - Shape concerns (score/6) 
3.1 ± 0.3 
(0.4 - 5.3) 
3.2 ± 0.3 
(0.4 - 6.0) 
2.3 ± 0.3 
(0.1 - 5.9) 
0.050 
RYGB < BAND 0.020 
              EDE-Q - Eating concerns  (score/6) 
0.8 [0.3 - 1.8] 
(0.0 - 5.5) 
0.8 [0.3 - 1.7] 
(0.0 - 4.8) 
0.4 [0.0 - 1.0] 
(0.0 - 5.4) 
 
0.40  
              EDE-Q - Global score (score/6) 
2.1 ± 0.2 
(0.4 - 4.5) 
2.3 ± 0.2 
(0.1 - 4.5) 
1.5 ± 0.2 
(0.0 - 5.2) 
0.024 
RYGB < BAND 0.007 
 
Data are presented as mean ± standard error of the mean (SEM) or  median [interquartile range] for data that is  not normally distributed, and range in brackets. Data 
appear in the raw format, but were analyzed adjusting for age, gender and BMI as covariates. Comparisons between groups used one-way ANOVA with post hoc Fisher’s 
LSD test or, if not normally distributed, Friedman ANOVA on Ranks with post hoc Dunn’s test. Below the statistically significant P values (<0.05) for the overall  ANOVA, the 
statistically significant pairwise comparisons and the direction of the result are shown using > or <. BMI -M: body mass index matched, BAND: gastric banding, RYGB: gastric 
bypass, n/a not applicable, EDE-Q: Eating Disorder Examination Questionnaire, DEBQ: Dutch Eating Behaviour Questionnaire.  
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 Table 3.8: Eating behaviour of the scanned subjects 
 
BMI-M 
n=20 
BAND 
n=20 
RYGB 
n=21 
P value 
Dietary restraint     
               EDEQ - Restraint (score/6) 
0.8 [0.4 - 1.6] 
(0. 0 - 3.0) 
1.7 [0.8 - 3.0] 
(0.0 - 3.8) 
0.4 [0.0 - 1.4] 
(0.0 - 4.4) 
0.021 
RYGB < BAND 0.014 
BAND > BMI-M 0.018  
               DEBQ - Restraint (score/5) 
2.6 ± 0.1 
(1.4 – 3.5) 
3.0 ± 0.1 
(1.4 – 4.5) 
2.5 ± 0.2 
(0.0 – 3.9) 
0.21 
Disinhibited  eating      
               DEBQ - External eating (score/5) 
3.0 ± 0.2 
(1.5 – 4.4) 
2.9 ± 0.1 
(1.7 – 3.7) 
2.5 ± 0.2 
(0.6 – 4.2) 
0.052 
               DEBQ - Emotional eating (score/5) 
2.7 ± 0.4 
(1.0 – 4.8) 
3.0 ± 0.3 
(1.2 – 4.8) 
2.4 ± 0.4 
(0.0 – 5.0) 
0.43 
Disordered eating questionnaire      
               EDE-Q - Weight concerns (score/6) 
2.4 ± 0.2 
(0.4 - 4.4) 
2.8 ± 0.3 
(0.0 - 5.2) 
1.9 ± 0.3 
(0.0 - 5.9) 
0.14 
               EDE-Q - Shape concerns (score/6) 
2.5 ± 0.3 
(0.4 - 4.4) 
3.2 ± 0.4 
(0.4 - 6.0) 
2.4 ± 0.3 
(0.1 - 5.0) 
0.21 
               EDE-Q - Eating concerns (score/6) 
0.5 [0.3 - 1.5] 
(0.0 - 3.8) 
1.3 [0.5 - 2.6] 
(0.0 - 4.8) 
0.3 [0.0 - 0.9] 
(0.0 - 5.4) 
0.10  
               EDE-Q - Global score (score/6) 
1.6 [1.2 - 2.4] 
(0.4 - 3.3) 
2.5 [1.7 - 3.2] 
(0.1 - 4.5) 
0.9 [0.7 - 2.1] 
(0.0 - 5.2) 
0.044 
RYGB < BAND 0.014  
 
Data are presented as mean ± standard error of the mean (SEM) or  median [interquartile range] for data that is not n ormally distributed, and range in brackets. Data 
appear in the raw format, but were analyzed adjusting for age, gender and BMI as covariates. Comparisons between groups used one-way ANOVA with post hoc Fisher’s 
LSD test or, if not normally distributed, Fri edman ANOVA on Ranks with post hoc Dunn’s test. Below the statistically significant P values (<0.05) for the overall  ANOVA, the 
statistically significant pairwise comparisons and the direction of the result are shown using > or <. BMI -M: body mass index matched, BAND: gastric banding, RYGB: gastric 
bypass, n/a not applicable, EDE-Q: Eating Disorder Examination Questionnaire, DEBQ: Dutch Eating Behaviour Questionnaire.  
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 Whole brain food picture fMRI analysis 
 
FMRI scans of 2 participants from the scanned cohort (1 RYGB, 1 BMI-M) were excluded from 
analysis due to excess motion and/or poor image quality. The results of the whole brain analysis is 
detailed in Table 3.9 and illustrated in Figure 3.4. 
 
Clusters within the orbitofrontal cortex (bilateral), subcallosal cortex (bilateral), putamen, caudate 
and nucleus accumbens (left) had significantly lower BOLD activation in the RYGB compared to the 
BAND group when viewing food pictures (high or low-calorie). 
 
Clusters within the orbitofrontal cortex (bilateral), subcallosal cortex (bilateral), putamen, caudate 
and nucleus accumbens (left), hippocampus (left), cingulate and paracingulate gyrus (right) had 
significantly lower BOLD activation in the RYGB compared to the BAND group when viewing high-
calorie food pictures.  
 
Clusters within the orbitofrontal cortex (bilateral) and subcallosal cortex (bilateral) had significantly 
lower BOLD activation in the RYGB compared to the BAND group when viewing low-calorie food 
pictures.  
 
By contrast, there were no significant clusters with greater BOLD activation in the RYGB compared to 
the BAND group when separately viewing any food, high-calorie or low-calorie food pictures.  
 
There were no significant clusters with different BOLD activation in the RYGB compared to the BAND 
group when viewing high-calorie vs. low-calorie food pictures.  
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 Figure 3.4: Whole brain comparison of activation to high-calorie foods between obese patients 
after gastric bypass and gastric banding. 
 
Whole brain group level comparison for high-calorie vs. object picture contrast to demonstrate clusters in 
which BOLD signal was lower in patients after gastric bypass (RYGB) compared with gastric banding (BAND) 
surgery, adjusting for age, gender and body mass index. No clusters showed greater activation in RYGB than 
BAND groups. Colour bar indicates Z values. Cluster activation thresholded at Z>2.1, P<0.05, overlaid onto the 
average T1 scan for all  subjects (n=20 per group). Co-ordinates given in standard MNI space. Abbreviations: 
ACC; anterior cingulate cortex, Amy: amygdala, Caud: caudate, NAcc: nucleus accumbens, Hipp: hippocampus, 
MFG: middle frontal gyrus, OFC: orbitofrontal cortex, Put: putamen.  
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 Table 3.9: Spatial coordinates of whole brain comparison of activation to food between surgical groups 
Contrast Number of voxels Z statistic X y z Brain region 
GASTRIC BANDING > GASTRIC BYPASS       
Any food (high-calorie or low-calorie)  Cluster 1 - 1470 4.12 16 30 -12 Right orbi tofrontal  cortex 
  3.69 -18 44 -8 Left orbi tofrontal cortex 
  3.61 -6 8 -20 Left orbi tofrontal cortex 
  3.45 -16 40 -14 Left orbi tofrontal cortex 
  3.42 16 16 -18 Right orbi tofrontal  cortex 
  3.20 0 22 -8 Right orbi tofrontal  cortex 
  3.18 4 10 -14 Right subcallosal cortex 
  2.93 38 34 -16 Right orbi tofrontal  cortex / subcallosal cortex 
  2.89 -8 18 -20 Left orbi tofrontal cortex / subcallosal cortex 
  2.83 -16 18 -8 Left putamen / caudate / nucleus accumbens 
High-calorie food Cluster 1 - 980 4.05 -38 18 -30 Left  temporal  cortex 
  3.55 -18 44 -10 Left orbi tofrontal cortex 
  3.51 16 30 -10 Right orbi tofrontal  cortex 
  3.21 -42 26 -14 Left orbi tofrontal cortex 
  3.17 40 34 -14 Right  orbitofrontal cortex 
  3.12 -36 38 -12 Right orbi tofrontal  cortex 
  3.04 32 42 -8 Right orbi tofrontal  cortex / frontal pole 
  3.03 -42 30 -16 Left orbi tofrontal cortex / frontal  pole 
  3.00 10 46 -8 Right cingulate/paracingulate gyrus 
  2.92 -34 44 -8 Left frontal pole 
 Cluster 2 – 1232 3.54 -6 6 -18 Left subcallosal cortex 
  3.28 10 -32 -18 Right brainstem 
  3.22 4 10 -14 Right subcallosal cortex 
  3.21 32 -32 -18 Right hippocampus 
  3.05 10 -22 -24 Right brainstem 
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   3.04 2 -22 -22 Right brainstem 
  2.89 -16 18 -8 Left putamen / caudate / nucleus accumbens 
  2.88 12 -40 -22 Left brainstem 
Contrast Number of voxels Z s tatistic X y z Brain region 
Low-calorie food Cluster 1 – 1041 3.95 14 30 -12 Right orbi tofrontal  cortex 
  3.46 -16 40 -14 Left orbi tofrontal cortex 
  3.43 4 22 -8 Right subcallosal cortex 
  3.32 -4 8 -18 Left subcallosal cortex 
  3.25 16 16 -18 Left orbi tofrontal cortex 
  3.20 -16 46 -6 Left orbi tofrontal cortex 
  3.17 12 8 -18 Right orbi tofrontal  cortex / subcallosal cortex 
  3.02 -6 18 -18 Left subcallosal cortex 
  3.01 -18 42 -20 Left orbi tofrontal cortex / frontal  pole 
  2.94 -8 12 -22 Left orbi tofrontal cortex / subcallosal cortex 
       
GASTRIC BYPASS > GASTRIC BANDING       
Any food (high-calorie or low-calorie)       Nil signi ficant 
High-calorie food      Nil signi ficant 
Low-calorie food      Nil signi ficant 
 
Stereotactic coordinates (x, y, z) for peak voxel of group activation for food category vs. objects, adjusted for age, gender and BMI, cluster thresholded at Z>2.1, P<0.0 5 
(n=20 per group), given in standard MNI space.
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 FROI food picture fMRI analysis 
 
The results of the fROI analysis are detailed in Table 3.10 and illustrated in Figure 3.5. 
 
BOLD activation within a reward system network (combining average activation in the orbitofrontal 
cortex, amygdala, nucleus accumbens, anterior insula and caudate fROIs) was significantly lower for 
the RYGB compared to the BAND and/or BMI-M groups for high-calorie food, but was not 
significantly different for low-calorie food pictures. BOLD activation within this reward system 
network was significantly lower in the BAND compared to the BMI-M group for the high vs. low-
calorie food picture contrast. 
 
When examining individual fROIs, BOLD activation in the orbitofrontal cortex fROI was significantly 
lower in the RYGB compared to the BAND and/or BMI-M groups for any food and low-calorie food, 
with a trend also for high-calorie food pictures. 
 
BOLD activation in the amygdala fROI was significantly lower in the RYGB compared to the BAND and 
BMI-M groups for any food, with a similar pattern for high-calorie and low-calorie food pictures, 
though only the high-calorie food showed a statistical trend. 
 
There were no significant or trends for differences in BOLD activation between the three groups for 
any food, high-calorie food or low-calorie food pictures in the nucleus accumbens, anterior insula or 
caudate nucleus fROIs. However, BOLD activation within the caudate nucleus was significantly lower 
in the BAND compared to the BMI-M group for the high vs. low-calorie food contrast. 
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 Figure 3.5: Region of interest activation to food in obese patients after gastric bypass and gastric 
banding and unoperated controls 
 
Comparison of BOLD signal to any food, only high-calorie or only low-calorie food (vs. objects) in a priori 
functional regions of interest (fROI) between body mass index-matched unoperated controls (BMI-M, white), 
and obese patients after gastric banding (BAND, dotted) and gastric bypass (RYGB, striped) surgery, adjusting 
for age, gender and BMI. (A) Average in all  five fROIs, (B) orbitofrontal cortex (OFC), (C) a mygdala, (D) anterior 
insula, (E) nucleus accumbens, (F) caudate. Data are presented as mean ± SEM. 
#
P<0.05, 
##
P<0.01, 
###
P<0.005 
vs. BMI-M; *P<0.05, **P<0.01, ***P<0.005 vs. BAND; n=19-20 per group.  
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 Table 3.10: Region of interest activation during food evaluation and auditory-motor-visual control task 
Region of interest Contrast BMI–M BAND RYGB P value 
a
 
N  19 20 20  
FOOD EVALUATION TASK      
Reward system (all 5 ROIs) Food 
0.082 ± 0.029 
(-0.127 to 0.335) 
0.138 ± 0.020 
(0.005 to 0.340) 
0.064 ± 0.021 
(-0.101 to 0.225) 
0.08 
BAND > RYGB 0.03 
 High-calorie 
0.100 ± 0.027 
(-0.152 to 0.294) 
0.131 ± 0.022 
(-0.012 to 0.372) 
0.049 ± 0.023 
(-0.176 to 0.235) 
0.05 
BAND > RYGB 0.02 
 Low-calorie 
0.060 ± 0.033 
(-0.150 to 0.348) 
0.128 ± 0.026 
(-0.042 to 0.472) 
0.078 ± 0.022 
(-0.060 to 0.253) 
0.28 
 
High vs. Low 
calorie 
0.177 [0.151 - 0.221] 
(0.128 - 0.364) 
0.150 [0.130 - 0.196] 
(0.113 - 0.318) 
0.175 [0.135 - 0.205] 
(0.104 - 0.409) 
0.033 
(BAND < BMI-M) 
 Objects  0.101 ± 0.015 
(-0.008 to 0.254) 
0.064 ± 0.024 
(-0.306 to 0.204) 
0.086 ± 0.034 
(-0.221 to 0.356) 
0.47 
Orbitofrontal cortex  Food 
0.177 ± 0.050 
(-0.064 to 0.878) 
0.235 ± 0.040 
(-0.121 to 0.543) 
0.066 ± 0.040 
(-0.459 to 0.306) 
0.029 
BAND > RYGB 0.008 
 High-calorie 0.191 ± 0.060 
(-0.099 to 0.853) 
0.182 ± 0.044 
(-0.285 to 0.474) 
0.043 ± 0.045 
(-0.357 to 0.478) 
0.09 
 Low-calorie 
0.160 ± 0.046 
(-0.076 to 0.793) 
0.250 ± 0.038 
(-0.04 to 0.646) 
0.085 ± 0.042 
(-0.498 to 0.372) 
0.03 
BAND > RYGB 0.01 
 High vs. Low 
calorie 
0.186 [0.163 - 0.294] 
(0.139 - 0.498) 
0.184[0.147 - 0.235] 
(0.107 - 0.584) 
0.224 [0.155 - 0.276] 
(0.106 - 0.484) 
0.52 
 Objects  0.061 ± 0.043 
(-0.301 to 0.353) 
0.031 ± 0.050 
(-0.246 to 0.767) 
0.006 ± 0.065 
(-0.558 to 0.714) 
0.85 
Amygdala Food 
0.086 ± 0.051 
(-0.172 to 0.592) 
0.121± 0.035 
(-0.187 to 0.543) 
-0.027 ± 0.047 
(-0.694 to 0.243) 
0.04 
BAND > RYGB 0.02 
BMI-M > RYGB 0.04 
 High-calorie 0.124 ± 0.056 
(-0.187 to 0.787) 
0.110 ± 0.046 
(-0.345 to 0.527) 
-0.023 ± 0.055 
(-0.690 to 0.298) 
0.059 
 Low-calorie 0.049 ± 0.056 
(-0.263 to 0.624) 
0.114 ± 0.039 
(-0.087 to 0.589) 
-0.011 ± 0.056 
(-0.633 to 0.425) 
0.24 
 High vs. Low 
calorie 
0.210 [0.173 - 0.364] 
(0.115 - 0.497) 
0.184 [0.158 - 0.274] 
(0.140 - 0.344) 
0.195 [0.139 - 0.234] 
(0.117 - 0.623) 
0.13 
 Objects  0.214 ± 0.028 
(-0.039 to 0.414) 
0.199 ± 0.032 
(-0.110 to 0.384) 
0.090 ± 0.073 
(-0.847 to 0.496) 
0.16 
Nucleus accumbens  Food 0.061 ± 0.035 
(-0.21 to 0.356) 
0.097 ± 0.024 
(-0.058 to 0.259) 
0.060 ± 0.030 
(-0.182 to 0..333) 
0.67 
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  High-calorie 
0.075 ± 0.034 
(-0.295 to 0.376) 
0.107 ± 0.026 
(-0.063 to 0.367) 
0.048 ± 0.032 
(-0.281 to 0.297) 
0.43 
 Low-calorie (0.038 ± 0.038) 
(-0.28 to 0.298) 
0.080 ± 0.033 
(-0.209 to 0.428) 
0.065 ± 0.031 
(-0.217 to 0.454) 
0.79 
 
High vs. Low 
calorie 
0.131 [0.113 - 0.192] 
(0.088 - 0.411) 
0.115 [0.094 - 0.151] 
(0.084 - 0.325) 
0.145 [0.097 - 0.189] 
(0.081 - 0.444) 
0.17 
 Objects  
0.0730 ± 0.0241 
(-0.134 to 0.329) 
-0.026 ± 0.033 
(-0.543 to 0.139) 
0.0382 ± 0.032 
(-0.189 to 0.327) 
0.10 
Anterior Insula  Food 
0.0534 ± 0.025 
(-0.212 to 0.256) 
0.095 ± 0.034 
(-0.094 to 0.496) 
0.134 ± 0.037 
(-0.218 to 0.532) 
0.47 
 High-calorie 
0.062 ± 0.032 
(-0.237 to 0.254) 
0.102 ± 0.028 
(-0.132 to 0.336) 
0.127 ± 0.037 
(-0.240 to 0.468) 
0.64 
 Low-calorie 
0.038 [-0.058 to 0.107] 
(-0.148 to 0.310) 
0.051 [-0.034 to 0.106] 
(-0.181 to 0.678) 
0.129 [0.040 to 0.182] 
(-0.192 to 0.545) 
0.43 
 High vs. Low 
calorie 
0.134 [0.118 - 0.182] 
(0.072 - 0.491) 
0.128 [0.097 - 0.195] 
(0.076 - 0.275) 
0.136 [0.106 - 0.200] 
(0.079 - 0.320) 
0.79 
 Objects  
-0.008 ± 0.029 
(-0.212 to 0.283) 
0.051 ± 0.022 
(-0.091 to 0.297) 
0.064 ± 0.030 
(-0.239 to 0.281) 
0.15 
Caudate Food 0.031 ± 0.051 
(-0.371 to 0.638) 
0.141 ± 0.033 
(-0.059 to 0.605) 
0.087 ± 0.032 
(-0.100 to 0.411) 
0.23 
 High-calorie 
0.040 [-0.045 to 0.177] 
(-0.403 to 0.595) 
0.013 [0.081 to 0.197] 
(-0.094 to 0.733) 
0.038 [-0.057 to 0.150] 
(-0.189 to 0.415) 
0.15 
 Low-calorie 0.025 [-0.120 to 0.117] 
(-0.375 to 0.639) 
0.075 [0.019 to 0.166] 
(-0.117 to 0.488) 
0.010 [0.017 to 0.170] 
(-0.075 to 0.432) 
0.15 
 
High vs. Low 
calorie 
0.150 [0.129 - 0.191] 
(0.118 - 0.351) 
0.124 [0.095 - 0.148] 
(0.080 - 0.342) 
0.144 [0.110 - 0.203] 
(0.071 - 0.412) 
0.020 
(BAND < BMI-M) 
 Objects  0.165 ± 0.036 
(-0.108 to 0.568) 
0.063 ± 0.046 
(-0.672 to 0.293) 
0.230 ± 0.049 
(-0.360 to 0.590) 
0.037 
(BAND < BMI-M) 
CONTROL TASK      
Combined (all 3 ROIs)  0.816 ± 0.089 
(0.221 - 1.815) 
0.856 ± 0.077 
(0.323 - 1.605) 
0.798 ± 0.068 
(0.415 - 1.331) 
0.85 
Posterior division superior temporal gyrus  Auditory  
0.853 ± 0.134 
(0.168 to 2.172) 
0.942 ± 0.117 
(0.065 to 2.098) 
0.728 ± 0.074 
(0.288 to 1.443) 
0.41 
Left precentral gyrus  Motor 0.276 ± 0.104 
(-0.807 to 0.846) 
0.415 ± 0.077 
(-0.076 to 0.973) 
0.360 ± 0.057 
(-0.049 to 0.727) 
0.33 
Lingual gyrus Visual 
1.320 ± 0.169 
(0.156 to 2.906) 
1.212 ± 0.152 
(0.152 to 2.739) 
1.304 ± 0.146 
(0.357 to 2.581) 
0.92 
 
Average group activation in separate and combined a priori regions of interest (ROI) for food category vs. objects during food evaluation task, or auditory, motor or visual 
cortex during control task, adjusted for age, gender and BMI. Data presented as mean ± SEM and (range).  
a 
P value for overall comparison of averages between groups 
using ANOVA, with post-hoc comparison given beneath. Abbreviations: BAND: gastric banding, BMI -M: body mass index matched, RYGB: gastric bypass 
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 Auditory-motor-visual control fMRI task 
 
The results of the analysis for the Audio-Motor-Visual control task are detailed in Table 3.10 and 
illustrated in Figure 3.6B. 
 
There were no clusters with significantly different BOLD activation in the RYGB compared to the 
BAND group for either the auditory, motor or visual fMRI tasks in whole brain analysis. 
 
There were also no significant differences in BOLD activation within the superior temporal gyrus 
posterior division, precentral gyrus and lingual gyrus fROIs between the three groups for the 
auditory, motor and visual control tasks respectively. 
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 Figure 3.6: A priori functional regions of interest for auditory, motor and visual cortex activation 
during control task 
 
 
 
 
(A) Group activation maps of separate cohort of overweight/obese subjects overlaid with a priori anatomical 
regions of interest for control auditory-motor-visual task: auditory (red: l istening to story) with bilateral 
posterior division of superior temporal gyrus (overlaid in yellow), motor  task (green: button press) with 
left pre-central gyrus (overlaid in magenta), and visual (dark blue: flashing checkerboard) with lingual 
gyrus (overlaid in light blue). Activation is thresholded at FDR P<0.05, overlaid onto the average T1 scan 
for all  subjects (n=23). Co-ordinates are given in standard MNI space.  
 
(B) Comparison of BOLD signal for auditory, motor and visual control task in a priori functional regions of 
interest between body mass index-matched unoperated controls (BMI-M, white), and obese patients after  
gastric banding (BAND, dotted) and gastric bypass (RYGB, striped) surgery, adjusting for a ge, gender and 
BMI. Data are presented as mean ± SEM. n=19-20 per group.  
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 Appetite and food palatability ratings 
 
Over the scanning period, both the RYGB and BAND groups rated their “hunger”, “pleasantness to 
eat” and “volume of food they could eat” as significantly lower than the BMI-M group, but there was 
no significant difference between the two surgical groups. There were no significant differences in 
“fullness” between the 3 groups. The RYGB patients were also significantly less nauseated than the 
BAND patients, but absolute nausea ratings were still low (Figure 3.7, Table 3.11)  
 
After scanning, the RYGB and BAND patients consumed similar amounts of ice-cream, but the RYGB 
patients rated it as significantly less “pleasant to eat” than the BAND patients , but similarly sweet. 
The two surgical groups had similar changes in fullness after the meal (Figure 3.7, Table 3.12). 
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 Figure 3.7: Appetite visual analogue scales during fMRI and after meal 
Comparison of visual analogue scale (VAS) ratings of (A,B) hunger, (C,D) nausea, (E,F) pleasantness to eat, (G,H) 
volume of food that could be eaten, and (I,J) fullness. (A,C,E,G,I) levels during fMRI scanning (area under curve 
(AUC) +40 to +150 mins) between body mass index-matched unoperated controls (BMI-M, white), and obese 
patients after gastric banding (BAND, dotted) and gastric bypass (RYGB, striped) surgery. (B,D,F,H,J) change in 
levels after ice cream meal (ΔAUC +150 to +210 mins) in surgical groups.  Data are presented as mean ± SEM. 
###
P<0.005 vs. BMI-M; *P<0.05, ***P<0.005 vs. BAND; n=20-21 per group.  
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 Table 3.11: Appetite visual analogue scales over the scanning period  
 
 
BMI - M 
n=20 
BAND 
n=20 
RYGB 
n=21 
P value 
VAS Hunger     
During fMRI AUC (cm.min) 
 
708.4 ± 52.3 
(219.3 - 1100.0) 
419.2 ± 55.5 
(0.0 - 857.5) 
350.2 ± 49.4 
(87.0 - 807.0) 
<0.001 
RYGB < BMI-M <0.001 
BAND < BMI-M <0.001 
VAS Nausea     
During fMRI AUC (cm.min) 
 
126.1  [8.3 - 202.2] 
(0.0 - 471.8) 
112.8 [45.8 - 241.2] 
(0.0 - 499.8) 
11.0 [3.4 - 30.5] 
(0.0 - 491.3) 
0.018 
RYGB < BAND <0.05 
VAS Pleasantness to eat      
During fMRI AUC (cm.min) 
 
681.6 ± 53.0 
(276.3 - 1100.0) 
438.7 ± 50.3 
(0.0 - 821.5) 
431.8 ± 50.4 
(110.3 - 858.0) 
0.001 
RYGB < BMI-M 0.001 
BAND < BMI-M 0.002 
VAS Volume      
During fMRI AUC (cm.min) 
 
668.2 ± 51.8 
(274.8 - 1046.8) 
411.3 ± 49.1 
(0.0 - 845.3) 
394.3 ± 41.7 
(72.8 - 703.3) 
<0.001 
RYGB < BMI-M <0.001  
BAND < BMI-M <0.001 
VAS Fullness     
During fMRI AUC (cm.min) 
167.8 [60.7- 415.2] 
(0.0 - 681.8) 
245.3 [106.7 - 400.9] 
(9.5 - 875.0) 
206.5 [25.1 - 274.8] 
(0.0 - 749.5) 
0.61 
 
Data are presented as mean ± standard error of the mean (SEM) or median [interquartile range] for data that is not normally d istributed, and range in brackets. 
Comparisons between groups used one-way ANOVA with post hoc Fisher’s LSD test or, if not normally distributed, Friedman ANOVA on Ranks with post hoc Dunn’s test. 
Below statistically significant P values (<0.05) for the overall  ANOVA, the statistically significant pairwise comparisons an d the direction of the result are shown using > or <. 
BMI-M: body mass index matched, BAND: gastric banding, RYGB: gastric bypass, VAS: visual analogue scale, AUC: area under the curve betw een time points +40 to +150.  
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 Table 3.12 Appetite visual analogue scales after the meal 
 
BMI - M 
n=20 
BAND 
n=20 
RYGB 
n=21 
P value 
Lunch intake                                                       
      Total  (kCal) n/a 
317.8 ± 35.8 
(34.0 - 563.0) 
285.5 ± 37.0 
(34.0 - 604.0) 
0.54 
      Corrected (kCal/kg per LBM) n/a 
5.8 ± 0.7 
(0.6 - 10.4) 
5.2 ± 0.7 
(0.4 - 11.8) 
0.54 
VAS lunch palatability  (cm)     
                       Tastiness n/a 
6.1 ± 0.6 
(0.3 - 9.5) 
4.5 ± 0.6 
(0.6 - 9.6) 
0.07 
                       Pleasantness to eat n/a 
5.8 ± 0.6 
(0.3 - 9.6) 
4.1 ± 0.5 
(0.5 - 9.6) 
0.047  
RYGB < BAND 
                       Sweetness n/a 
7.7 ± 0.4 
(4.4 - 10.0) 
7.8 ± 0.4 
(3.0 - 9.7) 
0.96 
VAS Hunger     
 After meal Δ AUC (cm.min) n/a 
-175.8 ± 47.2 
(-504.0 to 214.5) 
-182.0 ± 39.2 
(-547.0 to 85.5) 
0.92 
VAS Nausea     
After meal Δ AUC (cm.min) n/a 
-19.5 [-69.8 to 0.0] 
(-549.0 to 186.0) 
9.0 [0.0 to 79.1] 
(-10.5 to 408.0) 
<0.001  
RYGB > BAND 
VAS Pleasantness to eat      
 After meal Δ AUC (cm.min) n/a 
-135.0 [-396.8 to 30.4] 
(-519.0 to 430.5) 
-174.0 [-289.1 to -109.9] 
(-433.5 to 126.0) 
0.55 
VAS Volume      
 After meal Δ AUC (cm.min) n/a 
-117.1 ± 44.5 
(-469.5 to 330.0) 
-186.6 ± 28.7 
(-367.5 to 93.0) 
0.19 
VAS Fullness     
 After meal Δ AUC (cm.min) 
 
n/a 
252.7 ± 49.4 
(-90.0 to 634.5) 
240.0 ± 44.4 
(-142.5 to 609.0) 
0.85 
Data are presented as mean ± standard error of the mean (SEM) or median [interquartile range] for data that is not normally d istributed, and range in brackets. 
Comparisons between groups used Student’s unpaired t-tests or, if not normally disturbed. Note statistical comparisons not made with the BMI -M patients for lunch 
palatability or intake as test lunch differed between un-operated and post-operative groups (n/a: not applicable). The statistically significant pairwise comparisons and the 
direction of the result are shown using > or <. BMI-M: body mass index matched, BAND: gastric banding, RYGB: gastric bypass, VAS: visual analogue scale, Δ AUC: change in 
the area under the curve between time point +150 and time points +180 to +240, LBM: lean body mass.  
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 Appeal scores 
The results of the appeal scores are detailed in Table 3.13 and illustrated in Figure 3.8. During fMRI 
scanning, RYGB patients consistently rated food pictures (high- or low-calorie) and high-calorie food 
pictures, including each of the sub-groups of chocolate, non-chocolate sweet and savoury pictures, 
as significantly less appealing than the BAND and/or BMI-M subjects. By contrast no significant 
differences in appeal rating for low-calorie food, object or blurred pictures were observed between 
the three groups. 
 
Figure 3.8: Food hedonics, appetite and dietary records in obese patients after gastric bypass and 
gastric banding and controls 
 
Comparison of (A) appeal of any food, only high-calorie or only low-calorie food pictures; (B) appeal of sub-
categories of high-calorie food pictures; (C) visual analogue scale (VAS) hunger rating (area under curve (AUC) 
+40 to +150 mins); (D) ice-cream meal palatability; (E) average daily calorie intake (kCal per kg lean body mass 
(LBM) from 3 day food diary; (F) average percentage of total calories from fat from 3 day food diary, between 
body mass index-matched unoperated controls (BMI-M, white), and obese patients after gastric banding 
(BAND, dotted) and gastric bypass (RYGB, striped) surgery. Data are presented as mean ± SEM. 
#
P<0.05, 
###
P<0.005 vs. BMI-M; *P<0.05, ***P<0.005 vs. BAND; n=20-21 per group.  
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 Table 3.13: Food appeal scores of the scanned subjects 
 
Appeal scores a  
BMI-M 
n=20 
BAND 
n=20 
RYGB 
n=21 
P value 
Food pictures 
3.6 [2.9 - 4.8] 
(3.3 - 4.10) 
3.5  [3.2 - 7.3] 
(2.6 - 4.9) 
3.1 [2.2 - 3.6] 
(1.4 - 4.6) 
0.028 
RYGB < BMI-M <0.05 
High-Calorie food pictures 
3.7 ± 0.1 
(2.4 - 4.9) 
3.5 ± 0.2 
(1.8 - 4.9) 
2.7 ± 0.2 
(1.1 - 4.6) 
<0.001 
RYGB < BAND 0.003  
RYGB < BMI-M <0.001 
       Chocolate 
3.7 ± 0.2 
(1.8 - 5.0) 
3.6 ± 0.2 
(1.0 - 4.8) 
2.6 ± 0.2 
(1.1 - 4.7) 
0.001 
RYGB < BAND 0.002  
RYGB < BMI-M 0.001 
       Sweet non-chocolate 
3.6 ± 0.2 
(1.6 - 5.0) 
3.4 ± 0.2 
(1.9 - 5.0) 
2.6 ± 0.2 
(1.1 - 4.8) 
0.002 
RYGB < BAND 0.011  
RYGB < BMI-M 0.001 
       Non-sweet (savory) 
3.8 ± 0.2 
(2.3 - 5.0) 
 
3.4 ± 0.2 
(2.2 - 4.9) 
 
2.7 ± 0.2 
(1.1 - 4.9) 
 
0.002 
RYGB < BAND 0.022  
RYGB < BMI-M <0.001 
Low-calorie food pictures 
3.6 ± 0.2 
(2.3 - 4.9) 
3.6 ± 0.2 
(2.2 - 4.8) 
3.3 ± 0.2 
(1.7 - 4.8) 
0.41 
Object pictures 
2.7 [1.6 - 3.3] 
(1.2 - 4.3) 
2.7 [2.3 - 3.2] 
(1.4 - 4.9) 
2.4 [1.5 - 2.7] 
(1.1 - 4.3) 
0.17 
 
Blurred pictures 
1.5 [1.0 - 1.9] 
(1.0 - 3.4) 
1.3 [1.1 - 2.7] 
(1.0 - 3.8) 
1.0 [1.0 - 2.0] 
(1.0 - 3.0) 
0.23 
 
 
Data are presented as mean ± standard error of the mean (SEM) or median [interquartile range] for data that is not normally d istributed, and range in brackets. 
Comparisons between groups used one-way ANOVA with post hoc Fisher’s LSD test or, if not normally distributed, Friedman ANOVA on Ranks with post hoc Dunn’s test. 
a
 1  
= Not at all, 5 = A lot. Below statistically significant P values (<0.05) for the overall ANOV A, the statistically significant pairwise comparisons and the direction of the result 
are shown using > or <. BMI-M: body mass index matched, BAND: gastric banding, RYGB: gastric bypass. 
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 Metabolic and hormonal phenotyping 
 
The results of the metabolic and hormonal test are detailed in Table 3.14 and illustrated in Figures 
3.9 and 3.10. 
 
Glucose homeostasis 
 
Plasma glucose levels over the scanning period before the meal were significantly lower in both 
surgical groups compared to the BMI-M group, but increased significantly more after the meal in the 
RYGB compared to the BAND group. 
 
Plasma insulin levels over the scan were significantly lower in both surgical groups compared to the 
BMI-M group, and increased similarly after the meal between the RYGB and BAND. HOMA-IR was 
significantly lower in the RYGB group compared to the BMI-M group. 
 
Gut hormones 
 
Plasma GLP-1 levels were similar between all three groups over the scan, but increased significantly 
more in the RYGB compared to the BAND patients after the meal. Plasma PYY levels over the scan 
were significantly higher in the RYGB compared to the BMI-M group and increased significantly more 
in the RYGB compared to the BAND group after the meal.  
 
By contrast, there were no significant differences in the plasma acyl ghrelin levels between the 
groups either before or after the meal. 
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 Bile acids 
The levels of total and glycine conjugated bile acids were significantly higher in the RYGB compared 
to the BAND groups both over the scan and after the meal. The sub-fractions of primary and 
deoxycholic bile acids were significantly higher in the RYGB compared to the BAND patients only 
after the meal. 
Figure 3.9: Plasma levels of gut hormones and bile acids in obese patients after gastric bypass, 
gastric banding and controls 
 
Comparison of (A,C,E) plasma hormone levels (GLP-1, PYY, acyl ghrelin, area under curve (AUC) +40 to +150 
mins) and (G) total bile acid levels during fMRI scan (AUC +70 to +150 mins) between body mass index -
matched unoperated controls (BMI-M, white), and obese patients after gastric banding (BAND, dotted) and 
gastric bypass (RYGB, striped) surgery. Comparison of (B,D,F) change in plasma hormone levels and (H) change 
in total bile acid levels after ice-cream meal (both ΔAUC +150 to +210 mins) between two surgical groups. Data 
are presented as median and interquartile ranges. 
##
P<0.01 vs. BMI-M; *P<0.05, ***P<0.005 vs. BAND; n=20-
21 per group.  
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 Figure 3.10: Plasma levels of bile acid subfractions, glucose and insulin 
 
Comparison of plasma (A-F) bile acid sub-fractions (glycine, primary bile acid, deoxycholic bile acid), (G,H) 
glucose and (I,J) insulin levels. (A,C,E) levels during fMRI scan (area under curve (AUC) +70 to +150 mins), and 
(G,I) during fMRI scan (AUC +40 to +150 mins) between body mass index-matched unoperated controls (BMI-
M, white), and obese patients after gastric banding (BAND, dotted) and gastric bypass (RYGB, striped) surgery. 
(B,D,F,H,J) change in levels after ice-cream meal (ΔAUC +150 to +210 mins) in surgical groups. Data are 
presented as median and interquartile range. 
#
P<0.05, 
##
P<0.01 vs. BMI-M; *P<0.05, **P<0.05, ***P<0.005 vs. 
BAND; n=20-21 per group.  
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 Table 3.14 Metabolic and hormonal phenotyping 
 
BMI - M  
n=20 
BAND 
n=20 
RYGB 
n=21 
P value 
Glucose     
During fMRI AUC 
a
 (mmol/L.min)  
530 [495 - 550] 
(427 - 747) 
494 [450 - 521] 
(417 - 569) 
489 [475 - 512] 
(386 - 613) 
0.025 
BAND < BMI-M <0.05 
After meal Δ AUC b (mmol/L/kCal .min) n/a  
0.06 [0.01 to 0.10] 
(-0.13 to 0.68) 
0.29 [0.22 to 0.40] 
(-0.05 to 0.63) 
<0.001 
RYGB > BAND 
Insulin     
During fMRI AUC 
a
 (mU/L.min) 
1,146 [708 - 1531] 
(315 - 2471) 
702.5 [495 - 945] 
(374 - 2375) 
532 [379 - 695] 
(214 - 920) 
<0.001 
RYGB < BMI-M <0.01 
After meal Δ AUC b (mU /L/kCal .min) n/a  
2.65 [0.77 to 4.98] 
(0.00 to 48.57) 
2.77 [1.73 to 5.23] 
(0.00 to 15.80) 
0.47 
HOMA –IR 
2.1 [0.6 - 9.8] 
(1.3 - 4.0) 
1.7 [1.0 - 2.0] 
(0.7 - 4.7) 
1.1 [0.8 - 1.6] 
(0.4 -2.5) 
0.013 
RYGB < BMI-M <0.05 
Triglycerides     
During fMRI AUC a (mmol/L.min) 
153 ± 16 
(52 - 348) 
147 ± 78 
(53 - 202) 
144 ± 87 
(73 - 168) 
0.07 
After meal Δ AUC b (mmol/L/kCal .min) n/a  
0.00 [0.00 to 0.00] 
(-0.21 to 0.11) 
0.00 [-0.01 to 0.01] 
(-0.13 to 0.02) 
0.75 
Glucagon like peptide 1 (GLP-1)     
During fMRI AUC a (pmol/L.min) 
6,299 [5,278 - 7,571] 
(3,815 - 11,534) 
6,343 [4,255 - 7,830]  
(3,478 - 16,859) 
7,092 [5,388 - 8,474] 
(3,871 - 13,397) 
0.66 
After meal Δ AUC b (pmol/L/kCal .min) n/a  
2.88 [0.01 to 5.39] 
(-0.88 to 29.41) 
13.72 [10.06 to 27.71] 
(0.09 - 43.73) 
<0.001 
RYGB > BAND 
Peptide YY (PYY)      
During fMRI AUC a (pmol/L.min) 
1,842 [1,479 - 2,217]  
(1,109 - 3,357) 
1,969 [1,625 – 2,365]  
(1,100 - 3,358) 
2,760 [1,939 - 3,648] 
(1,262 – 8,463) 
<0.007 
RYGB > BMI-M <0.01 
After meal Δ AUC b (pmol/L/kCal .min) n/a  
0.35 [0.08 to 1.02] 
(-1.48 to 8.54) 
4.41 [2.03 to 6.70] 
(-2.66 to 11.31) 
<0.001 
RYGB > BAND 
Acyl Ghrelin     
During fMRI AUC a (pg/mL.min) 
5,987 [2,529 - 15,654] 
(1,376 - 35,601) 
7,742 [4,712 - 16,052] 
(3,127 - 48,651) 
5,411 [3,022 - 13,465]  
(919 - 29,725) 
0.48 
After meal Δ AUC b (pg/mL/kCal.min) n/a  
-3.01 [-7.11 to -1.73] 
(-22.24 to 2.96) 
-2.44 [-10.60 to -1.11] 
(-19.16 to 10.06) 
1.00 
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 Total Bile Acids 
During fMRI AUC c (micromole/L.min) 
109 [71 - 136] 
(10 - 304) 
67 [37 - 100] 
(7 - 397) 
137 [82 - 303] 
(16 - 870) 
0.031 
RYGB > BAND <0.05 
After meal Δ AUC b (micromole/L/ kCal .min) n/a  
0.13 [0.05 to 0.18] 
(-0.06 to 2.41) 
0.54 [0.39 to 0.72] 
(-0.34 to 1.93) 
<0.001 
RYGB > BAND 
Total Glycine conjugated Bile Acid     
During fMRI AUC c (micromole/L.min) 
56 [33 – 84] 
(10 - 175) 
35 [23 - 48] 
(7 - 290) 
75 [48 - 143] 
(7 - 443) 
0.013 
RYGB > BAND <0.01 
After meal Δ AUC b (micromole/L/kCal.min) n/a  
0.14 [0.03 - 0.31] 
(0.00 - 1.30) 
0.40 [0.29 - 0.63] 
(0.00 - 1.66) 
0.014 
RYGB > BAND 
Total Primary Bile Acids      
During fMRI AUC c (micromole/L.min) 
54 [28 - 73] 
(9 - 238) 
27 [14 - 60] 
(7 - 292) 
81 [31 - 177] 
(7 - 456) 
0.07 
After meal Δ AUC b (micromole/L/kCal.min) n/a  
0.10 [0.03 - 0.13] 
(-0.04 to 1.60) 
0.31 [0.22 - 0.55] 
(-0.31 to 1.44) 
<0.001 
RYGB > BAND 
Total deoxycholic Bile Acids      
During fMRI AUC c (micromole/L.min) 
29 (14 - 45) 
(0 - 76) 
28 [16 - 36] 
(0 - 91) 
41 [17 - 62] 
(0 - 206) 
0.22 
After meal Δ AUC b (micromole/L/kCal.min) n/a  
0.02 [0.01 to 0.05] 
(-0.02 to 0.66) 
0.10 [0.07 to 0.17] 
(-0.02 to 0.42) 
0.006 
RYGB > BAND 
 
Data are presented as mean ± standard error of the mean (SEM) or median [interquartile range] for data that is not normally d istributed, and range in brackets. 
Comparisons between groups used Student’s unpaired t-tests or one-way ANOVA with post hoc Fisher’s LSD test or, if not normally distributed, Mann Whitney U test or 
Friedman ANOVA on Ranks with post hoc Dunn’s test. 
a 
Area under the curve between time +40 to +150, 
b
 change (Δ) in area under the curve between time points +150 
and +180 to +210 per kCal consumed during the meal, 
c 
Area under the curve between time +70 to +150. 
 
Note statistical comparisons were not made with un-operated 
patients as test lunch differed between un-operated and post-operative groups (n/a: not applicable). Below statistically significant P values (<0.05) for the overall  ANOVA, 
the statistically significant pairwise comparisons and the direction of the result are shown using > or <.  BMI -M: body mass index matched group, BAND: gastric banding 
group, RYGB: gastric bypass group, HOMA - IR: homeostatic model assessment insulin resistance. 
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 Dumping syndrome 
Whilst the RYGB group had significantly higher dumping symptom and nausea scores compared to 
the BAND group, the change in physiological markers after the meal, including blood pressure and 
heart rate, was not statistically different between the two groups (Table 3.15, Figure 3.11).  
 
Figure 3.11: Assessment of dumping syndrome in the surgical groups 
Comparison of (A) retrospective Sigstad’s dumping syndrome scores during first 3 months after surgery  (n=18-
19 per group), and (B) visual analogue scale (VAS) ratings of nausea (n=20-21 per group) during the scanning 
visit (with MRI scan indicated by black bar, and lunch given at +150 mins indicated by arrow), between obese 
patients after gastric banding (BAND: dotted, □ and dashed line) and gastric bypass (RYGB: striped,  and solid 
line) surgery. Data are presented as (A) median and interquartile range, and (B) mean ± SEM. ***P<0.005 vs. 
BAND. 
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 Table 3.15: Assessment of dumping syndrome in the surgical groups 
 BAND RYGB P value 
N 20 21  
Sigstad’s score 
1.5 [0.0 - 5.0] 
(-4.0 to 11.0) 
9.0 [3.0 - 11.0] 
 (0.0 -29.0) 
0.002 
RYGB > BAND 
Arts’ score  
3.0 [2.0 - 5.0] 
(0.0 - 8.0) 
5.0 [4.0 - 12.0] 
 (0.0 - 24.0) 
0.02 
RYGB > BAND 
Δ Heart rate (beats per minute) 
7.9 ± 1.4 
(-6.0 to 20.0) 
5.3 ± 1.7 
(-7.0 to 21.0) 
0.24 
Δ Systolic BP (mm Hg) 
-2.4 ± 3.8 
(-23.0 to 38.0) 
-10.7 ± 3.4 
(-40.0 to 19.0) 
0.11 
Δ Diastolic BP (mm Hg) 
-2.5 ± 2.9 
(-28.0 to 17.0) 
-3.7 ± 1.8 
(-16.0 to 10.0) 
0.72 
VAS Sleepiness    
After meal Δ AUC (cm.min) 
0.0 [-78.0 to 28.5] 
(-396.0 to 442.5) 
-30.0 [-113.6 to 3.0] 
(-217.5 to 63.0) 
0.34 
VAS Nausea    
After meal Δ AUC (cm.min) 
-19.5 [-69.8 to 0.0] 
(-549.0 to 186.0) 
9.0 [0.0 to 79.1] 
(-10.5 to 408.0) 
<0.001 
RYGB > BAND 
 
Data are presented as mean ± standard error of the mean (SEM) or median [interquartile range] for data that 
is not normally distributed, and range in brackets. Comparisons between groups used Student’s unpaired t -
tests or, if not normally disturbed, Mann Whitney U test. Note statistical comparisons were not made with un-
operated patients as test lunch differed between un-operated and post-operative groups (n/a: not applicable). 
Below the statistically significant P values (<0.05) for the overall  ANOVA, the direction of the result is shown 
using > or <. BMI-M: body mass index matched group, BAND: gastric banding group, RYGB: gastric bypass, BP: 
blood pressure, VAS: visual analogue scale, Δ: change between time points +150 and +210, Δ AUC: change in 
the area under the curve between time points +150 and +180 to +210, mmHg: millimetres of Mercury.  
 
 
 
3-day dietary records 
 
Patients after RYGB consumed less calories than after BAND (Figure 3.8, Table 3.16). Furthermore 
percentage of energy intake from fat, but not carbohydrate or protein was significantly lower in the 
RYGB than BAND group. 
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 Table 3.16 Dietary records in the surgical groups 
 
 
 
BAND RYGB P-value a 
N 18 15  
Total energy intake    
Average daily intake (kCal/day) 
1682 ± 133 
(878-2620) 
1191 ± 117 
(587-2088) 
0.01 
BAND > RYGB 
Average daily intake (kCal/day per kg LBM) 
31.1 ± 2.9 
(15.1-56.9) 
21.7 ± 2.3 
(8.5-38.3) 
0.02 
BAND > RYGB 
Average daily intake (% REE)  
99.6 ± 8.0 
(50-160.2) 
69.85 ± 7.1 
(28.7-128.9) 
0.01 
BAND > RYGB 
Macronutrient composition    
Protein (% total kCal intake) 
17.7 ± 1.1 
(9.0-27.0) 
18.1 ± 0.8 
(14.0-26.0) 
0.75 
Carbohydrate (% total kCal intake) 
42.1 ± 2.0 
(26.0-63.0) 
46.0 ± 1.9 
(31.0-61.0) 
0.17 
Fat (% total  kCal  intake) 
39.1 ± 1.6 
(28.0-54.0) 
33.8 ± 1.6 
(22.0-42.0) 
0.03 
BAND > RYGB 
Data presented as mean ± SEM (range). Abbreviations: BAND: gastric banding, BMI -M: body mass index 
matched, LBM: lean body mass, REE: resting energy expenditure calculated using Cunningham equation, RYGB: 
gastric bypass, VAS: visual analogue scale.  
 
Confounding variables 
 
There were no significant differences in potential confounding factors known to affect BOLD 
activation to food cues or non-specifically between the three groups in BMI, % body fat, time since 
last meal, sleep duration the night before the visit [589], or positive or negative affect (PANAS) at the 
scanning visit (Table 3.17) [567]. During scanning there were no significant differences between the 
groups in absolute or relative head motion during the food evaluation or Audio-Motor-Visual fMRI 
tasks. 
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  Table 3.17 Potential confounding variables at scanning visit 
 BMI-M BAND RYGB P value  
N 20 20 21  
PANAS positive (score /50)  
32.0 ± 1.9 
(16.0 - 51.0) 
28.9 ± 2.0 
(14.0 - 44.0) 
31.0 ± 1.9 
(11.0 - 44.0) 
0.52 
PANAS negative (score /50) 
15.0 [12.0 - 20.0] 
(10.0 - 33.0) 
13.5 [11.0 - 16.5] 
(9.0 - 26.0) 
13.0 [11.0 - 16.5] 
(10.0 - 24.0) 
0.33 
Sleep duration previous night (hours)  
6.8 [6.0 - 7.8] 
(4.2 - 12.0) 
7.5 [7.0 - 7.5] 
(6.0 - 10.0) 
6.5 [5.2 - 7.6] 
(4.3 - 9.3) 
0.16 
Time since supper to fMRI scan (hours)  
16.4 [15.7 - 17.0] 
(14.8 - 19.1) 
16.1 [15.6 - 16.7] 
(14.9 - 20.3) 
16.5 [16.0 - 17.3] 
(15.0 - 18.6) 
0.41 
Absolute motion during food task (mm) 
0.24 [0.19 - 0.38] 
(0.13 - 1.09) 
0.37 [0.25 - 0.50] 
(0.1 - 0.9) 
0.36 [0.26 - 0.52] 
(0.17 - 1.03) 
0.13 
Relative motion during food task (mm/TR) 
0.10 [0.08 - 0.13] 
(0.05 - 0.22) 
0.07 [0.15 - 0.09] 
(0.05 - 0.23) 
0.11 [0.08 - 0.13] 
(0.06 - 0.36) 
0.66 
Absolute motion during Audio-Motor-Visual task 
(mm) 
0.23 [0.17 - 0.43] 
(0.09 - 1.25) 
0.28 [0.14 - 0.44] 
(0.09 - 0.91) 
0.20 [0.19 - 0.37] 
(0.09 - 1.20) 
0.99 
Relative motion during Audio-Motor-Visual task 
(mm/TR) 
0.09 [0.07 - 0.12] 
(0.05 - 0.22) 
0.10 [0.07 - 0.12] 
(0.05 - 0.39) 
0.09 [0.08 - 0.12] 
(0.06 - 0.35) 
0.79 
 
Data are presented as mean ± standard error of the mean (SEM) or median [interquartile range] for data that 
is not normally distributed, and range in brackets. Comparisons betwe en groups used one-way ANOVA with 
post hoc Fisher’s LSD test or, if not normally distributed, Friedman ANOVA on Ranks with post hoc Dunn’s test. 
BMI-M: body mass index matched group, BAND: gastric banding group, RYGB: gastric bypass, VAS: visual 
analogue scale, AUC: change in the area under the curve between time points +40 and +150 to +210, PANAS: 
positive and negative affect schedule, TR: repetition time.  
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 3.7 DISCUSSION 
 
This study has shown that in the context of similar age, gender ratios, current BMI and psychological 
characteristics between the 3 groups: 
 
1. Patients after RYGB and BAND had similarly lower hunger ratings during scanning compared to 
the BMI-M group and similar changes in “hunger”, “fullness” and “volume of food they can eat” 
after the test meal.   
2. Patients after RYGB ate less calories from fat, found a fatty/sweet meal as less pleasant to eat, 
and rated high-calorie food pictures as less appealing than patients after BAND and/or 
unoperated obese controls. 
3. In a whole brain and/or ROI analysis of fMRI data, patients after RYGB had lower activation of 
brain reward systems in response to active evaluation of any food, high-calorie food, and low 
calorie food, pictures compared to patients after BAND or BMI-M controls.  
4. Patients after RYGB exhibited lower dietary restraint, external eating and weight/shape concerns 
than patients after BAND and/or BMI-M controls. 
5. The differences in food hedonics took place in the context of higher post- ± pre-prandial levels of 
GLP-1, PYY, bile acids, and post-prandial nausea ratings in the RYGB group compared to the 
BAND group. Retrospective dumping syndrome scores for the 3 months after surgery were also 
significantly higher in the RYGB group compared to the BAND group. 
 
Hunger and satiation  
 
It is important to note that the differences in food hedonics seen in this study took place in the 
context of similar internal states between the participants in the two surgical groups. This was one 
of the most important confounders to control for, as it can have a strong influence on food hedonics. 
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 Indeed as mentioned in Section 1.1.6 page 51, hunger increases the appeal of food, in particular 
high-calorie food, and the activation of brain reward areas including the parahippocampal gyrus, 
amygdala, nucleus accumbens, insula cortex, orbitofrontal cortex and inferior frontal gyrus is higher 
in the hungry compared to the sated state [30, 69, 73, 75, 82, 83]. The hunger ratings between the 2 
surgical groups were similar, but were both lower than the un-operated BMI-M group, even in the 
fasted state. This is in line with the other published studies in the literature showing that the RYGB 
and BAND promote weight loss through reductions in hunger and/or increase in satiation after a 
meal [433-435]. This study also showed that the consumption of similar amounts of calories from 
the test meal resulted in similar decreases in satiation, further reinforcing the similarities in the 
internal state between the two groups. Of note, the visual analogue ratings after the test meal were 
not compared between all 3 groups because the BMI-M group had a different meal to the surgical 
patients.  
 
Dietary records, food picture appeal and test meal ratings 
 
These differences in food preferences and food picture appeal between patients after RYGB and 
patients after BAND and/or BMI-M controls are consistent with the animal and human literature 
(Section 1.3.3.2, page 108) [319, 441, 442, 506, 518, 519, 522-529, 531, 532, 538], and the results of 
Chapter 2. Patients after RYGB have a lower overall caloric intake, but also lower percentage 
contribution of fat and sugars in their diet compared to pre-operatively, to obese/overweight 
patients that have not been operated or to patients that have had the vertical banded gastroplasty 
procedure. This latter procedure is now obsolete and therefore the novelty of the above findings lies 
in the direct comparison of patients that both lost weight through the two most commonly 
performed bariatric surgery procedures, the RYGB and BAND, and yet had very different food 
preferences and food hedonics. Only one other group have directly compared patients after RYGB 
and BAND, but used only a single food frequency questionnaire [529]. In their cross-sectional study 
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 comparing 48 RYGB, 73 BAND and 45 un-operated obese patients the two surgical groups were at 
least 1 year post-operatively. RYGB patients consumed food high in protein (poultry, eggs) and 
vegetables more frequently, and fatty sweets less frequently compared to the un-operated obese 
group. Compared to the BAND group, RYGB patients consumed more fruit and eggs, but less 
chocolate.  
 
An advantage of the appeal rating method used in my study is that participants had to respond to 
the picture shown within a very small space of time (3 seconds). This probably reduces the 
contribution of cognitive restraint in their responses and indeed similar behavioural tasks have been 
shown to be valid and reliable in assessing human eating behaviour [590]. 
 
Overall, the results of this and the other studies suggest that the changes in food preferences and 
food appeal that take place after RYGB are not the result of dietary advice or social desirability bias, 
but of alterations in the underlying determining physiology. In this study, patients after RYGB lost 
significantly more weight compared to patients after BAND, even though when the groups were 
scanned they were of similar BMI. Even though cause-effect relationship inferences should be 
limited in cross-sectional studies, it is possible that the healthier food preferences in the RYGB group 
may have contributed to the higher weight loss efficacy of the procedure. This finding is not unique 
to my study but to the majority of studies that have compared weight loss between these two 
procedures (e.g. [423, 591]). 
 
Functional neuroimaging 
 
The fMRI activation data showed that patients after RYGB had lower activation of brain reward 
system to food in general, but also to high-calorie and low-calorie food, compared to BAND. The 
209
 novelty of these findings is in that a direct comparison between RYGB and BAND has never been 
performed so far.  
 
Orbitofrontal cortex 
The orbitofrontal cortex receives inputs from the five basic senses (taste, olfaction, touch, hearing 
and vision), but also visceral sensory signals [27-29]. These signals converge in the posterior part of 
the cortex before they undergo multimodal integration and the reward value of the stimulus is 
represented in the most anterior parts [27-29]. The medial orbitofrontal cortex affects this 
processing by responding to learning, memory and monitoring, whilst the lateral orbitofrontal cortex 
is more involved with the evaluation of punishers. The integration of all these complex inputs leads 
to decision making and goal-directed behaviour, but also prediction of the anticipated reward value 
of specific actions. Lesions of the orbitofrontal cortex in humans, either through vascular events or 
trauma, can lead to weight gain, a preference for sweet foods, difficulties with decision making, lack 
of responding to environmental signals and inappropriate social behaviour [27-29].  
In healthy adults, the orbitofrontal cortex is activated preferentially to high-calorie vs. low calorie 
food cues in fMRI studies, and the increase in associated activation of medial and lateral 
orbitofrontal cortex when switching from fed to fasted state has been correlated with the increase in 
appeal bias towards high-calorie food [30]. The orbitofrontal cortex is involved in the process of 
sensory specific satiety as demonstrated early in electrophysiological studies in macaques [31] and 
more recently in a PET study, in which as healthy volunteers ate increasing amount of chocolates to 
the point that it became unpleasant (i.e. they reached sensory specific satiety) the blood flow to the 
medial orbitofrontal cortex decreased and to the lateral orbitofrontal cortex increased [32]. The 
lateral orbitofrontal cortex also responds to the anticipation of receipt of a pleasant taste in healthy 
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 adults [33], and its activation in such fMRI tasks has been shown to correlate with future weight gain 
(which is modulated by dopamine receptor DRD2 gene polymorphisms) in adolescent girls [34].  
The finding that the activation of the orbitofrontal cortex in response to any food picture (whole 
brain and fROI), high-calorie (whole brain and non-significant trend in fROI), and low-calorie food 
pictures (whole brain and fROI) is lower after RYGB than BAND suggests that the reward value and 
“pleasantness” of food in general is lower after RYGB compared to BAND surgery. In addition, these 
results may suggest that patients after RYGB re-evaluate their decision making and relationship with 
food and avoid it as its consumption may lead to adverse outcomes in terms of weight gain. It is 
reassuring that in this study the reduction in the subjective appeal ratings for food pictures was also 
accompanied by a reduction in the orbitofrontal cortex activation after RYGB compared to BAND. 
Indeed, in the fMRI paradigm participants did not passively view food pictures, but actively 
evaluated them through the appeal button presses; this may have made it easier for us to detect 
differences in orbitofrontal cortex (and amygdala) activation between the groups [592, 593].  
 
 
Amygdala 
The amygdala has long been known to be key in the processing of emotions, mainly negative ones 
(e.g. fear) [35, 36]. However, it has also been shown to respond to positive emotions and thus play a 
role in stimulus-reward association and learning which eventually determines behaviour [35, 36].  
The central and basolateral amygdala also receive gustatory inputs, but is not involved in multimodal 
integration in the same way as the orbitofrontal cortex. Early PET studies showed that the 
administration of aversive tastants or olfactory cues was associated with increased cerebral flow in 
the amygdala in healthy women [37], but subsequent studies have shown that the amygdala, unlike 
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 the orbitofrontal cortex and insula, is similarly activated both in response to pleasant stimuli like 
glucose and aversive ones like sodium chloride [38-40]. 
The finding of lower amygdala activation in response to any food pictures (in the fROI approach) 
after RYGB compared to BAND and BMI-M controls would be consistent with food and taste being 
associated with negative aversive consequences. These results are internally consistent with the 
findings of higher dumping syndrome scores and higher nausea ratings after the test meal in the 
RYGB compared to the BAND group. Even though the nausea ratings were lower in the RYGB group 
compared to the BAND group during scanning, the condition taste aversion caused by previous 
experiences with food in the former group may have caused the distinct “deactivation” in the 
amygdala. Even though food addiction scores were not assessed in this patient cohort and the 
prevalence of binge eating disorder was similar between the groups, it is still possible that the 
“addictive” relationship with food in some of my participants was lower after RYGB compared to the 
BAND and BMI-M groups. 
Additional areas in brain reward system 
The nucleus accumbens is part of the ventral striatum, and responds to both positive and negative 
stimuli from the environment and determines goal directed behaviour [54, 55]. In particular, novel 
stimuli activate the nucleus accumbens which in turn initiates seeking behaviour and motivation to 
the stimulus. Depending on the reward value of the stimulus, the same seeking behaviour will be 
continued or avoided in the future, both for this and other related stimuli [54, 55]. The nucleus 
accumbens responds directly to both the appetitive and consummatory reward of food/taste and 
forms parts of both the dopaminergic and opioid/endocannabinoid system [54]. In healthy women, 
fMRI activation of the nucleus accumbens in response to food pictures predicts subsequent food 
intake independent of subjective ratings of the desire to eat [56]. In healthy adults, differences in 
reward sensitivity correlate with fMRI activation in the nucleus accumbens in response to pictures of 
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 appetizing foods [57]. Nucleus accumbens activation to food cues in overweight adults is attenuated 
by satiation and further this predicts subsequent food intake [59]. 
The dorsal striatum, including the caudate and putamen, as part of the reward system, is important 
in learning through the association of a specific action with their expected reward value, including 
both food and non-food rewards. This goal-directed behaviour is expressed through the release of 
dopamine in the dorsal striatum in response to a specific cue, especially when hungry [51, 52]. The 
release of dopamine in the dorsal striatum in healthy volunteers also correlates with the subjective 
pleasantness of food in a seminal PET study [53]. In particular, fMRI activation of the caudate 
correlates with cravings for food when healthy volunteers are asked to imagine the sensory 
properties of their favourite food [43].  
The anterior cingulate cortex and subcallosal cortex are involved both with the interpretation and 
regulation of emotional responses but also with motivation for a specific cue and the assessment of 
reward and risk [46]. The anterior cingulate cortex is activated in response to fatty tastants in human 
fMRI studies [48], and its activation in response to the anticipation of palatable food cues as 
assessed by fMRI in healthy volunteers (together with the medial orbitofrontal cortex and amygdala) 
also correlates with “food addiction scores”  [49]. In obese adults, higher fMRI activation in the 
anterior cingulate cortex in response to high-calorie food cues at baseline was associated with less 
weight loss at 12 weeks of a lifestyle/psychosocial intervention and at 9 months follow up [50]. 
The hippocampus is not only involved in memory function; lesions of the hippocampus increase food 
intake but also appetitive behaviour in rodents [65]. Hippocampus fMRI activation correlated with 
cravings for food when healthy volunteers were asked to imagine the sensory properties of their 
favourite food [43]. In an fMRI study of healthy non-obese volunteers performed by our group, the 
subcutaneous administration of ghrelin in healthy adults mimicked fasting to significantly increase 
hippocampal activation to food pictures [174].  
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 At the whole brain analysis, RYGB patients had lower activation in clusters within the nucleus 
accumbens (ventral striatum), caudate nucleus and putamen (dorsal striatum) and 
cingulate/subcallosal cortices (in response to any food, high-calorie-food and/or low-calorie food 
pictures), and hippocampus (in response to high-calorie food pictures). These differences in 
activation may underlie potential differences in the eating behaviour of the surgical groups. Indeed 
the cravings for food as assessed by the “external eating” questionnaires and the appeal scores were 
also lower after RYGB compared to BAND. The appetitive and/or consummatory responses to food 
or taste have been shown to be lower after RYGB in some human and animal studies comparing 
subjects with baseline, or sham-operated animals [319, 541, 544, 594]. Some human studies have 
showed that food reward responses are reduced after BAND as well [530, 550]. As my study was 
cross-sectional, I cannot exclude that such a decrease might have taken place in the BAND group, 
but it is possible that the decrease in food hedonics was even greater after RYGB compared to 
BAND. From a mechanistic point of view, the reduction in activation in the striatum may pinpoint to 
specific changes in central neurotransmission, including lower dopamine, opioid and 
endocannabinoid release in this region in response to food after RYGB.  
Other functional neuroimaging studies after bariatric surgery 
These results are broadly in line with previous preliminary prospective studies of RYGB performed by 
Geliebter’s group. They have published the results of the same cohort in 3 different papers, the first 
including 10 participants after a small fixed food preload (250 kCal) [546], the second 14 participants 
after a small fixed food preload [547], and the third 5 participants in the fasted and fed state [595]. 
Patients underwent the study 1 month before and 1 month after RYGB. The fMRI paradi gm included 
exposure to food pictures (high-calorie and low-calorie) and auditory stimuli (name of a food). In the 
first study, activation for the high-calorie vs. low-calorie food contrast was significantly reduced after 
surgery in the dorsolateral prefrontal cortex, precuneus, dorsal cingulate, lentiform nucleus, and 
ventral striatum, and patients’ ratings of “desire to eat”  decreased more for high than low-calorie 
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 density foods [546]. There are problems with interpretation of these results as the neuroimaging 
statistics did not include correction for multiple comparisons and the sample size was small. More 
conclusions can be drawn from the second study of 14 patients in which a post-operative reduction 
in the activation of the lentiform nucleus, putamen and dorsolateral prefrontal cortex was seen to 
high-calorie foods, whilst there was no reduction in activation to the low-calorie food cues [547]. 
These changes were also accompanied and predicted the reduction in the subjective “desire to eat” 
of high-calorie but not low-calorie foods.   
 
Overall, the general pattern of a reduction in both the rewarding value of food and activation of the 
brain reward systems is consistent with my findings. The differences in the regions in which the 
reductions in activation were observed between Geliebter’s group and my study may be because of 
differences in study design (prospective vs. cross-sectional), statistical methods, use of 
auditory/visual vs. only visual cues and the use of passive vs. active viewing of pictures. Geliebter 
recruited only female participants and no controls (and therefore order effects cannot be excluded 
in that study), whereas I recruited patients from both genders and 2 control groups [76, 364]. 
Additional sources of variation may include differences in factors that have been shown to affect 
hedonic responses/brain activation to food including the length of fasting [76, 364], inter-individual 
differences in food preference [371, 565], genetic predisposition [34, 82, 332], personality and 
psychological traits [57, 269, 365, 366], co-morbid conditions including type 2 diabetes/insulin 
resistance [190-192] and binge eating disorder [74, 269, 357], use of centrally acting medications 
[371, 565] and lack of control for the stage in the menstrual period [367, 368] in the first of the 3 
studies from the Geliebter group [546]. Additionally, in Geliebter’s study, patients consumed a 250 
kCal meal 60 minutes before scanning to allow patients to be scanned at the same internal state. 
The problem with such an approach is that while it may be useful in the cross-sectional setting, 250 
kCal of food may have very different effects in a post gastric bypass population; in the obese pre-
operative setting it is unlikely to cause satiation whereas post-operatively it may do. Therefore it is 
215
 possible that the internal state of the groups before vs. after surgery was very different and could 
have affected activation of the brain reward systems.   
 
In search of mechanisms, and hypothesizing that the reductions in activation were due to the 
exaggerated release of gut hormones in the post-operative post-prandial state, the same group 
studied 5 participants in the fasted and fed state both pre- and post-RYGB [595]. They found that the 
activation in the precuneus and superior parietal lobule was lower in the fed vs. fasted state pre-
operatively and that activation in the insula, frontal gyrus, and precentral gyrus was lower after vs.  
before RYGB when participants were assessed in the fasted state. The authors did not find 
differences between the fed state pre vs. post-operatively or larger differences in the fed vs. fasted 
contrast post-operatively vs. pre-operatively. They concluded that gut hormones were not the main 
drivers of the hyporesponsivity of the brain reward systems after RYGB. Unfortunately very few 
inferences can be drawn from this study firstly because with 5 participants the power to detect 
differences in fMRI paradigms is minimal, even in a within subjects design and secondly because gut 
hormones were not actually measured in the study. Another limitation of the 3 studies is that they 
were performed very early after RYGB; this is a phase of very rapid weight loss and some of the 
patients may not have resumed normal eating patterns. 
 
The only fMRI study after BAND, assessed 10 patients before and 3 months after BAND, without  
[550]. Using food pictures as cues, they found that in the fasted state, activation in the middle 
frontal and superior frontal gyri was higher after BAND, whereas in the post-prandial state activation 
in the right frontal gyrus, insula, inferior frontal gyri and parahippocampal gyrus were lower after 
surgery. The authors suggest that this allowed patients to exercise more cognitive “restraint” over 
food intake, as supported by their questionnaire results. The interpretation of these results should 
be very cautious in view of the uncorrected statistics, lack of a control group and lack of any 
information on the how much fluid was inserted in each patient’s band at the time  of scanning. As in 
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 the RYGB studies discussed above, the absence of a control group cannot exclude an order effect 
and a reduction in the activation in brain reward systems due to increased familiarity with the cues 
[174, 551]. Nevertheless, the results are consistent with the human study showing reduction in the 
“power of food” (a questionnaire that assesses motivation towards food after BAND [530]. Again, it 
is possible that such reductions do take place after BAND but the reductions after RYGB are of 
greater magnitude.  
 
Few conclusions can be drawn from the 2 preliminary PET studies after RYGB as they are limited by 
statistical power and completely opposing results [548, 549]. Dunn et al. used 18F-fallypride (a ligand 
that binds to dopamine receptor D2 and D3 sub-types, similar to raclopride) and found reduced 
dopamine receptor availability only in the substantia nigra region of interest and postulated that this 
was the result of higher dopamine levels in this region after surgery. A study published in the same 
year showed exactly the opposite result [549]. Steele et al. found that average raclopride binding 
(measure of DRD2/DRD3 receptor availability) across 5 regions of interest (anterior putamen, 
posterior putamen, anterior caudate nucleus, posterior caudate nucleus and ventral striatum) 
increased after surgery, therefore “reversing” the low dopamine receptor availability which is 
present in obesity. These studies have numerous problems including the small sample size, lack of 
controls, lack of actual measurement of dopamine release (e.g. performing PET before and after 
amphetamine), lack of behavioural measures and information on the menstrual stage when 
scanning, and in the first study mixing RYGB and VSG patients in the same cohort. The discrepancy 
between the two PET studies may be in part explained by differences between the 2 cohorts as in 
the Steele study participants were older and more depressed as well as the mix of surgeries by Dunn 
et al.  
Recently a 18F FDG-PET study showed that obese patients (some of which had type 2 diabetes 
mellitus or impaired glucose handling), but not normal weight controls, had higher uptake of glucose 
globally in response to a euglycaemic hyperinsulinaemic clamp (vs. fasting) and this was reversed 6 
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 months after bariatric surgery (i.e. no difference between the clamp and fasting) [596]. The study is 
limited by the lack of any behavioural data, lack of control for the stage of the menstrual cycle, the 
fact that patients had either RYGB or VSG, without differentiation between the two procedures, the 
correction for multiple comparisons at the voxel but not cluster level and the inclusion of patients 
with different metabolic control at baseline (normal and abnormal glucose tolerance).  
 
Responses to low-calorie foods 
It was surprising to observe that the activation in some brain regions was lower not just to high-
calorie foods, but also to any food and low-calorie food after RYGB. This was in contrast to the food 
appeal scores, which were lower for high-calorie food, but not low-calorie food after RYGB 
compared to BAND and/or BMI-M groups. The absolute consumption of fruit and vegetables has 
been shown to be higher [529], stable [518] or lower [557] after RYGB. The relative preference of 
animals for low-calorie options has been shown to increase after RYGB [442, 538]. The animal 
literature suggests that the reward of low-calorie food is increased [541, 544] and the human 
literature that the appetitive reward value of vegetables stays the same [594]. Overall it appears that 
independently of the reward value of low-fat food, subjects have to consume relatively more of it 
after RYGB as they have to eat something in order to avoid losing more weight. Low-calorie food 
may also be less likely to cause unpleasant post-ingestive side effects and is thus considered as “the 
lesser of two evils”. 
In a minority of patients, this generalised anhedonia to food might lead to an emotional gap and the 
pursuit of pleasure from other substances and indeed there are a number of reports of higher rates 
of alcohol excess, recreational drug use and smoking after RYGB in a small cohort of patients [597]. 
This highlights the importance of individualised assessment of each patient and early substitution of 
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 the comforting value of food through exercise or new hobbies for example, in the subgroup of 
patients who have a heightened emotional relationship with food. 
 
Eating behaviour psychology 
 
Our findings of lower dietary restraint, external eating  (the inability to resist external sensory cues 
to eat e.g. smell) and weight/shape concerns after RYGB compared to BAND, are broadly in line with 
those from Olbers’s group that has performed the longest prospective study in the field so far [441], 
but with other studies as well [598-600]. Olbers’s group studied patients undergoing RYGB 
prospectively for 2 years and compared them to a normal weight control group that did not undergo 
any intervention, and found that “uncontrolled” (tendency to lose control over eating when feeling 
hungry) and “emotional” eating (whereby the individual deals with low mood, anxiety or stress by 
consuming more fatty and sweet foods), as measured by the Three Factor Eating Questionnaire 
(TFEQ), were lower at 2 years compared to preoperatively. Cognitive restraint scores remained 
unaltered. The subtle differences with our results (in the restraint scores) may be  due to the 
differences in study design (within group prospective vs. between surgical groups cross-sectional, 
the type of questionnaire used (TFEQ vs. DEBQ), nationalities and psychological support before and 
after the surgery. The Dutch Eating Behavior Questionnaire has been shown to be more internally 
consistent and reliable across subjects of different weight and gender compared to other 
questionnaires [257]. Baseline cognitive restraint scores, but not emotional eating scores, have also 
been shown to correlate with weight loss after RYGB [601, 602]  
 
The lower external eating in our study may be a direct result of the reduced food hedonics. 
Interestingly, dietary restraint was higher in BAND compared to the unoperated BMI-M and RYGB 
groups, suggesting that even though the BAND patients had lost weight and had reduced hunger, 
they had to exercise restraint to stop them from consuming high-calorie foods that they still found 
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 pleasant postoperatively. This is in line with higher cognitive restraint seen after BAND in other 
studies [550, 603-605]. The lower weight/shape concerns in the RYGB group may reflect the higher 
magnitude of weight loss but also a higher level of control over their shape. Observations from the 
clinic also support that patients after BAND are more preoccupied with their weight and many are 
never content with their new shape, even if they have lost more weight than originally predicted.   
 
 
 
Potential mediators 
 
This study explored specific hormonal and metabolic mediators that may underlie the differences in 
food hedonics. In the post-prandial state, the RYGB group had higher plasma levels of both PYY and 
GLP-1 compared to the BAND group. This finding is consistent with the published literature [433, 
446, 456, 461]. Peripheral and central administration of a GLP-1 agonist (Exendin-4) in rats led to a 
reduction in the progressive ratio task responding (appetitive reward) for sucrose and a reduction in 
the condition place preference for an environment previously associated with chocolate pellets 
[108]. GLP-1 receptors are expressed on taste afferent nerve fibres and GLP-1 knockout mice are less 
responsive to low sucrose concentrations in a brief access test [111, 112]. In a recent fMRI study, 
intravenous infusion of GLP-1 in healthy, non-obese adults led not only to reduced ad libitum food 
intake but also to reduced activation across the brain reward system (amygdala, insula, caudate, 
nucleus accumbens, orbitofrontal cortex, and putamen) and in the insula in particular, in response to 
passive viewing of food pictures [110]. In the same study the combined administration of GLP-1 and 
PYY was additive in its reduction of food intake and activation across the brain reward system. I did 
find lower activation across the reward system in the RYGB group in our study, but not in the insula. 
This may be due to the use of the anterior insula as my fROI (which I used because of its involvement 
with taste input processing), compared to the whole insula in the latter study. Additionally, the 
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 design of the two studies was different (acute vs. chronic exposure to high gut hormone levels), and 
in the latter study participants did not actively evaluate the food pictures but viewed them passively 
[593].  In another study, when PYY was infused intravenously, there were increases in the resting 
activity of the orbitofrontal cortex, anterior cingulate cortex, ventral striatum and this predicted 
subsequent food intake [127]. The conclusion of this study was that PYY “moved” the control of food 
intake, from the homeostatic to the reward system. 
Further indirect support for the role of gut hormones in altering hedonic responses comes from 
rodent models of VSG. After this procedure, the rise in GLP-1 and PYY is similar to RYGB [562] and in 
some studies rodents after VSG exhibit similar shifts in food preferences way from high-calorie food 
[437, 563]. However, this finding has not been universal [489] and more recently the effects of VSG 
on food preferences in one study were shown to be GLP-1 independent [452].  
In my study, there were no significant differences in GLP-1 or PYY levels between the surgical groups 
over the scanning period (even though there were trends for PYY to be higher after RYGB compared 
to BAND). It cannot be however be excluded that the chronic exposure of the brain to higher levels 
of these hormones may have lead to the reduction in brain reward responses even in the fasted 
state [120]. 
The levels of the active form of ghrelin, acyl ghrelin, were not different either in the fasted or post-
prandial state after RYGB compared to BAND. This finding is in line with the most recent publications 
that have directly compared fasting ghrelin levels between RYGB and BAND [433, 446, 461, 606, 
607]. However, in these studies there are discrepancies in the results of post-prandial ghrelin, with 
some studies showing similar and others greater suppression after RYGB compared to BAND. Older 
studies have shown that fasting ghrelin levels are lower after RYGB compared to BAND [608, 609]. 
The inconsistencies in ghrelin results may be due to measurement of different forms (active vs. 
inactive), but also differences in the handling of samples between studies, as both factors are known 
to affect ghrelin measurements [610]. It is therefore unlikely that differences in plasma ghrelin 
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 account for the differential activation of the reward system between the two surgical procedures. 
Indeed, the physiological role of ghrelin after bariatric surgery has recently been questioned in a 
rodent study which recently showed that ghrelin knock-out models of VSG did not differ in weight 
loss, food intake, glucose control or food preferences compared to the wild type animals [460].  
 
My findings on bile acids are particularly novel and in line with the few published studies in the 
literature which have shown that they are higher after RYGB compared to pre -operatively or 
compared to after BAND surgery [492, 493, 495]. Bile acids act on FXR a nuclear receptor (expressed 
in the gut, liver, kidney and adrenal cortex) that leads to stimulation of fibroblast growth factor 19 
and 21 from the gut. Both are  known to improve body weight and glycaemic control [498, 499] 
through their actions in the brain, amongst other tissues,  and both are increased after RYGB [611]. 
Additionally, antibodies to the fibroblast growth factor 1 receptors have been shown to induce 
weight loss [612]. Tauroursodeoxycholic acid is a bile acid subfraction that reduced endoplasmic 
reticulum stress and potently sensitises mice to leptin [613]. Bile acids also act on the membrane 
receptor TGR5 (which is expressed in the liver, intestine, brown adipose tissue, muscle and immune 
cells) which in turn increases thermogenesis in brown adipose tissue and also production of GLP -1 in 
the gut [497]. Bile acids cross the blood-brain-barrier [500] and the TGR5 receptors have been 
identified in the brain [501]. I can therefore not exclude that bile acids (or the fibroblast growth 
factors 19 and 21) may also exert their effects on the brain reward systems and thus contributing to 
differences in activation seen in this study, especially as bile acids were higher after RYGB even 
during the scanning period. 
 
Whilst gut hormones and bile acids may be altering food choices “unconsciously”, there is increasing 
support for the notion that the reduced consumption of sweets and fatty foods after RYGB are the 
result of a more conscious mechanism of aversion and learning. As shown in this study, patients 
after RYGB had higher scores in retrospective dumping syndrome symptom questionnaires in the 
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 early post-operative period and higher levels of nausea after eating ice cream compared to BAND. 
This is consistent with the other studies in the literature that have shown that the dumping 
syndrome is much more common after RYGB and can lead to the avoidance of foods that precipitate 
unpleasant symptoms, including nausea, sweating, pain , diarrhoea and even collapse, through a 
learning mechanism [555]. A simplistic explanation of the pathophysiology of the dumping 
syndromes implicates osmotic shifts of fluid from the intravascular space to the gut, leading to 
hypotension and tachycardia [554]. However, there are some patients that have dumping syndrome 
symptoms even in the absence of cardiovascular changes, as in this study, suggesting the 
contribution of neural or hormonal mechanisms. Further support for the contribution of post-
ingestive factors in the change in the rewarding aspect of food comes from the animal literature in 
which condition taste aversion paradigms have shown that corn oil  and peanut oil caused aversion in 
rodent models of RYGB and VSG respectively [437, 538]. Administration of GLP-1 and PYY in rodents 
can also cause a conditioned taste aversion through activation of brainstem neurons [122, 561] and 
therefore gut hormones may contribute to the development of the dumping syndrome. 
 
Insulin is known to affect the mesolimbic system through its receptors in the striatum and midbrain 
[183]. Intracerebroventricular and arcuate injections of insulin not only reduce food intake, but also 
appetitive responses to sucrose in animals [184, 185].  Intranasal administration of insulin in healthy 
volunteers has been shown to improve the speed of detection of food (vs. non-food) pictures and to 
reduce associated activation of the hippocampus, temporal superior cortex, and frontal middle 
cortex in an fMRI study [186]. Intranasal insulin administration also reduced resting state activity in 
the orbitofrontal cortex and hypothalamus of normal weight women [187], but also reduced 
peripheral insulin sensitivity simultaneously, perhaps through an indirect central effect [188]. In a 
18FDG-PET study, the administration of low dose exogenous insulin resulted in increases in glucose 
uptake in the anterior cingulate cortex, prefrontal cortex, insula and ventral striatum and reduced 
glucose uptake in the amygdala and hippocampus [190]. In participants with peripheral/hepatic 
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 insulin resistance, glucose uptake in the ventral striatum and prefrontal cortex was attenuated 
compared to insulin sensitive participants, suggesting increased central insulin resistance in the 
former group.  
Insulin levels during scanning were not significantly different between the 2 groups and therefore at 
first sight it appears that differences in activation between the groups were not due to insulin 
signalling. However, HOMA-IR was significantly lower after RYGB compared to BAND if the statistical 
analysis was restricted to these two groups (i.e. without incorporating the BMI-M group). If we were 
to infer that brain insulin resistance was also lower after RYGB compared to after BAND, the similar 
circulating levels of insulin may therefore have been more effective in reducing activation in the 
RYGB compared to the BAND group. It was surprising to find that post-prandial insulin release was 
similar after RYGB and BAND, as this has been shown to be higher after RYGB due to the incretin 
effects of GLP-1 [607]. This result may have been influenced by the higher prevalence of type 2 
diabetes mellitus in the RYGB group pre-operatively. Even though many of them were diagnosed as 
being in glycaemic “remission”, their insulin release may still be impaired compared to participants 
without diabetes. The alternative explanation is that even though the incretin effect was still present 
in the RYGB group, it was dampened in the face of lower insulin resistance compared to the BAND 
group. 
Leptin is also known to modulate taste and brain reward responses. Leptin may act on dopaminergic 
neurons expressing the leptin receptor on the gateway to the mesolimbic system, the ventral 
tegmental area, to reduce food intake and the preference for palatable food through projections to 
limbic nuclei [137]. Leptin inhibits orexin neurons but not melanin concentrating hormone neurons 
in the lateral hypothalamus [135]. Central administration of leptin, inhibits dopamine release in the 
nucleus accumbens and suppresses the preference for high fat and sucrose [135]. Food restriction in 
mice increases the rewarding value of sucrose and administration of leptin decreases it [138]. In a 
fMRI study of obese, but not leptin deficient subjects, 10% weight loss through dietary means was 
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 associated with higher activation of brain reward systems, including the brainstem and 
parahippocampal gyrus, in response to food pictures compared to baseline [144]. Plasma leptin 
levels were not measured in my study, but the lack of any significant differences in BMI or % body 
fat between the groups suggests that differences in leptin are unlikely to be the mediator behind 
reduced reward system activation after RYGB. 
 
Limitations 
The main limitation of this study is its cross-sectional design. Even though the patients were not 
selected to have a particular type of bariatric surgery based on their pre-operative food preferences, 
I cannot exclude that pre-operative differences between the surgical groups in terms of their 
psychological or eating behaviour assessment may have affected the results. Indeed, the inevitable 
inclusion of more patients with type 2 diabetes mellitus in the RYGB group (pre -operatively) may 
have biased my results, as traditionally these patients are strongly discouraged from the 
consumption of sweet foods.  However, the 3 groups were well matched for a number of important 
factors that could have affected their food preferences, hedonics and brain activation, including age, 
gender ratio, current BMI, percentage body fat, time after surgery (for the surgical groups), current 
prevalence of type 2 diabetes and binge eating disorder, stage of the menstrual cycle, sleep 
duration, depression, use of anti-depressants, mood, impulsivity and other psychological traits [74, 
86, 190, 191, 269, 358, 364, 367, 371, 614-616]. 
 
Even though I have provided some mechanistic evidence that operations of the gut can have very 
different effects on brain activation, the hormonal, metabolic or neural signals were only implicated 
through association. In particular I did not study the effects of feeding, blocking the release of gut 
hormones with octreotide or blocking gut hormone receptors, in order to assess whether the 
differences between the surgical groups were exaggerated or attenuated. However, such a study is 
currently ongoing using the administration of octreotide in the same group of participants. The 
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 results of this study are eagerly awaited as they will shed light in the nature of the signalling involved 
in the alteration of brain responses. 
 
Another unexpected result of this study was that the consumption of the ice-cream test meal was 
not statistically different between RYGB and BAND, even though the former group found it less 
pleasant to eat. This finding may have been due to the lack of choice in the test meal provided, 
which together with the prolonged fasting in both groups may have urged the RYGB patients to eat 
for calories, even if they did not enjoy the meal.  
 
Another limitation was the use of food diaries to assess caloric and macronutrient intake. Their 
drawback is that by recording every meal, many participants start realising that what they are 
consuming too much or too unhealthy food and this may affect their reporting [4, 222, 223]. The 
underreporting of caloric intake is more of a problem in the context of obesity [224]. Even though 
underreporting could have taken place in this study, it may have been similar between the surgical 
groups. In view of their coefficient of variation, the visual analogue scales are more suited to within 
subject designs [227]. However, the ratings of hunger and fullness were consistent with the results 
of other studies showing reduction in hunger and increases in satiety after RYGB and BAND [433, 
434], and the test-meal intake was similar between the groups, suggesting that the groups were at 
the same internal state during scanning. Even though the patterns seen in eating behaviour between 
the whole cohort and the scanned subject were in the same direction, subtle discrepancies between 
the cohorts may reflect the different number of participants in each. This may have increased the 
power of detecting significant differences in the larger whole cohort compared to the smaller 
scanned cohort. Additionally, there was variation in the timing of the scanning study following 
surgery within, but not between, the surgical groups. This may have affected the results as some 
patients were scanned soon after surgery (~2 months) when they would have not reached a stable 
body weight. Even though samples for genetic analysis have been obtained, these have not been 
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 analysed yet. Therefore patients with genetic contributions to obesity may have been included in 
this cohort, further adding to variability, either from mutations such as melanocortin 4 receptor or 
single nucleotide polymorphism variants of the fat mass and obesity-associated (FTO) and DRD2 
genes. 
 
The lack of significant differences between the groups in more fROIs, for example the anterior insula, 
caudate and nucleus accumbens was intriguing. This may have been due to lack of power due to the 
cross-sectional design of the study, the inclusion of three groups and small number of subjects 
within the groups. In the whole brain analysis comparison was limited to between the two surgical 
groups and not all three groups to allow enough statistical power to detect differences.  The other 
pair-wise comparisons between the groups could also have been made at the whole  brain level (e.g. 
BAND vs. BMI-M, RYGB vs BMI-M), but that would have increased the number of multiple 
comparisons and the chance of a type 1 statistical error.  
 
Additionally, in the context of functional neuroimaging, the fMRI paradigm used was not very 
specific. In neuroimaging studies of language or hearing for example, the tasks and cues used are 
very specific to a particular process in the brain, which usually takes place in a distinct brain area. 
Such fMRI paradigms suffer with less “noise” and variability and are therefore more likely to detect 
differences between or within groups. In appetite neuroimaging the cues that can be used are 
limited by the fact that subjects cannot swallow food during scanning. Therefore activation in the 
brain is commonly quantified in response to food pictures; however this can be affected by a 
number of factors including luminosity and appeal of the picture, imagination of the food and 
memory of previous eating episodes. As such, the variability in responses increases and the 
statistical power to detect differences between groups decreases. In this study, even with the above 
caveats, significant differences were seen between the RYGB and BAND groups. This suggests that 
the magnitude of the physiological difference between RYGB and BAND is so large that it can be 
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 detected even at the whole brain level. Our fMRI paradigm also included a control task to ensure 
that the differences between the groups were not due to non-specific changes for example in 
neurovascular coupling, but more specific to the brain reward system.  
 
It is also difficult to know how much the limitations of the fMRI methodology itself could have 
affected the results of this study. This is indeed a very difficult question to answer and one which is a 
matter of heated controversy in the neuroimaging world. The debate has been sparked by a number 
of publications, the most important of which suggested that the reproducibility of fMRI results using 
the same task and stimuli using the same group of participants was only 50% [370]. In terms of 
appetite and the use of food pictures, a meta-analysis of the published literature has shown that the 
consistency of the areas in the brain that are activated by food pictures is at best 41% [67]. There are 
also no test-retest appetite fMRI studies to provide an estimate of the coefficient of variation using 
these paradigms. Another limitation of fMRI or PET neuroimaging techniques is that they do not 
measure neural activity directly, but indirectly (e.g. though blood flow or tracer uptake). 
 
There are numerous sources of variation in appetite fMRI studies; some of them stem f rom the 
investigators and some by the participants. Over the last 20 years, researchers have used different 
food pictures, MRI scanners, analysis software, regions of interest and statistical methods. Further 
variability comes from differences in the length of fasting [76, 364], caloric value of meal preloads 
(and whether adjusted for gender, resting energy expenditure,  valence of cues used), inter-
individual differences in food preference [371, 565], gender distribution [76, 364], genetic 
predisposition [34, 82, 332], personality and psychological traits [57, 269, 365, 366], co-morbid 
conditions including type 2 diabetes and insulin resistance [190-192] and binge eating disorder [74, 
269, 357], use of centrally acting medications [371, 565], stage in the menstrual period [367, 368] 
which can have a significant effect on activation.  
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 The above may perhaps sound over-pessimistic, but they are not. Neuroimaging has evolved 
significantly in the last few decades and now allows us access to information we were not able to 
obtain ever before. However, we have probably stretched the limits of what we can safely infer from 
the wealth of data neuroimaging has provided us. This is why there are many calls for the 
harmonisation of paradigms, statistical analyses and the funding of large multicentre studies, 
specifically in obesity, in an attempt to minimise variability and produce more robust findings [617]. 
These efforts will be accelerated firstly by the natural improvement in neuroimaging methodologies 
but also by the recognition of obesity as a very heterogeneous condition [363]. An elevated BMI is 
only the end result of a number of different physiological, genetic, social and psychological processes 
and the detailed phenotyping of patients will not only produce more consistent neuroimaging and 
indeed eating behaviour results, but also allow the personalisation of treatments [363]. 
 
The results of my study should be replicated in the future in order to allow more safe conclusions. 
Ideally a future study should prospective and randomised, have more participants in each group and 
investigate them in the fasted and fed state. More mechanistic conclusions can be made if the 
release/action of the most likely mediators of the difference in reward responses (e.g. gut 
hormones, bile acids) is experimentally manipulated. Instead of food pictures, liquid tastants of 
different textures and fat/sweet concentrations could also be used as cues to further narrow down 
the relative role of specific food attributes in the changes in food hedonics after RYGB.  
 
What becomes obvious when going through the above results is that any conclusions on eating 
behaviour should be based on the results of complimentary methodologies.  When analysing the 
data, there are some occasions were differences between groups do not reach statistical significance 
in one test but do so in another. This may have led to erroneous conclusions if the tests were used in 
isolation. In contrast, the pattern that emerges from this study, across methodological modalities, is 
that food (high-calorie or low-calorie, or both) elicits lower reward responses after RYGB compared 
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 to BAND and/or an unoperated obese control group. Indeed, in many occasions, the reward value of 
food tends to be higher after BAND compared to the BMI-M control group. Both surgical groups 
received the same dietary advice, in the same bariatric centre, and looked after by the same 
healthcare professionals, but exhibited very different responses in terms of food hedonics. The 
differences in food reward responses between the two surgical groups may have contributed to the 
greater weight loss efficacy of the RYGB. This finding could be used to individualise treatment in 
obesity clinics, by offering RYGB surgery to those patients with heightened reward responsiveness to 
food pre-operatively. Finally, the investigation of the neural mechanisms through which RYGB 
surgery reduces food reward may allow its mimicry with safer but equally effective 
pharmacotherapy. 
 
3.8 SUMMARY OF CHAPTER 3 
 
1. In this fMRI study, patients after RYGB lost more weight, ate less calories from fat, found a 
fatty/sweet meal as less pleasant to eat, rated any food, and in particular high-calorie food, 
pictures as less appealing  and had lower brain reward responses to food than patients after 
BAND and/or unoperated obese controls. 
2. The mechanisms underlying these observations may include altered signalling from gut 
hormones, bile acids and post-ingestive nutrient sensing causing aversion to fat and/or sugar 
after RYGB but not BAND surgery. 
3. Future studies are needed to confirm these findings. These should build up on the strength of 
the current study, but also avoid its limitations.  
4. Eating behaviour research should rely on the findings of complimentary methodologies and 
neuroimaging methodologies. These should be further improved in terms of validity and 
reliability and the participants should also be phenotyped in depth in order to reflect the 
heterogeneity of obesity itself. 
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CHAPTER 4 
 
EFFECTS OF GASTRIC BYPASS ON TASTE FUNCTION IN 
HUMANS 
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 4.1 ABSTRACT 
 
Background: Patients and animal models after gastric bypass surgery (RYGB) have a reduced 
preference for high-calorie fat and sweet foods. No studies in the human literature have investigated 
the contribution of alterations in taste function in the food preferences observed after RYGB in 
humans. 
  
 
 
Methods: 
Experiment 1: The effect of RYGB on the appetitive reward value of a fat/sweet and a vegetable 
reinforcer was assessed in two cohorts of obese humans before and after RYGB using a progressive 
ratio behavioural computer task and compared to normal weight controls tested twice. 
Experiment 2: The effect of RYGB on the consummatory reward value of taste was assessed using 
visual analogue scale ratings. Obese patients were tested before and after RYGB surgery and their 
ratings for intensity and reward were assessed for: 
 Sweet solutions (vs. normal weight controls) 
 Fat solutions (vs. patients undergoing gastric banding surgery and normal weight controls) 
 Fat and sweet solutions (vs. patients undergoing a very low calorie diet and normal weight 
controls) 
  
 
 
Results: 
Experiment 1: The appetitive reward value of a fat/sweet reinforcer, but not of vegetable reinforcer, 
was reduced after RYGB. Patients with the largest reduction in consummatory reward had the largest 
decrease in BMI. 
Experiment 2:  
 Sweet solutions: The consummatory reward value, but not intensity, of sweet taste was reduced 
after RYGB. Ratings remained stable in the normal weight control group.  
 Fat solutions: The intensity, but not the consummatory reward value, of fat taste was reduced 
after RYGB. Ratings remained stable in the gastric banding and normal weight groups. 
 Fat and sweet solutions: The intensity of fat and sweet taste mixtures was increased and the 
consummatory reward value decreased after RYGB. The reward responses after dieting were in 
similar directions but significantly lower in magnitude compared to RYGB 
 
 
 
Conclusions: Alterations in the sensory and reward domain of taste function may contribute to the 
change in food preferences and weight loss after RYGB. Mechanistic studies are needed in order to 
investigate the role of gut hormones, gut nutrient sensing and condition taste aversion as mediators of 
this mechanism. 
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 4.2 INTRODUCTION 
 
In the previous two chapters I showed that gastric bypass surgery (RYGB) reduced the preference and 
reward value of high-calorie fat and/or sweet food in animals and/or in humans. The next step was to 
investigate the contribution of changes in taste function as a mechanism. RYGB has been shown to 
alter the sensory domain of taste, by increasing patients’ acuity for sweet (i.e. patients detection of 
sweet is improved) [537, 553]. The effects of RYGB on the reward domain of taste have not been 
studied in humans before.  
I decided to study the appetitive reward value of taste through the use of the progressive ratio task, a 
behavioural test that has been used in animals for decades but in humans only relatively recently. In 
this task, the participant has to work harder in order to obtain a taste reward, and the point at which 
they stop responding is a measure of the reward value of the stimulus. I developed a novel and simple 
paradigm that minimises any post-ingestive feedback to study patients before and after RYGB. 
The consummatory sensory and reward value of taste lends itself to the use of visual analogue scales 
[381, 397, 618]. They are relatively easy, efficient and inexpensive to use. The general labelled 
magnitude scale (gLMS) in particular has been shown to be superior in its validity to other VAS as it 
can not only be used for within group but also cross-sectional comparisons between groups which 
may differ in their perception of intensity (e.g. non vs. super tasters). The “Just About Right” (JAR) 
scale has also been validated and used successfully by previous taste investigators [378, 388, 619]. By 
using the appropriate anchors on both sides of the scale, it provides more comprehensive information 
on rewarding aspects of the tastant, by incorporating both intensity and preference characteristics. 
These visual analogue scales can be used to assess intensity and reward responses across a range of 
taste concentrations. 
As a control the study included normal weight control subjects who were tested twice in order to test 
the reliability of the methodology and to control for any order effects. Other control groups included 
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 patients undergoing gastric banding (BAND) or a 2 week very low-calorie diet (VLCD). The latter is 
commonly used in obesity clinics for 2-6 weeks prior to bariatric surgery because it improves 
glycaemic control in patients with type 2 diabetes mellitus, blood pressure and reduces liver fat and 
size, thus making it easier for the laparoscopic surgeon to perform gastric surgery [620]. Even though 
there are no data on taste function after BAND, the expectation was that both interventions would 
have either no effect or even up-regulate taste responses.  
4.3 HYPOTHESES 
1. RYGB reduced the appetitive reward value of fat/sweet taste 
2. RYGB increases the intensity and reduces the consummatory reward value of sweet, fat and 
fat/sweet taste 
 
4.4 AIMS  
To investigate: 
1. the effects of RYGB on the appetitive reward value of fat/sweet taste in humans using a 
progressive ratio behavioural task 
2. the effects of RYGB on the intensity and consummatory reward value of sweet, fat and fat/sweet 
taste in humans using visual analogue scales 
 
4.5 Experiment 1: Investigation of the effects of RYGB surgery on the appetitive reward value of 
taste using the progressive ratio task  
4.5.1 Experiment 1 - Methods 
This was a prospective case-control study. Inclusion criteria for the obese patients were a BMI ≥ 35 
kg/m2, of either gender, aged 18-57 years and approval for obesity surgery from the clinical team at 
Imperial Weight Centre, Imperial College Healthcare Hospital Trust. Patients were recruited 
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 consecutively. Exclusion criteria for all patients and control subjects in the study included lack of 
understanding of the test instructions, a diagnosis of diabetes mellitus, active smoking, pregnancy, 
breast feeding, substance abuse, more than three alcoholic units per day, psychiatri c illness, chronic 
medical conditions that would make it unsafe to have a general anaesthetic and dislike or allergy to 
the stimulus ingredients. Dislike to the stimuli ingredients was assessed through direct questioning at 
first contact with the participants. Two different cohorts of normal weight participants (controls) with 
BMI between 19 and 25 kg/m2 were recruited from the community meeting the other inclusion and 
exclusion criteria above. During recruitment efforts were made to match the healthy volunteers to the 
patient group in terms of age and gender ratio. Written, informed consent was obtained from all the 
subjects. The study was conducted according to the Declaration of Helsinki and all procedures were 
approved by the West London 2 Research Ethics Committee (Reference 10/H0711/22), (Appendix 12).  
 
Experiment 1a:  Investigation of the effects of RYGB surgery on the appetitive reward value of 
fat/sweet taste using the progressive ratio task  
The first cohort of obese patients undergoing RYGB and normal weight participants were instructed to 
have their usual breakfast until they felt comfortably full before attending. Testing occurred 2-3 hours 
after breakfast (~9-11 am) in a quiet room within the clinical research facility. Room temperature was 
maintained at 22°C. I was the instructor throughout the experimental period, and provided patients 
and controls with exactly the same test information and information sheet. Subjects were told "Press 
as little or as much as you like. There are no right or wrong answers in the task.  When you no longer 
want to continue, press the space bar. This is not a competition". Hunger scores were obtained just 
before testing, using a horizontal 100 mm visual analogue scale with the anchors “not at all hungry” 
and “extremely hungry” on either end.  
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 Subjects were placed in front of a computer screen and a plate of 20 chocolate sweets (M&M® crispy 
Mars UK Limited, Slough UK, each one containing a mean of 4 kCal (energy contribution: 43.7% sugars, 
44.1% fat). The following prompt appeared on the screen: “You can earn food by clicking on the 
mouse button. Click as much or as little as you like. When you no longer want to continue, press the 
spacebar to stop the session”.  
Upon completion of each ratio a message box appeared on the screen: “You have earned food. Enjoy 
your reward and after you have swallowed it completely you may click on OK to continue with the 
programme.” After ingesting the reward, the subjects then pressed the OK button in the message box 
only if they wished to progress to the next ratio in order to obtain another chocolate sweet.   
The starting ratio was 10 clicks with a geometric increment of 2 (i.e. 10, 20, 40, 80 etc). This 
progression schedule was chosen based on pilot experiments in both obese and normal weight 
volunteers. Presumably, when the effort in pressing the mouse button was greater than the rewarding 
value of the chocolate sweet, subjects pressed on the space bar to terminate the session indicating 
the breakpoint was reached.  
One trial run was initially performed using the first ratio without reinforcement, to allow participants 
to become familiar with the computer software.  Following this, the instructor left the room and 
subjects were left on their own to complete the task. No food or fluid was offered after termination. 
The same numbers of chocolate sweets (n=20) were presented to all participants. The number left 
after completion of the experiment was subtracted from 20 to give the total number consumed. This 
was correlated with the number of completed ratios from the computer software to ensure 
participants followed the instructions correctly.  Patients due to have RYGB underwent testing 2 weeks 
pre- and 8 weeks post-operatively, whilst normal weight controls were tested on two occasions 10 
weeks apart.  
236
 Experiment 1b: Investigation of the effects of RYGB surgery on the appetitive reward value of 
vegetable using the progressive ratio task  
A cohort of obese patients undergoing RYGB and normal weight participants underwent testing using 
the paradigm described in experiment 1 but the sweet and fat stimulus was replaced with vegetable 
pieces. Participants were offered a combination of 20 vegetable pieces including tinned sweet corn, 
baby peas and carrots, which were preserved in water and presented at 22°C after being cut to similar 
volume pieces to the chocolate sweets. They used a small plastic fork to pick each piece of vegetable. 
The approximate calorie content of each vegetable piece was 0.78 kcal (energy contribution: 15.0% 
sugars, 11.5% fat).  
In both experiments I aimed to match cases to controls for the potential confounders of age, and 
gender and also to keep hunger scores stable between the first and second testing sessions of each 
experiment. Participants were therefore instructed to eat their normal breakfast until they were 
“comfortably full”. In order to limit bias, patients were recruited in the order they attended our clinic 
by an investigator who was blinded to the hypothesis of the study. The investigator performing the 
experiments was not present during the task, as this influenced the responses to the task in our pilot 
studies. Experiments 1a and 1b were performed by two different investigators (Alexander Miras and 
Robert Jackson respectively). Additionally, participants were given exactly the same verbal and written 
instruction and specifically instructed that there were no right or wrong responses to the task. 
Participants were told that the purpose of the experiment was to assess changes in taste, but not 
given any more detailed information about the study hypothesis as this could affect their responses.   
Statistical analysis 
The variables measured included hunger ratings in millimetres and mouse clicks in the last completed 
ratio (breakpoint). Comparisons between and within groups were for hunger scores were made using 
unpaired and paired t-tests respectively (normally distributed data). Comparisons between and within 
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 groups for mouse clicks in the last completed ratio were made using the Mann-Witney and Wilcoxon 
matched pairs test respectively (not normally distributed data). Normality distribution was assessed 
using D’Agostino and Pearson omnibus normality test. Correlations were made using the Spearman 
non parametric test, but the graphs include a parametric linear regression curve for visual comparison. 
The patient characteristic data were normally distributed and thus t-tests were used for within and 
between group comparisons for age and BMI, whilst gender comparisons were made with Fisher’s 
exact test. Results are expressed either as mean ± SEM or median (interquartile range). GraphPad 
Prism® version 5 was used for statistical comparisons.  
4.5.2 Experiment 1 - Results 
Subject characteristics 
The basic characteristics of the participants are shown in Table 4.1. All eligible normal weight 
participants were recruited and completed the study (n=11 in experiment 1, n=10 in experiment 2). In 
the obese group of experiment 1a (n=21 eligible and recruited), 4 patients did not complete the study 
because their operations were cancelled, 4 had a different type of obesity surgery for technical 
reasons and 2 did not understand the study instructions (n=11 completers). In experiment 1b, out of 
the 15 obese patients who were eligible and recruited for the study, 6 had a different surgical 
procedure to the RYGB (n=9 completers). Data from non-completers were not used.  
In experiment 1a, the groups were matched for age and gender at baseline; in experiment 1b normal 
weight volunteers were younger than obese patients. There was no significant change in the BMI of 
the normal weight control groups between the two sessions. There was no significant difference in the 
% BMI loss between the obese patients groups undergoing RYGB surgery in experiments 1a and 1b 
(14.5 ± 0.8% vs. 15.9 ± 0.7%, p=0.21).  
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 There were no discrepancies between the number of reinforcers actually consumed and the number 
predicted to have been consumed based on the software results for either the patient or normal 
weight volunteer groups in either experiment. 
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Table 4.1: Experiment 1-Participant characteristics  
 Normal weight control group Obese patient group p value  
(between group 
comparisons) 
Expt. 1a Expt. 1b Expt. 1a Expt. 1b Expt. 1a Expt. 1b 
Total n, Gender (M/F) 11, 4/7 10, 4/6 11, 4/7 9, 4/5 1.00 1.00 
Age (years ) 38.2 ± 2.9 39.4 ± 4.6 44.4 ± 3.0 56.0 ± 0.9 0.15 0.004 
BMI at first session / pre-operative (kg/m2) 22.7 ± 0.8 22.6 ± 0.7 49.3 ± 1.5 46.9 ± 1.4 <0.0001 <0.0001 
BMI at second session / post-operative 
(kg/m2) 
22.7 ± 0.7 22.5 ± 0.7 42.2 ± 1.6 39.5 ± 1.3 <0.0001 <0.0001 
p value (within group comparisons for BMI) 0.84 0.71 <0.0001 <0.0001   
 
Results given as mean ± SEM. Statistical tests used: Fisher’s exact test for gender comparisons and unpaired Student t -test for continuous data. Experiment 1a using 
chocolate sweets as reinforcers and experiment 1b using vegetable as reinforcers 
240
 
 
Breakpoints 
In both experiments 1a and 1b, breakpoints as assessed by the number of mouse clicks in the last 
completed ratio of the test, did not significantly differ in the normal weight control group between the 
two sessions for either chocolate sweets or vegetables (p=0.78 and 0.85 respectively) (Figure 4.1).  
Moreover, there was a high and significant correlation between the breakpoints for sessions 1 and 2 
for the control subjects for both chocolate sweets and vegetables (Figure 4.2A and 4.2C). There was no 
significant difference in breakpoints between the normal weight and obese group for the chocolate 
sweets and vegetables at baseline (p=0.53 and 0.51 respectively), (Figure 4.1).  However, there was a 
50% reduction in the median breakpoint of the obese group after RYGB surgery for chocolate sweets 
but not vegetables (p=0.015 and 0.40 respectively). There was a significant correlation between the 
breakpoints for sessions 1 and 2 for the obese subjects when vegetables, but not when chocolate 
sweets, were used as the reinforcer (Figure 4.2B, 4.2D).  The postoperative decrease in BMI in patients 
correlated with the decrease in breakpoint for chocolate sweet but not vegetables (Figure 4.3).  
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 Figure 4.1: Experiment 1-Breakpoint Results  
 
 
Box plot of breakpoint (i.e. clicks in the last completed ratio) for A) chocolate sweets and B) vegetables in the 
normal weight control group in triangles (n=11 in A, n=10 in B) and gastric  bypass group in circles (n=11 in A, n=9  
in B) for session 1/pre operatively (fil led) and session 2/post operatively (empty). The lower and upper 
boundaries of the box represent the 25
th
 and 75
th
 percentiles respectively.  The lower and upper whiskers 
represent the 10
th
 and 90
th
 percentile respectively. The median is the black line in bold inside the box.  Asterisk 
indicates significant differences within groups between sessions 1/pre operatively & 2/post operatively as 
determined by a Wilcoxon matched pairs test. 
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 Figure 4.2: Experiment 1 - Correlation of breakpoints between sessions  
 
 
Correlation of the breakpoint (i.e. clicks in the last completed ratio) in the A) normal weight control group for 
chocolate sweets (n=11), B) gastric bypass group for  chocolate sweets (n=11), C) gastric bypass group for 
vegetables (n=9) and D) normal weight control group for vegetables (n=10) between sessions 1/pre operatively 
and 2/post operatively using the Spearman correlation coefficient (r s). 
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 Figure 4.3: Experiment 1 – Correlation of change in breakpoint with change in BMI   
 
 
Correlation of change in BMI vs change in breakpoint (i.e. clicks in the last completed ratio) in the gastric bypass 
group for A) chocolate sweets (n=11) and B) vegetables (n=9), using the Spearman correlation coefficient (rs) 
 
Hunger ratings 
The results of the hunger ratings are summarised in Table 4.2. Hunger was unchanged in the normal 
weight control group in both experiments 1a and 1b (p=0.26 and 0.33 respectively). Hunger ratings 
were significantly reduced after RYGB in experiment 1a (p=0.05) but did not reach statistical 
significance in experiment 1b (p=0.18). Hunger ratings did not correlate with breakpoints in either the 
normal weight control or the obese patient group for any test session in both experiments. Moreover, 
the change in hunger ratings also did not correlate with the change in breakpoints between the 
sessions in either the normal weight or the obese groups. 
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Table 4.2: Experiment 1 - Summary of hunger rating results   
 Hunger rating 1 p value 2 
 
 
Correlation of hunger 
rating with breakpoint 3 
Correlation of change in 
hunger rating with change in 
breakpoint 3 
Experiment 1a- Session 1 Normal 
weight group (n=11) 
26.0 (11.0-45.0)  0.26 rs= -0.30  
p=0.37 
rs= 0.11 
p=0.73 
Experiment 1a- Session 2 Normal 
weight group (n=11) 
42.0 (18.0-53.0)  rs= -0.14  
p=0.69 
Experiment 1a- Pre-op Obese patient 
group (n=11) 
24.0 (11.0-45.0)  0.05 rs= -0.32  
p=0.34 
rs= -0.67 
p=0.17 
Experiment 1a- Post-op Obese patient 
group (n=11)  
13.0 (3.0-28.0) rs= 0.05  
p=0.88 
Experiment 1b- Session 1 Normal 
weight group (n=10) 
49.5 (23.5-67.5)  0.33 rs= 0.34  
p=0.33 
rs= 0.54 
p=0.11 
Experiment 1b- Session 2 Normal 
weight group (n=10) 
26.5 (20.5-55.8)  rs= 0.16  
p=0.65 
Experiment 1b- Pre-op Obese patient 
group (n=9) 
21.0 (4.0-75.0) 0.18 rs= -0.14  
p=0.71 
rs= 0.10 
p=0.81 
Experiment 1b- Post-op  Obese 
patient group (n=9) 
5.0 (2.0-34.0)  rs= -0.54  
p=0.13 
 
1 
Hunger rating in mm – median (interquartile range) 
2 
Within group comparisons (Session 1 vs Session 2 in the normal weight groups and pre operatively vs post operatively in the obese patient groups) using the 
Wilcoxon matched pairs test 
3
 rs: Spearman correlation coefficient  
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 4.6. Experiment 2: Assessment of the effects of RYGB surgery on taste intensity and 
consummatory reward using visual analogue scales 
4.6.1. Experiment 2a: Assessment of the effects of RYGB surgery on SWEET taste intensity and 
consummatory reward 
4.6.1.1 Experiment 2a - Methods 
Subject characteristics 
This was a prospective case-control study. Obese patients with a BMI greater than 35 kg/m2 and 
approved for obesity surgery based on the United Kingdom National Institute of Clinical Excellence 
guidelines were recruited consecutively from the Imperial Weight Centre, Imperial Col lege 
Healthcare Hospital Trust. Inclusion and exclusion criteria were identical to Experiment 1. Eighteen 
participants completed the experiment before their RYGB. Nine normal weight controls were 
recruited from staff of the Charing Cross Hospital, London. The inclusion criterion was a BMI ≥ 18.5 
and <25 kg/m2, with the same exclusion criteria applied. In all experiments I aimed to match cases to 
controls for the potential confounders of age and gender. In obese patients this study was 
completed 2 weeks before surgery and 6 weeks post-surgery. In the normal weight control group the 
experiments were completed 8 weeks apart. Written, informed consent was obtained from all the 
subjects. The study was conducted according to the Declaration of Helsinki and all procedures were 
approved by the West London 2 Research Ethics Committee (10/H0711/85), (Appendix 13).  
Generalised labelled magnitude scales 
Seven ascending sucrose solution concentrations were used to test responses in intensity ratings and 
hedonic reward. These were made up by digitally weighing a designated amount of granulated sugar 
(Silver Spoon®) and adding it to a particular volume of commercially available mineral water 
(Sainsbury’s Caledonian®) to produce a specific molarity (Table 4.3). A syringe was used to draw 20 
ml of each concentration to participants in polystyrene cups. 
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 Table 4.3: Experiment 2a - Amount of sucrose used to make the 7 ascending concentrations of 
SWEET solutions   
 
Wt: weight, Vol: volume, w/w: weight per weight, w/v: weight pre volume 
 
 
The tool used to measure intensity ratings was Bartoshuk’s generalised labelled magnitude scale 
(gLMS) which allows participants to judge the intensity of sweetness compared to the strongest 
sensation of any type (this allows a similar mental limit for maximum intensities) [381] (Appendix 
14). For the hedonic ratings a ‘just about right’ (JAR) and a standard pleasantness rating scale were 
used to allow participants to rate the samples compared to an ideal level of sweetness in a soft drink 
[621]. The intensity, JAR and pleasantness scales are 200 mm long, so a ruler was used to measure 
where participants had marked their ratings. The intensity scale ranged from 0 to 200 mm and the 
JAR hedonic scale ranged from 0 (at just right) to -100 mm (far too weak) and from 0 to +100 mm 
(far too sweet). The pleasantness scale ranged from 0 (neither pleasant nor unpleasant) to -100mm 
(extremely unpleasant) and from 0 to +100 (extremely pleasant).  
 
The 7 sucrose concentrations used were 0.00M, 0.0125M, 0.250M, 0.050M, 0.100M, 0.200M and 
0.400M (commercial cola drinks have a sucrose concentration of ~0.1M). Each sucrose concentration 
solution was made fresh on the day of test and kept at room temperature.  
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Each participant sampled 7 concentrations 3 times after an overnight fast. In total 21 polystyrene cups 
were labelled A1-7, B1-7 and C1-7 and set up for the sucrose solutions, then 20 ml (x3) of each 
concentration was put into a cup using a syringe. The full cups were then put into a random order 
ready for testing (Table 4.4). A further 21 polystyrene cups were filled with 15 ml of mineral water and 
used as a rinse after each sucrose solution. 
Table 4.4: Experiment 2a - Randomisation and order of presentation of the seven concentrations of 
the SWEET solutions across the three tested blocks  
Block A Concentration (Molar)         Order of presentation 
1 0.000 6 
2 0.0125 4 
3 0.025 2 
4 0.050 5 
5 0.100 7 
6 0.201 1 
7 0.402 3 
Block B   
7 0.000 5 
1 0.0125 2 
2 0.025 6 
3 0.050 7 
4 0.100 4 
5 0.201 1 
6 0.402 3 
Block C   
6 0.000 1 
7 0.0125 7 
1 0.025 3 
2 0.050 5 
3 0.100 6 
4 0.201 4 
5 0.402 2 
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 The intensity scale was described to participants by explaining they were to mark horizontally across 
the vertical scale where they found the intensity of the solutions to be relative to any sensation they 
have experienced (varying from barely detectable to the strongest sensation of any kind).  
The JAR scale was described to the participant by explaining they had to compare the taste of the 
solution to the sweetness in their ideal soft drink (varying from not sweet enough, just right or too 
sweet).  
The pleasantness scale was described to the participants by explaining they had to mark horizontally 
across the vertical scale where they found the pleasantness of the solution to lie (varying from 
extremely unpleasant to extremely pleasant). Each set of instructions were al so written at the top of 
the scales as a reminder. 
Each set of 7 cups were individually given to the participant in random order with the instruction to 
put the solutions into their mouths, swirl it around and then to spit it out into a bucket – the “sip and 
spit” technique. After each cup of sucrose solution, a water cup was also given for the participant to 
swirl and spit in order to cleanse their mouths for the next tastant. While the solutions were being 
swirled around in the participants’ mouths they were asked to mark the 3 scales. 
Statistical analysis 
Comparisons between groups for age and BMI at the first visit were made using unpaired Student t 
tests and for within groups for BMI using paired Student t tests. Categorical data for gender were 
compared using the Fisher’s exact test. The dependent variables used for 2-way repeated measures 
ANOVA analysis were created by averaging each set of ratings across the 3 trials for each of the 7 
concentrations. Within group comparisons for VAS ratings were performed using concentration as the 
first factor and time (for the normal weight control group) or surgery (for the obese patient group) as 
the second factor. Between group comparisons for VAS ratings were made using group as the first 
factor and concentration as the second factor.  
249
 4.6.1.2 Experiment 2a - Results 
Subject characteristics 
Eighteen participants completed the experiment before their RYGB surgery and 10 returned to 
complete it after surgery (5 had their surgery cancelled/postponed and 3 patients chose not to 
return). All 9 normal weight controls attended both visits, 8 weeks apart.  
Table 4.5 summarises the participant characteristics of the two groups. At baseline the obese and 
normal weight groups had similar gender distribution, but the normal we ight group was significantly 
younger (p=0.025). There was no change in the BMI of the control group between visits, but there was 
a significant reduction in BMI in the surgical group (p<0.0001). Before surgery, there were no 
significant differences between the obese and normal weight groups in ratings for intensity (p=0.85), 
JAR (p=0.40) or pleasantness (p=0.60) (Figures 4.4, 4.5, 4.6).   
Table 4.5: Experiment 2a (responses to SWEET) - Participant characteristics  
 Normal weight 
control group 
Obese group p value  
(between group 
comparisons) 
Gender (M/F) 4/5 4/6 1.00 
Age (years) 32.9 ± 2.4 46.3 ± 4.7 0.025 
BMI at first visit /  
pre-operative (kg/m2)   
22.4 ± 0.9 42.7 ± 1.7 <0.0001 
BMI at second visit /  
post-operative (kg/m2)  
22.5 ± 1.0 37.6 ± 1.7 <0.0001 
p value  
(within group comparisons) 
0.35 <0.0001  
   
Comparisons between groups for age and BMI at the first visit were made using unpaired and for within groups 
for BMI using paired student t tests. Categorical data for gender were compared using the Fisher’s exact test. 
Data shown as mean ± SEM. M: male, F: female, BMI: body mass index. 
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 Taste ratings 
In the obese patient group, RYGB surgery had a significant main effect on the JAR ratings in that JAR 
ratings decreased after RYGB surgery, seen as a shift of the curve to the left (p=0.048). This meant that 
the JAR concentration for sweet was reduced after surgery. RYGB surgery did not have a significant 
main effect on the ratings of intensity (p=0.57) or pleasantness (p=0.47), (Figures 4.4, 4.5, 4.6, Table 
4.6). There were no significant differences in any of the ratings between visits 1 and 2 in the normal 
weight group. 
Table 4.6:  Results of Experiment 2a (responses to SWEET) – Taste Ratings  
Sweet Intensity ratings Concentration Time/Surgery 
Concentration x 
time/surgery 
Normal Weight Controls F(6,56)=35.86; p<0.0001 F(1,56)=4.48; p=0.38 F(6,56)=0.80; p=0.57 
Obese Patients  F(6,63)=36.00; p<0.0001 F(1,63)=0.33; p=0.57 F(6,63)=0.49; p=0.81 
Sweet JAR ratings Concentration Time/Surgery 
Concentration x 
time/surgery 
Normal Weight Controls F(6,56)=39.21; p<0.0001 F(1,56)=3.73; p=0.10 F(6,56)=0.10; p=0.99 
Obese Patients  F(6,63)=29.02; p<0.0001 F(1,63)=4.06; p=0.048 F(6,63)=1.06; p=0.40 
Sweet Pleasantness 
ratings 
Concentration Time/Surgery 
Concentration x 
time/surgery 
Normal Weight Controls F(6,56)=10.49; p<0.0001 F(1,56)=2.78; p=0.10 F(6,56)=1.73; p=0.13 
Obese Patients F(6,63)=2.25; p=0.049 F(1,63)=0.51; p=0.47 F(6,63)=0.60; p=0.73 
 
Table summarises the results of the effects of time (for normal weight controls) or gastric bypass surgery (RYGB-
for obese patients) on the ratings for intensity, just about right (JAR) and pleasantness across the 7 
concentrations of sweet solutions. Comparison within groups made using 2 -way ANOVAs. 
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 Figure 4.4:  Experiment 2a - Intensity ratings  
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Intensity ratings as a function of the 7 concentrations of sweet in A) obese bypass (RYGB) patients pre vs. post 
treatment, B) normal weight controls at visit 1 vs. visit 2 and C) obese patients vs. normal weight controls at 
baseline. Comparisons performed using 2-way repeated measures ANOVA.  
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 Figure 4.5 Experiment 2a - “Just About Right” ratings  
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“Just About Right” ratings as a function of the 7 concentrations of sweet in A) obese bypass (RYGB) patients pre 
vs. post treatment, B) normal weight controls at visit 1 vs. visit 2 and C) obese patients vs. normal weight 
controls at baseline. Comparisons performed using 2-way repeated measures ANOVA. 
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 Figure 4.6: Experiment 2a - Pleasantness ratings  
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Pleasantness ratings as a function of the 7 concentrations of sweet in A) obese bypass (RYGB) patients pre vs. 
post treatment, B) normal weight controls at visit 1 vs. visit 2 and C) obese patients vs. normal  weight controls at 
baseline. Comparisons performed using 2-way repeated measures ANOVA.  
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 4.6.2. Experiment 2b: Assessment of the effects of RYGB and BAND surgery on FAT taste intensity 
and consummatory reward 
4.6.2.1 Experiment 2b - Methods  
Recruitment of 3 different cohorts was performed as per experiment 2a. Seventeen patients due to 
undergo RYGB surgery, 9 due to undergo BAND and 14 normal weight controls were recruited. 
Patients were tested 2 weeks before surgery, 8 weeks after surgery in the RYGB group, 12 weeks after 
surgery in the BAND group and normal weight controls were tested 12 weeks apart. The BAND group 
was tested later in time in order to attempt to match them in weight loss with the RYGB group, as 
weight loss after gastric banding takes place more slowly. 
The same methodology was used as in Experiment 2a. Instead of mineral water and sucrose, 
Sainsbury’s milk and Elmlea single cream were used to make up 7 concentrations of fat with stable 
concentrations of protein, CHO and fat (Table 4.7). The 7 fat concentrations used were 0.1%, 0.5%, 1%, 
1.7%, 3.6%, 8.3% and 13% (full-fat milk has a fat concentration of 3.6%). Each fat solution was made 
fresh on the day of test and kept refrigerated at 4°C. The same VASs were used, but instead the word 
“sweet” was replaced by the words “creamy/fatty”. Statistical analysis was performed as per 
experiment 2a, however in the presence of 3 groups, the baseline characteristics were compared using 
one way ANOVA. 
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Table 4.7: Experiment 2b and 2c - Macronutrient content of the 7 ascending concentrations of FAT solutions 
Concentration number 1 2 3 4 5 6 7 
Fat concentration 0.10% 0.50% 1.00%  1.70% 3.60% 8.30% 13.00% 
Volume 
20 mls skimmed milk 
11 mls skimmed milk  
+ 9 ml 1% milk 
20 mls 1% milk 
20 mls semi 
skimmed milk 
20 mls whole 
fat milk 
10 mls whole milk  
+ 10 mls Elmlea® cream 
20 mls Elmlea® 
cream 
Protein 0.68 0.65 0.62 0.68 0.66 0.64 0.62 
Carbohydrates 1.00 0.96 0.92 1.00 0.94 0.93 0.92 
Fat 0.02 0.11 0.20 0.34 0.72 1.66 2.60 
Sodium 0.01 0.01 0.01 0.01 0.03 0.02 0.02 
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4.6.2.2 Experiment 2b - Results 
Subject characteristics 
From the 17 RYGB patients recruited pre-operatively, 6 were unable to return post-operatively; hence 
11 patients completed the experiment twice. Out of the 9 BAND patients, 6 returned to complete the 
post operative test, as 3 developed surgical complications. Out of the 11 controls participants 
recruited, 7 were tested on two occasions as 4 were unable to return to carry out the experiment on a 
second time.  
Table 4.8 summarises the participant characteristics of the three groups. At baseline the groups were 
similar in gender distribution and age. There was no significant change in the BMI of the control group 
between visits (p=0.91), but there was a significant reduction in BMI in both the RYGB and BAND 
groups (p<0.0001). 
Table 4.8: Experiment 2b (responses to FAT) - Participant characteristics  
 Normal 
weight 
control group 
Obese 
bypass 
group 
Obese 
banding 
group 
p value (between groups) 
Overall ANOVA/Fisher’s 
Post hoc tests 
Gender (M/F) 2/5 4/7 2/4 0.94 
Age in years (mean ± SEM) 33.2 ± 5.2  44.2 ± 3.3  40.9 ± 2.3 0.15 
BMI at first visit/pre op 
(kg/m2) 
23.8 ± 1.3  50.3 ± 2.1 49.3 ± 3.0 <0.0001 
RYGB<controls, p<0.0001 
RYGB<controls, p<0.0001 
BMI at second visit/post op 
(kg/m2) 
23.8 ± 1.4  43.1 ± 1.8  42.7 ± 4.7 0.0002 
RYGB<controls, p<0.0001 
RYGB<controls, p<0.0001 
p value (within group 
comparisons) 
0.91 <0.0001  <0.0001  
 
Comparisons within groups for BMI were made using paired student t tests. Comparisons between groups were 
made using one way ANOVA. Categorical data were compared using the Fisher’s exact test. Data shown as mean 
± standard error of the mean or raw values. M: male, F: female, BMI: body mass index.  
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 Taste ratings 
Before surgery, the obese group (comprising of patients before RYGB and BAND) had a higher “Just 
about right” concentration of fat as demonstrated by a shift of the curve to the right of the normal 
weight group (p=0.01) (Figures 4.7-4.9). There were no significant differences between the normal 
weight and obese groups in terms of their intensity (p=0.10) or pleasantness (p=0.75) ratings. 
After RYGB surgery, the intensity of fat taste was significantly reduced (p=0.002), but there were no 
significant changes in JAR (p=0.66) or pleasantness ratings (p=0.87). None of the ratings changed 
significantly after BAND surgery (intensity p=0.35, JAR p=0.53, pleasantness (p=0.62) , (Figures 4.7-4.9, 
Table 4.9). 
None of the ratings differed significantly between the two assessments of the normal weight group 
(intensity p=0.34, JAR p=0.81, pleasantness (p=0.78), (Figures 4.7-4.9, Table 4.9). 
Table 4.9: Experiment 2b (responses to FAT) – Taste Ratings  
Fat Intensity Concentration Time/Surgery Concentration x time/surgery 
Controls F(6,42)=47.57; p<0.0001 F(1,42)=0.93; p=0.34 F(6,42)=0.28; p=0.93 
RYGB F(6,70)=40.06; p<0.0001 F(1,70)=10.43; p=0.002 F(6,70)=0.19; p=0.99 
BAND F(6,35)=18.77; p<0.0001 F(1,35)=0.90; p=0.35 F(6,35)=0.66; p=0.68 
Fat JAR Concentration Time/Surgery Concentration x time/surgery 
Controls F(6,42)=34.53; p<0.0001 F(1,42)=0.06; p=0.81 F(6,42)=1.45; p=0.21 
RYGB F(6,70)=25.63; p<0.0001 F(1,70)=0.19; p=0.66 F(6,70)=0.39; p=0.88 
BAND F(6,35)=9.41; p<0.0001 F(1,35)=0.40; p=0.53 F(6,35)=0.48; p=0.82 
Fat Pleasantness Concentration Time/Surgery Concentration x time/surgery 
Controls F(6,42)=6.8; p<0.0001 F(1,42)=0.08; p=0.78 F(6,56)=0.33; p=0.92 
RYGB F(6,70)=11.06; p<0.0001 F(1,70)=0.03; p=0.82 F(6,70)=0.65; p=0.69 
BAND F(6,35)=5.12; p=0.0007 F(1,35)=0.24; p=0.62 F(6,35)=0.76; p=0.61 
 
Table summarises the results of the effects of time (for normal weight controls), gastric bypass surgery (RYGB) or  
gastric banding surgery (BAND) on the ratings for intensity, just about right (JAR) and pleasantness across the 7 
concentrations of FAT solutions. Comparison within groups made using 2-way ANOVAs.  
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Figure 4.7:  Experiment 2b - Intensity ratings  
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Intensity ratings as a function of the 7 concentrations of fat in obese patients undergoing A) gastric bypass (RYGB) pre vs. post treatment, B) obese patients undergoing 
gastric banding (BAND), C) normal weight controls at visit 1 vs. visit 2 and D) obese patients vs. normal weight controls at baseline. Comparisons performed using 2-way 
repeated measures ANOVA.  
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Figure 4.8: Experiment 2b – “Just about right” ratings 
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Just about right (JAR) ratings as a function of the 7 concentrations of fat in obese patients undergoing A) gastric bypass (R YGB) pre vs. post treatment, B) obese patients 
undergoing gastric banding (BAND), C) normal weight controls at visit 1 vs. visit 2 and D) obese patients vs. normal weight controls at baseline. Comparisons perfo rmed 
using 2-way repeated measures ANOVA. 
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Figure 4.9: Experiment 2b - Pleasantness ratings  
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Pleasantness ratings as a function of the 7 concentrations of fat in A) obese patients undergoing gastric bypass (RYGB) pre vs. post treatment, B) obese patients undergoing 
gastric banding (BAND), C) normal weight controls at visit 1 vs. visit 2 and D) obese patients vs. normal weight controls at baseline. Comparisons performed using 2-way 
repeated measures ANOVA.  
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 4.6.3. Experiment 2c: Investigation of the effects of RYGB surgery and VLCD on the intensity and 
consummatory reward value of COMBINED FAT AND SWEET taste solutions 
4.6.3.1 Experiment 2c - Methods  
Recruitment of 3 different cohorts was performed as per experiment 2a and 2b. Twelve patients due 
to undergo RYGB surgery, 16 due to undergo a very low calorie diet (VLCD) of 800-1000 kCal/day 
pre-operatively and 9 normal weight controls were recruited. Patients due for surgery were tested 2 
weeks before and 10 weeks after surgery. Patients due to undergo a VLCD were tested a day before 
going on the diet and 2 weeks after being on the diet. Normal weight controls were tested once as 
the above experiments have proven the stability of the methodology used.  
The same methodology was used as in Experiment 2a and 2b, but 0.68 g of granulated sugar (Silver 
Spoon®) were added to each 20 ml fat solution. The same VASs were used, but instead the word 
“sweet” or “creamy/fatty” was replaced by the words “sweet and fatty”. Statistical analysis was 
performed as per experiment 2a and 2b. 
4.6.3.2 Experiment 2c - Results 
Subject characteristics 
Eleven RYGB patients, 14 VLCD patients and 9 normal weight controls completed the study. At 
baseline, the normal weight control group was significantly younger (p<0.05) and of lower BMI 
compared to the 2 obese groups (p<0.0001) (Table 4.10). There were no significant differences 
between the 2 intervention groups in terms of starting BMI, age or gender distribution (p>0.05). 
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 Table 4.10: Experiment 2c (responses to a mixture of FAT and SWEET) - Participant characteristics  
 Normal weight 
control group 
Obese 
bypass 
group 
Obese VLCD 
group 
p value(between groups) 
Overall ANOVA/t-test/Fisher’s exact 
Post hoc test 
Gender (M/F) 4/5 3/8 4/10 0.66 
Age in years  32.9 ± 2.4 46.4 ± 4.8 44.4 ± 3.9 0.03 
RYGB<controls, p<0.05 
RYGB<controls, p<0.05 
BMI at first visit / pre op 
(kg/m2) 
22.4 ± 0.9 42.7 ± 1.7 43.6 ± 0.4 <0.0001 
RYGB<controls, p<0.0001 
RYGB<controls, p<0.0001 
BMI post op (kg/m2) n/a 37.7 ± 1.7 40.1 ± 1.1 0.04 
p value  
(within group 
comparisons) 
n/a 0.0001 0.07  
 
Comparisons within groups for BMI were made using paired student t tests. Comparisons between groups 
were made using one way ANOVA or aired Student t tests. Categorical data were compared using the Fisher’s 
exact test. Data shown as mean ± standard error of the mean or raw values. M: male, F: female, BMI: body 
mass index. 
 
Table 4.11: Experiment 2c (responses to FAT and SWEET) – Taste Ratings  
Fat and sweet intensity Concentration Diet/Surgery Concentration x diet/surgery 
VLCD F(6,91)=83.85; p<0.0001 F(1,91)=13.20; p=0.0005 F(6,91)=1.66; p=0.14 
RYGB F(6,70)=42.92; p<0.0001 F(1,70)=15.82; p=0.0002 F(6,42)=0.51; p=0.65 
Fat and sweet JAR Concentration Diet/Surgery Concentration x diet/surgery 
VLCD F(6,91)=28.29; p<0.0001 F(1,91)=0.81; p=0.37 F(6,91)=1.33; p=0.25 
RYGB F(6,70)=44.72; p<0.0001 F(1,70)=15.43; p=0.0002 F(6,70)=0.30; p=0.93 
Fat and sweet 
pleasantness  
Concentration Diet/Surgery Concentration x diet/surgery 
VLCD F(6,91)= 6.00; p<0.0001 F(1,91)=4.27; p=0.04 F(6,91)=1.27; p=0.28 
RYGB F(6,70)=10.47; p<0.0001 F(1,70)=4.70; p=0.03 F(6,70)=0.69; p=0.66 
 
Table summarises the results of the effects of a very low calorie diet (VLCD) and gastric bypass surgery (RYGB) 
on 2 groups of obese patients in terms of ratings for intensity, just about right (JAR) and pleasantness across 
the 7 concentrations of fat/sweet mixtures. Comparison within groups made using 2-way ANOVAs. 
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 Taste ratings 
Comparisons between the normal weight and the obese groups (including patients due to undergo 
RYGB and VLCD) showed that the obese found the fat/sweet solutions as significantly less intense 
than the normal weight group (p<0.0001). The obese group also rated the JAR attribute of fat/sweet 
solutions significantly lower, but there was no clear pattern to the differences between the response 
curves (p=0.03). There were no differences in ratings for pleasantness between the groups (p=0.12), 
(Figures 4.10-4.12, Table 4.11). 
After intervention, RYGB patients lost significantly more weight compared to pre -operatively 
(p=0.0001), whereas there was a trend for a reduction in weight in the VLCD group (p=0.07). The 
intensity of fat/sweet mixtures increased significantly and similarly in both intervention groups 
(p=0.87 between groups). However, JAR ratings decreased significantly only in the RYGB group 
(p=0.005 between groups), in that the JAR concentration was reduced after RYGB (from 4.5% to 
1.0%). The pleasantness ratings decreased significantly and similarly (p=0.15 between groups) in the 
intervention groups (Figures 4.10-4.12, Table 4.11). 
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 Figure 4.10: Experiment 2c - Intensity ratings  
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Intensity ratings as a function of the 7 concentrations of fat and sweet in the A) obese bypass (RYGB) group pre 
vs. post treatment, B) very low calorie diet (VLCD) group before and on treatment and C) the obese vs normal 
weight groups. Comparisons performed using 2-way repeated measures ANOVA. *p<0.05, **p<0.01, 
***p<0.001 at the concentration shown. 
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 Figure 4.11: Experiment 2c – “Just About Right” ratings  
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Just About Right ratings as a function of the 7 concentrations of fat and sweet in A) obese bypass (RYGB) group 
pre vs. post treatment, B) very low calorie diet (VLCD) group before and on treatment and C) the obese vs. 
normal weight groups. Comparisons performed using 2-way repeated measures ANOVA.  
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 Figure 4.12: Experiment 2c - Pleasantness ratings  
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Pleasantness ratings as a function of the 7 concentrations of fat and sweet in A0 obese bypass (RYGB) group 
pre vs. post treatment, B) very low calorie diet (VLCD) group before and on treatment and the C) obese vs. 
normal weight groups. Comparisons performed using 2-way repeated measures ANOVA.  
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 4.7 DISCUSSION 
The main results of study of the effects of RYGB on taste reward are summarised below: 
 RYGB surgery decreased the appetitive reward value of a combined fat and sweet taste but not 
of a vegetable reinforcer  
 In terms of consummatory reward the results are summarised in Table 4.12. 
 
Table 4.12: Summary of findings for Experiment 2 (consummatory taste reward)  
 RYGB BAND VLCD Obesity 
Sweet 
Intensity → N/A N/A → 
Just About Right ↓ N/A N/A → 
Pleasantness → N/A N/A → 
Fat 
Intensity ↓ → N/A → 
Just About Right → → N/A ↑ 
Pleasantness → → N/A → 
Fat and Sweet 
Intensity ↑ N/A ↑ ↓ 
Just About Right ↓ N/A → → 
Pleasantness ↓ N/A ↓ → 
 
N/A: not available 
 
4.7.1. Experiment 1: Effects of RYGB surgery on the appetitive reward value of taste using the 
progressive ratio task  
This is the first study to use the progressive ratio task to assess changes in the rewarding properties 
of a food item after RYGB surgery.  The reinforcing efficacy of the sweet/fat sweet stimulus 
decreased by a factor of two after RYGB surgery and remained unchanged across a similar test-retest 
interval in normal weight control subjects.  There was no change in the reinforcer efficacy of 
vegetable stimuli using the same testing paradigm in a separate group of obese patients undergoing 
RYGB surgery with similar weight loss. 
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 I adapted this operant technique widely used in animals to investigate the hedonic value of a 
reinforcer [622-625]. My method built on the literature involving the use of progressive ratio tasks in 
the assessment of appetitive responses in humans (e.g. effect of hunger, obesity, genetics) [212, 615, 
626-630], and the reliability of our adaptation in the context of RYGB was validated in part by the 
high correlation between breakpoints for sessions 1 and 2 in the normal weight control groups in 
two separate experiments.  
One of the key merits of the task used here is that the assessment is based on the actual behaviour 
of the subject. This study answered the question of how hard was a subject willing to work for a 
given reinforcer. This model employed simple computer software, in which participants actually 
tasted the reinforcer during the task rather than postponing the consumption to the end. Thus, 
appetitive responsiveness was determined directly by the orosensory properties (e.g. taste) of the 
reward and did not depend on the association between a stimulus like a token, money or images 
with the reward. Completion of the schedule was not dependent on computer skills or the 
completion of an intellectually demanding task. In an attempt to minimise post-ingestive effects, 
reinforcers were of minimal volume and calories. It is this property that makes it beneficial for 
studying changes in appetitive responsiveness in RYGB patients so that ingestion of a food reward 
may not lead to premature satiation and interfere with its orally based evaluation.  Participants were 
briefed about each experiment by the same investigator who was not present during the task in 
order to minimise bias in the responses. The above methodological features differentiate our 
paradigm from others used in humans in previous studies [212, 615, 626-630].   
The human and animal literature has shown that patients and animals after RYGB have healthier 
food preferences compared to pre-operatively or compared to the now obsolete procedures vertical 
and horizontal banded gastroplasty (or sham surgery for animals) , [319, 441, 442, 506, 518, 519, 522-
529, 531, 532, 537, 538, 541, 543, 544], (Section 1.3.3.2, page 108). It is reassuring that the change in 
breakpoints observed in this study matches these reports of reduced preference, but as noted, this 
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 assessment was actually quantified on the basis of the measurement of the objective behaviour of 
the subject. Of note, there was no correlation between hunger ratings and breakpoint or between 
the across-session change in hunger ratings and the change in breakpoints in either controls or 
patients.  This would suggest that the change in breakpoints may have been related to the evaluation 
of the affective orosensory properties of the reinforcer and not to changes in physiological appetitive 
drive state at the start of each test.  
The breakpoints of the unoperated obese and normal weight groups were the same in both 
experiments suggesting that the subjects in these groups were prepared to work equally hard for the 
reward of chocolate sweets or vegetables. Even though this was not the primary endpoint in this 
study, this finding is in contrast to the other behavioural experiments that have found appetitive 
responses to food in a progressive ratio task to be higher in the obese [281, 283, 285, 631]. The 
discrepancy may be due to a number of reasons. In some of these studies for example children were 
used instead of adults in the current study. The tasks used in the other studies did not examine 
appetitive responses to taste, but to food intake. Therefore it is possible that taste itself does not 
contribute to the higher appetitive responses to food, but this is a result of post-ingestive feedback. 
Additionally, participants were entered in the studies based on their BMI. Obesity is a heterogeneous 
condition and it may indeed be the case that higher appetitive responses are predominantly seen in 
specific obesity phenotypes (e.g. binge eating disorder, higher impulsivity, delay discounting). The 
discrepancies in the behavioural and neuroimaging literature may therefore be due to lack of control 
for these phenotypes [363]. 
Importantly, the same task could in principle be conducted in an animal model of RYGB, which may 
open up the field to more in-depth interrogation of mechanisms that underlie the change in 
behaviour.  To date, the investigation of the effects of RYGB surgery on sweet and/or fat taste 
reward in animals has yielded mixed and complex results.  As discussed in Chapter 2, some groups 
have found post-operative decreases in consummatory responsiveness to high concentrations of 
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 sucrose [541, 543, 544] and a fat emulsion [541] and, in one case, at low concentrations of these 
stimuli rats actually increased their licking responses after RYGB [541].  Still others have found no 
changes in consummatory responsiveness to these stimuli [538, 545].  Some studies have found 
increases in appetitive responsiveness to sweet tasting stimuli [541, 545] and others have not [543].  
What is clear about many of these studies is that they differed in methodologically significant ways 
including the maintenance diet used, the body weight of the animals at surgery, the size of the 
stomach pouch and relative limb lengths, the pre-operative diet and the choice of procedural 
parameters in the behavioural tests conducted.  The latter is critical because it can have a strong 
influence on how much a behavioural measure reflects appetitive vs. consummatory processes.  The 
progressive ratio task is a pure measure of appetitive responsiveness to a taste stimulus and should 
prove useful in clarifying the effects of RYGB on motivated behaviour. 
The novel methodological adaptation of the progressive ratio task to study the appetitive 
responsiveness to taste stimuli has limitations and can therefore be improved further. Ideally it 
should be fully automated and camera-recorded, so as to minimise any investigator bias in the way 
instructions are given and to ensure that the reinforcer is actually ingested. The administration of a 
preload, under supervised controlled conditions, may help standardize physiological state and 
perceived hunger levels before the task. Peri-operative dietary advice may have introduced the 
confounding element of unintentional pre-judging towards high sweet/fatty foods. “Blinding” the 
participants to the reinforcers used, so that they rely purely on their orosensory properties for 
evaluation, may therefore prove useful in future experiments.  These may also include an obese 
group not undergoing surgery or a group undergoing BAND surgery or VLCD as control. Indeed, the 
use of the former group will be particularly useful, as if differences were detected between the two 
surgical groups, this would automatically reduce the impact of dietary advice as an important 
confounding variable, while both BAND surgery and VLCD can be used as a control for weight loss 
itself. In order to investigate whether the RYGB effects on sweet and fat taste reward are chronic, 
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 the same experiments should be repeated in the same patient cohort one year af ter surgery, when 
weight loss has plateaued.  
The possibility that subjects responses were influenced by their own cognitive expectations 
regarding how they thought they were supposed to behave toward the reward stimuli cannot be 
entirely dismissed. However, this is an inescapable limitation of any assessment of food preference 
and hedonics in an experimental setting.  It should be stressed that the subjects were clearly 
instructed that there was no right or wrong performance.  Indeed, the small volumes of rewards 
ingested coupled with the simple response requirement associated with the task probably helped to 
circumvent the influence of cognitive factors on the outcome.  It is impossible objectively to assess a 
subject’s intent, but we can measure a subject’s behaviour, and in the context of these experiments, 
the behavioural outcomes correspond remarkably well with the changes in BMI observed after RYGB 
and are consistent with at least some reports in the literature regarding changes in food preferences.  
 
4.7.2. Experiment 2: Effects of RYGB surgery on taste intensity and consummatory reward using 
visual analogue scales 
This is the first study to show that RYGB surgery altered the consummatory reward value of 
calorically dense tastants in humans. Patients were investigated prospectively and against different 
control groups in each experiment. These included normal weight controls tested, patients 
undergoing BAND or a VLCD. It was reassuring that the methodology we used was stable in normal 
weight controls when tested twice, 8 weeks apart. 
The consummatory reward value of sweet taste was significantly reduced after RYGB, as seen by a 
shift of the JAR-concentration response curve to the left. This suggests that patients after surgery 
prefer a lower concentration of sweet and they rate it as their “ideal”. Even though the reduction 
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 seen is very mild in terms of physiological terms, the cumulative reduction in calories consumed as a 
result may still contribute to weight loss in the long term. 
It was surprising to find that RYGB did not increase the intensity of sweet taste but it significantly 
reduced the intensity of fat taste. Additionally it was surprising that RYGB reduced the 
consummatory reward value of sweet taste (JAR scale) but it did not an effect on the consummatory 
reward value of fat taste (JAR or pleasantness). However, when fat was combined with sweet in a 
mixture, patients after RYGB found the mixture more intense and a reduction of consummatory 
responses was seen (both for the JAR and pleasantness ratings). At a stable sweet concentration, the 
JAR-concentration response curve was shifted to the left, resulting in a significant decrease of the 
“ideal” fat concentration from 4.5% to 1%. In every day terms, this equates to a change in 
preference from full fat milk to skimmed milk. The clinical effect of such a change in food choice is 
likely to be significant in terms of long term reduction in calories consumed and weight loss. This 
finding is consistent with some [541, 543, 544], but not all [538, 545], the results from the animal 
literature, in which rodents after RYGB had lower consummatory reward responses to fat and sweet 
stimuli.  
The most likely explanation for these varied changes in different tastes is that the nature of the fat 
and sweet mixture is much more applicable to everyday life, where they are normally consumed 
together and not in isolation. Therefore, participants rate their taste attributes more easily and 
reproducibly as they are much more relevant to their taste experiences. Indeed, when previous 
investigators used pure sweet or fat stimuli expecting to see differences in preference/pleasantness 
taste ratings between obese and normal weight participants, the results were also discrepant  
(Section 1.2.4.3, page 86) [379-381, 383-386, 389-396, 632]. In a similar manner to our study, 
Drewnonski was however able to detect consistent differences between obese and normal weight 
groups when fat was combined with sweet [397]. Obese patients preferred mixtures of high-fat with 
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 low-sweet, very much in line with the positive association of BMI with the consumption of food high 
in fat and low in sugar.  
The comparison between obese and normal weight participants was not the primary outcome of this 
study and therefore any results should be interpreted with great caution due to the reduced power 
to detect between group differences. Nevertheless, I found no differences in terms of their 
appetitive behaviour towards a fat/sweet reinforcer in the progressive ratio task. In terms of 
consummatory evaluation, the obese group found fat/sweet mixtures less intense and rated higher 
fat concentrations as their “ideal”. The combination of the two findings may suggest that obese 
patients seek foods with higher caloric density, in order to compensate for a reduced sensory 
perception compared to normal weight individuals. This is in line with the reward deficiency 
hypothesis which has been discussed in Section 1.2.4.2, page 81.   
Interestingly, after a two week VLCD, patients lost a small amount of weight (which was not 
statistically significant), and their fat/sweet intensity ratings increased similarly to the RYGB group. 
Surprisingly, there is little published data on the effects of intentional  weight loss on the intensity of 
sweet or fat taste. Some researchers have shown increases in sweet taste detection thresholds after 
weight loss [633], whereas others found no change in sweet intensity ratings [385].  
The pleasantness ratings in my study were lower after a short duration VLCD. This is in line with 
some of the published literature [618, 634]. Other studies have shown either no change [385], or 
increases in the pleasantness of sweet or fat taste after weight loss [385, 397, 635]. The differences 
between the studies are due to differences in stimuli used (pure vs. mixed), types of scales used to 
determine intensity or pleasantness, the administration of a preload before testing, type of dietary 
intervention and its length. It is possible that a more prolonged duration of a VLCD than in this 
current study, with consequent significant weight loss, may have actually increased the pleasantness 
ratings of the fat and sweet mixtures and magnified the difference between the VLCD and RYGB 
patients. 
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 Additional factors that may have affected the results using VAS, include the use of 7 different 
concentrations in each experiment, which confused some of the participants. The use of 3-4 
concentrations instead may have been preferable. I did not assess hunger levels and can also not 
exclude that hunger differences between or even within groups may have affected the taste ratings. 
I used validated scales to measure intensity, JAR and pleasantness and found the first two useful in 
quantifying responses. I was however surprised by the low readings obtained in the pleasantness 
ratings; this may have been due to the use of very basic stimuli that are not normally consumed in 
everyday life and therefore not associated with enjoyment. Instead, when ice -cream was used as a 
test-meal in chapter 2, significant differences in pleasantness ratings were observed between the 
RYGB and BAND patients.   
 
4.7.3 Limitations of both experiments 
I was also not always able to match the groups for age, and the normal weight group of  volunteers 
tended to be younger than the intervention groups. Even though ageing is associated with reduced 
perception to most taste modalities [636, 637], this is mostly relevant to old age and none of the 
participants were in that age group. I also did not control for the contribution of the menstrual cycle. 
Indeed, the luteal and premenstrual phase have been linked with higher reward response and 
preference to high calorie foods, but also with lower detection thresholds for sweet taste and its 
different stages on the evaluation of reward [367, 536, 638, 639]. Other confounders that I did not 
control and could have affected the results either between or within groups were the presence of 
genetic polymorphisms known to affect taste detection [640] and zinc levels as low zinc levels are 
associated with taste detection dysfunction [641] and they can sometimes be low after bariatric 
surgery [642]. Even though I minimised the contribution of post-ingestive feedback in the paradigms 
used, I cannot exclude that a previously formed condition taste aversion to fat and/or sweet taste 
may have affected the reward responses observed. This aversion may be mediated by gut hormones 
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 themselves [122, 561] or through direct neural signalling from the small bowel. I would also have 
liked to measure gut hormone responses and correlate them within groups with the taste responses. 
4.7.4. Potential mediators 
In this section I have provided a further potential mechanism for the change in food preferences 
after RYGB, by dissecting the contributory role of the taste system. Taste signals originate from the 
oral cavity and are transmitted through the brainstem to the insula which is the primary taste cortex 
and to the orbitofrontal cortex, the secondary taste cortex [196]. In the orbitofrontal cortex, the 
multimodal processing of taste, olfactory, texture and even vision takes place and their reward value 
encoded [42]. From the brainstem, the ventral forebrain pathway conveys the taste the central and 
basolateral amygdala [198, 199]. The amygdala acts as an interface of the taste and dopaminergic 
systems and it projects to the other structures of the mesolimbic system, including the nucleus 
accumbens and anterior cingulate cortex to determine behaviour [198, 199].  
The orbitofrontal cortex and the amygdala are the two areas in which I observed significant 
reductions in activation after RYGB surgery in the fMRI study (chapter 2). The altered taste signalling 
after RYGB may have contributed to the reduction in activation of this 2 key region of the brain 
reward system and the reduction in the appetitive responses to fat/sweet taste. Even though there 
are numerous ways that taste system signalling may be altered after RYGB, the most likel y mediators 
based on the current literature appear to be gut hormones. Indeed the taste system has been shown 
to have receptors and to be modulated by the action of GLP-1, CCK, VIP hormones but also NPY and 
leptin [643]. In mice, taste cells produce PYY and chronic increases in salivary PYY can reduce food 
intake [123].  The levels of both GLP-1 and PYY are higher after RYGB compared to pre-operatively in 
the postprandial ± fasting state [644] (and chapter 3), and even VIP, but not CCK, has been shown to 
be elevated in some patients after RYGB [645, 646]. These hormones may exert their effects to 
modulate either the sensory, reward or physiological domains of taste function.  
276
 4.8 SUMMARY OF CHAPTER 4 
 In this chapter I have shown that alterations in the perception of taste may be another 
mechanism underlying the change in food preferences after RYGB in humans.  
 After RYGB, the appetitive and consummatory reward value of fat/sweet tastants was reduced 
in patients compared to pre-operatively. 
 The results are novel, but will need to be replicated in future studies that avoid some of the 
limitations of the current study and also provide more insights in the mechanisms underlying 
these changes in taste function after RYGB.  
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CHAPTER 5 
CONCLUSIONS AND FUTURE DIRECTIONS 
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 5.1 CONCLUSIONS 
In this thesis I have shown that: 
1. Rats after RYGB showed a lower preference for high-calorie sweet/fatty liquids and high-fat 
solids, and a higher preference for low fat/sweet liquids and solids. The behaviour of the RYGB 
rats was consistent with condition taste aversion to the sweet/fat food. This was of such 
magnitude as to cause weight loss, which is not physiological in the context of weight stability 
after RYGB. The use of diets of low or high-fat content pre-operatively did not affect caloric 
intake or weight loss after RYGB. However, animals exposed to low fat diets pre-operatively 
reduced their intake of high fat food immediately (aversion to a novel stimulus) compared to a 
slower reduction in the rats exposed to high-fat food pre-operatively (aversion to a familiar 
stimulus).  
 
2. Patients after RYGB lost more weight, ate less calories from fat, found a fatty/sweet meal less 
pleasant to eat, rated high-calorie food pictures as less appealing, had lower activation in brain 
reward systems to food, and healthier eating behaviour than patients after BAND and/or 
unoperated BMI-matched controls. These findings suggested that the hedonic value of food was 
lower after RYGB and may have contributed to the superior weight loss efficacy of this surgical 
procedure compared to BAND. Patients after RYGB had higher post-prandial ± fasting plasma 
levels of GLP-1, PYY and bile acids, and higher symptoms of dumping syndrome compared to 
patients after BAND and/or unoperated obese controls. These mediators could have acted 
independently, additively or synergistically to influence the brain-hedonic response to food.  
 
3. The appetitive reward value of sweet/fat, but not vegetable, taste reinforcers was reduced after 
RYGB in humans. The reduction in the appetitive reward value of the sweet/fat reinforcer 
correlated with the reduction in BMI after RYGB. The consummatory reward value of sweet/fat 
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 taste mixtures was reduced after RYGB, whilst similar reductions were either smaller or absent 
when sweet or fat were assessed separately. These results suggest that alterations in taste 
function may be a mechanism underlying the change in food preferences seen after RYGB and 
contribute to weight loss.  
 
These findings have first provided more clarity to the literature, which when this work begun, 
suffered from significant discrepancies and uncertainties as to whether RYGB does indeed lead to 
changes in food preferences [558]. Secondly, this work has helped provide evidence for the 
mechanisms that underlie this healthy shift in food preferences, which is seen after RYGB but not 
other bariatric surgery procedures such as the BAND or gastroplasty.  
 
An important finding is that these healthier food preferences take place independent of dietary 
advice and social desirability bias. The anatomical manipulations after RYGB are accompanied by 
numerous physiological changes as shown in Tables 5.1, 5.2 and Figure 5.1. These mediate the 
multiple positive effects of RYGB on weight loss, type 2 diabetes mellitus, morbidity and mortality. 
When my findings are added to the current knowledge in the field a number of general conclusions 
can be reached. The first is that patients after RYGB do not “see” food as they did before the 
surgery. After surgery, patients eat because they have to, rather than because they necessarily want 
to.  Patients not only feel less hungry and more full with smaller amounts of food, but the overall 
pleasure of eating is dramatically reduced. Anecdotally, this new relationship with food comes as a 
pleasant surprise to most patients and in particular to those for whom food was an “addiction” or an 
emotion-regulating substance.  
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 Figure 5.1: Mechanisms underlying weight loss and glycaemic improvements after the gastric 
bypass 
 
The anatomical rearrangement of the gut is the major source of altered signalling to the brain, liver, pancreas 
and adipose tissue amongst other tissues. The signals originating from the gut are conveyed through neural 
pathways (continuous blue) and the circulation (dotted blue) to the target organs. A question mark has been 
inserted in front of the physiological actions of the gastric bypass to indicate either that the mechanism is still 
under scientific exploration or that the results of published studies are controversial . GLP-1: glucagon like 
peptide 1, PYY: peptide tyrosine tyrosine, OXY: oxyntomodulin. 
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 Table 5.1: Summary of the main physiological mechanisms underlying the weight loss after bariatric surgery 
  RYGB BAND VSG 
Food intake ↓ ↓ ↓ 
Gastric emptying ↑ / ↓ ↔ ↑ 
Macronutrient malabsorption Minimal fat malabsorption N/A N/A 
Hypothalamic peptide expression N/A N/A ↔ 
Vagal signalling Implicated Implicated N/A 
Plasma GLP-1 ↑ ↑ / ↔ ↑ 
Plasma PYY ↑ ↔ ↑ 
Plasma Ghrelin ↑ / ↓ / ↔ ↑ ↓ 
Plasma CCK ↔ N/A ↔ 
Plasma Leptin ↓ ↓ ↓ 
Plasma Bile acids ↑ ↔ ↑ 
Gut microbiota Altered N/A N/A 
Energy expenditure ↑ / ↓ / ↔ N/A ↔ 
Food preferences 
↓ consumption of fat and 
sugar 
↔ or ↑consumption of fat 
and sugar 
↔ or ↓ consumption of fat 
and sugar 
Meal frequency ↑ ↓ / ↔ N/A 
Food reward ↓ ↔ / ↑/↓ ↔ / ↓ 
Appetitive reward  of sweet/fatty food/taste  ↓/↑/↔  N/A ↔ 
Consummatory reward of sweet/fatty food/taste  ↓/↑/↔ ↔  N/A 
Taste detection Improved for sweet N/A N/A 
Condition taste aversion For fat N/A For fat 
Salivation N/A N/A N/A 
Evidence was obtained from both human and animal studies. RYGB: Roux-en-Y gastric bypass, BAND: adjustable gastric banding, VSG: vertical sleeve gastrectomy, GLP-1: 
glucagon-like peptide-1, PYY: peptide tyrosine tyrosine, CCK: cholecystokinin, ↑: increase; ↓: decrease; ↔: no change, N/A: no available evidence.
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Table 5.2: Summary of the main physiological mechanisms underlying the glycaemic improvements 
after bariatric surgery 
  RYGB BAND VSG 
Hepatic insulin resistance 
Early reductions before 
weight loss which may 
be caloric restriction 
dependent or 
independent 
Early reductions before 
weight loss which are 
caloric restriction 
dependent  
Early reductions before 
weight loss which may 
be caloric restriction 
dependent or 
independent 
Peripheral insulin resistance 
Gradual reduction with 
weight loss 
Gradual reduction with 
weight loss 
Gradual reduction with 
weight loss 
Insulin release 
Rapid and exaggerated 
rise with total insulin 
AUC either  unchanged 
or reduced in response 
to decreases in insulin 
sensitivity 
Unchanged or reduced 
in response to 
decreases in insulin 
sensitivity 
Rapid and exaggerated 
rise with total insulin 
AUC either  unchanged 
or reduced in response 
to decreases in insulin 
sensitivity 
 
Evidence was obtained from both human and animal studies. RYGB: Roux-en-Y gastric bypass, BAND: adjustable 
gastric banding, VSG: vertical sleeve gastrectomy, AUC: area under the curve.  
 
 
The second conclusion is that the main mechanisms leading to these changes in eating behaviour after 
RYGB appear to be a reduction in the rewarding value of food/taste, and also the conscious 
unpleasant post-ingestive effects of energy-dense sweet and fatty food. These two mechanisms act 
independently in some patients or additively/synergistically in others. Anecdotally, a number of 
patients after RYGB report that they do not “crave” chocolate anymore, even though chocolate does 
not make them feel unwell, whilst others report that high-fat foods makes them nauseated and 
therefore they consciously avoid it. The majority of patients fall in the middle of this spectrum and yet 
there is a small minority of patients that do not exhibit any changes in their preference for energy -
dense food, but just keep consuming the same types of foods as pre-operatively but smaller amounts 
of them.    
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 The third conclusion is that the mediators underlying these two mechanisms are not yet fully 
understood. The majority of researchers in the field still consider gut hormones as key players, but the 
evidence is only indirect. GLP-1 and PYY lower the activation of brain reward systems in response to 
food pictures in humans [110] and reduce the preference for and rewarding value of energy-dense 
foods [108], affect taste function [111, 112], and cause condition taste aversion in animals [122, 561]. 
However, in the context of RYGB, there is no direct evidence of their role in changing food 
preferences. In the only small neuroimaging study which compared brain response to food pictures 
before and after RYGB both in the fasted and fed states, feeding after RYGB did not reduce activation 
in the reward system more than it did pre-operatively [595]. In my study, the lower activation of brain 
reward system in the context of higher post-prandial levels of GLP-1 and PYY in patients after RYGB 
compared to BAND, was associative but not causative. In the only animal study which examined the 
effect of GLP-1 on reward responses after RYGB, administration of GLP-1 antagonists in RYGB models, 
did not affect appetitive or consummatory responses in a brief access test [545]. More recently, 
vertical sleeve gastrectomy (VSG) (after which the release of these anorexigenic gut hormones is also 
exaggerated), was shown to have similar effects to the RYGB in changing food preferences in rodents 
[437, 563]. Even though these results came only from one group and have not been replicated by 
others [489], the healthier food preferences after VSG were still present even in GLP-1 or ghrelin 
knockout models [452, 460].  
 
The fourth conclusion is that we do not know if the shift in food preferences away from energy-dense 
foods after RYGB has an independent effect on weight loss or whether it is just an epiphenomenon of 
surgery. In my study, the reduction in the reward value of energy dense tastants correlated with the 
reduction in BMI after RYGB. However, in other studies sweet vs. non-sweet eaters (pre-operatively) 
and dumpers vs. non-dumpers (post-operatively) lost similar amounts of weight after RYGB [449, 519], 
and rodent models of VSG lost weight even when they were exclusively exposed to a high -fat diet 
post-operatively [437, 563]. By contrast, when the comparison is moved from within to between 
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 surgical procedures, the superior weight loss efficacy of RYGB and VSG compared to BAND [431, 647]  
may be partly due to the healthier food preferences in the first two procedures. Another explanation 
is that the change in food preferences may take place alongside the reductions in hunger if both 
processes share the same underlying mechanisms. These uncertainties do not detract any value from 
the importance of studying the mechanisms underlying food preferences. If anything their in-depth 
understanding may first allow the personalisation of bariatric surgery, and more importantly 
accelerate the development of novel pharmacological targets. Such pharmacological agents could act 
selectively in the reward system and used selectively in the subgroup of obese patients with 
abnormally high cravings for energy-dense foods. These agents should have a very specific mode of 
action and act on specific receptors in order to avoid a more generalised anhedonia; the latter led to 
high rates of psychiatric side effects and discontinuation of the cannabinoid 1 receptor antagonist 
Rimonabant [265], and there are some concerns whether the two new weight loss agents approved in 
the USA, lorcaserin and topiramate/phentermine may have a similar fate. 
 
The fifth conclusion is that the study of human eating behaviour is lagging behind other research fields 
e.g. metabolism or genetics. This is due to the variability and difficulty in capturing human behaviour 
in general and also due to the imprecise nature of our methodologies. Even currently, too many 
inferences on eating behaviour are based on the results of one method in isolation. This has, at least in 
part, led to remarkable inconsistencies in the published literature. As such, robust conclusions on 
behaviour should be obtained by comprehensive and complimentary phenotyping of participants 
through verbal/written reports, direct observation, behavioural testing and neuroimaging. These 
should be improved in such ways as to increase reproducibility and reduce the influence of 
confounders and bias. Additionally, specific care should be taken in the study of obesity which  is a 
highly heterogeneous condition and a high BMI is only the end result of numerous processes acting 
variably across individuals [363]. 
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 5.2 FUTURE DIRECTIONS 
 
Future studies need to achieve two main goals: the first is to replicate the results of this thesis and of 
the other published studies whilst avoiding their limitations, and the second to provide new insights 
into the mechanism underlying these findings.  
 
5.2.1 Animal studies 
 
The first priority is to further explain the discrepant results of the available studies and by doing so 
also understand the contribution of specific factors to the actual mechanisms of food preferences. For 
example the size of the biliopancreatic and common limbs and the manipulation of the vagus nerve in 
the RYGB design need to be studied in more detail. It is possible that the length of the common limb 
correlates inversely with consumption of fat/sweets after RYGB. One explanation for this may be that 
shorter common limbs cause more fat malabsorption and therefore more aversive post-ingestive 
signalling. Sparing of vagal fibres during RYGB has been shown to be beneficial for weight loss [473] 
and may also be important for the food preferences seen after surgery. Presumably, the reason for 
this is that any disruption of the vagal fibres also disrupts hormonal, bile and nutrient signals from the 
gut to the brain [648]. Longer biliopancreatic limbs are associated with more weight loss and be tter 
glycaemic control [649] and the same may be true for food preferences. The reasons for this are 
unclear, but may involve an increased surface area for undiluted bile acids (i.e. not mixed with food) to 
act on, with the end result of higher gut hormone production, energy expenditure and lower hepatic 
glucose output compared to shorter limbs [649]. These experiments should be performed on different 
animal strains, in case this is another factor that affects food preferences post-operatively [650, 651]. 
These animals should be offered a combination of high and low fat/sugar diets pre - and post-
operatively to mirror the human situation more closely. Similar experiments should be performed in 
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 rodent models of VSG and these should focus on whether the volume of the gastric sleeve plays a role 
in the food preferences observed after the surgery. 
 
The second priority is to understand the role of gut hormones, bile acids and nutrient sensing in the 
shaping of food preferences after surgery. The behaviour of RYGB rats could be assessed in paradigms 
of appetitive and consummatory taste reward (e.g. progressive ratio task and taste reactivity). Rats 
could then be treated with GLP-1, PYY, ghrelin and bile acid/fibroblast growth factor (e.g. at their FXR 
or TGR5 receptors) receptor antagonists in order to find out if their responses are altered, thus 
providing a causative role for these mediators. Similar experiments could be performed in RYGB mice 
with GLP-1, PYY, ghrelin and bile acid/fibroblast growth factor gene or receptor knockouts. Currently, 
there are RYGB mouse models available, but experimentation is limited by high mortality rates and the 
need of highly skilled surgeons with expertise in microsurgery [652].  
 
The role of small bowel nutrient sensing and of the vagus nerve needs to be further explored through 
selective vagotomy of the coeliac branches to the small bowel. Recently, the duodenal-jejunal bypass 
procedure has been used to provide more information on the role of the bypassed proximal small 
bowel and the role of nutrient sensing [653]. This procedure incorporates only one of the components 
of RYGB (Figure 5.2); administration of glucose in the distal jejunum of duodenal-jejunal bypass 
animals with diabetes reduced hepatic glucose output through the gut-brain-liver axis, independently 
of food intake, body weight and insulin production [653]. It is possible that the same gut-brain axis is 
operational for the signalling of gut nutrients to the reward system in the brain after RYGB. Therefore 
the exposure of the distal jejunum to large amounts of undigested fat and sugar (which was not the 
case pre-RYGB) may signal to the brain in such a way as to either reduce their rewarding value or 
increase their aversive properties (e.g. malaise, nausea) and therefore lead to their reduced 
consumption post-operatively.  
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 Figure 5.2: Duodenal-jejunal bypass in rats 
 
Anatomical manipulations of the gastrointestinal tract for the duodenal-jejunal bypass, BP representing the 
biliopancreatic limb, AL the alimentary limb and CC the common channel. The grey areas represent parts of the 
gastrointestinal tract that are bypassed from nutrient flow. The arrows represent the flow of nutrients. 
 
Rather than performing the duodenal-jejunal bypass surgery in animal models, the insertion of an 
endoscopic duodenal-jejunal bypass liner could be used instead. Such liners are now available for 
weight loss and glycaemic control in humans (e.g. Endobarrier TM, GI dynamics, Lexington, USA). They 
are made of a nitinol anchor that keeps the upper part of the device in the duodenal bulb and a 
fluoropolymer sleeve that lines the first 60-70 cm of the small bowel, thus not allowing food to come 
in contact with its walls (Figure 5.3). The device causes 10-20% total body weight loss and absolute 
reductions of ~2% in the levels of glycated haemoglobin [654]. Similar devices are available for animal 
experimentation [655] and they could be used in a reductionist approach in order to study the 
contribution of the bypass of the proximal small bowel to the altered food preferences obse rved after 
RYGB. 
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 Figure 5.3: The endoluminal duodenal-jejunal bypass liner 
 
 
Endobarrier 
TM
, GI Dynamics, Lexington, USA  
 
 
5.2.2 Human studies 
 
The first priority in human experimentation is to perform the study described in chapter 3 but with a 
different design. Patients should be randomised to RYGB, BAND, VSG or VLCD and studied 
longitudinally after similar degrees of weight loss. This design will minimise the impact of confounders 
such as pre-operative food preferences and weight loss and allow more cause-effect conclusions to be 
made. A fourth group of obese unoperated controls could be added to provide more information on 
the effects of order on all outcome variables and in particular brain activation.  Previous fMRI study by 
our group has shown that repeated exposure to the food evaluation fMRI paradigm using identical 
pictures tends to reduce activation of the nucleus accumbens and insula cortex, perhaps related to 
habituation with reduced novelty [174]. Indeed there is evidence for a hippocampus-nucleus 
accumbens network in encoding stimulus novelty [656]. The control group will also provide evidence 
for the reliability of food cue functional neuroimaging; such test - retest reliability data are not 
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 available in the published literature. The neuroimaging paradigm and its analysis could be used as part 
of a larger multicentre study that will have more power to detect significant differences between and 
within the groups. More importantly the participants will need to be further phenotyped in terms of 
their genetic make-up, psychological and eating behaviour profiles and these could be correlated with 
the brain responses and overall food preferences observed after surgery. This will not only provide 
mechanistic information on the actions of surgery but also allow the use of the appropriate surgical 
procedure for the appropriate patient. Participant should also be studied at various time points, 
including years, after the surgery in order to assess the longevity of the effects of surgery on food 
preferences but also develop early predictive markers (behavioural, neuroimaging or metabolic ) of 
long term weight loss.   
 
Resting state imaging (in which participants are not performing a particular task) could also be used as 
it may have a better signal-to-noise ratio compared to paradigms that use picture or auditory cues and 
will allow removal of the need for food cues which may vary in their salience and preference between 
individuals [657]. These data have been collected from my fMRI study and will be analysed shortly. 
Analyses of connectivity within the brain reward system may also provide further mechanistic 
evidence of the organisation of the system and how bariatric surgery may affect the cross-talk 
between its regions [658].   
 
In terms of more mechanistic studies and similar to the animal studies, brain reward responses could 
be studied through the use of neuroimaging in larger studies comparing activation in the fed vs. fasted 
states after RYGB. Additionally, RYGB patients could be studied after the administration of GLP-1, PYY, 
ghrelin and bile acid/fibroblast growth factor receptor antagonists or octreotide vs. placebo. Such 
experimentation may prove challenging as such receptor antagonists are not readily or widely 
available (the only available compound for human use is the GLP-1 antagonist exendin (9-39)) and 
octreotide is not specific as it inhibits the release of numerous hormones [659].  The contribution of 
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 altered jejunal nutrient sensing in food preferences after RYGB could be assessed through behavioural 
and neuroimaging paradigms in patients that have undergone the Endobarrier® procedure for weight 
loss.   
 
In order to dissect the role of taste in the food preferences observed after RYGB, brain reward 
responses could be assessed in neuroimaging paradigms in which fatty/sweet tastants of different 
concentrations (e.g. milkshakes) are delivered directly on their tongue through an electronic stimulus 
delivery device [340]. The amount of milkshake infused is kept to a minimum in order to limit the 
contribution of post-ingestive signalling on brain activation. Both the anticipation and actual 
consumption (appetitive vs. consummatory responses) could be added in the same paradigm, as has 
been done successfully by other groups [340, 342].  
 
Further behavioural evidence on the effects of RYGB on taste function could be obtained from 
consummatory paradigms in humans in which patients are not asked to rate their evaluation of 
tastants but they are filmed when these are delivered directly in their oral cavity. This exact paradigm 
has been used for decades in animal psychophysics research; in the taste reactivity test a fluid tastant 
is delivered to the animal’s mouth through an implanted cannula and its facial responses are 
videotaped and then analysed second by second by a trained observer [542]. These facial reactions 
can be classified into either ingestive/”positive” (i.e. tongue protrusions, paw licking in res ponse to 
sweet) or aversive/”negative” (i.e. gapes, chin rubs in response to bitter). The same methodology has 
been applied successfully to human newborns  [660]. It remains to be seen whether this direct 
measurement approach is valid and reliable in adult humans and how difficult it is to evaluate the 
contribution of cognitive, emotional and restraint cortical inputs to the observed behaviour.  
 
Rates of salivation to fat and sweet tastants have yet to be assessed after bariatric surgery. The 
decrease in saliva production is a measure of sensory specific satiety to a particular stimulus and 
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 obese patients have been shown to habituate more slowly to fat/sweet tastants (i.e. reach sensory 
specific satiety later) than normal weight controls [399, 400]. It is possible that RYGB reverses this 
abnormality and restores the rates of salivation to normal.  
 
Additional behavioural evidence for the operated and un-operated groups could in theory be provided 
by more elaborate paradigms. Rather than capturing snapshots of participants in a particular point in 
time and in the context of the “sterility” of the laboratory, their behaviour could be studied through 
an admission to a research unit which has hotel-like facilities. Observations on general and eating 
behaviour could then be collected over a number of days. Even though the effects of social desirability 
bias can never be completely abolished, its magnitude should hopefully be reduced with time and 
after a few days the information collected should be as close and valid to the real-life behaviour of the 
participants as possible. 
 
From a clinical and academic point of view it is also important to investigate the effects of surgery on 
non-food reward. Clinically this is of great importance as there are a number of studies that have 
shown that some patients after RYGB develop new “addictions” for example to alcohol, recreational 
drug use, sex and gambling [597]. The reward obtained by these activities is also encoded in the same 
brain reward systems as food [661]. It is therefore possible that for the majority of patients, the 
reward value of eating and non-eating activities is reduced after RYGB, but that for a small minority 
with more “addictive” personalities, the addiction is converted from food to alcohol for example. 
Understanding these mechanisms may not only help clinicians manage this challenging group of 
patients pre- and post-operatively, but may also lead to the extended use of pharmacological agents 
that reduce food reward (and body weight) in the context of non-food addiction [662].   
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 5.3.3 Final words 
 
Bariatric surgery is still in the centre of clinical controversy and is attracting a heated debate in a way 
that very few other procedures have in the history of surgery. Independent of the side of the debate 
on which someone stands, bariatric surgery has proven to be a superb research tool.  Through its 
impressive efficacy, it has created new scientific questions and clues into the pathogenesis of obesity 
itself. What is intriguing and unusual is that we are now increasingly realising that the clinical effects of 
these surgical procedures are mediated by very different mechanisms from those in the minds of the 
surgeons that originally designed them. The field has now attracted the considerable interest of a wide 
range of clinical and basic science researchers, as the elucidation of the altered physiology after 
surgery may allow its mimicry through safer non-surgical means. The clinical use of gut hormone 
analogues, vagal stimulators and the endoluminal duodeno-jejunal bypass liner, are good examples of 
such therapies. Thus, the “medical bypass” may not be as far away as we thought in the beginning of 
this century.   
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THIS INFORMATION SHEET IS VALID FOR USE UNTIL: 1 October 2011 
 
INFORMATION SHEET FOR RESEARCH PARTICIPANTS 
 
You will be given a copy of this Information Sheet and a signed copy of your consent form to 
keep, should you decide to participate in the study. 
 
STUDY TITLE: OBESITY SURGERY AND FUNCTIONAL MAGNETIC RESONANCE 
IMAGING OF APPETITE.  
 
You are being invited to take part in a research study. Before you decide, it is important for you to 
understand why the research is being done and what it will involve. Please take time to read the 
following information carefully and discuss it with friends, relatives and your GP if you wish. Ask us if 
there is anything that is not clear or if you would like more information. Take time to decide whether 
or not you wish to take part. 
 
If you do decide to take part, please let us know beforehand if you have been involved in any other 
study during the last year. You are free to withdraw at any time without explanation. Thank you for 
reading this. 
 
WHAT IS THE PURPOSE OF THE STUDY? 
 
We do not understand fully why people with obesity overeat. Obesity surgery reduces appetite, 
which leads to weight loss. How this happens is not fully understood. 
 
We do know that restriction of stomach size after surgery may play some part, but it is likely that 
changes in hormones released from the gut play a role by acting on the appetite and reward 
centers in the brain. 
 
This study aims to see how obesity alters the brain’s response to food and how obesity surgery 
changes this by comparing people who have undergone obesity surgery and those that have not. 
Participants will undergo brain scans while looking at pictures of food, after fasting overnight or after 
having eaten. They will also be injected under the skin either with Octreotide, a hormone that 
temporarily reduces the release of hormones from your gut, or with water as a dummy injection for 
comparison. 
 
This study is an important step towards finding out how appetite is altered in obesity and how 
obesity surgery works. This will help with the development of new treatments for obesity, which are 
as successful as obesity surgery. 
 
 
WHY HAVE I BEEN CHOSEN? 
 
We are recruiting the following groups of people:  
1. Healthy individuals who are not obese   
2. People who are obese but have not had surgery.   
3. People who have had obesity surgery, either gastric banding or gastric bypass surgery.  
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 You should not take part in this study if you: 
 
1) Have any illnesses which we feel make you unsuitable   
2) If you take any medication which we feel make you unsuitable   
3) If you are pregnant or breast feeding   
4) If you have donated blood in the last three months  
 
It is important that you should not become pregnant during the course of the study or for one 
month after. It is therefore important that you have adequate and reliable contraception during this 
period. 
 
DO I HAVE TO TAKE PART?  
 
It is up to you to decide whether or not to take part. If you do decide to take part you will be given this 
information sheet to keep and be asked to sign a consent form. If you decide to take part you are still 
free to withdraw at any time and without giving a reason. 
 
WHAT WILL HAPPEN TO ME IF I TAKE PART? 
 
Screening visit 
 
If you agree to take part in this study, you will first be examined by one of the research doctors and 
have a number of blood tests after an overnight fast (no more than 30ml blood equivalent to around 2 
tablespoons), a pregnancy test (if female) and a heart recording (ECG) to ensure you are fit and 
healthy enough to take part. 
 
You will be asked to complete some questionnaires about your eating habits, personality and mood. 
This information will be related to the results from your brain scans. Individual diffe rences in these 
factors between people have been shown to influence appetite and how the brain responds to 
looking at pictures, such as food. You will also be asked to look at some pictures of food and say 
which ones you prefer to eat. It will take about 30-40 minutes to complete these questionnaires. A 
researcher will be available to assist you with this if necessary. 
 
You will also be asked to taste the meal that will be used later on in the study. We will also ask you to 
keep a record of all food and drink consumed for three days. 
 
You will also have your height and weight taken and your body fat content measured using a ‘bio -
electrical impedance’ machine. This is a painless safe method that involves measuring the electrical 
current from your body and takes only about 5 minutes. As long as these medical checks are 
satisfactory and you are still happy to participate, you will then be asked to attend for the first of up to 
4 study visits. 
 
With your permission, we will also take a sample of DNA from blood or saliva to look for changes in 
your genes that may be involved in the how the body controls appetite and body weight and 
responds to gut hormones. This will enable us to see what effect such changes may have on your 
brain scans. 
 
Number of visits 
 
You will be asked to attend the Clinical Investigation Ward at Hammersmith Hospital as an outpatient 
on up to another 4 occasions, following your screening visit, each separated by at least 3 days. 
These will be completed on dates convenient to you and the investigators, but should usually be 
completed within a maximum of 3 months. 
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 Study design  
 
On each study visit you will be asked to have nothing to eat and only water to drink from 8 pm on the 
evening before the study. You will be asked to attend in the morning and each visit will last around 5 
hours. You will be asked to abstain from alcohol and strenuous exercise for 24 hours before the visit. 
We will also ask you to keep a record of all food and drink consumed for one day before the visit, the 
day of the visit and for one day afterwards. You will also have a pregnancy test on each visit (if 
female), and have your height, weight and body fat content measured. You will also complete 
questionnaires about your mood on each study visit. These questionnaires should take about 5 
minutes to complete. 
 
On each study day you will have a small plastic cannula tube inserted into a vein in one arm. A vein 
is the type of blood vessel commonly used for taking blood samples. You may feel some discomfort 
whilst the cannula is being inserted. After the cannula tube has been inserted this will be used to take 
blood samples. 
 
On each of the visits, you will then receive either a saline (salt water) or Octreotide injection under the 
skin on the thigh or tummy. You may fell some slight discomfort at the time of the injection. You will 
also receive at the same time another injection under the skin on the thigh or tummy of either saline 
(salt water) or a small dose of insulin. The insulin injection is to prevent your sugar level going too 
high after the Octreotide injection. 
 
What is Octreotide? 
 
Octreotide is a man-made hormone that is very similar to a substance that occurs naturally in the 
body, called somatostatin. It temporarily reduces the release of some hormones in the body includ ing 
those from the gut that reduce appetite. We have used this substance in other studies to investigate 
appetite without problems. Only very mild side effects are occasionally seen, such as abdominal 
discomfort and bloating, loose stools or nausea, increase in blood sugar level after eating. These 
effects of Octreotide are not expected to last longer than 6 hours. Octreotide is widely prescribed as 
a medicine for certain intestinal conditions. 
 
What is saline? 
 
The saline is a placebo or dummy treatment that is commonly used in studies of this nature. It 
contains no active ingredient and is not expected to alter your appetite. The saline treatment will 
serve as a baseline measurement to which all active treatments are compared. This is a randomised, 
double-blind trial. This means that neither you, nor your research doctors, will know what substance 
you are being given on some visits (although, if your doctor needs to find out, he/she can do so). 
Throughout the study, we will monitor your heart rate and blood pressure. 
 
Breakfast 
 
You will either be given a moderate size breakfast to eat over 20 minutes, or continue fasting. 
 
Paracetamol 
 
You will be given a solution of paracetamol in water with breakfast. The levels of paracetamol in your 
blood will then be measured. This will allow us to have an accurate measure of the rate at which your 
stomach is emptying. We do not expect that you will suffer any side effects from this. You should not 
take any further paracetamol at home for at least 12 hours after the study visit is over. 
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 Blood tests 
 
Blood samples will be taken from the cannula in your arm. The total amount of blood taken on each 
study visit will not be more than 150 ml (about 10 tablespoonfuls). The total amount of blood taken 
over all your visits will not be more than 630 ml (a little less than a pint and the same amount taken 
when making a single donation of blood for blood transfusion). During blood testing, you will be 
seated or lying on a couch, and can read or watch television. 
 
Visual analogue scales 
 
Over the morning, we will regularly ask you to score how you are feeling (e.g. rating your hunger) 
by placing a mark on a line called a visual analogue scale. 
 
Scanning 
 
You will have magnetic resonance imaging (MRI) brain scans by lying in an MRI scanner for up to 1 
hour. This will take place in the Robert Steiner Magnetic Resonance Imaging Unit, nearby the Clinical 
Investigation Ward. This will enable us to look at the structure and activity of your brain. 
 
During the functional brain scans we look at the activity of the brain at rest, while you look at a 
variety of pictures on a screen, and perform simple tasks like viewing a flashing light, pressing a 
button, reading, listening, speaking, recalling, thinking about words or numbers. You will be aske d to 
make responses to the pictures while in the scanner using a keypad. You will have the opportunity 
to practice lying in the scanner while looking at various pictures on the screen. This will enable us to 
ensure that you can follow the instructions and lie still while in the scanner. While in the scanner 
your heart and breathing rate and finger skin sweat production may be monitored. 
 
Meal 
 
At the end of the brain scan, you will be taken back to the Clinical Investigation Ward. At this stage, 
you will be presented with a meal and you will be asked to eat as much as you want of the meal until 
you feel comfortably full. 
 
We will continue to monitor you for another 2 hour after the scan, after which you are free to go. At 
the end of the final visit you will also be asked to score how much you usually like to eat the 
foodstuffs shown in the food pictures using a visual analogue scale. 
 
WHAT DO I HAVE TO DO? 
 
The only restrictions on your lifestyle are that you will be asked to have nothing to eat and only wate r 
to drink from 8pm on the night before the meal days. You will need to keep a record of all food and 
drinks consumed in the day before every study and for a day afterwards. For twenty -four hours 
before each study meal you will be asked to refrain from taking strenuous exercise and drinking 
alcohol. 
 
Female volunteers should have adequate contraception for the period of the study and for one month 
afterwards. Pregnancy tests will be carried out to confirm that women of child bearing age are not 
pregnant on the morning before each study day. 
 
WHAT IS THE DRUG THAT IS BEING USED? 
 
Octreotide is a synthetic copy of the naturally occurring hormone found in the blood, called 
somatostatin. Octreotide has been used acutely in several other research studies in our d epartment 
and worldwide, in men and women, without harmful effects. It is also widely prescribed to patients 
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 with intestinal problems for long term use. The dose of Octreotide that you will be given is small and 
will decrease the levels of gut hormones in your body. 
 
Insulin is a naturally occurring hormone found in the blood that regulates your blood sugar and is 
used to treat people with sugar diabetes. When we give you an injection of Octreotide you will also 
have a single injection of insulin since the Octreotide may temporarily suppress you body’s own 
production of insulin which may cause your sugar to rise for a few hours. The injection of insulin will 
prevent the sugar rising too much. Your sugar levels will be monitored. 
 
 
WHAT ARE THE SIDE EFFECTS OF TAKING PART? 
 
Some people experience mild abdominal discomfort, loose stools, nausea and flatulence after having 
Octreotide, but these symptoms are usually mild and settle within a few hours. If your sugar levels 
rise after the Octreotide injection you may feel thirsty, pass more urine than usual, or feel a little 
sleepy, but this will settle within a few hours and you will be able to drink water if you wish.  
 
From our previous studies we do not expect any significant side effects, but the unexpected can 
occur. During the study, at least one experienced doctor will monitor you closely. If you suffer from 
any ill effects during the study you should report them to the doctors monitoring you immediately. If 
you suffer from any ill effects afterwards you should report them to one of the research doctors at the 
contact number below or when you next see them. You may ask for the study to stop at any time 
without giving a reason. If any unexpected side effects occur, the study will be stopped. 
 
MRI is a powerful, diagnostic body scanning technique, which is used in hospitals worldwide to 
create images of the inside of the body. MRI has been used safely for several decades and has no 
known side-effects. Each scan is directed to the specific requirements of your referring doctor or to 
research study in which you are taking part. 
 
 
WHAT ARE THE POSSIBLE DISADVANTAGES AND RISKS OF TAKING PART?  
 
Octreotide has been administered in several studies by our laboratory and therefore we do not 
anticipate any problems with the injection. Insertion of the cannula (drip) into your arm on each of the 
study days may cause minor discomfort or superficial bruising, as may the injection of saline or 
Octreotide under the skin. 
 
Magnetic resonance imaging (MRI) is a procedure that allows doctors to look inside the body by 
using a scanner that sends out a strong magnetic field and radio waves. MRI does not use X-rays. 
This procedure is used routinely for medical care and is very safe for most people, but you will be 
monitored during the entire MRI scan in case any problems occur. The risks of having an MRI scan 
are: 
 
• The MRI scanner contains a very strong magnet. Therefore, you will not be able to have the MRI 
if you have any type of metal implanted in your body, for example, any pacing device (such as a 
heart pacer), any metal in your eyes, or certain types of heart valves or brain aneurysm clips. 
Someone will ask you questions about this before you have the MRI. If you have previously 
undergone gastric bypass or banding surgery, then the devices used in your surgery will have 
been approved as safe for MRI.  
 
• There is not much room inside the MRI scanner. You may be uncomfortable if you do not like to 
be in close spaces (“claustrophobia”). During the procedure, you will be able to talk to a nd hear 
the MRI staff through a speaker and earphone system, and, in the event of an emergency, you  
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 can tell them to stop the scan. You will be closely monitored and repeatedly checked on to make sure 
you are as comfortable as possible. While your head is in the scanner, we will support it, so you can’t 
move it. If this upsets you, you will be able to signal and speak to the investigator and stop the scan 
through the use of a radio system and a signaling button. You will have the opportunity during the 
first MRI scan to ensure that you can tolerate having the scan before the next scans are done. 
 
• The MRI produces a “hammering noise”. You will wear earplugs and headphones to prevent 
discomfort or damage to hearing. The headphones will also allow you to be able to hear us talk to 
you.  
 
• You will be fully awake during the MRI scan and will not be sedated at any time. We will make 
every effort to ensure your comfort during this experiment.  
 
It should be noted that the MRI brain scan cannot be viewed as a comprehensive health screening 
procedure. However, vary rarely, unexpected information can be detected which may warrant further 
investigation. In this event, you will be informed and a report will be sent to your GP, who will arrange 
further tests and coordinate your further care. In the rare event that we find a significant abnormality 
on your structural brain scan on the first visit this may exclude you from continuing with the rest of the 
study. 
 
It is possible that if the treatment is given to a pregnant woman it will harm the unborn child. Pregnant 
women must therefore not take part in this study; neither should women who plan to become 
pregnant during the study. Women who are at risk of pregnancy will be asked to have a pregnancy 
test before taking part, to exclude the possibility of pregnancy. Women who could become pregnant 
must use an effective contraceptive during the course of this study. Any woman who finds that she 
has become pregnant while taking part in the study should immediately tell her research doctor. 
 
 
 
WHAT ARE THE POSSIBLE BENEFITS OF TAKING PART?  
 
The information that we get from this study will help us to better understand appetite regulation and 
may help us to better treat future patients who suffer from being overweight or obese. 
 
If any of the screening questionnaires or blood tests reveal any medical problems (e.g. depression, 
diabetes, high cholesterol, thyroid, kidney or liver problems), your GP will be informed so that they 
can coordinate your further care, arrange any further tests, and refer you on to Hospital Doctors if 
necessary. 
 
WHAT IF NEW INFORMATION BECOMES AVAILABLE?  
 
Sometimes during the course of a research project, new information becomes available about the 
treatment that is being studied. If this happens, your research doctor will tell you about it and discuss 
with you whether you want to continue in the study. If you decide to continue in the study you will be 
asked to sign an updated consent form. Also, on receiving new information your research doctor 
might consider it to be in your best interests to withdraw you from the study. 
 
 
WHAT HAPPENS WHEN THE RESEARCH STUDY STOPS?  
 
Once the study has finished, the results of the study can be made available to you and/or your GP 
should you wish. If you have any problems immediately following the study, then you should 
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 contact one of the research doctors on the numbers provided below.  
 
WHAT IF SOMETHING GOES WRONG? 
 
Imperial College London holds insurance policies which apply to this study. If you experience harm 
or injury as a result of taking part in this study, you may be eligible to claim compensation without 
having to prove that Imperial College is at fault. This does not affect your lega l rights to seek 
compensation. 
 
If you are harmed due to someone’s negligence, then you may have grounds for a legal action. 
Regardless of this, if you wish to complain, or have any concerns about any aspect of the way you 
have been treated during the course of this study then you should immediately inform the 
Investigator Dr. Goldstone (Tel: 020 8383 1029). 
 
WILL MY TAKING PART IN THIS STUDY BE KEPT CONFIDENTIAL?  
 
All information which is collected about you during the course of the research will be kept s trictly 
confidential. Any information about you which leaves the hospital will have your name and address 
removed so that you cannot be recognised from it. 
 
It is a requirement that your GP is informed, with your consent, of your participation in this stud y, at 
the start of the study. 
 
WHAT WILL HAPPEN TO THE RESULTS OF THE RESEARCH STUDY?  
 
The results are likely to be published in the year following the study. Your confidentiality will be 
ensured at all times and you will not be identified in any publication. At the end of the study, the 
results of the study can be made available to you and/or your GP should you wish.  
 
WHO IS ORGANISING AND FUNDING THE RESEARCH? 
 
This study is being organised and funded by the MRC Clinical Sciences Centre and the Department 
of Investigative Medicine, Imperial College London. 
 
PAYMENT 
 
You will receive a fixed payment to cover expenses including travel costs. This sum of £20 for the 
screening visit and £50 for each study visit (total £220) will be paid when you have completed  your 
visits. 
 
WHO HAS REVIEWED THE STUDY? 
 
This study has been reviewed by the Hammersmith Hospitals Research Ethics Committee (Ref 
08/H0707/139). 
 
CONTACT FOR FURTHER INFORMATION 
 
If you experience any problems during the study, you may withdraw at any s tage. The doctors 
involved in the study, Dr Scholtz and Dr. Goldstone, will be available by telephone during working 
hours (020 8383 1029 or via the paging system). The hospital switchboard (020 8383 1000) has 
home and mobile phone numbers for all the doctors involved in the study and can contact them at 
any time outside normal working hours. 
 
If you agree to take part in the trial, you will also be given the mobile phone numbers of the doctors. 
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 DUTCH EATING QUESTIONNAIRE 
 
Volunteer Initials:  Date: 
Volunteer No.   
 
Please place an () in the box which applies best to each of the numbered statements. All of 
the results will be strictly confidential. Most of the questions directly relate to food or eating, 
although other types of questions have been included. Please answer each question carefully. 
Thank you. 
 
1. If you have put on weight, do you eat less than you usually do? 
 
‰ Never ‰ Seldom   ‰ Sometimes   ‰ Often   ‰ Very Often   ‰ Not Relevant 
 
2. Do you try to eat less at mealtimes than you would like to eat?  
‰ Never ‰ Seldom       ‰ Sometimes    ‰ Often        ‰ Very Often 
 
 
3. How often do you refuse food or drink offered because you are concerned about your 
weight? 
‰ Never ‰ Seldom       ‰ Sometimes    ‰ Often        ‰ Very Often 
 
 
4.  Do you watch exactly what you eat? 
 
‰ Never ‰ Seldom       ‰ Sometimes    ‰ Often        ‰ Very Often 
 
 
5.  Do you deliberately eat foods that are slimming? 
 
‰ Never ‰ Seldom       ‰ Sometimes    ‰ Often        ‰ Very Often 
 
 
6.  When you have eaten too much, do you eat less than usual the following days? 
 
‰ Never ‰ Seldom   ‰ Sometimes   ‰ Often   ‰ Very Often   ‰ Not Relevant 
 
 
7. Do you deliberately eat less in order not to become heavier? 
 
‰ Never ‰ Seldom       ‰ Sometimes    ‰ Often        ‰ Very Often 
 
 
8. How often do you try not to eat between meals because you are watching your weight? 
 
‰ Never ‰ Seldom       ‰ Sometimes    ‰ Often        ‰ Very Often 
 
 
9.  How often in the evening do you try not to eat because you are watching your weight? 
 
‰ Never ‰ Seldom       ‰ Sometimes    ‰ Often        ‰ Very Often 
 
 
10. Do you take into account your weight with what you eat? 
 
‰ Never ‰ Seldom       ‰ Sometimes    ‰ Often        ‰ Very Often 
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 11. Do you have the desire to eat when you are irritated? 
 
‰ Never ‰ Seldom   ‰ Sometimes   ‰ Often   ‰ Very Often   ‰ Not Relevant 
 
 
12. Do you have a desire to eat when you have nothing to do? 
 
‰ Never ‰ Seldom   ‰ Sometimes   ‰ Often   ‰ Very Often   ‰ Not Relevant 
 
 
13. Do you have a desire to eat when you are depressed or discouraged? 
 
‰ Never ‰ Seldom   ‰ Sometimes   ‰ Often   ‰ Very Often   ‰ Not Relevant 
 
 
14. Do you have a desire to eat when you are feeling lonely? 
 
‰ Never ‰ Seldom   ‰ Sometimes   ‰ Often   ‰ Very Often   ‰ Not Relevant 
 
 
15. Do you have a desire to eat when somebody lets you down?  
‰ Never ‰ Seldom   ‰ Sometimes   ‰ Often   ‰ Very Often   ‰ Not Relevant 
 
 
16. Do you have a desire to eat when you are cross?  
‰ Never ‰ Seldom   ‰ Sometimes   ‰ Often   ‰ Very Often   ‰ Not Relevant 
 
 
17. Do you have a desire to eat when you are approaching something unpleasant to happen? 
 
‰ Never ‰ Seldom       ‰ Sometimes    ‰ Often        ‰ Very Often 
 
 
18. Do you get the desire to eat when you are anxious, worried or tense? 
 
‰ Never ‰ Seldom       ‰ Sometimes    ‰ Often        ‰ Very Often 
 
 
19. Do you have a desire to eat when things are going against you or when things have gone wrong? 
 
‰ Never ‰ Seldom       ‰ Sometimes    ‰ Often        ‰ Very Often 
 
 
20. Do you have a desire to eat when you are frightened? 
 
‰ Never ‰ Seldom   ‰ Sometimes   ‰ Often   ‰ Very Often   ‰ Not Relevant 
 
 
21. Do you have a desire to eat when you are disappointed? 
 
‰ Never ‰ Seldom   ‰ Sometimes   ‰ Often   ‰ Very Often   ‰ Not Relevant 
 
 
22. Do you have a desire to eat when you are bore or restless? 
 
‰ Never ‰ Seldom   ‰ Sometimes   ‰ Often   ‰ Very Often   ‰ Not Relevant 
 
 
23. Do you have a desire to eat when you are emotionally upset? 
 
‰ Never ‰ Seldom   ‰ Sometimes   ‰ Often   ‰ Very Often   ‰ Not Relevant 
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 24. If food tastes good to you, do you eat more than usual? 
 
‰ Never ‰ Seldom       ‰ Sometimes    ‰ Often        ‰ Very Often 
 
 
25. If food smells and looks good do you eat more than usual? 
 
‰ Never ‰ Seldom       ‰ Sometimes    ‰ Often        ‰ Very Often 
 
 
26. If you see or smell something delicious, do you have the desire to eat it? 
 
‰ Never ‰ Seldom       ‰ Sometimes    ‰ Often        ‰ Very Often 
 
 
27. If you have something delicious to e at, do you eat it straight away? 
 
‰ Never ‰ Seldom       ‰ Sometimes    ‰ Often        ‰ Very Often 
 
 
28. If you walk past the baker do you have the desire to buy something delicious?  
‰ Never ‰ Seldom       ‰ Sometimes    ‰ Often        ‰ Very Often 
 
 
29. If you walk past a snackbar or a café, do you have the desire to buy something delicious? 
 
‰ Never ‰ Seldom       ‰ Sometimes    ‰ Often        ‰ Very Often 
 
 
30. If you see others eating, do you also have the desire to eat? 
 
‰ Never ‰ Seldom       ‰ Sometimes    ‰ Often        ‰ Very Often 
 
 
31. Can you resist eating delicious foods? 
 
‰ Never ‰ Seldom       ‰ Sometimes    ‰ Often        ‰ Very Often 
 
 
32. Do you eat more than usual, when you see others eating? 
 
‰ Never ‰ Seldom       ‰ Sometimes    ‰ Often        ‰ Very Often 
 
 
33. When preparing a meal are you inclined to eat something? 
 
‰ Never ‰ Seldom       ‰ Sometimes    ‰ Often        ‰ Very Often 
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 PANAS Scale 
 
 
Initials: ID: Date: 
 
This scale consists of a number of words that describe different feelings and emotions. 
Read each item and then mark [x] the appropriate answer in the space next to the word. 
Indicate to what extent you have felt this way on average during the past week. 
Use the following scale to record your answer: 
 
No. Feeling 
very slightly  
a little moderately quite a bit extremely 
 
or not at all        
 
1 interested      
 
       
 
2 distressed      
 
       
 
3 excited      
 
       
 
4 upset      
 
       
 
5 strong      
 
       
 
6 guilty      
 
       
 
7 scared      
 
       
 
8 hostile      
 
       
 
9 enthusiastic      
 
       
 
10 proud      
 
       
 
11 irritable      
 
       
 
12 alert      
 
       
 
13 ashamed      
 
       
 
14 inspired      
 
       
 
15 nervous      
 
       
 
16 determined      
 
       
 
17 attentive      
 
       
 
18 jittery      
 
       
 
19 active      
 
       
 
20 afraid      
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 Barratt Impulsivity Scale 
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 Initials: ID #: Date: 
 
EPQ-R 
 
Instructions: 
 
Please answer each question by putting a circle around the 'YES' or the 'NO' following the question.  
 
There are no right or wrong answers, and no trick questions.  
 
Work quickly and do not think too long about the exact meaning of the questions.  
 
 
 PLEASE REMEMBER TO ANSWER EACH QUESTION  
1. Do you have many different hobbies? …………………………………………...…………………………………. YES  NO  
2. Do you stop to think things over before doing anything? …………………………………………………. YES  NO  
3. Does your mood often go up and down? ……………………………………………………………………………. YES NO  
4. Have you ever taken the praise for something you knew someone else had really done?. YES  NO 
5. Do you take much notice of what people think? ………………………………………………………..……… YES NO  
6. Are you a talkative person? ……………………………………………………………………………..…………………. YES NO  
7. Would being in debt worry you? ……………………………………………………………………………..….……… YES  NO  
8. Do you ever feel ‘just miserable' for no reason? ……………………………………………………….………. YES  NO  
9. Do you give money to charities? ……………………………………………………………………………..…………. YES NO  
10.  Were you ever greedy by helping yourself to more than your share of anything? ………..… YES  NO  
11.  Are you rather lively? ……………………………………………………………………………………………………….…. YES  NO  
12.  Would it upset you a lot to see a child or animal suffer? ………………………………………………..… YES NO  
13.  Do you often worry about things you should not have done or said? …………………………….… YES NO  
14.  Do you dislike people who don’t know how to behave themselves? …………………………………. YES NO  
15.  lf you say you will do something , do you always keep your promise no matter how   
 inconvenient it might be? ……………………………………………………………………………………………………. YES NO  
16.  Can you usually let yourself go and enjoy yourself at a lively party? ………………………………. YES  NO 
17.  Are you an irritable person? …………………………………………………………………………………………....…. YES NO  
18.  Should people always respect the law? ………………………………………………………………………………. YES NO  
19.  Have you ever blamed someone for doing something you knew was really your fault? ….. YES NO 
20.  Do you enjoy meeting new people? ……………………………………………………………………………..…….. YES NO  
21.  Are good manners very important? …………………………………………………………………………………….. YES NO  
22.  Are your feelings easily hurt? ……………………………………………………………………………..………………. YES NO  
23.  Are all your habits good and desirable ones? ……………………………………………………………………… YES NO  
24.  Do you tend to keep in the background on social occasions? ……………………………………………. YES NO  
25.  Would you take drugs which may have strange or dangerous effects? …………………………….. YES  NO  
26.  Do you often feel ‘fed-up’? ……………………………………………………………………………..…………………… YES NO  
27.  Have you ever taken anything (even a pin or button) that belonged to someone else? …. YES  NO 
28.  Do you like going out a lot? ……………………………………………………………………………..…………………. YES  NO  
29.  Do you prefer to go your own way rather than act by the rules? ……………………………………… YES NO 
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30. Do you enjoy hurting people you love? ………………………………………………………………………………. YES NO  
31. Are you often troubled about feelings of guilt? ………………………………………..………………………… YES  NO  
32. Do you sometimes talk about things you know nothing about? ………………………………………… YES NO  
33. Do you prefer reading to meeting people? …………………………………………………………………………. YES  NO  
34. Do you have enemies who want to harm you? ………………………………………………………………..… YES  NO 
35. Would you call yourself a nervous person? …………………………………………………………………………. YES  NO  
36. Do you have many friends? ……………………………………………………………………………………………….… YES NO  
37. Do you enjoy practical jokes that can sometimes really hurt people? ………………………………. YES  NO  
38. Are you a worrier? ………………………………………………………………………………………………………..…..… YES NO  
39. As a child did you do us you were told immediately and without grumbling? …………………… YES  NO  
40. Would you call yourself happy-go- lucky? ……………………………………………………………………………. YES NO  
41. Do good manners and cleanliness matter much to you? …………………………………………………… YES  NO  
42. Have you often gone against your parents' wishes? …………………………………………………………… YES  NO  
43. Do you worry about awful things that might happen? ……………………………………………………….. YES  NO  
44. Have you ever broken or lost something belonging to someone else? ……………………………… YES  NO 
45. Do you usually take the initiative in making new friends? …………………………………………………. YES NO  
46. Would you call yourself tense or 'highly-strung’? ….………………………………………………………..… YES NO  
47. Are you mostly quiet when you are with other people? …………………………………………………….. YES NO  
48. Do you think marriage is old-fashioned and should be done away with? …………………………. YES  NO 
49. Do you sometimes boast a little? ……………………………………………………………………………………..… YES NO  
50. Are you more easy-going about right and wrong than most people? ………………………………… YES NO  
51. Can you easily get some life into a rather dull party? ………………………………………………………… YES  NO  
52. Do you worry about your health? ……………………………………………………………………………..………… YES NO  
53. Have you ever said anything bad or nasty about anyone? ………………………………………………… YES NO  
54. Do you enjoy co-operating with others? …………………………………………………………………………….. YES NO  
55. Do you like telling jokes and funny stories to your friends? ………………………………………………. YES NO 
56. Do most things taste the same to you? ………………………………………………………………………………. YES  NO  
57. As a child were you ever cheeky to your parents? ……………………………………………………………… YES NO  
58. Do you like mixing with people? ……………………………………………………………………………..………….. YES NO  
59. Does it worry you if you know there are mistakes in your work? ……………………………………… YES  NO  
60. Do you suffer from sleeplessness? …………………………………………………………………………………….… YES  NO  
61. Have people said that you sometimes act too rashly? …………………………………………………….… YES NO  
62. Do you always wash before a meal? …………………………………………………………………………………… YES  NO  
63. Do you nearly always have a 'ready answer' when people talk to you? ………………………...… YES NO  
64. Do you like to arrive at appointments in plenty of t ime? …………………………………………………… YES NO  
65. Have you often felt listless and tired for no reason? ………………………………………………………….. YES  NO  
66. Have you ever cheated at a game? ……………………………………………………………………………..…….. YES  NO  
67. Do you like doing things in which you have to act quickly? ………………………………………………. YES NO  
68. Is (or was) your mother a good woman? …………………………………………………………………………… YES  NO  
EPQ-R 08-H0707-139  
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69.  Do you often make decisions on the spur of the moment? ………………………………………………… YES NO  
70.  Do you often feel life is very dull? …………………………………………………………………………………….… YES  NO  
71.  Have you ever taken advantage of someone? ………………………………………………………………..… YES  NO  
72.  Do you often take on more activities than you have time for? …………………………………………. YES  NO  
73.  Are there several people who keep trying to avoid you? …………………………………………………… YES  NO  
74.  Do you worry a lot about your looks? ……………………………………………………………………………..…. YES NO  
75.  Do you think people spend too much time safeguarding their future with savings   
 and insurance? ……………………………………………………………………………..……………………………………… YES NO  
76.  Have you ever wished that you were dead? ………………………………………………………………………. YES NO  
77.  Would you dodge paying taxes if you were sure you could never be found out? …………….. YES NO  
78.  Clan you get a party going? ……………………………………………………………………………..…………………. YES  NO  
79.  Do you try not to be rude to people? ……………………………………………………………………………..….. YES  NO  
80.  Do you worry too long after an embarrassing experience? ……………………………………………….. YES  NO  
81.  Do you generally 'look before you leap'? ……………………………………………………………………………. YES NO  
82.  Have you ever insisted on having your own way? ……………………………………………………………… YES  NO  
83.  Do you suffer from 'nerves'? ……………………………………………………………………………..……………….. YES NO  
84.  Do you often feel lonely? ……………………………………………………………………………..……………………… YES  NO  
85.  Can you on the whole trust people to tell the truth? …………………………………………………………. YES NO  
86.  Do you always practice what you preach? ………………………………………………………………………….. YES NO  
87.  Are you easily hurt when people find fault with you or the work you do? ………………………… YES NO  
88.  Is it better to follow society's rules than go your own way? ……………………………………………… YES  NO  
89.  Have you ever been late for an appointment or work? ……………………………………………………… YES NO  
90.  Do you like plenty of bustle and excitement around you? ……………………………………………...… YES  NO  
91.  Would you like other people to be afraid of you? ……….…………………………………………………..… YES NO  
92.  Are you sometimes bubbling over with energy and sometimes very sluggish? …………………  YES NO 
93.  Do you sometimes put off until tomorrow what you ought to do today? ……………………….… YES  NO 
94.  Do other people think of you as being very lively? ……………………………………………………………. YES NO  
95.  Do people tell you a lot of lies? ……………………………………………………………………………..……………. YES NO  
96.  Do you believe one has special duties to one's family? ……………………………………………………… YES NO  
97.  Are you touchy about some things? ……………………………………………………………………………..……. YES NO  
98.  Are you always wiling to admit it when you have made a mistake? …………………………………. YES NO  
99.  Would you feel very sorry for an animal caught in a trap? ……………………………………………….. YES  NO  
100.  When your temper rises, do you find it difficult to control? ………………………………………………. YES  NO  
 
 
PLEASE CHECK THAT YOU HAVE ANSWERED ALL THE QUESTIONS  
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 BIS / BAS Scales  
Each item of this questionnaire is a statement that a person may either agree with or disagree with. For each item, indicate how much you agree 
or disagree with what the item says. Please respond to all the items; do not leave any blank. Choose only one response to each statement and 
mark your answer with a tick. Please be as accurate and honest as you can be. Respond to each item as if it were the only ite m. That is, don't 
worry about being "consistent" in your responses.  
 
N° Question 
Very t rue  Somewhat  Somewhat  Very false  
 
for me  true for me  false for me  for me     
 
1. A person's family is the most important thing in life.     
 
      
 
2. Even if something bad is about to happen to me, I rarely experience fear or nervousness.      
 
       
3. I go out of my way to get things I want.     
 
       
4. When I'm doing well at something I love to keep at it.     
 
       
5. I'm always willing to try something new if I think it will be fun.      
 
       
6. How I dress is important to me.      
 
       
7. When I get something I want, I feel excited and energized.      
 
       
8. Criticism or scolding hurts me quite a bit.     
 
       
9. When I want something I usually go all-out to get it.     
 
       
10. I will often do things for no other reason than that they might be fun.      
 
       
11. It's hard for me to find the time to do things such as get a haircut.     
 
       
12. If I see a chance to get something I want I move on it right away.      
 
       
13. I feel pretty worried or upset when I think or know somebody is angry at me.      
 
       
14. When I see an opportunity for something I like I get excited right away.      
 
       
15. I often act on the spur of the moment.     
 
       
16. If I think something unpleasant is going to happen I usually get pretty "worked up."     
 
      
 
17. I often wonder why people act the way they do.     
 
       
18. When good things happen to me, it affects me strongly.      
 
       
19. I feel worried when I think I have done poorly at something important.     
 
       
20. I crave excitement and new sensations.     
 
      
 
21. When I go after something I use a "no holds barred" approach.     
 
       
22. I have very few fears compared to my friends.      
 
       
23. It would excite me to win a contest.     
 
       
24. I worry about making mistakes.      
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 Dumping Syndrome Questionnaire 
At 3 MONTHS after your surgery, did you have any of the following symptoms 1 HOUR after a meal? 
For each symptom please delete Yes or No, and if Yes then please rate your symptoms as 1-mild, 2-
moderate or 3- severe 
SYMPTOM YES or NO 
(please delete) 
SEVERITY. If Yes,  
please write 1 if mild, 2 if 
moderate or 3 if severe 
 
Shock 
  
Yes             No  
Wanting to lie down 
 
Yes             No  
Breathlessness 
 
Yes             No  
Weakness / exhaustion 
 
Yes             No  
Sleepiness / falling asleep 
 
Yes             No  
Felling your heart beating fast 
 
Yes             No  
Irritability/restlessness 
 
Yes             No  
Dizziness 
 
Yes             No  
Headache 
 
Yes             No  
Sweating / feeling warm / clammy skin 
 
Yes             No  
Nausea (feeling sick)  
 
Yes             No  
Tummy bloating 
 
Yes             No  
Tummy rumbling 
 
Yes             No  
Burping or belching 
 
Yes             No  
Vomiting 
 
Yes             No  
Feeling faint or losing consciousness 
 
Yes             No  
Tummy pain 
 
Yes             No  
Diarrhoea 
 
Yes             No  
Hunger 
 
Yes             No  
Shaking / tremor 
 
Yes             No  
Flushing 
 
Yes             No  
Please list the foods that caused any of the above:  
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 FMRI Study visual analogue scales 
 
Time                  -30  
 
 
HOW HUNGRY DO YOU FEEL RIGHT NOW?  
 
 
 
 NOT AT ALL       EXTREMELY 
 
 
 
 
HOW SICK DO YOU FEEL RIGHT NOW?  
 
     
 
 NOT AT ALL       EXTREMELY 
 
 
 
HOW PLEASANT WOUL D IT BE TO EAT RIGHT NOW?  
 
  
 
 NOT AT ALL       EXTREMELY 
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 Time                  -30  
 
HOW MUCH DO YOU THINK YOU COULD EAT RIGHT NOW?  
 
  
 
 NOTHING       A LARGE AMOUNT 
 
HOW FULL DO YOU FEEL RIGHT NOW?  
 
  
 
 NOT AT ALL       EXTREMELY 
 
HOW STRESSED DO YOU FEEL RIGHT NOW?  
 
 
 
 NOT AT ALL       EXTREMELY 
 
HOW SLEEPY DO YOU FEEL RIGHT NOW?  
 
  
 
 NOT AT ALL       EXTREMELY  
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 3 DAY 
 
STUDY VISIT 
DIETARY RECORD 
 
 
 
NAME: __________________________________________ 
 
 
 
 
ID: _____________________  
 
 
 
 
DATE: _____________________  
 
 
 
 
STUDY VISIT:   1 2 3 4 
 
 
 
This record is designed to obtain accurate information about 
the type and quantity of food that you eat. 
 
Please answer the General Question section and then go on to 
the Food Record. 
 
Please return to : _______________________________ 
 
Robert Steiner MRI Unit Hammersmith 
Hospital Du Cane Road LONDON W12 
0NN 
 
Tel:  020 8383 1029 
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 GENERAL QUESTIONS 
 
 
Which type of bread do you usually eat? 
 
White 
 
Brown/Hovis   
Granary  
Wholemeal  
None 
 
Do you usually buy large or small loaves, sliced or unsliced? 
 
Large  
Small  
Sliced  
Unsliced 
 
If you eat any type of biscuit regularly, please specify which brands? 
 
__________________________________________________________________ 
 
__________________________________________________________________ 
 
__________________________________________________________________ 
 
Which type of milk do you usually use? 
 
Full cream milk (silver top) 
 
Semi-skimmed milk (red striped top)  
Skimmed milk (blue top)  
None 
 
How much milk do you usually use? 
 
1-2 pints daily ½-1 pint  
¼-½ pint None 
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How many tablespoons of milk do you take in tea and coffee? 
 
_____ tablespoons milk in a cup of tea 
 
_____ tablespoons milk in coffee 
 
_____ None. 
 
Which kind of fat do you usually use on bread, crispbreads etc? 
 
Butter  
Margarine  
Low fat spread 
 
Which brand do you usually use? ___________________ 
 
What do you do with the visible fat on your meat?  
 
Eat most of the fat  
Eat as little as possible  
Eat some of the fat  
Don't eat meat 
 
How often do you eat food that is fried?  
 
Daily 
 
1-3 times/week  
4-6 times/week Less than 
once/week 
 
Do you drink alcoholic drinks? 
 
YES  NO 
 
If the answer is Yes, please indicate how many units you drink per week?  
 
1 unit =   ½ pint beer/lager  
1 glass wine,  
1 tot spirit. 
 
_____ units per week.  
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 FOOD RECORD 
 
 
 
Read through these instructions and the example carefully once or twice before 
you start. 
 
We would like you to record, as accurately as possible, what you eat and drink for 3 
days, the day before the study, the day of the study (excluding your study meal) and 
the day after the study. Please also use the first food diary to make sure you have the 
same food at the same time on the evening before the study. 
 
Please just eat what you would normally eat. Do NOT change your eating habits. 
We are NOT assessing the quality of your diet from this food record. 
 
Please record ALL food and drink consumed. Record at the time of eating and NOT 
from memory at the end of the day. Keep this record sheet with you throughout 
theday. 
 
You should include all meals and snacks, plus sweets, drinks etc. When recording 
food eaten at meals, please include any sauces, dressing or extras eg: gravy, salad 
dressing, pickles, as well as the main food. 
If you do not eat a particular meal or snack simply draw a line across the page at 
this point.  
 
Guidelines for describing food & drink:  
 
1. Please give details of method of cooking eg: grilled, boiled, roasted.  
 
2. Give as many details as possible about the type of food you eat:  
 
a) State brand name where applicable  
 
eg: 'Princes' sardines in tomato sauce OR 'Sainsburys' 
half-fat Edam cheese. 
 
b) Name the type of biscuit, cake or cereal 
 
eg: Rich Tea, Madeira, Branflakes. 
 
c) Name the type of cheese, fish or meat 
 
eg: Cheshire cheese, haddock fillet, pork cho
 
Obesity Surgery fMRI study visit food diary 3 day 08-H0707-139  
365
 3. Suggestions for recording quantity of food and drink:  
 
a) For many foods such as vegetables, cereals and some fruit a household 
measure is adequate, state the number of teaspoons (tsp) or tablespoons 
(tbsp) or cups, and whether level, rounded or heaped.  
 
 
 
Level 
 
 
 
 
Rounded 
 
 
 
 
 
Heaped 
 
b) All convenience foods have their weight on the packaging and this can 
be quoted   
eg: 150g carton Ski raspberry yoghurt OR  
½ 15 oz can baked beans.  
 
c) Bread, fruit loaves etc. Indicate the size of the loaf and the thickness of the 
slice   
eg: 1 thick slice granary bread, small loaf. 
 
d) Cheese, fish, meat. When possible, please weigh your portions of these 
foods. Otherwise describe as well as you can.  
 
eg: 2 large thin slices ham OR  
2 small lamb chops (no fat eaten) OR  
Medium fillet of cod grilled with 1 tsp flora OR Cube of cheddar 
cheese the size of a matchbox. 
 
Remember to include everything you eat and drink includ ing snacks and nibbles. 
Please do not change what you normally eat just because you are filling in this 
record - Be Honest! 
 
Look at the example of how to fill in you record - you may find this helpful.  
THANK YOU VERY MUCH FOR YOUR HELP 
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 DIETARY RECORD SHEET – DAY 1 
 
Record ALL food and drink consumed during the day including snacks, nibbles, 
sauces and dressings. 
 
Record method of cooking, type and quantity of food eg: 
6 tbsp boiled wholemeal spaghetti  
2 egg sized roast potatoes. 
 
DAY 1: ______________________  DATE: _____________________________ 
 
MEAL/ QUANTITY  DETAILS OF FOOD & DRINK Leave 
SNACK EATEN   Blank 
    
Early    
Morning:    
    
Breakfast:    
    
During    
Morning:    
    
Midday:    
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DAY 1: ______________________ DATE:______________________________ 
 
MEAL/ QUANTITY  DETAILS OF FOOD & DRINK Leave 
SNACK EATEN   Blank 
    
During    
Afternoon:    
    
Evening    
Meal:    
Please eat    
supper    
at 8pm    
    
During No food or drink after   
Evening: supper other than water.   
    
Bedtime    
Snack:    
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Imperial Weight Centre 
 Charing Cross Hospital, 
London W6 8RF 
Tel 020 8383 3242 
Fax 020 8383 3142 
 
Information Sheet for Patient Research Participants  
(Version 3, 16 March 2011) 
 
 
You will be given a copy of this Information Sheet and a signed copy of your consent form to keep, should 
you decide to participate in the study. 
 
 
Study title: Investigation of the effects of bariatric surgery on taste reward in humans  
 
You are being invited to take part in a research study. Before you decide it is important for you to 
understand why the research is being done and what it will involve. Please take time to read the following 
information carefully and discuss it with friends, relatives and your GP if you wish. Ask us if there is 
anything that is not clear or if you would like more information. Take time to decide whether or not you 
wish to take part. If you do decide to take part, please let us know beforehand if you have been involved 
in any other study during the last year. You are free to withdraw at any time without explanation Thank 
you for reading this. 
 
What is the purpose of the study? 
Severe obesity is associated with excessive food eating and appetite. Bariatric surgery (also known as 
‘obesity surgery’ or ‘weight loss surgery’) is a well known treatment for severely obese individuals. The 
way in which these operations achieve weight loss is not fully understood. We hypothesize that some of 
these changes in the reduced appetite after surgery may be due to alterations in taste. Our aims are to 
compare obese patients before and after bariatric surgery (gastric bypass and banding) to define the 
reward value of sweet, fatty and vegetable/fruit taste in obese individuals, and how this changes after 
surgery. 
 
Why have I been chosen? 
We are looking for patients already due to undergo bariatric surgery and healthy volunteers.  
 
You SHOULD NOT take part in this study if you 
1) have any serious illness  
2) are pregnant or breast feeding 
3) take more than three alcoholic drinks per day 
4) substance abuse 
5) suffer from any psychiatric illness  
6) have recently participated in other studies  
7) have had any significant longstanding heart disease or heart intervention  
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 (for example, patients who have had heart attacks, have pacemakers or have 
had heart surgery) 
 
Do I have to take part? 
 
It is up to you to decide whether or not to take part. If you do decide to take part you will be given this 
information sheet to keep and be asked to sign a consent form. If you decide to take part you are still free 
to withdraw at any time without giving a reason. A decision to withdraw at any time, or a decision not to 
take part, will not affect the standard of care you receive.  
 
Travel Costs 
 
You will be reimbursed for all travel costs. 
 
What will happen to me if I take part? 
 
Approximately one month before your operation, we will bring you into hospital to have up to three taste 
reward tasks. This will involve coming to the hospital at 8 am and having a prepared breakfast but n othing 
else to eat. The sweet taste reward test will begin around 11am. You will be sat in front of a computer and 
click on the left mouse button. You will have to left click the mouse a number of times before the 
computer beeps, the screen turns green and a M&M® sweet or milk/yoghurt or vegetable/fruit is given to 
you to eat. The task will become progressively more difficult and you will have to left click the mouse 
more and more times before the candy is provided. When you feel it is not worthwhile clicking the mouse 
any more to obtain the sweet then press the space bar and the task will be terminated. The same task will 
be repeated after the gastric bypass or banding operation. You can take part in either test or in all 3 of 
them. 
 
What do I have to do? 
There will be no restrictions for you. You will be investigated and followed-up in the same way as all other 
patients in our hospital undergoing treatment for obesity and bariatric surgery. The only difference being 
that you will also undergo a taste test one month before and after surgery. Pregnant patients will be 
excluded for the study. 
 
What are the side effects of taking part? 
We do not expect any extra side effects as we are performing a non-invasive taste test. 
 
Bariatric Surgery 
This will be explained to you in the clinic and described in the bariatric clinic standard information sheet 
(attached to this sheet information sheet), which specifies the benefits and risks of procedures.  
 
What are the possible disadvantages and risks of taking part in the study? 
 
We do not foresee any disadvantages or any risks from taking part in this study other than the known 
side-effects of surgery. 
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 What are the possible benefits of taking part in the study?  
 
This study will have no benefit to you but the information that we get from this study may help us to treat 
future patients who are overweight. 
 
What if new information becomes available? 
 
Sometimes during the course of a research project, new information becomes available about the 
treatment that is being studied. If this happens, your research doctor will tell you about it and discuss with 
you whether you want to continue in the study. If you decide to continue with the study, you will be asked 
to sign an updated consent form. Also, on receiving new information your research doctor might consider 
it to be in your best interests to withdraw you from the study. He/she will explain the reasons and arrange 
for your care to continue. 
 
What happens when the research study stops? 
 
Once the study has finished, the results of the study can be made available to you and/or your GP should 
you wish. If you have any problems immediately following the study, then you should contact one of the 
research doctors on the numbers provided below. 
 
What if something goes wrong? 
 
If you are harmed by taking part in this research project, there are no special compensation 
arrangements. If you are harmed due to someone’s negligence, then you may have grounds for a legal 
action. Regardless of this, if you wish to complain, or have any concerns about any aspect of the way you 
have been treated during the course of this study then you should immediately inform the Investigators: 
Dr Miras, Dr Bueter and Dr le Roux (investigative medicine), can be contacted through bleep 7063, 
through the Department of Investigative Medicine (020 8383 3242) or through the Hammersmith 
Hospitals NHS Trust switchboard (020 8383 1000) outside normal working hours. The normal National 
Health Service complaint complaints mechanisms are also available to you. If you are still not satisfied 
with the response, you may contact the Imperial College Clinical Research Governance Office.  
 
Will my taking part in this study be kept confidential? 
 
All information which is collected about you during the course of the research will be kept strictly 
confidential. Any information about you which leaves the hospital will have your name and address 
removed so that you cannot be recognised from it. With your consent, your GP will be informed of your 
participation in this study. 
 
What will happen to the results of the research study? 
 
The results are likely to be published in the six to eighteen months following the study. Your confidentiality 
will be ensured at all times and you will not be identified in any publication. At the end of the study, the 
results of the study can be made available to you and/or your GP should you wish.  
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 Who is organizing and funding the research? 
 
This study is being funded by the National Institute for Health Research. 
 
Who has reviewed the study? 
 
This study has been reviewed by the West London 2 Research ethics committee.  
 
Contact for Further Information 
 
If you experience any problems during the study, you may withdraw at any stage. The doctors involved in 
the study, Dr Miras, Dr Bueter and Dr le Roux (Investigative medicine), can be contacted through bleep 
7063, through the Department of Investigative Medicine (020 8383 3242) or through the Hammersmith 
Hospitals NHS Trust switchboard (020 8383 1000) outside normal working hours. 
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Imperial Weight Centre 
                                                                                  Charing Cross Hospital, 
London W6 8RF 
Tel 020 8383 5970 
Fax 020 8383 0673 
 
Information Sheet for Research Participants  
(Version 5, 6 September 2012) 
 
 
You will be given a copy of this Information Sheet and a signed copy of your consent form to keep, 
should you decide to participate in the study. 
 
 
Study title: Investigation of the effects of obesity surgery on taste reward 
Chief Investigator: Dr Carel le Roux 
 
You are being invited to take part in a research study. Before you decide it is important for you to understand 
why the research is being done and what it will involve. Please take time to read the following information 
carefully and discuss it with friends, relatives and your GP if you wish. Ask us if there is anything that is not 
clear or if you would like more information. Take time to decide whether or not you wish to take part. If you do 
decide to take part, please let us know beforehand if you have been involved in any other study during the last 
year. You are free to withdraw at any time without explanation Thank you for reading this. 
 
What is the purpose of the study? 
Severe obesity is associated with excessive food eating and appetite. Bariatric surgery (also known as ‘obesity 
surgery’ or ‘weight loss surgery’) is a well known treatment for severely obese individuals. The way in which 
these operations achieve weight loss is not fully understood. We hypothesize that some of these changes 
causing the reduced appetite after surgery or the Endobarrier procedure may be due to alterations in taste 
intensity and pleasantness. Our aims are to compare the intensity and pleasantness value of sweet, salt and 
fat solutions in obese patients before and after bariatric surgery or the Endobarrier procedure (gastric bypass, 
banding and sleeve gastrectomy) versus lean healthy volunteers. 
 
Why have I been chosen? 
We are looking for patients who have been offered obesity surgery, the Endobarrier or a diet treatment at the 
Imperial Weight Centre. We are also looking for healthy volunteers who will not have surgery/interventions. 
 
You SHOULD NOT take part in this study if you 
1) You have been refused obesity surgery for any reason 
2) You do not understand or cannot read or write in English 
 
Do I have to take part? 
It is up to you to decide whether or not to take part. If you do decide to take part you will be given this 
information sheet to keep and be asked to sign a consent form. If you decide to take part you are still free to 
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 withdraw at any time without giving a reason. A decision to withdraw at any time, or a decision not to take part, 
will not affect the standard of care you receive. 
 
What will happen to me if I take part? 
 
Patients 
Before your treatment, you will be asked to come to the Imperial Weight Centre, Room 8, 9th Floor East, 
Charing Cross Hospital, or the Research ward at Hammersmith Hospital, to complete the first part of the 
experiment. DO NOT have anything to eat the morning of the test (Water is allowed). First, you will be asked 
to complete a computer software task in which you rate your food preferences. Food/object pictures will be 
shown and you will be asked to rate them using the computer mouse/keyboard. The experiment will involve 
sampling liquids (15-30 ml) of different concentrations of sweet, salt and fat. You will be randomly allocated to 
sample one of the tastes via an anonymous “toss a coin” computer programme. Each taste will be tested on a 
separate occasion and you can choose how many tests you would like to be involved with. You will not sample 
the same taste twice. The liquids will be in cups, and you will have to swirl the fluid, spit, then have some water 
that we provide. You will then be asked to identify how intense you find the taste and how much you like it on a 
piece of paper. Each taste testing session will take less than one hour. Four to twelve weeks and twelve 
months after your treatment, we will ask you to come back to the hospital for the second tasting session. This 
will involve doing exactly the same.  
 
You may also be asked to attend on another day for a different test in which you are asked and to consume as 
much of a sweet, fat or fat and sweet and vegetable juice solution as you wish and answer why you stopped 
drinking more on a piece of paper. On the postoperative/second session test you will either be allowed to 
choose the concentration you wish to consume or only allowed to ingest the solution you chose on the first 
session. During tasting we may videotape your facial reactions or measure your saliva production by placing 
sterile cotton wool buds in your mouth, when tasting the different solutions. We will keep the tapes in a secure 
location in our department and only members of our team will watch and analyse them. During the saliva 
production test the investigator will place drops of the taste solution on your tongue and measure saliva 
production by weighing the cotton wool buds over 10 separate trials. The cotton wool buds used will be 
disposed of immediately after testing and therefore not get used for any other analysis. 
 
Healthy Volunteers 
You will be asked to participate in the above experiment three times, 6-14 weeks apart and at in 12 months. 
 
What do I have to do? 
There will be no restrictions for you. If you are a patient, you will be investigated and followed-up in the same 
way as all other patients in our hospital undergoing treatment for obesity..  
 
What are the side effects of taking part? 
We do not foresee any side effects as a result of the study.  
 
Bariatric Surgery 
This will be explained to you in the clinic and described in the obesity clinic standard information sheet 
(attached to this sheet information sheet), which specifies the benefits and risks of procedures. 
 
What are the possible benefits of taking part in the study? 
You will find out in precise terms how you perceive different tastes. 
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 What if new information becomes available? 
Sometimes during the course of a research project, new information becomes available about the treatment 
that is being studied. If this happens, your research doctor will tell you about it and discuss with you whether 
you want to continue in the study. If you decide to continue with the study, you will be asked to sign an 
updated consent form. Also, on receiving new information your research doctor might consider it to be in your 
best interests to withdraw you from the study. He/she will explain the reasons and arrange for your care to 
continue 
 
What happens when the research study stops?  
Once the study has finished, the results of the study can be made available to you and/or your GP should you 
wish. If you have any problems following the study, then you should contact one of the research doctors on the 
numbers provided below. 
 
What if something goes wrong? 
In the unlikely event that you are harmed by taking part in this research project, there are no special 
compensation arrangements. If you are harmed due to someone’s negligence, then you may have grounds for 
a legal action. Regardless of this, if you wish to complain, or have any concerns about any aspect of the way 
you have been treated during the course of this study then you should immediately inform the Investigators: Dr 
Alex Miras (07958377674) and Dr le Roux can be contacted (07970719453) outside normal working hours. 
The normal National Health Service complaint complaints mechanisms are also available to you. If you are still 
not satisfied with the response, you may contact the Imperial College Joint Research Office. 
Will my taking part in this study be kept confidential? 
All information which is collected about you during the course of the research will be kept strictly confidential, 
including the videotapes of your facial reactions. These will be saved for a maximum of ten years as 
anonymous electronic password protected files in our secure laboratory computer and then deleted. Any 
information about you which leaves the hospital will have your name and address removed so that you cannot 
be recognised from it.  
 
What will happen to the results of the research study? 
The results are likely to be published in the six to eighteen months following the study. Your confidentiality will 
be ensured at all times and you will not be identified in any publication. At the end of the study, the results of 
the study can be made available to you and/or your GP should you wish.  
 
Who is organizing and funding the research? 
This study is organised by Imperial College London and funded by the Imperial College Obesity Research 
Fund. 
 
Who has reviewed the study? 
This study has been reviewed by the West London 2 Research Ethics Committee. 
 
Contact for Further Information 
If you experience any problems during the study, you may withdraw at any stage. The doctors involved in the 
study, Dr Miras can be contacted via mobile number 07958377674.  
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 Intensity Visual Analogue Scale 
On the scale below, please indicate, using a horizontal mark, how SWEET the drink tastes to you.   
NB: Use the scale to indicate how intense the sweet taste is relative to sensations you have experienced of any kind, 
not just taste (e.g. pain, noise, etc.). 
 
 
Barely detectable 
Weak 
Moderate 
Strong 
Very strong 
 Strongest sensation of any kind 
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 “Just About Right” visual analogue cale  
 
On the scale below, please indicate, using a horizontal mark, how close the SWEETNESS of the drink 
tastes to your ideal sweetness in a soft drink.   
 
 
 
 
Far too little 
sweetness 
Just right 
Far too 
sweet 
I would 
never drink 
it 
My ideal 
sweetness in 
a drink 
I would 
never drink 
it 
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 Pleasantness visual analogue scale 
On the scale below, please indicate, using a horizontal mark, how Pleasant this sweet solution is. 
 
 
Extremely Unpleasant 
 
Neither Pleasant or Unpleasant 
Extremely Pleasant 
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